<SEC-DOCUMENT>0001493152-23-017001.txt : 20230515
<SEC-HEADER>0001493152-23-017001.hdr.sgml : 20230515
<ACCEPTANCE-DATETIME>20230515100044
ACCESSION NUMBER:		0001493152-23-017001
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		50
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230515
DATE AS OF CHANGE:		20230515

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Processa Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001533743
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				451539785
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39531
		FILM NUMBER:		23919253

	BUSINESS ADDRESS:	
		STREET 1:		7380 COCA COLA DRIVE
		STREET 2:		SUITE 106
		CITY:			HANOVER
		STATE:			MD
		ZIP:			21076
		BUSINESS PHONE:		443-776-3133

	MAIL ADDRESS:	
		STREET 1:		7380 COCA COLA DRIVE
		STREET 2:		SUITE 106
		CITY:			HANOVER
		STATE:			MD
		ZIP:			21076

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Heatwurx, Inc.
		DATE OF NAME CHANGE:	20111028
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>form10-q.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:PCSA="http://processapharmaceuticals.com/20230331">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_03F_PCSA_processapharmaceuticals.com_20230331 -->
<!-- Field: Set; Name: xdx; ID: xdx_04A_20230101_20230331 -->
<!-- Field: Set; Name: xdx; ID: xdx_053_edei%2D%2DEntityCentralIndexKey_0001533743 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05F_edei%2D%2DDocumentFiscalPeriodFocus_Q1 -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_070_XDX_form10%2Dq.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_072_SO_form10%2Dq.xdxs -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:EntityCentralIndexKey">0001533743</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:DocumentFiscalPeriodFocus">Q1</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-03-31" id="xdx2ixbrl0058" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-12-31" id="xdx2ixbrl0059" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2023-03-31" id="xdx2ixbrl0091" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="AsOf2022-12-31" id="xdx2ixbrl0093" name="us-gaap:OtherLiabilityCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration">http://fasb.org/us-gaap/2023#RelatedPartyMember</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2023-03-31" id="xdx2ixbrl0110" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2022-12-31" id="xdx2ixbrl0111" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-01-01to2023-03-31" id="xdx2ixbrl0172" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-01-012022-03-31" id="xdx2ixbrl0173" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0186" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0192" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-01-012022-03-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0196" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0197" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0202" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0203" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0205" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PCSA:SharesIssuedInConnectionWithPurchaseAgreementValue" contextRef="From2022-01-012022-03-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0212" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PCSA:SharesIssuedInConnectionWithPurchaseAgreementValue" contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0213" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0218" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0219" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0220" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-012023-03-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0256" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0257" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-03-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0264" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0265" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0270" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0271" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0272" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="From2023-01-01to2023-03-31" id="xdx2ixbrl0308" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2023-01-01to2023-03-31" id="xdx2ixbrl0311" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2022-01-012022-03-31" id="xdx2ixbrl0318" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherReceivables" contextRef="From2023-01-01to2023-03-31" id="xdx2ixbrl0337" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-01-012022-03-31" id="xdx2ixbrl0350" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfEquity" contextRef="From2023-01-01to2023-03-31" id="xdx2ixbrl0352" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssued1" contextRef="From2023-01-01to2023-03-31" id="xdx2ixbrl0370" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="pcsa-20230331.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2023-01-01to2023-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-09">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_ConsultingAgreementMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:ConsultingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-08-182021-08-20_custom_SalesAgreementMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:SalesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-08-18</xbrli:startDate>
        <xbrli:endDate>2021-08-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_SalesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:SalesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_SalesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:SalesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-03-212022-03-23_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-03-21</xbrli:startDate>
        <xbrli:endDate>2022-03-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-23_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-082023-02-09_custom_SecuritiesPurchaseAgreementMember_custom_RegisteredDirectOfferingMember_custom_AccreditedInvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">PCSA:RegisteredDirectOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:AccreditedInvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-08</xbrli:startDate>
        <xbrli:endDate>2023-02-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-02-09_custom_SecuritiesPurchaseAgreementMember_custom_RegisteredDirectOfferingMember_custom_AccreditedInvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">PCSA:RegisteredDirectOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:AccreditedInvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-02-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-02-09_custom_SecuritiesPurchaseAgreementMember_custom_RegisteredDirectOfferingMember_custom_PlacementAgentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">PCSA:RegisteredDirectOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:PlacementAgentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-02-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-082023-02-09_custom_SecuritiesPurchaseAgreementMember_custom_RegisteredDirectOfferingMember_custom_PlacementAgentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">PCSA:RegisteredDirectOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:PlacementAgentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-08</xbrli:startDate>
        <xbrli:endDate>2023-02-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-04-17_custom_ConsultingAgreementMember_custom_SpartanCapitalSecuritesLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:ConsultingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:SpartanCapitalSecuritesLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-04-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_TwoThousandAndNineteenPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">PCSA:TwoThousandAndNineteenPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-01-01_us-gaap_RestrictedStockMember_custom_ThreeDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:ThreeDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-01-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_WarrantMember_custom_ConsultantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:ConsultantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-02-14_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-02-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-132023-02-14_us-gaap_WarrantMember_custom_ConsultantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:ConsultantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-13</xbrli:startDate>
        <xbrli:endDate>2023-02-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_CommittedWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PCSA:CommittedWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_FacilityLeaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">PCSA:FacilityLeaseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_EquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_CorLystLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:CorLystLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_CorLystLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:CorLystLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_CorLystLLCMember_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:CorLystLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedAndNonrelatedPartyStatusAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_CorLystLLCMember_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:CorLystLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedAndNonrelatedPartyStatusAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_AgreementsMember_custom_ContractResearchOrganizationsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:AgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:ContractResearchOrganizationsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt; text-transform: uppercase"><b>United
States</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt; text-transform: uppercase"><b>Securities
and Exchange Commission</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt; text-transform: uppercase"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt; text-transform: uppercase"><b>FORM
<span id="xdx_904_edei--DocumentType_c20230101__20230331_zdBIkN0ZB8G3"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:DocumentType">10-Q</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Mark
One)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--DocumentQuarterlyReport_c20230101__20230331_zo90nmlBGkw5"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" format="ixt:booleantrue" name="dei:DocumentQuarterlyReport">&#9746;</ix:nonNumeric></span><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>QUARTERLY
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the quarterly period ended <span id="xdx_90A_edei--DocumentPeriodEndDate_c20230101__20230331_zoOcowG3C2Ga"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">March 31, <span id="xdx_90B_edei--DocumentFiscalYearFocus_c20230101__20230331_z4MvUp0CgcVd"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:DocumentFiscalYearFocus">2023</ix:nonNumeric></span></ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">or</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--DocumentTransitionReport_c20230101__20230331_zag9krCZRkOc"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span>&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TRANSITION
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the transition period from ____ to ____</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
File Number <span id="xdx_90B_edei--EntityFileNumber_c20230101__20230331_zHNncIUFINi2"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:EntityFileNumber">001-39531</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span style="text-decoration: underline"><span id="xdx_909_edei--EntityRegistrantName_c20230101__20230331_zQnhJQi6LHK7"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:EntityRegistrantName">Processa
Pharmaceuticals, Inc.</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90C_edei--EntityIncorporationStateCountryCode_c20230101__20230331_zt0jkvsJ2mlh"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90F_edei--EntityTaxIdentificationNumber_c20230101__20230331_zL9XIi3T6Tse"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:EntityTaxIdentificationNumber">45-1539785</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
    or other jurisdiction</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of
    incorporation or organization)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS
    Employer</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
    No.)</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90E_edei--EntityAddressAddressLine1_c20230101__20230331_zWARgaFiB2xl"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:EntityAddressAddressLine1">7380
Coca Cola Drive</ix:nonNumeric></span>, <span id="xdx_90B_edei--EntityAddressAddressLine2_c20230101__20230331_zwkcp8xgLeH1"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:EntityAddressAddressLine2">Suite 106</ix:nonNumeric></span>,</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_90F_edei--EntityAddressCityOrTown_c20230101__20230331_zF3n2oFd1sll"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:EntityAddressCityOrTown">Hanover</ix:nonNumeric></span>,
<span id="xdx_900_edei--EntityAddressStateOrProvince_c20230101__20230331_zLCb88V0GkO8"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">Maryland</ix:nonNumeric></span> <span id="xdx_900_edei--EntityAddressPostalZipCode_c20230101__20230331_zcDSHb3YO7xa" title="Entity Address, Postal Zip Code"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:EntityAddressPostalZipCode">21076</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_904_edei--CityAreaCode_c20230101__20230331_z29Ev39OnR5h" title="City Area Code"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:CityAreaCode">(443)</ix:nonNumeric></span>
<span id="xdx_908_edei--LocalPhoneNumber_c20230101__20230331_zqJbcfVVi9Vb" title="Local Phone Number"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:LocalPhoneNumber">776-3133</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Exchange Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 36%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of Each Class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 42%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_edei--Security12bTitle_c20230101__20230331_zmq8LioxNZTc"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:Security12bTitle">Common
    Stock, $0.0001 par value per share</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--TradingSymbol_c20230101__20230331_ztwdG1n3cuMi"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:TradingSymbol">PCSA</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--SecurityExchangeName_c20230101__20230331_zX4cCCR3OTb7"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">The
    Nasdaq Stock Market LLC</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. <span id="xdx_901_edei--EntityCurrentReportingStatus_c20230101__20230331_zBIekJhSk7R5"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
<span id="xdx_90E_edei--EntityInteractiveDataCurrent_c20230101__20230331_z1vbXFCqlUt"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or emerging growth company. See definition of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller
reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 35%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--EntityFilerCategory_c20230101__20230331_zZ0F0iFld9x3"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated
    filer</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--EntitySmallBusiness_c20230101__20230331_z1tY1XKJQpIb"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" format="ixt:booleantrue" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--EntityEmergingGrowthCompany_c20230101__20230331_zPtAA4XuZ7nk"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744; <span id="xdx_904_edei--EntityShellCompany_c20230101__20230331_zexcAuIEU8gj"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of outstanding shares of the registrant&#8217;s common stock at May 9, 2023 was <span id="xdx_906_edei--EntityCommonStockSharesOutstanding_iI_pid_c20230509_zKalEqIwJYw"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2023-05-09" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,531,474</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROCESSA
PHARMACEUTICALS, INC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TABLE
OF CONTENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_001">Part
    I. Financial Information</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_002">Item
    1: Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 48px; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_003">Item
    2: Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_004">Item
    3. Quantitative and Qualitative Disclosures about Market Risk</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">24</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_005">Item
    4. Controls and Procedures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">24</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_006">Part
    II. Other Information</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">25</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_007">Item
    1. Legal Procedures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_008">Item
    1A. Risk Factors</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_009">Item
    2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_010">Item
    3. Defaults Upon Senior Securities</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_011">Item
    4. Mine Safety Disclosures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_012">Item
    5. Other Information</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span>5</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_013">Item
    6. Exhibits</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#s_001">Signatures</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">26</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_001"></span>Part
I: Financial Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="a_002"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
1: Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Processa
Pharmaceuticals, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed
Consolidated Balance Sheets</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_306_111_zVeeWfNsU6Mh" summary="xdx: Statement - Condensed Consolidated Balance Sheets (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20230331_zRvSSjrL4hL" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2023</p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20221231_zMxuQ7wNXBfi" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">December 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2022</p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AssetsAbstract_iB_zyuMvFsTCXs2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AssetsCurrentAbstract_i01B_zRDzz2eVoh21" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">Current Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maACzsB6_zHc9sh0kvKd4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 60%; text-align: justify">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,741,602</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,503,595</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maACzsB6_zfyjXiOCC4Zi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Prepaid expenses and other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,477,519</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,883,134</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AssetsCurrent_i02TI_mtACzsB6_maAzmjq_zn3WUevooGAj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: justify; padding-bottom: 1.5pt">Total Current Assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,219,121</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,386,729</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentNet_i01I_pp0p0_maAzmjq_zcVLhWzlRRl7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Property and Equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0058">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0059">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OtherAssetsNoncurrentAbstract_i01B_zsrwWh27nVXc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Other Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingLeaseRightOfUseAsset_i02I_pp0p0_maOANzX3l_zxb2m0rrr2al" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Operating lease right-of-use assets, net of accumulated amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">207,787</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">227,587</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--SecurityDeposit_i02I_pp0p0_maOANzX3l_zZozCusncB11" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Security deposit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:SecurityDeposit" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,535</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:SecurityDeposit" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,535</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OtherAssetsNoncurrent_i02TI_pp0p0_mtOANzX3l_maAzmjq_zCvmunPHO4g8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: justify; padding-bottom: 1.5pt">Total Other Assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">213,322</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">233,122</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--Assets_i01TI_pp0p0_mtAzmjq_zi8w0M2G4Lo9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Total Assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,432,443</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,619,851</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_z5jCasvySDEg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LiabilitiesCurrentAbstract_i01B_zok1zTPu3dt1" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">Current Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_pp0p0_maLCzt2S_zSNCWtqOmBPk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Current maturities of operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">81,166</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">78,896</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccountsPayableCurrent_i02I_pp0p0_maLCzt2S_zFnCxV63MZX1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">316,709</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">327,548</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--DueToLicensor_i02I_pp0p0_maLCzt2S_zwETZpdvxN1k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Due to licensor</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="PCSA:DueToLicensor" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">189,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="PCSA:DueToLicensor" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">189,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OtherLiabilitiesCurrent_i02I_pp0p0_maLCzt2S_zmnFWF5ZVpg5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify"><span id="xdx_90A_eus-gaap--OtherLiabilityCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration_iI_dxL_c20221231_zUlhNd1YO5Ef" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2023%23RelatedPartyMember" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBCYWxhbmNlIFNoZWV0cyAoVW5hdWRpdGVkKQA_"><span style="-sec-ix-hidden: xdx2ixbrl0093">Due to related parties</span></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0091">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">51</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AccruedLiabilitiesCurrent_i02I_pp0p0_maLCzt2S_zTar0ttWuib3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Accrued expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,573,961</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">403,061</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesCurrent_i01TI_pp0p0_mtLCzt2S_maLzaGD_z9UBA2pfzeQa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: justify; padding-bottom: 1.5pt">Total Current Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,160,836</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">998,556</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LiabilitiesNoncurrentAbstract_i01B_zls3bIhQphk9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Non-current Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseLiabilityNoncurrent_i02I_pp0p0_maLzaGD_zynRnQZsLDph" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Non-current operating lease liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">129,358</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">150,554</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--Liabilities_i01TI_pp0p0_mtLzaGD_maLASEzQLi_zcgYrQ5o2q57" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">Total Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,290,194</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,149,110</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CommitmentsAndContingencies_i01I_pp0p0_maLASEzQLi_z8yPebYiQVNd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Commitments and Contingencies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0110">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0111">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockholdersEquityAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Stockholders&#8217; Equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CommonStockValue_i02I_pp0p0_maSEzXfb_zMTghZU6zxD3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Common stock, par value $<span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20221231_z65LjoG34em8" title="Common stock, par value"><span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230331_zYjNRvEWoWXe" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span>, <span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_c20221231_zRPkpICLRaDd" title="Common stock, shares authorized"><span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_c20230331_zFumYZefp3X6" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized: <span id="xdx_905_eus-gaap--CommonStockSharesIssued_iI_c20230331_zRPKpuPbaMS5" title="Common stock, shares issued"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,631,474</ix:nonFraction></span> issued and <span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_iI_c20230331_zI1QTw20HvI8" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,531,474</ix:nonFraction></span> outstanding at March 31, 2023 and <span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_c20221231_zSguPjC0cyv6" title="Common stock, shares issued"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,135,400</ix:nonFraction></span> issued and <span id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_iI_c20221231_zC7zpJlfUJo8" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,035,400</ix:nonFraction></span> outstanding at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,463</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,614</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AdditionalPaidInCapitalCommonStock_i02I_pp0p0_maSEzXfb_zu1KJHwfpRug" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">78,709,420</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">72,016,688</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--TreasuryStockValue_i02NI_pp0p0_di_msSEzXfb_zCfjMenEDhWh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Treasury stock at cost &#8212; <span id="xdx_903_eus-gaap--TreasuryStockCommonShares_iI_c20230331_zb3astCUAdSa" title="Treasury stock shares"><span id="xdx_905_eus-gaap--TreasuryStockCommonShares_iI_c20221231_z1aPrSSYD4w5" title="Treasury stock shares"><ix:nonFraction name="us-gaap:TreasuryStockCommonShares" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:TreasuryStockCommonShares" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></ix:nonFraction></span></span>
    shares at March 31, 2023 and December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:TreasuryStockValue" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">300,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:TreasuryStockValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">300,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_pp0p0_maSEzXfb_zNo9IvwjUaM7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">68,269,634</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">64,247,561</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--StockholdersEquity_i02TI_pp0p0_mtSEzXfb_maLASEzQLi_zjEA252FHKz" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">Total Stockholders&#8217; Equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,142,249</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,470,741</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_pp0p0_mtLASEzQLi_zG8jCtMGLeBf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Total Liabilities and Stockholders&#8217; Equity</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,432,443</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,619,851</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Processa
Pharmaceuticals, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed
Consolidated Statements of Operations</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_308_113_zircI3wkFF5d" summary="xdx: Statement - Condensed Consolidated Statements of Operations (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20230101__20230331_zkioYmayGxQ1" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20220101__20220331_zhO08YgDRmXg" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Three months ended March 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingExpensesAbstract_iB_zf1fLaFQEfyg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating Expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_i01_pp0p0_msOILzGQ6_zOJFZrtLmN2e" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Research and development expenses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,627,480</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,043,984</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--GeneralAndAdministrativeExpense_i01_pp0p0_msOILzGQ6_zRFyvz0ZiSr6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">General and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,478,055</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,184,730</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingIncomeLoss_iT_pp0p0_mtOILzGQ6_maILFCOzqL9_zWo04081Vdz1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating Loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">4,105,535</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">3,228,714</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OtherNonoperatingIncomeExpense_maILFCOzqL9_z0FL5BoVTdxg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Other Income (Expense), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">83,462</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,583</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtILFCOzqL9_maNILzqu1_zjC9yHDueQie" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net Operating Loss Before Income Tax Benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,022,073</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,227,131</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--IncomeTaxExpenseBenefit_iN_di_msNILzqu1_zum0I3ImGRR8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Income Tax Benefit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0172">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0173">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetIncomeLoss_iT_mtNILzqu1_zr7gsOReFPEh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net Loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,022,073</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,227,131</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--EarningsPerShareBasic_zO9DooJu1U3l" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net Loss Per Common Share - Basic and Diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.18</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.20</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zYZrG8AXn11f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Weighted Average Common Shares Used to Compute Net Loss Per Common Shares - Basic and Diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">22,770,789</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,831,118</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Processa
Pharmaceuticals, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed
Consolidated Statement of Changes in Stockholders&#8217; Equity</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_114_zgLazvJY1rFd" summary="xdx: Statement - Condensed Consolidated Statement of Changes in Stockholders&apos; Equity (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Shares</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_4B1_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zdPfAXBTraIf" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_4BE_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zg9woepu4Jp1" style="border-bottom: Black 1.5pt solid; text-align: center">Capital</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Shares</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_4B0_us-gaap--StatementEquityComponentsAxis_us-gaap--TreasuryStockCommonMember_zorVGVwcRhc2" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_4B1_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zkxoDjys89K5" style="border-bottom: Black 1.5pt solid; text-align: center">Deficit</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_4B5_zF1khy9vtcf2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Additional</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Common Stock</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Paid-In</td><td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Treasury Stock</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Accumulated</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Shares</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Capital</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Shares</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Deficit</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td>&#160;</td></tr>
  <tr id="xdx_43C_c20220101__20220331_eus-gaap--StockholdersEquity_iS_z8FhC3Oaonr7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 37%">Balance at January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharesOutstanding_iS_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0K4oWVAUCek" title="Balance, shares" style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,710,246</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,571</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">62,306,861</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharesOutstanding_iS_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_z85neO6qnbWj" title="Balance, shares" style="width: 5%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0192">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0186">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">36,823,332</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,485,100</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_zMFxFIHZo2Ti" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhtz6LpNgB5l" title="Stock-Based compensation, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">103,670</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">828,887</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0196">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0197">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">828,897</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--StockRepurchasedDuringPeriodValue_iN_di_zLHK92XVYn0f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Acquisition of treasury stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0202">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0203">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--StockRepurchasedDuringPeriodShares_iN_di_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zahr3ce72lL1" title="Acquisition of treasury stock, shares" style="text-align: right">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="From2022-01-012022-03-31_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2022-01-012022-03-31_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0205">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_ecustom--SharesIssuedInConnectionWithPurchaseAgreementValue_z53HfASkvnAa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Shares issued in connection with purchase agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--SharesIssuedInConnectionWithPurchaseAgreementShares_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znc3cZWVjSUb" title="Shares issued in connection with purchase agreement" style="text-align: right"><ix:nonFraction name="PCSA:SharesIssuedInConnectionWithPurchaseAgreementShares" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">123,609</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="PCSA:SharesIssuedInConnectionWithPurchaseAgreementValue" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="PCSA:SharesIssuedInConnectionWithPurchaseAgreementValue" contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">449,988</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0212">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0213">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="PCSA:SharesIssuedInConnectionWithPurchaseAgreementValue" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">450,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLoss_zgJ9b3uPEjS2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0218">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0219">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0220">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,227,131</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,227,131</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_43C_c20220101__20220331_eus-gaap--StockholdersEquity_iE_zMz5AsSoL7G5" style="vertical-align: bottom; background-color: White">
    <td>Balance, March 31, 2022</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharesOutstanding_iE_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z64vafCLZ90f" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,937,525</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,593</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">63,585,736</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iE_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zd6MPKNmPYb5" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-03-31_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">100,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">300,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">40,050,463</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,236,866</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_439_c20220101__20220331_eus-gaap--StockholdersEquity_iE_z3IDSI6HiNZ8" style="display: none; vertical-align: bottom; background-color: White">
    <td>Balance</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iE_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrijHPVvNZLd" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,937,525</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,593</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">63,585,736</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharesOutstanding_iE_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zEN9bHXOm5F1" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-03-31_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">100,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">300,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">40,050,463</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,236,866</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Additional</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Common Stock</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Paid-In</td><td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Treasury Stock</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Accumulated</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Shares</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Capital</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Shares</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Deficit</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td>&#160;</td></tr>
  <tr id="xdx_433_c20230101__20230331_eus-gaap--StockholdersEquity_iS_zwINHG1QAYQi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 37%">Balance at January 1, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharesOutstanding_iS_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkwxxeYL8li8" title="Balance, shares" style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,135,400</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,614</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">72,016,688</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharesOutstanding_iS_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zsjTMe45jGgf" title="Balance, shares" style="width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">100,000</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">300,000</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">64,247,561</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,470,741</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_zKJF7WfClDmh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrZegYuAGykk" title="Stock-Based compensation, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">63,882</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">341,498</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0256">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0257">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">341,504</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zYLnK49LRBg4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Shares issued in connection with capital raises, net of transaction costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpV5Lrzmep3e" title="Shares issued in connection with capital raises, net of transaction costs, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,432,192</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">843</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,351,234</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0264">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0265">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,352,077</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLoss_zU0cedw9IkB2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0270">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0271">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0272">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,022,073</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,022,073</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_43F_c20230101__20230331_eus-gaap--StockholdersEquity_iE_zwTXrzHpuxp1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance, March 31, 2023</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharesOutstanding_iE_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgVS2LgJI5bk" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,631,474</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,463</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">78,709,420</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iE_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_znyvvoYw5Phe" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-03-31_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">100,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">300,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">68,269,634</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,142,249</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_436_c20230101__20230331_eus-gaap--StockholdersEquity_iE_zU7aLyNhZE9h" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharesOutstanding_iE_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZnzubFnQUji" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,631,474</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,463</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">78,709,420</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharesOutstanding_iE_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zCKv9aUIYVXh" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-03-31_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">100,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">300,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">68,269,634</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,142,249</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Processa
Pharmaceuticals, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed
Consolidated Statements of Cash Flows</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_302_112_zi6bkAWn0kY4" summary="xdx: Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20230101__20230331_zO7s0s429Yk7" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20220101__20220331_zPt57E9oRy71" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zrvI74BuvGyd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash Flows From Operating Activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetIncomeLoss_i01_maNCPBUzTYd_z5qJBq26Z6Mk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,022,073</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,227,131</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_z6PS1pVr0F3i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseExpense_i02_pp0p0_maNCPBUzTYd_zMofz0YY5pn7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Non-cash lease expense for right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">19,800</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">22,559</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_i02_pp0p0_maNCPBUzTYd_zPTZlOQ6Icv5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Amortization of issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0308">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,113</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AmortizationOfIntangibleAssets_i02_maNCPBUzTYd_zB0pascKmjfj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Amortization of intangible asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0311">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">197,124</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ShareBasedCompensation_i02_maNCPBUzTYd_zp8Fze5nF5jl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">341,504</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">828,897</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_i02_maNCPBUzTYd_z2GNYXw8veL" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Recording of warrant to be issued to purchase <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230331__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJgkdzhfBOA8" title="Purchase of warrants, shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-03-31_custom_ConsultingAgreementMember_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,160,130</ix:nonFraction></span>
    shares of common stock in connection with a consulting agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,310,875</ix:nonFraction></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0318">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_zVr2QvcsGfPe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Net changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i03N_di_msNCPBUzTYd_z5E6VIH6JU56" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left">Prepaid expenses and other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">405,615</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">216,717</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i03_maNCPBUzTYd_zL7LRzq1xA13" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left">Operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,926</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">23,195</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--IncreaseDecreaseInAccountsPayable_i03_maNCPBUzTYd_zMKIzt6B6hol" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,839</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">97,187</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--IncreaseDecreaseInDueToRelatedParties_i03_maNCPBUzTYd_zsoXNRaRfDZa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left">Due (from) to related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDueToRelatedParties" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">51</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDueToRelatedParties" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,772</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--IncreaseDecreaseInOtherReceivables_i03N_di_msNCPBUzTYd_zat5hfoBY65i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left">Other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0337">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherReceivables" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">70,274</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncreaseDecreaseInAccruedLiabilities_i03_maNCPBUzTYd_zgD4gA0KAtJa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left; padding-bottom: 1.5pt">Accrued expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">139,975</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,301</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_mtNCPBUzTYd_maCCERCzxBg_zeC5JItyLTjd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 40pt; text-align: left; padding-bottom: 1.5pt">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,114,070</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,802,926</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_z1kgfLjk1Dz7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash Flows From Financing Activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_pp0p0_maNCPBUzYaN_zmVzdChyXH17" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Net proceeds from common stock issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,352,077</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0350">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PaymentsForRepurchaseOfEquity_i01N_di_msNCPBUzYaN_zDsZdGod2kY6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Acquisition of treasury stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0352">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfEquity" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInFinancingActivities_iT_pp0p0_mtNCPBUzYaN_maCCERCzxBg_znr9B5i2dkz7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Net cash provided by (used in) financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,352,077</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">300,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_pp0p0_mtCCERCzxBg_zeeUZm4hdrNb" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Net Increase (Decrease) in Cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,238,007</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">2,102,926</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Cash and Cash Equivalents &#8211; Beginning of Period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,503,595</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">16,497,581</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Cash and Cash Equivalents &#8211; End of Period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,741,602</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">14,394,655</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_iB_zlV5Cp28Gsi3" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Non-Cash Financing Activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--StockIssued1_i01_zWQzHmzMWNi7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Issuance of <span id="xdx_909_ecustom--SharesIssuedInConnectionWithPurchaseAgreementShares_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlS3YlGekYbe" title="Shares issued in connection with the Purchase Agreement with Lincoln Park"><ix:nonFraction name="PCSA:SharesIssuedInConnectionWithPurchaseAgreementShares" contextRef="From2022-01-012022-03-31_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">123,609</ix:nonFraction></span> shares of common stock in connection with the Purchase Agreement with Lincoln Park</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0370">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockIssued1" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">450,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these condensed consolidated financial statements.</span></p>
<!-- Field: Split-Segment; Name: 001 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Processa
Pharmaceuticals, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to Condensed Consolidated Financial Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock"><p id="xdx_803_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_z6Dsu1T422L1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
1 &#8211; <span id="xdx_82B_z0oH60v2wmgi">Organization and Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="PCSA:BusinessActivitiesAndOrganizationPolicyTextBlock"><p id="xdx_848_ecustom--BusinessActivitiesAndOrganizationPolicyTextBlock_zWPg5nWOcHCf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline"><span id="xdx_86D_zit5Z1FfCdU7">
  Organization</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We are a clinical-stage biopharmaceutical company focused on incorporating our Regulatory Science Approach into the development of our
Next Generation Chemotherapy (NGC) drugs to improve the safety and efficacy of cancer treatment. Our NGC drugs are modifications of existing
FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution while maintaining the well-known and established
existing mechanisms of killing the cancer cells. By modifying the NGC drugs in this manner, we believe our three NGC treatments will provide
improved safety-efficacy profiles when compared to their currently marketed counterparts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_84A_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zQDXva4NfD7a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_863_zcijPntvMeR2">Basis
of Presentation</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally
accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and with the instructions of the
Securities and Exchange Commission (&#8220;SEC&#8221;) on Form 10-Q and Article 8 of Regulation S-X.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly,
they do not include all the information and disclosures required by U.S. GAAP for complete financial statements. All material intercompany
accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated
financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our
financial position and of the results of operations and cash flows for the periods presented. These condensed consolidated financial
statements should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form
10-K for the year ended December 31, 2022, as filed with the SEC. The results of operations for the interim periods shown in this report
are not necessarily indicative of the results that may be expected for any other interim period or for the full year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="PCSA:LiquidityPolicyTextBlock"><p id="xdx_841_ecustom--LiquidityPolicyTextBlock_z6QHJWnDGuZg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_867_zUgb6NKEM6H6">Liquidity</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have incurred losses since inception, devoting substantially all of our efforts toward research and development, and have an
accumulated deficit of $<span id="xdx_90E_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20230331_zhcAN75ZW7fl" title="Accumulated deficit"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">68.3</ix:nonFraction>
million</span> at March 31, 2023. During the three months ended March 31, 2023, we generated a net loss of $<span id="xdx_902_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20230101__20230331_zeipuBUCSrWe" title="Net loss"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">4.0</ix:nonFraction>
million</span> and we expect to continue to generate operating losses and negative cash flow from operations for the foreseeable
future. Based on our current plans, we believe our current cash balances are adequate for at least the next twelve months. Our
ability to execute our longer-term operating plans, including future clinical trials for our portfolio of drugs depend on
our ability to obtain additional funding from the sale of equity and/or debt securities, a strategic transaction or other funding
transactions. We plan to continue to actively pursue financing alternatives, but there can be no assurance that we will obtain the
necessary funding in the future when necessary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
had <span id="xdx_90E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0d_do_c20230101__20230331_zFoSXWfQhvNi" title="Revenue"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-01to2023-03-31" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></span>
revenue during the three months ended March 31, 2023 and do not have any revenue under contract or any immediate sales prospects.
Our primary uses of cash are to fund our planned clinical trials, research and development expenditures and other operating
expenses. Cash used to fund operating expenses is impacted by the timing of when we incur and pay these expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2023, we raised gross proceeds of $<span id="xdx_90F_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20230101__20230331_zAfm4ciUPqT3" title="Proceeds from sale of common stock"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">7.0</ix:nonFraction></span>
million (net proceeds of $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20230101__20230331_zi7er2Ubhrwa" title="Net proceeds from sale of stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.4</ix:nonFraction></span> million) from the sale of <span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230101__20230331_zTH5NKFKOIvd" title="Sale of common stock, shares"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,432,192</ix:nonFraction></span>
shares of our common stock, as described in Note 2. We plan to use the net proceeds from these financings to prepare for future clinical trials; and on research and development
expenses, working capital and other general corporate purposes. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_84A_eus-gaap--UseOfEstimates_z9ZfaxUzdiQ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_868_zLciUkfXVJEg">Use
of Estimates</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
preparing our condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP and pursuant to the
rules and regulations of the SEC, we make estimates and judgments that affect the amounts reported in the condensed consolidated
financial statements and accompanying notes. Estimates are used for, but not limited to preclinical and clinical trial expenses,
stock-based compensation, intangible assets, future milestone payments and income taxes. These estimates and assumptions are
continuously evaluated and are based on management&#8217;s experience and knowledge of the relevant facts and circumstances. While
we believe the estimates to be reasonable, actual results could differ materially from those estimates and could impact future
results of operations and cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_z8fVWrWQfhh2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86D_zkvXTL7WAral">Income
Taxes</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
account for income taxes in accordance with ASC Topic 740, <i>Income Taxes.</i> Deferred income taxes are recorded for the expected tax
consequences of temporary differences between the basis of assets and liabilities for financial reporting purposes and amounts recognized
for income tax purposes. At March 31, 2023 and December 31, 2022, we recorded a valuation allowance equal to the full recorded amount
of our net deferred tax assets since it is more-likely-than-not that such benefits will not be realized. The valuation allowance is reviewed
quarterly and is maintained until sufficient positive evidence exists to support its reversal. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
ACS 740-270 <i>Income Taxes &#8211; Interim Reporting</i>, we are required to project our annual federal and state effective income tax
rate and apply it to the year-to-date ordinary operating tax basis loss before income taxes. Based on the projection, no current income
tax benefit or expense is expected for 2023 and the foreseeable future since the deferred tax liability has been offset completely at
 December 31, 2021 and we expect to generate taxable net operating losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_zv0Hleqydarh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline"><span id="xdx_86B_zpUFJDp1Yw2i">Concentration
of Credit Risk</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject us to significant concentration of credit risk consist primarily of our cash and cash equivalents.
We utilize only well-established banks and financial institutions with high credit ratings. Balances on deposit are insured by the Federal
Deposit Insurance Corporation (FDIC) up to specified limits. Total cash held by our banks at March 31, 2023, exceeded FDIC limits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_84C_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_ziUOxsYZJIfd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_863_zpOOHZcd0gK3">Recent
Accounting Pronouncements</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standard setting bodies issue new accounting pronouncements.
Updates to the FASB Accounting Standards Codification are communicated through issuance of an Accounting Standards Update (&#8220;ASU&#8221;).
We have implemented all new accounting pronouncements that are in effect and that may impact our condensed consolidated financial statements.
We have evaluated recently issued accounting pronouncements and determined that there is no material impact on our consolidated financial
position or results of operations.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_805_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zzYuHICslY8j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8211; <span id="xdx_828_zNbNKqUxhbBb">Stockholders&#8217; Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Preferred
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were <span id="xdx_905_eus-gaap--PreferredStockSharesIssued_iI_do_c20230331_zFY0X6ZK9Xn1" title="Preferred stock, shares issued"><span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20230331_zvApIldwVGyf" title="Preferred stock, shares outstanding"><span id="xdx_90C_eus-gaap--PreferredStockSharesIssued_iI_do_c20221231_zOxlHej2AbKe" title="Preferred stock, shares issued"><span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20221231_zP6Ho1mLuBc7" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-03-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-03-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> issued or outstanding shares of preferred stock at either March 31, 2023 or December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2023, we issued <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpIyeCbEliPa" title="Common stock shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,432,192</ix:nonFraction></span> shares of our common stock through several fundraising efforts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">ATM
Offering</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 20, 2021, we entered into the Sales Agreement with Oppenheimer &amp; Co. Inc. (the &#8220;Sales Agent&#8221;) under which we
may issue and sell up to $<span id="xdx_90F_ecustom--MaximumValueToBeSoldAtMarketOffering_pn5n6_c20210818__20210820__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember__srt--RangeAxis__srt--MaximumMember_zXYONC3iBkNf" title="Maximum value to be sold at the market offering"><ix:nonFraction name="PCSA:MaximumValueToBeSoldAtMarketOffering" contextRef="From2021-08-182021-08-20_custom_SalesAgreementMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">30.0</ix:nonFraction></span>
million from time to time under the ATM Offering. We expect to use net proceeds from the ATM Offering over time as a source for
working capital and general corporate purposes. During the three months ended March 31, 2023, we sold <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zrjJJdoDfgo8" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-03-31_custom_SalesAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">569,648</ix:nonFraction></span>
shares at an average price of $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_c20230331__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_z1IBZhXRYPCi"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-03-31_custom_SalesAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.22</ix:nonFraction></span>
per share for aggregate gross proceeds of $<span id="xdx_908_ecustom--GrossProceedsFromIssuanceOfCommonStock_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zmLQDUj3xO3f" title="Gross proceeds from common stock"><ix:nonFraction name="PCSA:GrossProceedsFromIssuanceOfCommonStock" contextRef="From2023-01-012023-03-31_custom_SalesAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">693,000</ix:nonFraction></span> (net proceeds of $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zeTzdAXw6M64" title="Net proceeds from issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-01-012023-03-31_custom_SalesAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">672,000</ix:nonFraction></span>) prior to deducting sales commissions. On February 5, 2023, in connection with our Registered Direct Offering,
we suspended the Sales Agreement with the Sales Agent, but we expect to reinstate it during 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline">Lincoln
Park Capital Fund, LLC Purchase Agreement</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
March 23, 2022, we entered into the Purchase Agreement with Lincoln Park, pursuant to which Lincoln Park has committed to purchase up
to $<span id="xdx_908_ecustom--MaximumCommitmenttoPurchaseCommonStockValue_pn5n6_c20220321__20220323__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__srt--RangeAxis__srt--MaximumMember_zBVsSuIfqZGc" title="Commitment to purchase common stock"><ix:nonFraction name="PCSA:MaximumCommitmenttoPurchaseCommonStockValue" contextRef="From2022-03-212022-03-23_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">15.0</ix:nonFraction></span> million of shares (the &#8220;Purchase Shares&#8221;) of our common stock, subject to the terms and conditions in the Purchase
Agreement with Lincoln Park<span style="background-color: white">, including that the closing sale
price of the common stock on the purchase date is not below a threshold price of $<span id="xdx_90F_ecustom--ThresholdPrice_iI_c20220323__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z56btwRD3os3" title="Threshold price"><ix:nonFraction name="PCSA:ThresholdPrice" contextRef="AsOf2022-03-23_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span></span>. Any proceeds that we receive under the Purchase Agreement are expected to be used for working capital and
general corporate purposes. During the three months ended March 31, 2023, we sold <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zU5TWDjUhlEa"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-03-31_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></span> shares at an average price of $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_c20230331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zYRqYIOM6CCb"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-03-31_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.08</ix:nonFraction></span> per share
for aggregate gross proceeds of $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z5Q5Cxd0qwxd"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-01-012023-03-31_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">54,000</ix:nonFraction></span> under the Purchase Agreement with Lincoln Park.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline">Registered
Direct Offering</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
February 14, 2023, we closed a registered direct offering <span style="background-color: white">(the &#8220;Offering&#8221;) </span>
for the sale <span style="background-color: white">of </span><span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230208__20230209__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorMember_zsS7HG7cKUlb"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-02-082023-02-09_custom_SecuritiesPurchaseAgreementMember_custom_RegisteredDirectOfferingMember_custom_AccreditedInvestorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,812,544</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">shares
of common stock at a purchase price of $<span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230209__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorMember_z1h2BhysrLqj"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-02-09_custom_SecuritiesPurchaseAgreementMember_custom_RegisteredDirectOfferingMember_custom_AccreditedInvestorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.80</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">per
share for gross proceeds of $<span id="xdx_90F_ecustom--GrossProceedsFromIssuanceOfCommonStock_pn5n6_c20230208__20230209__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorMember_zO7UPV6Fh088" title="Gross proceeds from common stock"><ix:nonFraction name="PCSA:GrossProceedsFromIssuanceOfCommonStock" contextRef="From2023-02-082023-02-09_custom_SecuritiesPurchaseAgreementMember_custom_RegisteredDirectOfferingMember_custom_AccreditedInvestorMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.3</ix:nonFraction></span>
million (net proceeds <span style="background-color: white">of</span> $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20230208__20230209__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorMember_z0Wlhqf7egfe" title="Net proceeds from common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-02-082023-02-09_custom_SecuritiesPurchaseAgreementMember_custom_RegisteredDirectOfferingMember_custom_AccreditedInvestorMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.6</ix:nonFraction></span>
million). <span id="xdx_909_ecustom--RestrictionsToIssueStock_c20230208__20230209__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorMember_zxhucPdyFoMi" title="Restrictions to issue stock"><ix:nonNumeric contextRef="From2023-02-082023-02-09_custom_SecuritiesPurchaseAgreementMember_custom_RegisteredDirectOfferingMember_custom_AccreditedInvestorMember" name="PCSA:RestrictionsToIssueStock">The
Purchase Agreement provides that, subject to certain exceptions, until the earlier of (i) 90 days after the closing of the Offering
or (ii) the trading day following the date that our common stock&#8217;s closing price exceeds $2.00 for a period of 10 consecutive
trading days</ix:nonNumeric><span style="background-color: white">,</span> neither we nor our subsidiary will issue or enter into any agreement to issue or announce the issuance or proposed
issuance of any shares of common stock or common stock equivalents</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
paid the Placement Agent a cash fee of <span id="xdx_903_ecustom--TransactionCostsPercentage_iI_pid_dp_c20230209__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember_zPSlMeifG4dk" title="Cash fee percentage"><ix:nonFraction name="PCSA:TransactionCostsPercentage" contextRef="AsOf2023-02-09_custom_SecuritiesPurchaseAgreementMember_custom_RegisteredDirectOfferingMember_custom_PlacementAgentMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.0</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">%
of the gross proceeds from the Offering, excluding proceeds received from our insiders, and reimbursed the Placement Agent for legal
fees of $<span id="xdx_902_ecustom--ReimbursementFees_c20230208__20230209__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember_zAtfIeMD5mC1" title="Reimbursement fees"><ix:nonFraction name="PCSA:ReimbursementFees" contextRef="From2023-02-082023-02-09_custom_SecuritiesPurchaseAgreementMember_custom_RegisteredDirectOfferingMember_custom_PlacementAgentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">.
The engagement agreement with the Placement Agent requires us to indemnify the Placement Agent and certain of its affiliates against
certain customary liabilities. On February 14, 2023, we amended our consulting agreement with Spartan originally entered into on
August 24, 2022, extending the term of the consulting agreement until February 10, 2024. As compensation for services under the
agreement, on April 17, 2023, we granted Spartan <span style="background-color: white">a </span> warrant to purchase <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230417__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--SpartanCapitalSecuritesLLCMember_zI3wOaNmyfkh" title="Warrants to purchase common stock, shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-04-17_custom_ConsultingAgreementMember_custom_SpartanCapitalSecuritesLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,160,130</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">shares
of our common stock with an exercise price of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230417__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--SpartanCapitalSecuritesLLCMember_zNYWJHkbqt9d" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-04-17_custom_ConsultingAgreementMember_custom_SpartanCapitalSecuritesLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.02</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">.
The warrant will expire <span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_pid_dc_c20230417__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--SpartanCapitalSecuritesLLCMember_zStLGUllcbec" title="Warrant term"><ix:nonNumeric contextRef="AsOf2023-04-17_custom_ConsultingAgreementMember_custom_SpartanCapitalSecuritesLLCMember" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm">three
years</ix:nonNumeric></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">from the date
of issuance and contains both call and cashless exercise provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 11pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p id="xdx_806_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zt9LJXU76mo1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 11pt; text-align: justify; text-indent: -11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>Note
3 - <span id="xdx_829_zudiICKz1p06">Stock-based Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 11pt; text-align: justify; text-indent: -11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
June 19, 2019, our stockholders approved, and we adopted the Processa Pharmaceuticals Inc. 2019 Omnibus Equity Incentive Plan (the &#8220;2019
Plan&#8221;). The 2019 Plan allows us, under the direction of our Board of Directors or a committee thereof, to make grants of stock
options, restricted and unrestricted stock and other stock-based awards to employees, including our executive officers, consultants and
directors. The 2019 Plan provides for the aggregate issuance of <span id="xdx_90C_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20230331__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenPlanMember_zLywRR171CSj" title="Maximum equity available for issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2023-03-31_custom_TwoThousandAndNineteenPlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,000,000</ix:nonFraction></span> shares of our common stock. At March 31, 2023, we have <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20230331__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenPlanMember_zzsUxjamZEH4" title="Shares available for future grants"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2023-03-31_custom_TwoThousandAndNineteenPlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,394,122</ix:nonFraction></span> shares available
for future grants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline">Stock
Compensation Expense</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zGCTfjHml3fa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
recorded stock-based compensation expense for the three month ended March 31, 2023 and 2022 as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_zsZn6a1OB5Ad" style="display: none">Schedule
of Stock-based Compensation Expense</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20230101__20230331_zNAV8ffA5zB" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20220101__20220331_zJNSaMhMkDH1" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zm5jkrYPMsV4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-03-31_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">99,621</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-03-31_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">191,875</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zYLxalDSMLZj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-03-31_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">241,883</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-03-31_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">637,022</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ShareBasedCompensation_zgAZOmJEGTL3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">341,504</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">828,897</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_zkijGtprwhN6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 11pt; text-align: justify; text-indent: -11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="background-color: white">At
March 31, 2023, we recorded an expense and related accrued liability of $<span id="xdx_90D_eus-gaap--AccruedLiabilitiesCurrent_iI_pn5n6_c20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zczkTpIdGJOl" title="Expenses and accrued liabilities"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-03-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.3</ix:nonFraction></span>
million related to the warrant we issued to Spartan<span style="background-color: white">, which is not included in the table
above</span>. No tax benefits were attributed to the stock-based compensation expense because a valuation allowance was maintained
for all net deferred tax assets relating to this expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline">Stock
Options</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span style="background-color: white">During
the three months ended March 31, 2023, </span>stock options to purchase <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zDHskWgdXZwb" title="Options, forfeited"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2023-01-012023-03-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">36,885</ix:nonFraction></span>
shares of common stock expired and there were no exercises or grants of stock options.
At March 31, 2023, we had outstanding and exercisable options for the purchase of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z15vcXPRIkV1" title="Options exercisable, shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2023-03-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">141,611</ix:nonFraction></span>
shares with a weighted average exercise price of $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zUGO9g7ausjd" title="Options exercisable weighted average exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-03-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18.22</ix:nonFraction></span>,
a weighted average remaining contractual life of <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zK9doGizmHVj" title="Exercisable weighted average remaining contractual term"><ix:nonNumeric contextRef="From2023-01-012023-03-31_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">2.9</ix:nonNumeric></span>
years. </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At March 31, 2023, we did not have any
unrecognized stock-based compensation expense related to our granted stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 10; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline">Restricted
Stock Awards</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="PCSA:ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock"><p id="xdx_89E_ecustom--ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock_z955np8I8Vl1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Activity
with respect to our Restricted Stock Awards (RSAs) during the three months ended March 31, 2023 was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_zn8EpLL52mWl" style="display: none">Schedule
of Restricted Stock Awards (&#8220;RSAs&#8221;) Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Number of</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">shares</p></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted- <br />average <br />grant-date fair <br />value per share</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Outstanding at January 1, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z4qfZlL34kp5" title="Number of restricted stock, shares outstanding" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2022-12-31_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">61,888</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zqnv0RlyN5jk" title="Weighted-average grant-date fair value per share, outstanding" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2022-12-31_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.72</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zs42uO9q0w1c" title="Number of shares, granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2023-01-012023-03-31_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">90,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_ziFp7wHyKqfb" title="Weighted-average grant-date fair value per share, awarded" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-03-31_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.10</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_iN_di_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zjJh5w1Osdyi" title="Number of shares, cancelled" style="text-align: right">(<ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" contextRef="From2023-01-012023-03-31_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">26,118</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zqePEnGG4Dg3" title="Weighted-average grant-date fair value per share, cancelled" style="text-align: right"><ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-03-31_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.72</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Outstanding and unvested at March 31, 2023</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zohY2FFPI6yf" title="Number of restricted stock shares outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2023-03-31_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">125,770</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zjHA7BiTCDt2" title="Weighted-average grant-date fair value per share, outstanding" style="padding-bottom: 2.5pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2023-03-31_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.75</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zLOMMcB2NQcg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
January 1, 2023, we granted RSAs totaling <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20230101__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__custom--ThreeDirectorsMember_zrc1LFHRBCB6" title="Number of shares, granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2023-01-012023-01-01_us-gaap_RestrictedStockMember_custom_ThreeDirectorsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">90,000</ix:nonFraction></span>
shares of common stock to three directors for their service for the six month period ending June 30, 2023 in order to align their
compensation plan with their service period and change the annual service period to begin and end on the date of respective Annual
Meetings rather than the calendar year. Our directors are compensated through a combination of cash and equity. On March 8, 2023,
the directors increased the cash component and decreased the equity component <span style="background-color: white">of their
compensation </span> by equal amounts <span style="background-color: white">on a retroactive basis, </span> to the beginning of their respective service periods. Accordingly, we cancelled
RSAs representing <span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zD6EwNlKSHka" title="Number of shares, cancelled"><ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" contextRef="From2023-01-012023-03-31_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">26,118</ix:nonFraction></span>
shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
March 31, 2023, the total unrecognized stock-based compensation expense related to the outstanding and unvested RSAs was $<span id="xdx_90A_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zGAufNNnOCJg"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2023-03-31_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">163,100</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
which is expected to be recognized over a weighted average period of <span id="xdx_90B_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z2WrA7hHJYt5"><ix:nonNumeric contextRef="From2023-01-012023-03-31_us-gaap_RestrictedStockMember" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">0.5</ix:nonNumeric>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline">Restricted
Stock Units</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zphmx1PqfJjb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Activity
with respect to our Restricted Stock Units (&#8220;RSUs&#8221;) during the three months ended March 31, 2023 was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zhH9RLTTWQ68" style="display: none">Schedule
of Restricted Stock Units (&#8220;RSUs&#8221;) Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Number of</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">shares</p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted- <br />average <br />grant-date fair <br />value per share</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Outstanding at January 1, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iS_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z9jw5ytK7pY4" title="Number of shares, Beginning balance" style="width: 16%; text-align: right"><ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" contextRef="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,713,977</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_iS_pid_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zEWfupI4HKsd" title="Weighted-average grant-date fair value per share, Beginning balance" style="width: 16%; text-align: right"><ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" contextRef="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.69</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zhguMdhwcht7" title="Number of shares, awarded" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2023-01-012023-03-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">966,503</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z2RVGc7TXZX3" title="Weighted-average grant-date fair value per share, awarded" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-03-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.10</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Outstanding at March 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iE_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zrCXjEkhuUY" title="Number of shares, Ending balance" style="text-align: right"><ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" contextRef="AsOf2023-03-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,680,480</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_iE_pid_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zM8htVtWC32f" title="Weighted-average grant-date fair value per share, Ending balance" style="text-align: right"><ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" contextRef="AsOf2023-03-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.01</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Vested and unissued</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z3BfsQVG1EHb" title="Number of shares, vested and unissued" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued" contextRef="AsOf2023-03-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,585,247</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zEAovR0UXlE3" title="Weighted-average grant-date fair value per share, vested and unissued" style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue" contextRef="AsOf2023-03-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.50</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Unvested at March 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zf49VO2uVCy9" title="Number of shares, unvested" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2023-03-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,095,233</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zBsZNmcwYMbg" title="Weighted-average grant-date fair value per share, unvested" style="padding-bottom: 2.5pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2023-03-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.86</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_zmbBc3D2mCH4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At  March 31, 2023, unrecognized stock-based compensation expense of $<span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zjprLk0qJakk" title="Unrecognized share based compensation expense"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2023-03-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.2</ix:nonFraction> million</span> for RSUs is expected to be fully recognized
over a weighted average period of <span id="xdx_90E_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zZDc3SUrFVjj" title="Weighted average period for recognition"><ix:nonNumeric contextRef="From2023-01-012023-03-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">2.1</ix:nonNumeric></span> years. The unrecognized expense excludes $<span id="xdx_90B_ecustom--UnrecognizedShareBasedCompensationExpense_pp0p0_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLAGdPK2iGX3" title="Unrecognized restricted stock expense"><ix:nonFraction name="PCSA:UnrecognizedShareBasedCompensationExpense" contextRef="From2023-01-012023-03-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">322,000</ix:nonFraction></span> of expense related to certain RSUs
with a performance milestone that is not probable of occurring at this time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 11; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<br /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Holders
of our vested RSUs have our promise to issue shares of our common stock upon <span style="background-color: white">meeting the </span> distribution restrictions contained
in their Restricted Stock Unit Award Agreement. The distribution restrictions are different (longer) than the vesting schedule,
imposing an additional restriction on the holder. Unlike RSAs, while certain employees may hold fully vested RSUs, the individual does
not hold any shares or have any rights of a shareholder until the distribution restrictions are met. Upon distribution to the employee,
each RSU converts into one share of our common stock. The RSUs contain dividend equivalent rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline">Warrants</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">During
the three months ended March 31, 2023, we agreed to grant a warrant to purchase a total of <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zTKousqDRLJ2" title="Warrants granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2023-01-012023-03-31_us-gaap_WarrantMember_custom_ConsultantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,160,130</ix:nonFraction></span>
shares of our common stock as compensation for services provided under an amended consulting agreement with Spartan, the placement
agent for the Offering</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The warrant was issued and
exercisable on April 17, 2023 with an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230214__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zmIHC4vnMhff" title="Warrants, weighted average exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-02-14_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.02</ix:nonFraction></span>
and expiration date of April 17, 2026. The warrant contains both call and cashless exercise provisions. We recorded $<span id="xdx_90F_eus-gaap--GeneralAndAdministrativeExpense_c20230213__20230214__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zYhaAJhQSsY6" title="General and administrative expense"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-02-132023-02-14_us-gaap_WarrantMember_custom_ConsultantMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,310,875</ix:nonFraction></span>
as a general and administrative expense and related accrued liability representing the fair value of this warrant on February 14,
2023, the date we amended the consulting agreement, since there were no contingent conditions on that date through April 17,
2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
March 31, 2023, we had outstanding stock purchase warrants, including the warrant issued on April 17, 2023, for the purchase of <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_ztrKz3H01X8c" title="Warrants to purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-03-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,366,480</ix:nonFraction></span> <span style="background-color: white">shares
with a weighted average exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zptTIcza6uVj" title="Weighted average exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-03-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.61</ix:nonFraction></span> and a weighted average remaining contractual life of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z86GevWAyxm" title="Weighted average remaining contractual life"><ix:nonNumeric contextRef="From2023-01-012023-03-31_us-gaap_WarrantMember" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">2.8</ix:nonNumeric></span> years. Stock purchase warrants
for the purchase of <span id="xdx_90D_ecustom--NumberOfWarrantExercisableShares_iI_pid_c20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zJNemtveKOCj" title="Number of warrant exercisable shares"><ix:nonFraction name="PCSA:NumberOfWarrantExercisableShares" contextRef="AsOf2023-03-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">206,350</ix:nonFraction></span> shares were <span style="background-color: white">exercisable </span> at March 31, 2023 and the remaining outstanding stock purchase warrants <span style="background-color: white">will be exercisable </span>in the second quarter of 2023.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At March 31, 2023, we did not have any unrecognized stock-based compensation expense related to our granted stock purchase warrants.</span></p>
<!-- Field: Split-Segment; Name: 002 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:EarningsPerShareTextBlock"><p id="xdx_80D_eus-gaap--EarningsPerShareTextBlock_zwajnyjxMIKc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
4 &#8211; <span id="xdx_824_zvD6ZJbVYCOg">Net Loss per Share of Common Stock</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Net
Loss Per Share</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
net loss per share is computed by dividing our net loss available to common shareholders by the weighted average number of shares of
common stock outstanding (which excludes unvested RSAs and includes vested RSUs) during the period. Diluted loss per share is computed
by dividing our net loss available to common shareholders by the diluted weighted average number of shares of common stock (which includes
the potentially dilutive effect of stock options, unvested RSAs, unvested RSUs and warrants) during the period. Since we experienced
a net loss for both periods presented, basic and diluted net loss per share are the same. As such, diluted loss per share for the three
months ended March 31, 2023 and 2022 excludes the impact of potentially dilutive common shares since those shares would have an anti-dilutive
effect on net loss per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"><p id="xdx_896_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zLKeQe5DDiRd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
computation of net loss per share for the three months ended March 31, 2023 and 2022 was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zAurCrAKbuoi" style="display: none">Schedule
of Net Loss Per Share Basic and Dilute</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20230101__20230331_zyeTYP7P4ar1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20220101__20220331_zirdy8J7T6Lc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three months ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31,</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Basic and diluted net loss per share:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLoss_zHmR1sqsJXg8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Net loss available to common stockholders</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,022,073</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,227,131</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zMZIQBWa9k2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Weighted average number of common shares-basic and diluted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">22,770,789</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,831,118</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--EarningsPerShareBasic_zDY3shJyo9sb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Basic and diluted net loss per share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.18</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.20</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zyQHFRYBYWd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
diluted net loss per share for the three months ended March 31, 2023 and 2022 excluded <span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230331_zOMeNTwJDNJ8" title="Antidilutive securities excluded from computation of earnings per share, amount"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,729,094</ix:nonFraction></span>
(including the committed warrant to purchase <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20230331__us-gaap--AwardTypeAxis__custom--CommittedWarrantMember_zb788BZbGpp2" title="Antidilutive securities including from computation of earnings per share, amount"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-03-31_custom_CommittedWarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,160,130</ix:nonFraction></span> shares of common stock) and <span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220331_zglh6wHa3pg7" title="Antidilutive securities excluded from computation of earnings per share, amount"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">795,342</ix:nonFraction></span>
of potentially dilutive common shares, respectively, related to outstanding stock options, warrants and unvested restricted stock
since those shares would have had an anti-dilutive effect on net loss per share during the periods then ended.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 12; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:LesseeOperatingLeasesTextBlock"><p id="xdx_808_eus-gaap--LesseeOperatingLeasesTextBlock_zxJNYXvbRy5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5 &#8211; <span id="xdx_827_zuwTiqHxEQK7">Operating Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
lease our office space under an operating lease agreement. This lease does not have significant rent escalation, concessions, leasehold
improvement incentives, or other build-out clauses. Further, the lease does not contain contingent rent provisions. Our office space
lease includes both lease (e.g., fixed payments including rent, taxes, and insurance costs) and non-lease components (e.g., common-area
or other maintenance costs), which are accounted for as a single lease component as we have elected the practical expedient to group
lease and non-lease components for all leases. We also lease office equipment under an operating lease. Our leases do not provide an
implicit rate and, as such, we have used our incremental borrowing rate of <span id="xdx_902_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_c20230331_zod9159Nvdhb" title="Operating lease borrowing rate"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span>% in determining the present value of the lease payments
based on the information available at the lease commencement date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
costs included in our condensed consolidated statements of operations totaled $<span id="xdx_90A_eus-gaap--LeaseCost_c20230101__20230331_z5sMHnA8D4Ti" title="Lease cost"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,461</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--LeaseCost_c20220101__20220331_zo4rhPrwNRck" title="Lease cost"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,918</ix:nonFraction></span> for the three months ended March 31,
2023 and 2022, respectively. The weighted average remaining lease terms and discount rate for our operating leases were as follows at
March 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="PCSA:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingLeasesTableTextBlock"><p id="xdx_891_ecustom--ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingLeasesTableTextBlock_zWTvc0Hr6mhd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zwkzhvwmqHs3" style="display: none">Schedule
of Weighted Average Remaining Lease Terms and Discount Rate for Operating Leases</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Remaining lease term (years) for our facility lease</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90F_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FacilityLeaseMember_zhqjFJSBVNyg" title="Remaining lease term (years)"><ix:nonNumeric contextRef="AsOf2023-03-31_custom_FacilityLeaseMember" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseTermOfContract">2.5</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Remaining lease term (years) for our equipment lease</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zFa8BMp2KGtk" title="Remaining lease term (years)"><ix:nonNumeric contextRef="AsOf2023-03-31_us-gaap_EquipmentMember" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseTermOfContract">1.0</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Weighted average remaining lease term (years) for our facility and equipment leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20230331_z4rLk2RbcMlc" title="Weighted average remaining lease term (years) for our facility and equipment leases"><ix:nonNumeric contextRef="AsOf2023-03-31" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">2.5</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Weighted average discount rate for our facility and equipment leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_c20230331_zv9J5IpLspQh" title="Weighted average discount rate for our facility and equipment leases"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.0</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_zacF5tSTrhge" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_89C_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zYvC53eUIBbe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
lease liabilities for all operating leases were as follows at  March 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zDB11ZHvR0E8" style="display: none">Schedule
of Annual Lease Liabilities for all Operating Leases</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49C_20230331_zMMGQLodYo3d" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pp0p0_maLOLLPz79B_zLytDzBsGHOi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">70,600</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPz79B_zU1KDQOWrjt2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">92,356</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPz79B_z4rpyevdfIGa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2025</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">70,040</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPz79B_zcHS0xvXhXNl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">232,996</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_z5uniCxC4fQ6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Less: Interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">22,472</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zQvgtzm7Bgoh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Present value of lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">210,524</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pp0p0_di_zPt33K7R4S8f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Less: current maturities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">81,166</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_z28dpRADJIk1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Non-current lease liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">129,358</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zfJyCFLexEp5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_80B_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zllUNX0bPQ7c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
6 &#8211; <span id="xdx_82F_zPY3693Cqlxl">Related Party Transactions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CorLyst,
LLC (&#8220;CorLyst&#8221;) reimburses us for shared costs related to payroll, health insurance and rent based on actual costs incurred,
which are recognized as a reduction of our general and administrative operating expenses being reimbursed in our condensed consolidated
statement of operations. We recorded $<span id="xdx_903_ecustom--ProceedsFromRentAndOtherCostsReimbursements_c20230101__20230331__dei--LegalEntityAxis__custom--CorLystLLCMember_zvzTQfZLsOHd" title="Rent and other costs reimbursements received"><ix:nonFraction name="PCSA:ProceedsFromRentAndOtherCostsReimbursements" contextRef="From2023-01-012023-03-31_custom_CorLystLLCMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,205</ix:nonFraction></span> and $<span id="xdx_905_ecustom--ProceedsFromRentAndOtherCostsReimbursements_c20220101__20220331__dei--LegalEntityAxis__custom--CorLystLLCMember_zO4XKVA1zlia" title="Rent and other costs reimbursements received"><ix:nonFraction name="PCSA:ProceedsFromRentAndOtherCostsReimbursements" contextRef="From2022-01-012022-03-31_custom_CorLystLLCMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,262</ix:nonFraction></span> of reimbursements during the three months ended March 31, 2023 and March 31,
2022, respectively. <span id="xdx_90C_eus-gaap--OtherReceivablesNetCurrent_iI_do_c20230331__dei--LegalEntityAxis__custom--CorLystLLCMember__us-gaap--RelatedAndNonrelatedPartyStatusAxis__us-gaap--RelatedPartyMember_zmKGdReXBSy2" title="Due from related parties"><span id="xdx_906_eus-gaap--OtherReceivablesNetCurrent_iI_do_c20220331__dei--LegalEntityAxis__custom--CorLystLLCMember__us-gaap--RelatedAndNonrelatedPartyStatusAxis__us-gaap--RelatedPartyMember_z8cARRZ39jqe" title="Due from related parties"><ix:nonFraction name="us-gaap:OtherReceivablesNetCurrent" contextRef="AsOf2023-03-31_custom_CorLystLLCMember_us-gaap_RelatedPartyMember" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:OtherReceivablesNetCurrent" contextRef="AsOf2022-03-31_custom_CorLystLLCMember_us-gaap_RelatedPartyMember" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">No</ix:nonFraction></ix:nonFraction></span></span> amounts were due from CorLyst at March 31, 2023 or 2022. Our CEO is also the CEO of CorLyst, and CorLyst is a
shareholder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_80D_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zrMVyJo21Ml7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
7 &#8211; <span id="xdx_821_zBF5RfjHDhld">Commitments and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Purchase
Obligations</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
enter into contracts in the normal course of business with contract research organizations (CROs) and subcontractors to further
develop our products. The contracts are cancelable, with varying provisions regarding termination. If we terminated a cancelable
contract with a specific vendor, we would only be obligated for products or services that we received at  the effective date of
the termination and any applicable cancellation fees. At  March 31, 2023, we are contractually obligated to pay up to $<span id="xdx_90C_eus-gaap--PurchaseObligation_iI_pn5n6_c20230331__us-gaap--TypeOfArrangementAxis__custom--AgreementsMember__dei--LegalEntityAxis__custom--ContractResearchOrganizationsMember_zLn5g3o1b1Ji" title="Purchase obligation"><ix:nonFraction name="us-gaap:PurchaseObligation" contextRef="AsOf2023-03-31_custom_AgreementsMember_custom_ContractResearchOrganizationsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.0</ix:nonFraction></span>
million of future services under the agreements with the CROs. Our actual contractual obligations will also vary depending on the
progress and results of the remaining clinical trials.</span></p>

</ix:nonNumeric><p id="xdx_811_zpvO2nEdFYZi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="a_003"></span><b>Item
2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Forward
Looking Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>This
Quarterly Report on Form 10-Q contains &#8220;forward-looking statements&#8221; that reflect, when made, the Company&#8217;s expectations
or beliefs concerning future events that involve risks and uncertainties. Forward-looking statements frequently are identified by the
words &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;expect,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;project,&#8221;
&#8220;will be,&#8221; &#8220;will continue,&#8221; &#8220;will likely result,&#8221; or other similar words and phrases. Similarly,
statements herein that describe the Company&#8217;s objectives, plans or goals also are forward-looking statements. Actual results could
differ materially from those projected, implied or anticipated by the Company&#8217;s forward-looking statements. Some of the factors
that could cause actual results to differ include: our limited operating history, limited cash and history of losses; our ability to
achieve profitability; our ability to obtain adequate financing to fund our business operations in the future; the impact of  COVID-19, including its impact on our ability to obtain financing or complete clinical trials;
our ability to secure required FDA or other governmental approvals for our product candidates and the breadth of the indication sought;
the impact of competitive or alternative products, technologies and pricing; whether we are successful in developing and commercializing
our technology, including through licensing; the adequacy of protections afforded to us and/or our licensors by the anticipated patents
that we own or license and the cost to us of maintaining, enforcing and defending those patents; our and our licensors&#8217; ability
to protect non-patented intellectual property rights; our exposure to and ability to defend third-party claims and challenges to our
and our licensors&#8217; anticipated patents and other intellectual property rights; and our ability to continue as a going concern.
For a discussion of these and all other known risks and uncertainties that could cause actual results to differ from those contained
in the forward-looking statements, see &#8220;Risk Factors&#8221; in the Company&#8217;s Annual Report on Form 10-K for the year ended
December 31, 2022, which is available on the SEC&#8217;s website at www.sec.gov. All forward-looking statements are qualified in their
entirety by this cautionary statement, and the Company undertakes no obligation to revise or update this Quarterly Report on Form 10-Q
to reflect events or circumstances after the date hereof.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>For
purposes of this Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, references to the &#8220;Company,&#8221;
&#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221; refer to the operations of Processa Pharmaceuticals, Inc. and its direct and
indirect subsidiaries for the periods described herein.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
are a clinical-stage biopharmaceutical company focused on utilizing our Regulatory Science Approach, including the principles
associated with FDA&#8217;s Project Optimus Oncology initiative and the related FDA Draft Guidance, in the development of Next Generation
Chemotherapy (NGC) oncology drug products. Our mission is to provide better treatment options than those that presently exist by extending
a patient&#8217;s survival and/or improving a patient&#8217;s quality of life. This is achieved by <span style="background-color: white">improving upon </span> FDA-approved, widely used oncology
drugs or the cancer-killing metabolites of these drugs by altering how they are metabolized and/or distributed in the body, including
how they are distributed to the actual cancer cells.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Regulatory
science was conceived in the early 1990s when the founders of Processa and other faculty at the University of Maryland worked with
the FDA to develop multiple FDA Guidance documents. Over the last 30 years, two of our founders, Dr. David Young and Dr. Sian
Bigora, have expanded the original regulatory science concept to include other factors, such as the principles of Project Optimus,
which can affect the risk-benefit analyses that FDA conducts for every FDA drug approval. In fact, the principles of FDA&#8217;s
Project Optimus have been used by Drs. Young and Bigora to identify and justify an &#8220;optimal&#8221; dosage regimen for a number
of non-oncology FDA-approved drugs. <span style="background-color: white">Our</span> Regulatory Science Approach and our past
experience with the principles of Project Optimus differentiates us from other biotechnology companies by focusing us not only on
the clinical science, but also on the equally important regulatory process. We believe utilizing <span style="background-color: white">our </span> Regulatory Science
Approach provides us with three distinct advantages:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">greater
    efficiencies (e.g., the right trial design and trial readouts);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">greater
    possibility of drug approval by the FDA or other regulatory authorities; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">improvement over existing therapy with greater acceptance by patients/prescribers.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In January 2023, we announced our strategic prioritization to advance our pipeline of Next Generation Chemotherapy proprietary small
molecule oncology drugs. By changing either the metabolism, distribution and/or elimination of already FDA-approved cancer drugs or
their active metabolites while maintaining the mechanism of how the drug kills cancer cells, we believe our NGC treatments will provide improved safety-efficacy profiles when compared to their currently marketed counterparts
- capecitabine, gemcitabine, and irinotecan. All future studies of these drugs are subject to availability of capital to conduct the
trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
three NGC treatments in our pipeline are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NGC-Capecitabine
    is a combination of PCS6422 and capecitabine. NGC-Capecitabine alters the metabolism of capecitabine without having any clinically
    meaningful biological effect itself. In clinical trials, NGC-Capecitabine has a safety profile different than capecitabine when
    administered alone. Side effects, such as Hand-Foot Syndrome (HFS) and cardiotoxicity that typically occur in up to 50-70% of
    patients treated with capecitabine and caused by specific capecitabine metabolites that are not formed to the same extent with
    NGC-Capecitabine, do not appear to be side effects associated with NGC-Capecitabine. These types of toxicities frequently result in
    decreased doses, interrupted doses or discontinuation of treatment with capecitabine. In addition, NGC-Capecitabine has been found
    to be 50 times more potent than capecitabine based on the systemic exposure of the capecitabine metabolite 5-FU, which
    is metabolized to the cancer-killing metabolites. Like capecitabine, NGC-Capecitabine could be used to treat patients with various
    cancers, such as metastatic colorectal, gastrointestinal, breast, and pancreatic. We estimate at least 200,000 patients in the
    United States were diagnosed in 2022 with metastatic colorectal, gastrointestinal, breast, and pancreatic cancers. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NGC-Gemcitabine,
    also identified as PCS3117, is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme
    system than gemcitabine resulting in a positive response in gemcitabine patients as well as some gemcitabine treatment-resistant
    patients. Like gemcitabine, NGC-Gemcitabine could be used to treat patients with various cancers such as pancreatic, lung, ovarian,
    and breast. We estimate at least 275,000 patients in the United States were diagnosed in 2022 with pancreatic, lung, ovarian, and
    breast cancer. We plan to meet with the FDA in 2023 to discuss potential study designs including implementation of the Project
    Optimus initiative as part of the design, and then submit the Phase 2B protocol to the Investigational New Drug (IND Application) in
    the second half of 2023.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NGC-Irinotecan,
    also identified as PCS11T, is a prodrug of the active metabolite of irinotecan (SN-38). The chemical structure of NGC-Irinotecan
    influences the uptake of the drug into cancer cells, resulting in more NGC-Irinotecan entering cancer cells than normal cells in
    mice. These levels were significantly greater than those seen with irinotecan, resulting in lower doses of NGC-Irinotecan having
    greater efficacy than irinotecan and improved safety in animal models. Like irinotecan, NGC-Irinotecan could be used to treat patients
    with various cancers such as lung, colorectal, gastrointestinal, and pancreatic cancer. We estimate at least 200,000 patients in
    the United States were diagnosed in 2022 with lung, colorectal, gastrointestinal, and pancreatic cancer. We plan to conduct IND-enabling
    and toxicology studies in 2023 and 2024.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
primarily to the inability to identify and enroll patients since the beginning of our rare disease Phase 2 trial for PCS499 in
ulcerative Necrobiosis Lipoidica (uNL), we decided to cease further enrollment in the PCS499 trial in February 2023. In addition,
we have completed our Phase 2A trial for PCS12852 in gastroparesis patients with positive results. We did not experience any safety concerns
during the conduct of either the PCS12852 or PCS499 trial. We are currently evaluating options to monetize PCS12852 and
PCS499.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
shift in prioritization to NGC oncology drugs does not change our mission. We continue to be focused on drug products that improve
the survival and/or quality of life for patients by improving the safety and/or efficacy of the drug in a targeted patient
population, while providing a more efficient and probable path to FDA approval, and
differentiating our drugs from those on the market or are currently being developed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historically, much of oncology drug development has searched for novel or different ways to treat cancer. Our de-risked approach is to
modify and improve three different and well-known, currently approved, and successfully used chemotherapy treatments so that the human
body metabolizes and/or distributes these NGC treatments differently than their presently approved counterpart drugs while maintaining
the cancer-killing mechanism of action. FDA&#8217;s newly issued Project Optimus Oncology initiative and draft guidance on determining
the optimal dose for oncology drugs recommends that the dose-response (both safety and efficacy) relationships be evaluated for all oncology
drugs. Our Regulatory Science Approach, developed over the last 30 years, is very well aligned with the principles of Project Optimus
and draft guidance where the objective is to identify the optimal dosage regimen, rather than the old approach of identifying
the maximum tolerated dose (MTD) and adjust dosing accordingly. To date, we have data that suggests our NGC treatments are likely to have
a better safety-efficacy profile than the current widely used marketed counterpart drugs, not only potentially making the development
and approval process more efficient, but also clearly differentiating our NGC treatments from the existing treatment. We believe our NGC
treatments have the potential to extend the survival and/or quality of life for more patients diagnosed with cancer while decreasing the
number of patients who are required to dose-adjust or discontinue treatment because of side effects or lack of response.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Strategy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Our strategy is to develop our
pipeline of Next Generation Chemotherapy (NGC) proprietary small molecule oncology drugs using our Regulatory Science approach, encompassing
the principles of the FDA&#8217;s recent Project Optimus initiative and draft guidance on determining the optimal dosage regimen of oncology
drugs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">By changing either the metabolism,
distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how
the drug kills cancer cells, we believe our three NGC treatments will provide improved safety-efficacy profiles when compared to their
currently marketed counterparts - capecitabine, gemcitabine, and irinotecan. By combining these modified approved cancer treatments with
our Regulatory Science Approach and our experience using the principles of FDA&#8217;s Project Optimus initiative, we will be able to
increase the probability of FDA approval, improve the safety-efficacy profile over their existing counterparts which is important to patients
and prescribers, and more efficiently develop each drug.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
pipeline of NGCs (i) already has data demonstrating the desired pharmacological activity in humans or appropriate animal models and
is able to provide improved safety and/or efficacy by some modification in the formation and/or distribution of the active moieties associated
with the drug and (ii) targets cancers for which a single positive pivotal trial demonstrating efficacy might provide enough evidence
that the clinical benefits of the drug and its approval outweighs the risks associated with the drug.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Our Drug Pipeline</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Our
pipeline currently consists of NGC-Capecitabine, NGC-Gemcitabine and NGC-Irinotecan (also identified as PCS6422, PCS3117 and PCS11T,
respectively) and two non-oncology drugs (PCS12852 and PCS499). A timeline and summary of each drug is provided below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><img src="f10-q_001.jpg" alt="" style="height: 385px; width: 670px" />&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><img src="f10-q_002.jpg" alt="" style="height: 186px; width: 670px" /></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Key:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; background-color: white"><img src="image_006.jpg" alt="" style="height: 48px; width: 200px" /></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Next
Generation Chemotherapy Pipeline</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Next
    Generation Capecitabine (NGC-Capecitabine), also identified as PCS6422, is a combination of PCS6422 and the FDA-approved cancer drug
    capecitabine. PCS6422 is an orally administered irreversible inhibitor of the enzyme dihydropyrimidine dehydrogenase (DPD). DPD metabolizes
    5-Fluorouracil (5-FU), the major metabolite of capecitabine and widely used itself as an intravenous chemotherapeutic agent in many
    types of cancer, to multiple metabolites classified as catabolites. These catabolites do not have any cancer-killing properties but
    frequently cause dose-limiting side effects that may require dose adjustments or discontinuation of therapy.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
    combining capecitabine with PCS6422 in NGC-Capecitabine, PCS6422 significantly changes the metabolism and distribution of 5-FU. After
    formation from capecitabine, 5-FU is metabolized to anabolites (which kill both cancer cells and normal duplicating cells) and catabolites
    (which cause side effects and have no cancer killing properties). Due to this change in metabolism of capecitabine and the change
    in the overall metabolite profile of anabolites and catabolites, the side effect and efficacy profile of NGC-Capecitabine has been
    found to be different than the existing FDA-approved capecitabine. Since the potency of NGC-Capecitabine is also more potent than
    FDA-approved capecitabine based on the 5-FU systemic exposure per mg of capecitabine administered, the amount of capecitabine anabolites
    formed from 1 mg of capecitabine administered in NGC-Capecitabine will, therefore, be much greater than formed from the administration
    of 1 mg of existing capecitabine.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    August 2, 2021, we enrolled the first patient in our Phase 1B dose-escalation maximum tolerated dose trial in patients with advanced
    refractory gastrointestinal (GI) tract tumors. Our interim analysis of Cohorts 1 and 2A of the ongoing clinical trial found no dose-limiting
    toxicities (DLTs), no drug-related adverse events greater than Grade 1, and no adverse events associated with the catabolites of
    5-FU such as HFS. In this Phase 1B trial, it was demonstrated that the irreversible inhibition of DPD by PCS6422 could alter the
    metabolism, distribution and elimination of 5-FU, making NGC-Capecitabine significantly more potent than capecitabine alone (50 times
    more potent) and potentially leading to higher levels of anabolites which can kill replicating cancer and normal cells. By administering
    NGC-Capecitabine to cancer patients, the balance between anabolites and catabolites changes depending on the dosage regimens of PCS6422
    and capecitabine used, making the efficacy-safety profile of NGC-Capecitabine different than that of FDA-approved capecitabine and
    requiring further evaluation of the PCS6422 and capecitabine regimens to determine the optimal NGC-Capecitabine regimens for patients.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    order for NGC-Capecitabine to provide a safer and more efficacious profile for cancer patients compared to existing chemotherapy,
    understanding how the different regimens of PCS6422 and capecitabine may affect the systemic and tumor exposure to the anabolites,
    as well as the systemic exposure to the catabolites, is required. This can be achieved by following the timeline of DPD irreversible
    inhibition and the formation of new DPD using the plasma concentrations of 5-FU and its catabolites.</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    an effort to better estimate the timeline of DPD inhibition and formation of new DPD, we modified the protocol for the Phase 1B trial
    and began enrolling patients in the amended Phase 1B trial in April 2022. On November 1, 2022, we announced that data from the Phase
    1B trial identified multiple dosage regimens with potentially better safety and efficacy profiles than currently existing chemotherapy
    regimens. Since 5-FU exposure is dependent on both the PCS6422 regimen and the capecitabine regimen, safe regimens were identified
    as well as regimens that cause DLTs. One of the regimens in the Phase 1B trial did cause DLTs in two patients, one of whom died.
    The Phase 1B trial is continuing to enroll patients and is expected to complete enrollment in 2023. The next trial will be a Phase
    2 trial to determine which regimens provide an improved efficacy-safety profile over present therapy using the principles of the
    FDA&#8217;s Project Optimus initiative to help guide the design of the trial. This FDA initiative requires us to consider NGC regimens
    that are not at the maximum tolerated dose or exposure level.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Discussions
    with the FDA in April 2023 have clarified that the major goal for the next Phase 2 trial will be to evaluate and understand the dose-
    and exposure-response relationship for anti-tumor activity, safety and tolerability. The specific dosage regimens for the trial will
    be defined following the determination of the MTD from our ongoing Phase 1B trial. As a result, we have begun trial preparation tasks
    and will collaborate with the FDA to further define the dosage regimens and final design prior to the trial. &#160;We will need to
    obtain additional funding before we can conduct this trial.</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NGC-Gemcitabine,
    also identified as PCS3117, is a cytidine analog similar to gemcitabine (Gemzar&#174;), but different enough in chemical structure
    that some patients are more likely to respond to PCS3117 than gemcitabine. The difference in response occurs because NGC-Gemcitabine
    is metabolized to its active metabolite through a different enzyme system than gemcitabine. We continue to evaluate the potential
    use of NGC-Gemcitabine in patients with pancreatic cancer and to evaluate ways to identify patients who are more likely to respond
    to NGC-Gemcitabine than gemcitabine. We plan to meet with the FDA in 2023 to discuss potential trial designs including implementation
    of the Project Optimus initiative as part of the design and then submit the Phase 2B protocol to the IND.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NGC-Irinotecan,
    also identified as PCS11T, is an analog of SN38 (SN38 is the active metabolite of irinotecan) and should have an improved safety/efficacy
    profile in every type of cancer that irinotecan is presently used. The manufacturing process and sites for drug substance and drug
    product are presently being evaluated and IND-enabling toxicology studies will then be initiated. In addition, we are defining the
    potential paths to approval, which include defining the targeted patient population and the type of cancer. We plan to conduct IND
    enabling and toxicology studies in 2023 and 2024, subject to available funding.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Non-Oncology
Pipeline for Out-licensing or Partnership</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCS12852
    is a highly specific and potent 5HT4 agonist that has already been evaluated in clinical studies in South Korea for gastric emptying
    and gastrointestinal motility in healthy volunteers and volunteers with a history of constipation. In October 2021, the FDA cleared
    our IND application to proceed with a Phase 2A trial for the treatment of gastroparesis. We enrolled our first patient on April 5,
    2022 and completed enrollment of the trial on September 2, 2022. Results from this Phase 2A trial, which included 25 patients with
    moderate to severe gastroparesis, demonstrated improvements in gastric emptying in patients receiving 0.5 mg of PCS12852 as compared
    to placebo. The results indicated that for the patients in the PCS12852 group, the mean time for 50% of the gastric contents to empty
    (t50) compared to their baseline value (&#177;SD) decreased by -31.90 min (&#177;50.53) (compared to the change seen in the placebo
    group of only -9.36 min (&#177;42.43). Significant gastric emptying differences were not observed between the placebo and the 0.1
    mg dose. Adverse events associated with the administration of PCS12852 were generally mild to moderate as expected, limited in duration,
    and quickly resolved without any sequelae. There were no cardiovascular safety events or serious adverse events reported during
    the trial. Additionally, the 0.5 mg of PCS12852 showed a greater improvement than placebo in the gastroparesis symptomology scales
    (including both total scores in the scales, as well as sub-scores such as nausea, vomiting and abdominal pain) used in the trial.
    With the trial now complete, we have the data necessary to finalize the development plan for the treatment of diabetic gastroparesis
    patients. We plan to monetize PCS12852 by looking for licensing and/or partnering opportunities.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCS499
    is an oral tablet of the deuterated analog of one of the major metabolites of pentoxifylline (PTX or Trental&#174;). PCS499 is a drug
    that can be used to treat unmet medical need conditions caused by multiple pathophysiological changes. We completed a Phase 2A trial
    for PCS499 in patients with ulcerative and non-ulcerative necrobiosis lipoidica (uNL and NL, respectively) in late 2020, and in May
    2021, we enrolled the first patient in our Phase 2B trial for the treatment of uNL. Although we initiated several recruitment programs
    to increase the enrollment of patients in this trial, we were only able to recruit four patients. We have experienced extremely slow
    enrollment in the trial given the extreme rarity of the condition (rarer than reported in the literature), the impact of COVID-19,
    and the reluctance of patients to be in a clinical trial. We will complete the Phase 2B uNL trial for those currently enrolled, but
    will halt further efforts to enroll new patients in the trial. There have been no safety concerns during the conduct of the trial.
    Although we believe that PCS499 can be effective in treating uNL, we received preliminary data in late February 2023 that indicated
    that the placebo response is likely much greater than the literature and clinical experts believe; thus, a much larger sample size
    would be required in a pivotal trial for an indication where it was extremely difficult to enroll even 10 patients. We are also evaluating
    other, less rare indications for PCS499. As with PCS12852, we plan to monetize PCS499 by looking for licensing and/or partnership
    opportunities.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Developments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2023, we raised gross proceeds of $7.0 million (net proceeds of $6.4 million) from the sale of
8,432,192 shares of our common stock through the following transactions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    January 2023, we sold 50,000 shares at an average price of $1.08 per share for an aggregate gross proceeds of $54,000 through the
    Purchase Agreement we entered into with Lincoln Park Capital in March 2022, under which we have the right, but not the obligation,
    to sell to Lincoln Park, and Lincoln Park is obligated to purchase up to $15.0 million of our shares of common stock, subject to
    the terms and conditions in the Purchase Agreement. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    February 3, 2023, we sold 569,648 shares at an average price of $1.22 per share for an aggregate gross proceeds of $693,000 (net proceeds of $672,000) prior to deducting sales commissions, pursuant to our Sales Agreement with Oppenheimer
    &amp; Co. Inc., under which we may issue and sell in a registered &#8220;at-the-market&#8221; offering shares of our common stock
    having an aggregate offering price of up to $30.0 million from time to time. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    February 14, 2023, we closed a registered direct offering for the sale of 7,812,544 shares of our common stock at a purchase price
    of $0.80 per share to accredited investors for gross proceeds of $6.3 million. Net proceeds from the offering were $5.6 million.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Termination of  PCS499 Trial</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to enrollment difficulties that we have experienced since the beginning of our rare disease trial for PCS499 in uNL, we decided to cease
further enrollment in the PCS499 trial in February 2023. There were no safety concerns noted during the trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Comparison
of the three months ended March 31, 2023 and 2022</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes our net loss during the periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: center">Three months ended</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">March 31,</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Change</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating Expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 46%; text-align: left">Research and development expenses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,627,480</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">2,043,984</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(416,504</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">General and administrative expenses</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,478,055</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,184,730</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,293,325</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating Loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,105,535</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,228,714</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">Other Income (Expense), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">83,462</td><td style="padding-bottom: 1.5pt; text-align: left"></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,583</td><td style="padding-bottom: 1.5pt; text-align: left"></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">81,879</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Net Operating Loss Before Income Tax Benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,022,073</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,227,131</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(794,942</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Income Tax Benefit</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Net Loss</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,022,073</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3,227,131</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Revenues</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently have any revenue under contract or any immediate sales prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our research and development costs are expensed as incurred. Research and
development expenses include (i) program and testing related expenses including external consulting and professional fees related to the
product testing and our development activities and (ii) internal research and development staff salaries and other payroll costs
including stock-based compensation, payroll taxes and employee benefits. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2023, our research and development expenses decreased by $416,504 to $1,627,480 from $2,043,984 for
the three months ended March 31, 2022. Costs for the three months ended March 31, 2023 and 2022 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Three months ended <br />March 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Amortization of intangible assets</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">197,124</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development salaries and benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">518,803</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">526,616</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Preclinical, clinical trial and other costs</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,108,677</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,320,244</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Total</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,627,480</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,043,984</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
decrease in research and development expenses, excluding amortization, was primarily due to a decrease  in preclinical, clinical trial and other costs
during the three months ended March 31, 2023 when compared to the same period in 2022. This decrease was attributable to the completion
of our clinical trial for PCS12852 and the early termination of our clinical trial for PCS499. We also did not have any amortization expense, as we fully impaired our
intangible asset at December 31, 2022. During the same period in 2022, we had
three active clinical trials and amortization expense for our intangible asset.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until
we begin our next clinical trial, we anticipate our research and development costs to remain consistent as we close out and receive
final reports related to our clinical trials for PCS499 and PCS12852. We will, however, continue incurring costs in our clinical
trial for NGC-Capecitabine, including the cost of having drug product manufactured and other tasks necessary for the Phase 2
clinical trial, as well as costs necessary to submit the Phase 2B protocol for NGC-Gemcitabine.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
funding necessary to bring a drug candidate to market is subject to numerous uncertainties. Once a drug candidate is identified, the
further development of that drug candidate may be halted or abandoned at any time due to a number of factors. These factors include,
but are not limited to, funding constraints, safety or a change in market demand. For each of our drug candidate programs, we periodically
assess the scientific progress and merits of the programs to determine if continued research and development is economically viable.
Some programs may be terminated due to the lack of scientific progress and lack of prospects for ultimate commercialization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
clinical trial cost accruals are based on estimates of patient enrollment and related costs at clinical investigator sites, as well as
estimates for the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct
and manage clinical trials on our behalf.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
estimate preclinical and clinical trial expenses based on the services performed, pursuant to contracts with research institutions
and clinical research organizations that conduct and manage preclinical studies and clinical trials on our behalf. In accruing
service fees, we estimate the time period over which services will be performed and the level of patient enrollment and activity
expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we
will adjust the accrual accordingly. Payments made to third parties under these arrangements in advance of the receipt of the
related services are recorded as prepaid expenses and expensed when the services are rendered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
and Administrative Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Our general and
                                                                                                                                                                               administrative expenses for the three months ended March 31, 2023 increased by $1,293,325 to $2,478,055 from $1,184,730 for the
                                                                                                                                                                               three months ended March 31, 2022. This increase is primarily attributable to the fair value of $1,310,875 related to the stock
                                                                                                                                                                               purchase warrant granted to Spartan under the amended consulting agreement (see Note 2 to the condensed consolidated financial
                                                                                                                                                                               statements), which was primarily offset by a decrease in taxes.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Income</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Other income represents interest income of $83,462 and $1,583 for the three
months ended March 31, 2023 and 2022, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Income
Tax Benefit</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We did not recognize any income tax benefit for the three months ended
March 31, 2023 or 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash
Flows</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 23.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth our sources and uses of cash and cash equivalents for the three months ended March 31, 2023 and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: center">Three months ended</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">March 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net cash (used in) provided by:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Operating activities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(2,114,070</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(1,802,926</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Financing activities</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,352,077</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(300,000</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net increase (decrease) in cash</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,238,077</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,102,926</td><td style="text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Net
cash used in operating activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
used net cash in our operating activities of $2,144,070 and $1,802,926 during the three months ended March 31, 2023 and 2022, respectively.
The increase in cash used in operating activities during the first quarter of 2023 compared to the same period in 2022 was primarily
related to increased cash compensation to our executive team and directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
we continue our clinical trial for NGC-Capecitabine and evaluate the other NGC drugs in our portfolio, we anticipate our research
and development efforts and ongoing general and administrative costs will continue to generate negative cash flows from operating
activities for the foreseeable future. These amounts will begin to decrease when compared to prior periods due to our current cash
balances unless we raise enough funds to conduct future clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Net
cash (used in) provided by financing activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2023, we raised net proceeds of $6.4 million from the sale of 8,432,192 shares of our common stock.
We used net cash in financing activities during the three months ended March 31, 2022 of $300,000 to purchase 100,000 shares of our common
stock from a licensee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
March 31, 2023 we had $10.7 million in cash and cash equivalents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">We have incurred losses and net cash used in our operating activities during the three months ended March 31, 2023, which we expect to
continue for the foreseeable future. We have no sales. We have incurred losses since our inception, devoting substantially all of our
efforts toward research and development, and have an accumulated deficit of $68.3 million at March 31, 2023. During the
three months ended March 31, 2023, we generated a net loss of $4.0 million, of which $1.7 million are non-cash expenses.
Based on our current plans, we believe our current cash balance is adequate for at least the next twelve months without considering amounts
available from the Purchase Agreement with Lincoln Park. Our ability to execute our longer-term operating plans, including future clinical
trials for our portfolio of drugs depend on our ability to obtain additional funding from the sale of equity and/or debt securities, a
strategic transaction or other funding transactions. We plan to continue to actively pursue financing alternatives, but there can be no
assurance that we will obtain the necessary funding in the future when needed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
estimate of future cash needs is based on assumptions that may prove to be wrong, and we could utilize our available cash sooner than
we currently expect. Our ultimate success depends on the outcome of our planned clinical trials and our research and development activities,
as disclosed above. We expect to incur additional losses in the future, and we will need to raise additional capital to fully implement
our business plan if the costs of our clinical trials are greater than we expect or they take longer than anticipated. We also expect
to incur increased general and administrative expenses in the future. In addition, there may be costs we incur as we develop these drug
products that we do not currently anticipate, requiring us to need additional capital sooner than currently expected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future capital requirements will depend on many factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of our current clinical trials and the cost of third-party manufacturing;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    initiation, progress, timing, costs and results of drug manufacturing, pre-clinical studies, and clinical trials of PCS3117 and PCS11T,
    as well as any other future product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number and characteristics of product candidates that we pursue;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    outcome, timing, and costs of seeking regulatory approvals;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs associated with hiring additional personnel and consultants for our pre-clinical and clinical activities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    emergence of competing therapies and other adverse market developments;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs involved in preparing, filing, prosecuting, maintaining, expanding, defending, and enforcing patent claims, including litigation
    costs and the outcome of such litigation;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    extent to which we in-license or acquire other products and technologies; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of operating as a public company.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until
such time as we can generate substantial product revenues to support our capital requirements, if ever, we expect to finance our cash
needs through a combination of public or private equity offerings, debt financings, collaborations and licensing arrangements or other
capital sources. We currently have an effective S-3 shelf registration statement on file with the SEC, which provides us flexibility
and optionality to raise capital, including pursuant to a Purchase Agreement with Lincoln Park Capital or a future at-the-market offering,
but there can be no assurance that capital will continue to be available to us on acceptable terms, won&#8217;t be limited, or be available
at all. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest
of our stockholders will or could be diluted, and the terms of these securities may include liquidation or other preferences that
adversely affect the rights of our common stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual
Obligations and Commitments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been no significant changes to the contractual obligations reported in our Annual Report on Form 10-K for the fiscal year ended
December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Off
Balance Sheet Arrangements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
March 31, 2023, we did not have any off-balance sheet arrangements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Policies and Use of Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
discussion and analysis of our financial condition and results of operations are based upon our unaudited condensed consolidated financial
statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make
estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent
assets and liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that the estimates, assumptions and judgments involved in the accounting policies described in the &#8220;Management&#8217;s
Discussion and Analysis of Financial Condition and Results of Operations&#8221; section of our most recent Annual Report on Form 10-K
have the greatest potential impact on our financial statements, so we consider these to be our critical accounting policies. Actual results
could differ from the estimates we use in applying our critical accounting policies. We are not currently aware of any reasonably likely
events or circumstances that would result in materially different amounts being reported.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been no changes in our critical accounting policies from our most recent Annual Report on Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recently
Issued Accounting Pronouncements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have evaluated recently issued accounting pronouncements and determined that there is no material impact on our financial position or
results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_004"></span>Item
3. Quantitative and Qualitative Disclosures About Market Risk</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
3 is not applicable to us as a smaller reporting company and has been omitted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_005"></span>Item
4. Controls and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
 March <span style="background-color: white">31, 2023</span>, management, with the participation of the Chief Executive Officer and
Chief Financial Officer, conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures,
as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on the evaluation of its disclosure controls and procedures,
the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at  March
<span style="background-color: white">31, 2023</span> to provide reasonable assurance that information required to be disclosed in our
reports under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s
rules and forms and (ii) accumulated and communicated to our management, as appropriate, to allow timely decisions regarding required
disclosure. In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures,
no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily
applies its judgment in evaluating the benefits of possible controls and procedures relative to their costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
in Internal Control over Financial Reporting</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no changes in our internal control over financial reporting during the quarter ended March 31, 2023 that have materially affected,
or are reasonably likely to materially affect the Company&#8217;s internal control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_006"></span>Part
II. Other Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_007"></span>Item
1. Legal Proceedings</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently not a party to any material legal proceedings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_008"></span>Item
1A. Risk Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been no material changes to our risk factors as described in Item 1A of our Annual Report on Form 10-K for the year ended December
31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="a_009"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
2. Unregistered Sales of Equity Securities and Use of Proceeds</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(b)
Use of Proceeds from Public Offering of Common Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(c)
Issuer Purchases of Equity Securities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_010"></span>Item
3. Defaults Upon Senior Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_011"></span>Item
4. Mine Safety Disclosures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_012"></span>Item
5. Other Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="a_013"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
6. Exhibits</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SEC
    Ref. No.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-1.htm">Rule 153-14(a) Certification by Principal Executive Officer</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-2.htm">Rule 153-14(a) Certification by Principal Financial Officer</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1*++</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32-1.htm">Section 1350 Certification of Principal Executive Officer and Principal Financial Officer</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    Files</span></td></tr>

<tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Instance Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Schema Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Calculation Linkbase
    Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Definition Linkbase
    Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Presentation Linkbase
    Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (embedded within the
    Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
Filed herewith.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">++
This certification is being furnished solely to accompany this Quarterly Report pursuant to 18 U.S.C. Section 1350 and are not being
filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and are not to be incorporated by reference into
any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing
herewith.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="s_001"></span><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PROCESSA
    PHARMACEUTICALS, INC.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    David Young</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    Young</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    May 15, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    James Stanker</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">James
    Stanker</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial and Accounting Officer)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    May 15, 2023</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<!-- Field: Page; Sequence: 26; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ex31-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5in; text-align: right; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
David Young, Chief Executive Officer of PROCESSA PHARMACEUTICALS, INC. certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
I have reviewed this quarterly report on Form 10-Q of PROCESSA PHARMACEUTICALS, INC. for the three months ended March 31, 2023;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant at, and for, the periods presented in this
report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules13a-15(f) and 15d-15 (f)) for the registrant
and have:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
within those entities, particularly during the period in which this report is being prepared;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.
Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, at  the end of the period covered by this report based on such evaluation;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.
Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
and the audit committee of registrant&rsquo;s board of directors (or persons performing equivalent functions):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    David Young</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    Young</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    May 15, 2023</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B>&nbsp;</FONT></P>


<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ex31-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
James Stanker, Chief Financial Officer of PROCESSA PHARMACEUTICALS, INC. certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
I have reviewed this quarterly report on Form 10-Q of PROCESSA PHARMACEUTICALS, INC. for the three months ended March 31, 2023;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant at, and for, the periods presented in this
report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules13a-15(f) and 15d-15 (f)) for the registrant
and have:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
within those entities, particularly during the period in which this report is being prepared;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.
Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, at  the end of the period covered by this report based on such evaluation;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.
Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
and the audit committee of registrant&rsquo;s board of directors (or persons performing equivalent functions):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    James Stanker</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James
    Stanker</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial and Accounting Officer)</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    May 15, 2023</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ex32-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Written
Statement of the Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. &sect;1350</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Solely
for the purposes of complying with 18 U.S.C. &sect;1350, I, the undersigned Chief Executive Officer of Processa Pharmaceuticals, Inc.
(the &ldquo;Company&rdquo;), hereby certify, to the best of my knowledge, that the quarterly report on Form 10-Q of the Company for the
quarter ended March 31, 2023 (the &ldquo;Report&rdquo;) fully complies with the requirements of Section 13(a) or Section 15(d) of the
Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial
condition and results of operations of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
certification is being furnished solely to accompany this Report pursuant to 18 U.S.C. 1350 and is not being filed for purposes of Section
18 of the Securities Exchange Act of 1934 and is not to be incorporated by reference into any filing of the registrant, whether made
before or after the date hereof, regardless of any general incorporation language in such filing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    David Young</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    Young</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    May 15, 2023</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Solely
for the purposes of complying with 18 U.S.C. &sect;1350, I, the undersigned Chief Financial Officer of Processa Pharmaceuticals, Inc.
(the &ldquo;Company&rdquo;), hereby certify, to the best of my knowledge, that the quarterly report on Form 10-Q of the Company for the
quarter ended March 31, 2023 (the &ldquo;Report&rdquo;) fully complies with the requirements of Section 13(a) or Section 15(d) of the
Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial
condition and results of operations of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
certification is being furnished solely to accompany this Report pursuant to 18 U.S.C. 1350 and is not being filed for purposes of Section
18 of the Securities Exchange Act of 1934 and is not to be incorporated by reference into any filing of the registrant, whether made
before or after the date hereof, regardless of any general incorporation language in such filing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    James Stanker</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James
    Stanker</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial and Accounting Officer)</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    May 15, 2023</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>















































<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>f10-q_001.jpg
<TEXT>
begin 644 f10-q_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'D TH# 2(  A$! Q$!_\0
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M Z"BN?\ ^$-TO_GZUS_P>WO_ ,>H_P"$-TO_ )^M<_\ ![>__'J .@HKG_\
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ML[A=\4G]MWZ[AG'1I01T[B@#K:*Y_P#X0W2_^?K7/_![>_\ QZC_ (0W2_\
MGZUS_P 'M[_\>H Z"BN?_P"$-TO_ )^M<_\ ![>__'J/^$-TO_GZUS_P>WO_
M ,>H Z"BN(UVT\*>&M,DU'5=5UV&TCE$4DB:QJ$OEL>@8)(2O;DX'(]16G!X
M3T>YMXYXKS7&CD4.C?V[?#((R#_K: .DHKG_ /A#=+_Y^M<_\'M[_P#'J/\
MA#=+_P"?K7/_  >WO_QZ@#H**Y__ (0W2_\ GZUS_P 'M[_\>H_X0W2_^?K7
M/_![>_\ QZ@#H**Y_P#X0W2_^?K7/_![>_\ QZJFI>'M#TFPDO;NZ\1^1$,N
M8=6U&9@/7:DA;'J<<4 =717"^'8/"?BNV>ZT74?$=Q;H<><VIZG$C'D85G<!
ML8YQG'>MK_A#=+_Y^M<_\'M[_P#'J .@HKG_ /A#=+_Y^M<_\'M[_P#'J/\
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MM<_\'M[_ /'J .@HKG_^$-TO_GZUS_P>WO\ \>H_X0W2_P#GZUS_ ,'M[_\
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M6NIJD/VJYDG9%-K;N0&D9FQN=CC/<UTE '/^._\ DGGB7_L%77_HIJZ"N?\
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MX27<TBW ;.=RLY!/)YQD9.,9K6T71-/\/::FGZ9 8;5/NJTC2'H /F8DG
MYX  ' H \R^#DDR7/CB:^@>775U-FN8A@2,,,44;B!@G>!D@>^*=J/Q3L(=%
M\6:YH?AZ]AU.P$5O=S7:Q"/S1)Y:!@DA+$;FY P0N,]*] U#PEHNI:F-3FM9
M8=0V&-KJSN9;65T.WY7>)E+CY5P&)QCBDM/!WAZRTB[TN'2H/LEYG[4'R[W!
M)))D=B6<Y)Y))':@#@+G7?'%CX*U_4;B6]AAAL8KNPU"Y6S,IDP-Z%(MR%#U
M!(! )&>F*_AKQOXCC\6:):ZIJ1U"UU'PTNJ21?9XX]LN&/RE0#T3N2,L< #
M'>K\/_#:Z-+I'V2Y:QDC$1B>_N&VQ@YV*2^53@952 <#(.*33_A]X:TO5;+4
M[2SN$O+*$6]M(U_</Y<0SA &<C;R>,8YH X[P'XG\:>*O[,U9X;AM*U#[2EV
MX^RK%:88B)H.3*Q&W#"0'KD<5'\-]:\;^*='MM:NO$-JUK;7T\5U#-:HAEC$
M?!+*O9BO3;QN)+< =UIO@7P[H\LKZ=8R6JR2/*88KJ81([#!=(]^Q&QP"H!
MX&*ET+P=H7AO3[K3]*LWAL[K)E@>XEE1LC!P'8XR#SC&>,]!0!YKX9\>>(;W
MQ[H6F3ZJM[9ZM;W6^6.&/[-YB;R&MSL20JNS;^\SGYL%N&K#T:[UA/AQ\0M8
MDUJ[EN(]1FC>*XA@ECE(\M<NKQG/R_+MX4#@**]6T[X:>$M)O-/N['3989]/
M+&T<7LY,08DLHR_W22V5/'S-Q\QS-)\//"TD&I0'366'4Y#)=QI<RHKL2"<
M,-N2%R%P#M&<X% '#:?XKUW5;S0]!L]0;3%C\*Q:K-<6]O#NEE** H5D*J@)
MSA0/08J@OQ"\3ZS:?#V[M=0.GMKES+:WL:6\;QMY<@3>NY2P)R>^ >W'/I<O
M@+PY-965HUE,([*%K>W=+R=)$B/6,R!PY3'&TD@#C%+>^ _#>H2:8\VGNG]E
M@"Q6WN985@YSE51@ >!SUXH Q?A9XCU7Q!IVMQZO=?:YM/U26TCG,:HS1KC&
MX* ,\GH!6%H+NW[1WB(:I_KUTY!IX?H(?D)V?B3T_P!KWKT#P]X3T;PL+L:/
M;2P"[D\V??<RR[WY^;YV."<\D=>,YP*DUCPQH^O2V\VHV8>XMFW07,4CPS1'
M_9D0AP.>@.* ,OQ];63>$M?NG2/[<FAWT<3$_-Y9C!< =QE4^G'K7FOP\\0Z
MUI-]\/\ 1C?B72]5L)R]MY" 1E-Y4AL;B?E&<G')X%>L'PCHSZ9>V$D%Q+%?
M)Y5S)+>3/-*G]PRES)MY/R[L?,W')S0L_AOX6T^]TZ[MK&Y2?3>+-CJ%PPA&
M22%!D(P<G(Q@@X/% ''>"?&/C+Q;>6NL6]I<2:5-?2P7,)^S)!;0@ *4.[SC
M(IP6W @Y. .*Y>X^('C.R\(:WK?_  D#32:7KOV&*)[. "6/N)"$&>@QMVD9
M;DY&WV2S\$>'M/U&:^L[%X))IOM$D<=S*(6D_OF+=Y>X<$';D$ CGFLQOA3X
M.>QGLGTVY:UN)A<31-J-R5DEY^<CS.3SU_PH Y:7QUK_ (>\4^-K"]NUU2+2
M=+CO;</ D860JI(&P [,OT8L0%'S$Y)-(\5^)(]8\+:==:K->CQ+H[79?[/$
M&LY?++@Q[4 (Q@8<-R ?4'NK3P-X?LM8N-6CM)WO;F'R+B2XO)IO.CP%VNKN
M0PP!U!J71O!N@Z#="ZT^R9)DB\B-Y9Y)O*CR3LCWL=BY/1<"@#PA'O;W]FS6
M=2O=2NKJ2YO59HYMA4-]H3+ [=Q)[Y8CT KLM(\:ZWH6O:WIM[=_VC::?X:3
M5((O)2/8RHA*@J,[3N_B+$ =?7MF^&GA)M'GTC^RF73YYA-);I=S*I8$D# ?
MA<DG:/ES@XR!5BP\!>'-.U8ZI;V4QO&M_LKR37D\V^' &QE=R&7 '!'84 <7
MX6\0>-M7TG^U;C[5_9MYI<LYNV%HHMK@9*^2JDLR8^7$BDY .>H)X%UKQKK7
M@ZR\47GB'3FMA:WAN([NW6)-Z%A$[L@^Z"#N(V_*!P3DUVEAX"\.:9:2VMG9
MSQ6TB.GDB]G*1A\[C&I?$9.3RF#R>:FT[P;H.E>';CP_:63KI5PKK);27$LB
MX<88#<Q*@Y)X(Y.>M 'G'A3QOX@U+Q8VD3ZK//:W6A&\BN6@B4K*"1YD/[M3
MY?7 E0G@9&.3FZ+X_P#%D?A/PKXEO=8>^^WZQ_9]Q9&UA5'C)89!50P<8XP0
M.%R.N[T>/X>^'-%/]HZ5I5Q_:%K:/!;A+V4LR8.(_GDVD<X ;@<= !CFOA;\
M/!I>@V'_  DNAS0ZKIUP\T!ENQ)#N;.'6-)&3< 0-Q4'@8Z#  K:WXDTKX@Z
MMX6U+7;J0:A:";09UM[==K%L%6'E_,RG.>ORJ3C)&/0-2BD@\+7D4MQ)<2)9
MR*TT@4-(0ARQ"@#)]@!61I%GJNI^(&U'Q%I%K;S:9-<Q:?-&RMYD4A4*X^8D
M':I!SC.[H*Z#4M.M]6L)+*[\[R)1AQ#.\+$>FY"&QZC/- '@^@ZWJOAS]FN/
M5M&OGL[R"];#K&CA@TNTJ0ZD8YSQ@Y YQD'=F\4>+8O%>JZ+_P )"3%%H']J
M^:+.$/'(%#;8_EP%)('SASM! ()W#MU^&/A)="?1!I]S_9;R+(UI_:-SY>X9
M(('F<<DD@<$X)R0,2'X;^&&O9+QK2\-S);?9'E.IW.YH=NW83YG*X[?CUH \
M[3QSXIU#3/AO/%K!MI==EEMKXI;1,'V2!-X!7AB"3QQGMVJY+XU\1Q>$_'L1
MU.4W_AV[V6VH?9X@TJ%CA77;L) ')"CJ.E3>,/A[)!J'A"U\-Z!>7&C:3<R7
M%Q''? ,@<H<1F64,#\I/! !.00:[L>!?#@T"[T06#BPO)3-<K]IEWSN3DL\F
M[>V3ZF@#SW5/%/C;0OA_:^(Y=6M;O^UK"RCMA]E53:W$HRTA 'S?+@\DC>3\
MH4;3?EUCQ;)XB\5>$-/UF>:^L;*.^T^_DMH/,+%5S"X"!"&)X.T$<\G%=Z/"
MNBGPN?#<EGYVD&+R?L\\KRX3L S$L,<;<'Y<#&,"GZ/X<TK07NI;"W=9[IE:
M>>:9YY9-JA5#22,S$ # &<#G'4T <#X:\2:IXJ\$)K$.O7D<UEI<WVY1#;D2
M7?S8SF+C;MW;1CAH\YYSR]AXL\1VOP_^'EQIVIQV<FIZB]G<1Q6,"PE//91\
M@0;< 8^4KGGOS7LL'AG2+32+S2[:T\BSO7DDGCBE="[2'+G<#D9]B,#@8%8X
M^&/A);&QLAI]R+;3Y3/:1C4+D"%R02R_O.#D9]B3ZF@#@&\>^,+7PCXY-M*V
MI7VB:J]K#=/;IOB@!93(RH K%0N<[<#))R!BND\!ZUK.L>-O$$1U^XUGP]8K
M$EI=B* 12R,@9U+QQC<RY[$8[@Y%2^)OAY;VOAC58?"MOJ$%_J-Q%+<20:@Y
ME9A(&,@\U]K,.21N0M_>'%4_ASX7\9:-K\USK.NZS=Z<UN4:#561F,F1M*;)
MY0 !NR25ZC@Y)4 G\;>&]=O_ !2=;\%:]%9>(+6R2"ZM)E!26!F=DZ@@$LK@
M9&#CJN.<FP\;:M-X(ENIH[/0-6&OFQU!(P2TK\;A;J5D'FG*C#!EX8DC.1Z1
MJ'AC2-2OFOKBWD6],:Q?:K>XD@F" DA0\;*P7+$D X/&<X%5;SP-X;O]*L],
MGTW_ $:SG%S!Y<TD;K+S\_F*P<L<DDDDD\G)YH \KN/$>L>*?@MXS_M6[F\_
M3;V2W#^7$KR1@J0DFT%<\\E,=!SUR:=J^JZ9_P (GX=T%+A;W4?#\-_<7EI!
M:"YG(B*Q1EI0J%$"]\OM &>I/I2?#?PK'IU_I\>GSI9ZA*)KJ!+Z=4D?GD@/
MQUY X.!GH,2R?#_PU);:; UE./[,!6RE6]G6:!<8VK*'W[<<!<X'84 >=ZQ/
MXFU'XB_#ZUUB]NM*NY[>>2:WM3$RPS+&X+KD.K$C/7=@-@8.2=2#6O$MCXYU
MKP?J?B"Z>YNX$GT.Z6WMU(0OSE?+PS*,[O54<@ XQW%WX+\/7SZ=)<:>'DT[
M=]F<3.K#=]_<0V7W<[MV=V3G.3FEH=GJNI:T=5\1Z3;6E[8&XMK22)E82Q.X
M(<88D?*B]<'+-P.X!H^(;NYT;PC>W4-_;1W-M;$K=ZAQ'N ^\X0=_11UX [5
MYMX;\:^(-0U7Q1I<VI7;1VVD)?V=S/! )D8QJVX;4"E&W9 =-V,9"G(KU;5]
M(L->TJXTO4[<7%E<+MEB+$;AD$<@@CD \5A6WPX\+6<TTUO8W$4L]M]DED6_
MN TD6,;6/F9.  !W   Z"@#S?PIX\\5W%U\/Y]0UC[7#KSW<=S ;6) /+<JI
M!50<_0@<#CJ3D>-->UCQ=\,/$VL7=^8[6#6A90Z:L2>7'&A3!+8W[\G))8CD
M_*,C;ZW:_#+PG92Z=);Z?<(=,8O9#^T+@K 2VX[09,#)Z^O>I;KX<>$[V>ZE
MN-*WBZG%S/#]HE$,DHQ\YB#;-W')QSDYZG(!NP_\@:/_ *]Q_P"@UXU\"K/5
M[CPI9NEQ;OHHO[E;FU\HAV)B !9BV&3)QMV]2#SV]EFTNTFTK^S!&\%F$6-8
M[65K?8JXPJF,J5' & 1QQTKG+3X9>%;#3Y=/L[6_MK*;=YMM#JUVD;[A@Y42
MX.1P<]10!Q/BBS@U;XY^#%2\>2QO=/F*H(XFC\HQ290!D(*.N0=V>&.,<8Y>
MPTI;*/XIRQS!SI,JM;I-9VTB;E\P!MC1%00H9<*%&';CH1[5)X$\/2ZO8ZJU
MI<"]L(UBM9$OIU\E%&T*JAP ,<$8YR<YR:K)\-O"R)J2"SN]NIC%Z#J5R?M'
M.<M^\Y.>_7!(Z$@@'#Z5XJU[59?"OA;3M0CTJ>Y\.B_^TQ6T0\R3:RI&$*%%
M0%<D*N<# Q6CXU\2>*-"T^SMI-7M8M372;BYEBTU%>62>-"V_$L900  DY*,
M>0N3\IZU_A]X9>TTVW^P3*-,!%E*EY.LT /\*RAP^.>F<#M2W_P_\,:G<03W
M>F;Y8;=K576XE0M$Q)96VL-^2S$[LY))/6@#B+;Q[K6M#P'I:W@TZ?7K>6:[
MOH849@8U;"HKAE&YEYR#U&,5)XBU3QOX.L_#.L:YKD<MFMPEMK<=E!%Y9!8[
M9 S1[@"N-P&.?N[<@CL6^'OA=])T_3&TY_LVG2^=9D74PDMWSG*2;]ZC.#@'
M&0/053U31;Z>]3PTFC6\_A2YM@;BXEEWRB<2AFWEV+-E1PV&.X@D@<T ;V@)
M=FSDN;K4+B[6YD:6 3)&OE1$_(HV*N>,'G)YQVK5I    !@#H!2T %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '/^'O^0YXL_P"P
MK'_Z16M=!7/^'O\ D.>+/^PK'_Z16M=!0!S_ ([_ .2>>)?^P5=?^BFKH*Y_
MQW_R3SQ+_P!@JZ_]%-1_PG?@_P#Z&O0__!C#_P#%4 =!17/_ /"=^#_^AKT/
M_P &,/\ \51_PG?@_P#Z&O0__!C#_P#%4 =!17/_ /"=^#_^AKT/_P &,/\
M\51_PG?@_P#Z&O0__!C#_P#%4 =!17/_ /"=^#_^AKT/_P &,/\ \51_PG?@
M_P#Z&O0__!C#_P#%4 =!17/_ /"=^#_^AKT/_P &,/\ \51_PG?@_P#Z&O0_
M_!C#_P#%4 =!17/_ /"=^#_^AKT/_P &,/\ \51_PG?@_P#Z&O0__!C#_P#%
M4 =!17/_ /"=^#_^AKT/_P &,/\ \51_PG?@_P#Z&O0__!C#_P#%4 =!17/_
M /"=^#_^AKT/_P &,/\ \51_PG?@_P#Z&O0__!C#_P#%4 =!17/_ /"=^#_^
MAKT/_P &,/\ \51_PG?@_P#Z&O0__!C#_P#%4 =!17/_ /"=^#_^AKT/_P &
M,/\ \51_PG?@_P#Z&O0__!C#_P#%4 =!17/_ /"=^#_^AKT/_P &,/\ \51_
MPG?@_P#Z&O0__!C#_P#%4 =!17/_ /"=^#_^AKT/_P &,/\ \51_PG?@_P#Z
M&O0__!C#_P#%4 =!17/_ /"=^#_^AKT/_P &,/\ \51_PG?@_P#Z&O0__!C#
M_P#%4 =!17/_ /"=^#_^AKT/_P &,/\ \51_PG?@_P#Z&O0__!C#_P#%4 =!
M17/_ /"=^#_^AKT/_P &,/\ \51_PG?@_P#Z&O0__!C#_P#%4 =!17/_ /"=
M^#_^AKT/_P &,/\ \51_PG?@_P#Z&O0__!C#_P#%4 =!17/_ /"=^#_^AKT/
M_P &,/\ \51_PG?@_P#Z&O0__!C#_P#%4 =!17/_ /"=^#_^AKT/_P &,/\
M\51_PG?@_P#Z&O0__!C#_P#%4 =!17/_ /"=^#_^AKT/_P &,/\ \51_PG?@
M_P#Z&O0__!C#_P#%4 =!17/_ /"=^#_^AKT/_P &,/\ \51_PG?@_P#Z&O0_
M_!C#_P#%4 =!17/_ /"=^#_^AKT/_P &,/\ \51_PG?@_P#Z&O0__!C#_P#%
M4 =!17/_ /"=^#_^AKT/_P &,/\ \51_PG?@_P#Z&O0__!C#_P#%4 =!17/_
M /"=^#_^AKT/_P &,/\ \51_PG?@_P#Z&O0__!C#_P#%4 =!17/_ /"=^#_^
MAKT/_P &,/\ \51_PG?@_P#Z&O0__!C#_P#%4 =!17/_ /"=^#_^AKT/_P &
M,/\ \51_PG?@_P#Z&O0__!C#_P#%4 =!17/_ /"=^#_^AKT/_P &,/\ \51_
MPG?@_P#Z&O0__!C#_P#%4 =!17/_ /"=^#_^AKT/_P &,/\ \51_PG?@_P#Z
M&O0__!C#_P#%4 =!17/_ /"=^#_^AKT/_P &,/\ \51_PG?@_P#Z&O0__!C#
M_P#%4 =!17/_ /"=^#_^AKT/_P &,/\ \51_PG?@_P#Z&O0__!C#_P#%4 =!
M17/_ /"=^#_^AKT/_P &,/\ \51_PG?@_P#Z&O0__!C#_P#%4 =!17/_ /"=
M^#_^AKT/_P &,/\ \51_PG?@_P#Z&O0__!C#_P#%4 =!17/_ /"=^#_^AKT/
M_P &,/\ \51_PG?@_P#Z&O0__!C#_P#%4 =!17/_ /"=^#_^AKT/_P &,/\
M\51_PG?@_P#Z&O0__!C#_P#%4 =!17/_ /"=^#_^AKT/_P &,/\ \51_PG?@
M_P#Z&O0__!C#_P#%4 =!17/_ /"=^#_^AKT/_P &,/\ \51_PG?@_P#Z&O0_
M_!C#_P#%4 =!17/_ /"=^#_^AKT/_P &,/\ \51_PG?@_P#Z&O0__!C#_P#%
M4 =!17/_ /"=^#_^AKT/_P &,/\ \51_PG?@_P#Z&O0__!C#_P#%4 =!17/_
M /"=^#_^AKT/_P &,/\ \51_PG?@_P#Z&O0__!C#_P#%4 =!17/_ /"=^#_^
MAKT/_P &,/\ \51_PG?@_P#Z&O0__!C#_P#%4 =!17/_ /"=^#_^AKT/_P &
M,/\ \51_PG?@_P#Z&O0__!C#_P#%4 =!17/_ /"=^#_^AKT/_P &,/\ \51_
MPG?@_P#Z&O0__!C#_P#%4 =!17/_ /"=^#_^AKT/_P &,/\ \51_PG?@_P#Z
M&O0__!C#_P#%4 =!17/_ /"=^#_^AKT/_P &,/\ \51_PG?@_P#Z&O0__!C#
M_P#%4 =!17/_ /"=^#_^AKT/_P &,/\ \51_PG?@_P#Z&O0__!C#_P#%4 =!
M17/_ /"=^#_^AKT/_P &,/\ \51_PG?@_P#Z&O0__!C#_P#%4 =!17/_ /"=
M^#_^AKT/_P &,/\ \51_PG?@_P#Z&O0__!C#_P#%4 =!17/_ /"=^#_^AKT/
M_P &,/\ \51_PG?@_P#Z&O0__!C#_P#%4 =!17/_ /"=^#_^AKT/_P &,/\
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MN/#&ISWD.DW,?G/8S2/;R* $C"$;4+;5^=E)VC"8)! ![%_P@G@__H5-#_\
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MR6UJD;,N<X)4 D9 /X5IT4 %%%% !1110!S]G_R4/6?^P58?^C;NN@KG[/\
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MOUM!;3S6$T<<GE1;7PS* ,'IGKVS7H] !7/^._\ DGGB7_L%77_HIJZ"N?\
M'?\ R3SQ+_V"KK_T4U '04444 %<JOQ TD^,XO##V^H1W$YD2WNI+<BWG=/O
MHCYY*\@\8!!&<XKJJ\]N=:74OB98Q2>&=?E73F>&TO&L&2U5W $DID;!P%!5
M>,')/.5( /0J*** "N?\"?\ )//#7_8*M?\ T4M=!7/^!/\ DGGAK_L%6O\
MZ*6@#H**** .9\6>.--\'1QR7UKJ%PAPTS6=N95MD)P'E.0%4D$#N<' .#72
M(ZR1K(ARK $'U!K@OB3!!X@TV\\-/8:[]KDMUGL[JSMY&MY)@QV1NR_)]Y1G
MS<* =V1P1V]@MTFG6JWKK)=B)!.ZC 9\#<1[9S0!8HHHH Y_P]_R'/%G_85C
M_P#2*UKH*Y_P]_R'/%G_ &%8_P#TBM:Z"@ HHHH **** .?O/^2AZ-_V"K__
M -&VE=!7/WG_ "4/1O\ L%7_ /Z-M*Z"@ HHHH **** "BBB@ HHHH ****
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M/^ASUS_OS9?_ "/7044 <_\ \(]JG_0YZY_WYLO_ )'H_P"$>U3_ *'/7/\
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M_H<]<_[\V7_R/1_PCVJ?]#GKG_?FR_\ D>N@HH Y_P#X1[5/^ASUS_OS9?\
MR/1_PCVJ?]#GKG_?FR_^1ZZ"B@#G_P#A'M4_Z'/7/^_-E_\ (]'_  CVJ?\
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M_?FR_P#D>N@HH Y__A'M4_Z'/7/^_-E_\CT?\(]JG_0YZY_WYLO_ )'KH**
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MI_T.>N?]^;+_ .1ZZ"B@#G_^$>U3_H<]<_[\V7_R/1_PCVJ?]#GKG_?FR_\
MD>N@HH Y_P#X1[5/^ASUS_OS9?\ R/1_PCVJ?]#GKG_?FR_^1ZZ"B@#@]"T+
M47UCQ.J^+-9C*:FBLRQ6>9#]DMSN;,!&<$#C PHXSDG<_P"$>U3_ *'/7/\
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MTK 32_$/AZYTVU35+:P?7]=N9KQ+*$2B(/ [*L;R#''E;B2G+-G& 0P!U?\
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M35T%<_X[_P"2>>)?^P5=?^BFKH* "BBB@ HHHH **** "BBB@ HHHH ****
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M5NG6W0-< ]0YQ\P.3US6A10!3TW2=-T:W:WTO3[2Q@9R[1VL*Q*6P!DA0!G
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M_P#TBM:Z"N?\/?\ (<\6?]A6/_TBM:Z"@ HHHH **** .?O/^2AZ-_V"K_\
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M.&FZ3.D*M%92W4LUE >D,#'Y5 _A4\L%XVA@,#&!T% '/^'O^0YXL_["L?\
MZ16M=!7/^'O^0YXL_P"PK'_Z16M=!0!S_CO_ ))YXE_[!5U_Z*:N@KG_ !W_
M ,D\\2_]@JZ_]%-704 %%%8OB+Q%#H$-JOD-<WM[,(+2V5@IE<^K'[JC(R>V
M:3:2NRZ=.522C%7;-JBLNSO]3?4%M+_2E@!B:3[1!<>;#P5 7)56#'<3@J!@
M<$\X>VOZ,D,TS:M8"*&3RY7-RFV-_P"ZQSP?8T<R&Z4[V2OZ:_D<UJGAF?Q+
MX?=7M9],U6TNIKBQGE:,E6:0N.49OE((!]QG!QSFZUX2U6[U2TD\J[ELYM(2
MQG2TFA1XG5@W)D!^4G'*<_+WX![V'5=.N8)YX+^UEAMR1-)',K+'@9.X@\8'
MK4?]MZ28[:0:I9;+HE;=OM"8F(."$.?F.>.*R=.#W9W4\7B(.T8[7TL]+I?/
MI?\ '8Y*73]8A^(L>N6N@S&U=#;71^T1#S-HPLX&_DX)4 C.T=B<5I>"])U#
M1CK5M>6BQ0S:E-<P2+(I#H^,8 Y&,=\5LGQ!HH:W4ZO8;KD P#[2F9<G V\_
M-SQQWJG=^+=(M[C4;-+VU:]L8?-:&2X2,,2#A=S' .0,^FX9ZT*,8N]PE5KU
M8>SY.B6SV3T_%V_X8W:*S+?7;%K73GO+NTM;B_C1XH&ND8NS ?*A!P_) RO7
MC'6G-K^C)=-:OJU@MPL@B,1N4#AST7&<Y..E:\R[G#[*I>W*_N?^1HT444S,
MY^S_ .2AZS_V"K#_ -&W==!7/V?_ "4/6?\ L%6'_HV[KH* ,/Q?KT_ACPQ>
M:U!91W@M%\R2%YS%E.^"%;GIQ@?6L/1OB#)=^(AH^K:;;V#-I:ZJMQ#>^=&D
M)//F%D381D>H]ZT/B)87^J^!-4TS3+&2\N[N(PI&CQIC/\1+LHQQVR>>E<;X
M>\)ZUIWB-+ZPT*?1=-CT?R;RS%Q"!J%R$(!6.-R@(X^=BN<^Y- '<7$W@S6\
MWMS)H-_Y5MYQGD:&79 &8;MQSA P;GID'WJK/;?#VUT^#4+B#PQ#97!Q#<2)
M;K'(?]ECP>AZ5PUI\/-8C^"]MI<.DQVOB.WF661"\6^X"S>8%\S++@@+C=D9
M49&*EUOPGXBDT>"TTW1KNX2[EU":YEO;BT%Y$\T>!\R82-'D)+",DE0,GDI4
M\L7T-56JQ5E)_>_\SN+C3? =I/:07-EX<AFO"!;1R10*T^2 -@(RV21T]15?
M2H? &MZA?V&G:=H5Q<V,GESQI;0D@X&2!CD G&>F01U!KF[/PWK]M8^%3!HU
MS!J-E96EK<N\\$ENRQR LLR%R?EV[XWCRV6YQBIK ZYX M_%EX=!6\CNM::Z
MM42\CC\Y)2H54!R2XP1LP"25"AL\')'L/ZQ6_G?WO_,V?%<7@[PEHXOKKPUI
MDTDLJP6UM%91;YY6X5!D8'J3V /THLM&MC>6MMJ?P_T: 7!.9[01SQQ *3AR
M8D8,2 !@%?\ :S@&7XA>%[WQ+I&GS:8T8U+2[Z+4+>*9MJ2LAY0D9QD'@^H'
M8Y%>!?&FJ^,K:ZW7^C:#'$'N;.Y-FYDD'1(V02-L./F+$'D[<=CDCV#ZQ6_G
M?WO_ #+UK8^ ;Z6YBL[7PU<26H)N$AC@<P@<'>!]WH>M4+R[^&5EIT.H21^&
M7M)KE;5)HHX'4R$@8R.!@,"?0<FN.\/^$_$ZZ])?:SX5403Z)=V$UI#=010;
MGE9UC0(WR1LI"Y )W$EN[&_=^%/$T^BZ3BPGN7TSQ':WT2WDENMY+;1QA3YK
MHVQG&  =V2JKGGBCDCV#ZQ6_G?WO_,[VQU7PGIHDL]/O]%M0)45X;>:)/WCC
M"@J#]Y@..YQ4>F>+]/N?#_\ ;&I76G:=:M</"DK:C%)$V&(4B13MR0,[<Y'3
MM7/Z3X9NV^*?B36]5T)6M+B&U-G/(T4@\R(+G:-VX'< 5) ^[G@US.B>$/$V
MGP^';RZT&2>/3[_4/M6F&> M+%<J0)%S)L. 2I!8'D]CFJV,FW)W;/9D=)8U
MDC971@&5E.00>A!IU<YH^KW/]O2>'SH<=E:6=E%(DL%PCQH2 /*V* 4Q_#G
M(4X&!71T".?\0_\ (<\)_P#85D_](KJN@KG_ !#_ ,ASPG_V%9/_ $BNJZ"@
M HHHH **** "BBB@#G_$/_(<\)_]A63_ -(KJN@KG_$/_(<\)_\ 85D_](KJ
MN@H **** "BBD+*I4%@"QP 3U/7^AH 6N?\ '?\ R3SQ+_V"KK_T4U=!7/\
MCO\ Y)YXE_[!5U_Z*:@#H**** "BBB@ HHHH *Y_P)_R3SPU_P!@JU_]%+70
M5S_@3_DGGAK_ +!5K_Z*6@#H**** "BBB@ HHHH Y_P]_P ASQ9_V%8__2*U
MKH*Y_P /?\ASQ9_V%8__ $BM:Z"@ HHHH **** .?O/^2AZ-_P!@J_\ _1MI
M6KJ>FVFL:?+87T1EMI<;T#LN<$$<J01R!WK*O/\ DH>C?]@J_P#_ $;:5/XB
MU:?3+>RBM!#]KO[M+2!YP3&C,&8LP!!;"JV ",G R,Y U<<9.+NMQ&\+:<Z,
MCS:JRL,$'5KH@C_OY2W7A72+SP_%H4L$PTV( +#%=2Q\#H"RL&(YZ$D=/2N%
MTK5M8T.RN=-L+87>JWFN7:;E7S5 10S,%EFC)SQ@&3C)Y;'.\WB?7;6]T:'5
M;*WTS[5'"L_G1/)&9F<J\:S1LR(V NT/PQD #94@I12V+E5G)6D[HZ'4O#VG
M:OHR:3?+<RV:A1M%Y,KN%&!N=6#/[[B<GDY-0V/A32-/O)+R**XDNY(O)^TW
M5Y-<2HG/RH\CLR#DD[2,\>@KE_\ A*KVRT]I7CT;2/-UNXL[B]D0M;P;0Y#O
M\R%F8H%W$J,D>P++?Q1XPGCT*%HM&CGU+3KF\DF:&;$9C,> L>[)&'')<9W9
MPNW#,S.KD\)Z1-X<DT"6*YDTV7.^-[V8LV3N(,A?>03VSBK5SHMA>Z')HUW"
M]S8R1>4Z3RO(S+[NQ+$]]V<@\YS3?#VIOK7AK2M5DC6-[VSAN613D*70,0/I
MFM*@#F6\ >&W@NHFL[@F[DCEN)C?3^=*T?W-TN_>0O! )QD ]0*NKX5T87,\
M[VKS&=)(Y(Y[B26(B3[^(V8H"W<@ G)SU-;-% &"G@[15TV33S#=/ [1-F6^
MG>1#&VZ/9(SETVD9&TC!SZFHD\">'8K>2&&SGA\V1I998;R>.65F #%Y%<.V
M<#.2<\^IKHZ* ,<^&-)_M 7JV\J2@#:B7,JQ*0GEAA&&V!@GRA@,@=ZJ#P)X
M?6RMK1;:Z1+9I&A=+^X65/,^^!('W[6ZE<X)YQ71T4 <]>^"/#^H/<&>TG"W
M%JME)'#>311^0O2,(CA57V '4^ISN6UO':6L5O$9#'$@13)(TC8 P,LQ))]R
M2:EHH 1@&4J<X(QP<&LS1_#VG:%!<0Z>MRJ7$AED\Z\FF)<Y)8%V)!)))(ZG
MFM2B@#"B\'Z'#H;:,+:9K$S?: LEW*[I)NW;TD9BZ'=\V5(Y)/4FJK^&Y!J.
MEV]O;P0Z5871OC,UU)+<3R^6ZX8,OJ^2Y=B=N,<Y'3T4 8<'A#0K=[G99$Q7
M*R+);//(\&)#E]L3,47=DYVJ.I]331X.T8:>UD8[QHBZ.'?4+AI4*?<VRE]Z
M@9. "!R?4UO44 5+_3+/5-/>QOH!/;N "K$Y!'1@W4,#R&!R" 0<UD7'A>WM
M-&U6+28=]_>V[0^??7<LK-E2 #*^]PHR3M'&2>.37144 <OH?@VQM/#9T_4+
M0/-<V:VEV/MDTZE "-L;/@HO)(50H&>!QFGW'@+0+M[A[B/4)6N($MYB^J71
M+QH<JI_>=CD_4M_>.>EHH YNX\":!=?:?.BOW^TO%),3J=SEVCQL)_>=1@$>
MX!["I+OP3X>O[]KV[L&GE:9)V22XE,32H JN8]VPL H&XC)'!KH** ,S3_#^
MFZ7=RW5K%,)I%V9EN))0BYR0@=B$!/)"@ X&>@JK=>#M!O;^YO+FQ,K71!N8
M6GD\B<@  R0[O+<@ <E2> >H%;M% %#2=%L=#M/LUBDRQ\<S7$DS8 P!N=B<
M =!G [5%HWA[3M %R-/%T/M+^9+Y]Y-/N?NW[QFP3W(Z\9Z"M2B@#F[?P'X?
MM6M6B@O/]%GDN(@^HW#@22??)#2$-NYR#D'<W]XY;;> ?#UH"(8+X?N5MQNU
M.Y8I&A#(JYD.W:1E<8VGIBNFHH P9/!NB2P6T9@N4>V9VBN([V=)P7^_F97$
MC;N,Y8YP/05=U#0[#4])72[B.5;-0H$<$\D/"]!N1@<>V<5HT4 4M,TJUTF%
MXK8W#!VW,]S=27#DXQ]^1F;''3./SJ[110!S_A[_ )#GBS_L*Q_^D5K705S_
M (>_Y#GBS_L*Q_\ I%:UT% '/^._^2>>)?\ L%77_HIJZ"N?\=_\D\\2_P#8
M*NO_ $4U=!0 5RWC#0K[4;G1]6TU4EN])N#,+9VV^<AQN4,> W P3Q73R21P
MQ/+*ZI&BEF=C@*!U)/85SL'C2TN;(ZA%INJ-II)$=YY V2<X!"[MX!_O,H'J
M143Y6K,ZL-[6,O:4U>VGWIJW3=7\RDMIXJU76KYI;J[T[1WMF6*WG%N9#*P(
MZQAB$ Y^\&SBN4/@S7?^$*O;+^S[Q]2>TBLPKW%N(BJ3;P4VX.,;B2YW?,!@
M]1ZY14.BGNS>GF%2G\,4EIT[?G?J>5W/A/7[RS\510Z<]J+UK66T1Y8L2>5C
M*?*Q S@8SQQS5C4/"VI7,&E :7?7"G6?M]XEW/;EPFU0^0A5<$YPHSQDG&<5
MZ9534;_^SH$E^RW5SNE6/9;1;V&XXW$?W1U)I.C&VII',:S:44OZ5N_SWW//
M?&WAG6M1O)K?2=$A^PK%"8FMVAB+.)-S!LD,0 3A?NY)/7&+UWH>L#4?&TD&
MEEX=:L8UMR)HU(<0LA4C/7<V2>F >2>#W,-W;W$\\,,RO);L%E53G82,@'WP
M0?QJAKFOV^@16DEU!/(ES<I;*T(4[6;IG)''TS0Z<=97_K;]10QE=J-)13?S
MN]5+O_=3//I_!^OR::;8:>7>]TBTL"SS1XM'B9=Q;YN5X+#9N/L*;K_A77[K
M4?$,MOI,MPUW-8_9YS+""RPKAR<OD9(!QWXS7INHW_\ 9T"2_9;JYW2K'LMH
MM[#<<;B/[HZDU;I>QB]+E+,ZT;3Y5_37GZ"*2R*Q4J2,E3C(]N*6BBN@\DY^
MS_Y*'K/_ &"K#_T;=UT%<_9_\E#UG_L%6'_HV[KH* "N;\0^,8O#VLZ;I;Z1
MJ5Y/J19;9K7R=K.O+*=\BD$#!R1CD<YR!TE>:_$>&ZN_&?@X6L>K(MI/++/>
M6-@\WD*Z[5.[RW3.01@@X') !!H [+PUXEL/%6D_VA8"9%65X)89U"R0R*<,
MC $C(XZ$]:V*\B\9^$+31?#NE:%IFA7VJ1S7%S/->-$]TZ3-$P$CH/E+NQ"A
MF7:O)P.HYZXTBXOK7P:VH:#JMP]MH%U;W?F:9.Q601D1(_R<_,#@'U![@D ]
M^HKQ&UTNZO=*\%0^)]#U.]T*/2YK2ZMC9S.\%P!A6>,#>/E7:K@<9X(!S6S8
M>&;;4_B]K4U_H]^ED;.TEB>6*5(VGC*MDRCY7=2!_$<\]>: /5:@O;VVTZRF
MO;R=(+:!#)+*YP%4=2:\4T#2-=L-/URZU.POKS4UM+V"\LX[":(Z@6?*,UR'
MQ+Q\J^6-P4D>YQW\-ZK<> O'.FV^A:BC3/8W=C;#3Y($)&SS?*0C&0,C&2Y
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MW!MQ<!?WH7=M*L&'&1GE?6JUY_R4/1O^P5?_ /HVTJ[XAU?^P?#][JGD>?\
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M=!7/^!/^2>>&O^P5:_\ HI: .@HHHH **** "BBB@#G_  ]_R'/%G_85C_\
M2*UKH*Y_P]_R'/%G_85C_P#2*UKH* "BBB@ HHHH Y^\_P"2AZ-_V"K_ /\
M1MI4GC+3[K5?"&IV-E%YMS/#MC3<%W'([D@5'>?\E#T;_L%7_P#Z-M*V[BY@
MM+=[BYFCAAC&7DE8*JCU)/ I22::9I2G*%2,H[IIF7_;5_\ ]"QJW_?VU_\
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M !7/^._^2>>)?^P5=?\ HIJZ"N?\=_\ )//$O_8*NO\ T4U '04444 %%%%
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MP: /,KGQ1XIGT:74X]8CMUA\*VVL"**S0EIF5RP9FW?*2IR  <8P002VW?\
MB'4(_&-BEGJ=U/;-J$5G=6RVL:VT >#=L:1AYCR$D."APHP& XW=&O@OPJJ,
MB^&=&",NQE%A%@KG=@_+TR <>HS3SX0\,M.DS>'=),L:HJ.;*/<H4 * =O
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M)WX/_P"AKT/_ ,&,/_Q5'_"=^#_^AKT/_P &,/\ \50 6?\ R4/6?^P58?\
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M *&O0_\ P8P__%4?\)WX/_Z&O0__  8P_P#Q5 '045S_ /PG?@__ *&O0_\
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M8P__ !5 '045S_\ PG?@_P#Z&O0__!C#_P#%4?\ "=^#_P#H:]#_ /!C#_\
M%4 =!17/_P#"=^#_ /H:]#_\&,/_ ,51_P )WX/_ .AKT/\ \&,/_P 50!T%
M<_X[_P"2>>)?^P5=?^BFH_X3OP?_ -#7H?\ X,8?_BJP_&GC3PK=>!?$-O;^
M)=&FGETRY2..._B9G8Q,   V22>,4 =Y17/_ /"=^#_^AKT/_P &,/\ \51_
MPG?@_P#Z&O0__!C#_P#%4 =!17/_ /"=^#_^AKT/_P &,/\ \51_PG?@_P#Z
M&O0__!C#_P#%4 =!17/_ /"=^#_^AKT/_P &,/\ \51_PG?@_P#Z&O0__!C#
M_P#%4 =!7/\ @3_DGGAK_L%6O_HI:/\ A._!_P#T->A_^#&'_P"*K#\%^-/"
MMKX%\/6]QXET:&>+3+9)(Y+^)61A$H((+9!!XQ0!WE%<_P#\)WX/_P"AKT/_
M ,&,/_Q5'_"=^#_^AKT/_P &,/\ \50!T%%<_P#\)WX/_P"AKT/_ ,&,/_Q5
M'_"=^#_^AKT/_P &,/\ \50!T%%<_P#\)WX/_P"AKT/_ ,&,/_Q5'_"=^#_^
MAKT/_P &,/\ \50 >'O^0YXL_P"PK'_Z16M=!7!Z%XT\*PZQXG>7Q+HR)-J:
M/$S7\0#K]DMUROS<C<K#([@CM6Y_PG?@_P#Z&O0__!C#_P#%4 =!17/_ /"=
M^#_^AKT/_P &,/\ \51_PG?@_P#Z&O0__!C#_P#%4 =!17/_ /"=^#_^AKT/
M_P &,/\ \51_PG?@_P#Z&O0__!C#_P#%4 %Y_P E#T;_ +!5_P#^C;2K'BN^
MN=-\)ZI>VDGEW$%L[QOM!VL!P<'@US=UXT\*MXZTFX7Q+HQ@33+U'D%_%M5F
MEM2H)W8!(5B!WVGTJYKOB?P?K6A7VF?\)CH</VJ%HO,^W0MMR.N-XS^=3*]G
M8UHN*J1<]KJ_I=&G;:3J,UK#*WB?50SH&.(K7'(_ZXU5\*ZU<3>#I-3U2X>=
MX'N/,DV*&*1NP'"@#.%]*RXO%UG#"D2_$+P:510HR@SQ_P!O-.\/Z[X/T;0?
M[+G\9:!=AGE:1OMD2*V]BQ&W>>/FQUJ$GS+^OU.FI.+I23:;NK6736_V5Y$N
MB#Q-KGA^RU]-<$$]_%'<I8&WC:VBB<!@@.WS-VW^(L1DD[<8 TI?&5A#J(MV
MMKS[*;O[#]O6-3"+CIY?#;\Y^7.W;NXSGBN8TK4]#TFUBTF#XDZ$=#A(6*'S
MXA=)$.D8G$N-O;.S=MX# X:F"Z\++>RHOC[0#I+ZC_:8M'N(C(D^X2<2>8!L
M\P;]NW.<C=BM3A-NS^(ECJ!MA:Z-K4@NS,ML3;*GG21-M9 &<%3WRV%Z@L""
M!(/B!I\W]F)9:9JU[/J5B;^"*"V .P%05+,RH&&[IN[8ZL@;E=.GTG3VTIE^
M)'A1VT^6ZD7*H YG)8@_Z3Q@L?PQ]:QX=?TK1/$'AC2+/QSH32V>EW4']H&W
M\RW 9XBBMB7:K8C8Y+CH./F (!W:^,4_MI=1?4$'AU]";454P[67#KEF)Y)P
M<;>.?4U6_P"%G6U[:12:/IEQ>S?;XK.6*.XMI-F\;@0RS%#N 8##<$'=C'.-
M-#X/EVVH\>Z$NFKI)TP1_:8C/@D-YGF>9C=N4'[F*OW6M:7J&G0I>_$?PO)?
M6US#<6\R>6L0*9^]'Y^6+9.<.!TP!SD WK7X@:'=^+/^$=BES=F22%6$T)!D
M0$NA0.9%(PPRR!25.">,KXG\?:)X2O(K749?WKQB9PLL2F.,MM#[7=6<9#<(
M&/RGCIG&TC6] T>_G$/Q!\.MI4MU+=FU,L7F*\A+.HD\W&S>68#9D9QNQ2ZC
MKGAY_$!UC2?'_AZRGFM5M+E)IHIU=%8LC+B5=KC>XR=P.[D<4 :T7CW3IM5D
ML4L-3V1:@-.DNFMPD2S,H9>6(8AMV 5![$X5E+%MX\LKNUFNHM+U7R$N6LXF
MDA2,SW D,?E(K.&!)&<L%4#.XJ00.3EFT9[B[D7XC^%@L^L1:JH8(2I154(2
M+@9R(TYP.=W'( E@G\.+H<UG-\0_#IO!J;ZI:W4,L2"*5I#(0R&9MZY9AC(^
M4XZ\T ;U[XKN+P:8VGM)8R)K,=AJ-G=0J9DR,[<ABH!!5@RE@01@CFH++QI-
MISR6NK)=ZC>7&L7-C9K8VF!\B[E4G.%XXRS>I)"JQ7*FNO#TQBN/^%@^&1?/
MJ<>HW<N^/9*R(L:*B^?E $4#DL2>?:J\<VCIJ-M=_P#"Q_"I\G5I=3*X3YB\
M9C*9^T< *S<^N/3! .PTKQQ8:M=VD"V.H6ZW22F.:XC54WQ']Y&2&)ROJ 4.
M" Q((K+A^+7AN>VOYXOM,J6D*W %OY<[2QLVW<%C=BF"5R) A&X9'7&)ILFA
M6;Z4+CXB>%KB&QENG=%V(95G)++G[0=N-S8.#VXXY5[C27\)R>'/^%F^&FLD
M@6VMG?RC(L:D;?,(G =@JA<@(.I(/& #HM1\?-!;M]DT+49+J/4;>RDMY1$C
M!92A5QF0#YE; !((;[P7!KLD)9%8J5)&2IQD>W%>6W-QH=U<ZA=2?$3PMY]S
M=6EW$5*!8Y("N,C[1EE(7&,@C/6NQ3QUX2$:B3Q;H+/@;BM_$ 3WP-YQ^= '
M145S_P#PG?@__H:]#_\ !C#_ /%4?\)WX/\ ^AKT/_P8P_\ Q5 '045S_P#P
MG?@__H:]#_\ !C#_ /%4?\)WX/\ ^AKT/_P8P_\ Q5 '045S_P#PG?@__H:]
M#_\ !C#_ /%4?\)WX/\ ^AKT/_P8P_\ Q5 '045S_P#PG?@__H:]#_\ !C#_
M /%4?\)WX/\ ^AKT/_P8P_\ Q5 '045S_P#PG?@__H:]#_\ !C#_ /%4?\)W
MX/\ ^AKT/_P8P_\ Q5 '045S_P#PG?@__H:]#_\ !C#_ /%4?\)WX/\ ^AKT
M/_P8P_\ Q5 '045S_P#PG?@__H:]#_\ !C#_ /%4?\)WX/\ ^AKT/_P8P_\
MQ5 '045S_P#PG?@__H:]#_\ !C#_ /%4?\)WX/\ ^AKT/_P8P_\ Q5 '045S
M_P#PG?@__H:]#_\ !C#_ /%4?\)WX/\ ^AKT/_P8P_\ Q5 !X>_Y#GBS_L*Q
M_P#I%:UT%<OX0O[/4]0\4WEA=P7=K)JJ;)H)!(C8L[8'##@X((_"NHH Y_QW
M_P D\\2_]@JZ_P#135T%<_X[_P"2>>)?^P5=?^BFKH* "BBB@ HHHH ****
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M-?\ 8*M?_12UT%<_X$_Y)YX:_P"P5:_^BEH Z"BBB@ HHHH **** .?\/?\
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M<,5X(ZG(&WXKTN6]\3>%;Z+0FU%+"[DEFE7R<PJ8F5?]8RG[Y1OES]S/4 $
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M67S%*!N6/3K6SI$6HQ^.->N)])N8+.YC@6&Z>2$HYC# \*Y<9W9&5'0YQQD
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MT/0=:HR(M'^&VG:)=Z%<6^J:H_\ 8L4L5K'*T)4K(26#8C!/7U'0>^>SHHH
MY_Q#_P ASPG_ -A63_TBNJZ"N?\ $/\ R'/"?_85D_\ 2*ZKH* "BBB@ HHH
MH **** .?\0_\ASPG_V%9/\ TBNJZ"N?\0_\ASPG_P!A63_TBNJZ"@ HHHH
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MY..X)KC?$5SIS^&-=3^WY+C0%N[+^S[E]4=@TQ;][&LV_,H"C=@LVTYZ;1M
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MX<@%E5MP!/4X]KK:VOB+1M-;5KV2\A\1WEM):_:Y9G^SLDIC$B9)*\1D,X.
M"00-QH ]2N;A+6WDGD61D09(BC:1C]%4$GZ 5+7C<GB&2#PAX@8>(I?.@BMV
M6_M]3\R-V+ME<2#?!*W.Z+/RC 4C&*=?>([:#Q!J]]_PF4CI;>(;"*",ZBBP
MI!((?-&U<*RX\P?-G'ED\-O8@'L5%>6:=?QW_P 1EMYM=G%Q;ZC<F2,ZSY<<
M\8R(H5M1+NW*<9S&%8(S9;<,^IT %%%% '/^'O\ D.>+/^PK'_Z16M=!7/\
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MIQJ@C,Q=HP59/N,FU!@C\O4&K-YX0BU :>;K5M3EEL;D74<K-'N9P %R-F,
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M!5__ .C;2MF]OK33;22[OKJ"UMH\;YIY B+DX&6/ Y(%8UY_R4/1O^P5?_\
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M%+M9T)W;MN55'!+$$#'.-N.*S-:^%=SJX\4QC7H88O$'V0./[/R85M\;,8D
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M*R?^D5U705A.A";O(]3"YKB<-3]G2:MZ=SPK_A1VN?\ 03T__P ?_P#B:/\
MA1VN?]!/3_\ Q_\ ^)KW6BH^JTNQT_V_COYE]R/"O^%':Y_T$]/_ /'_ /XF
MC_A1VN?]!/3_ /Q__P")KW6BCZK2[!_;^._F7W(\*_X4=KG_ $$]/_\ '_\
MXFC_ (4=KG_03T__ ,?_ /B:]UHH^JTNP?V_COYE]R/GV^^$&KV-WIMO)J%B
MS7]R;>,KOPK"*27)XZ8B(^I%7?\ A1VN?]!/3_\ Q_\ ^)KU7Q#_ ,ASPG_V
M%9/_ $BNJZ"CZK2[!_;^._F7W(\*_P"%':Y_T$]/_P#'_P#XFC_A1VN?]!/3
M_P#Q_P#^)KW6BCZK2[!_;^._F7W(\*_X4=KG_03T_P#\?_\ B:/^%':Y_P!!
M/3__ !__ .)KW6BCZK2[!_;^._F7W(\*_P"%':Y_T$]/_P#'_P#XFJ6L?"#5
M]&T2_P!4FU"Q>*RMI+AT3?N944L0,CKQ7T%7/^._^2>>)?\ L%77_HIJ/JM+
ML']OX[^9?<CYHUO2I=#UFZTR>1));9]C,F=I/MFO5OAI\--ODZ]KT'S</:VC
MCIZ.X_D/Q-=!IOP\AN/'&I^(]619$-R6M+<CCCC>WXC@?C7H-9T<,E+FE\CM
MS'.Y3I*C1>K2YG\M4OU^Y!1117<?*A1110 5S_@3_DGGAK_L%6O_ **6N@KG
M_ G_ "3SPU_V"K7_ -%+0!T%%%% !1110 4444 <_P"'O^0YXL_["L?_ *16
MM=!7/^'O^0YXL_["L?\ Z16M=!0 4444 %%%% '/WG_)0]&_[!5__P"C;2MF
M]L;34K22TOK6"ZMI,;X9XPZ-@Y&5/!Y -8UY_P E#T;_ +!5_P#^C;2D\=7,
M]IX(U:XMII(9HX,I)$Q5E.1R".12D[)LTI4W4J1@NK2^\TAH>D#2/[(&E6(T
MS_GS^SIY/WMWW,;?O<].O-,N/#VBWEE;V5SH^GSVEMCR();9&CBP,#:I&%X]
M*@_X1BP_Y^-6_P#!O=?_ !RJ'@EI=3\!6HO+BYF>831O*9W$I'F.O#@[@0.A
M!R,<&ES.]FBW2C[-SC*]FEM;>_F^Q=BT!Y]6O+[5Y;6]6:W:TC@6U*((&;)5
MPSMO)X!/ ./N\ULQQQPQ)%$BI&BA511@*!T '85YUX:UZ_TSP_X;L[>QO-5N
M]8$S&XO-18JCJ"?F9R[ 87HHP.2 2<&\/&4U]'HUU;Z1(MQ>:9<WD?FWI2%'
MC"AHV"@[^3]XKP,8Y) HP.GL- TG1_/?2-*T^PEF&'>WM4CW$9QNV@9QD]ZS
M?"7A*#PU:.95L+C49&?S+Z"R$$DBLVX*QW,3@\=>@''%9>B>)=1NU\,#4M,=
M[V^TN2\$MM>8C<A8SM*84%FW _,,)GACR12O_'NL'3M3BM=.TV/5-/N[*"=$
MU$S1H)Y0FTL(N'!^4J1P#NR<;2 =K9:#H^G/&]CI-C:M'N"-!;HA3=C=C XS
M@9]<"M"N/C\;W$GB==(CT2>:%)UM;JZ@2=UAE*!B0WD^64!(4DNK=3MQC-;Q
MO]GA\1>'I+FXUE+:=YHIXM-N+L%PL;,O[N Y)#=P,XZG H [FBO*-+U'Q;IT
MGA9KL7UW=3:;?LUE>SK!\B21&*2<A2?,\M@#PQ#$<#+M71WWCR6TTW1]6&F0
M#3-1CM&62:^6.5FG8#9%'M/F,BD,<E>.F<' !VE%<@_CR&WN]<6XMHE@TF&:
M641W2M<#80 &A(!7?DE6!92,9()Q5_POXAN]>2\%[I$^GR6[J%+QSK'*K#.5
M,T43$@@@C;QQR<T =!17+O875IXRTZ6TU&]E,RSOJ,,L[O#Y6/D*H<K&0^T+
MMP6&_.X@FI]>\3G1=7T[3UM[>1[W(7S[L0%SN50L>X;7?+@E=RG'(#'B@#H:
M*XNQ\2^(I(]>GETW37CLM0:"-FU Q1Q1JBEFD8Q<*!SD!CEL8 &:CL/'M_K$
MFD0Z7H44LNHV4UT)9K\) ABD6-E#JC,PYR&VC.5]6V@'<45QWAOQB'T*.\\4
M7FDZ;+<75Q%;AKT#S DK+@;U3E< <9R,$X)P'Q^,;LS6T<FDQ#S-7ETN39=E
MBK*C.KKE!NR%(()&..30!UU%<;HOC>\U.;2WN]":QL]2N)[2&4W2R.LT7F'#
M(HP%*Q/R&/(QC&&-J]UO6X?&YTRVL+:XL8]->ZVBYVRR-NP  4VYR-H!8##$
MD\ 4 =117#+\0)$LM6:YL]-BNM-NHK:4KJ1>U0OC_63"+,>TY4Y0X.!GG(IW
M'BRYMO%]@Z,\LVK:7&;'2I+Q!$93)DD.@9?N L6^;IA<Y (!Z+17-0>*9V\5
M1:#/9VD=QY:M,!?#S%S&7+HC*IDBW#9N7G.<JH&:Z6@ HHHH **** "BBB@
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MZQ7"VR12D1KD;XF4A02#P0#P1P15F_UK5O\ A4L&O1:C)#J*6B3M*D49$C'
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M%9/_ $BNJZ"N?\0_\ASPG_V%9/\ TBNJZ"@ HHHH **** "N?\=_\D\\2_\
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M_$/_ "'/"?\ V%9/_2*ZKH* "BBB@ HHHH **** .?\ $/\ R'/"?_85D_\
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M*.+S&:![>0"1&Q<1RG)&4W;X_G!)Q75W5EIKW=M?W=K:M<VYVV]Q+&I>(O\
M+A6/(W9 XZYQ5R@#S9M"U)9O$+1:#J5L)]:%[:R64UHKD&W\MY CN4;+!MRR
M8R)<_>! [G08;NV\/Z=!?1P174=O&DL=N@6-6"@$*!P /0<>E:%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 <_X>_P"0YXL_["L?_I%:UT%<
M_P"'O^0YXL_["L?_ *16M=!0!S_CO_DGGB7_ +!5U_Z*:N@KG_'?_)//$O\
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MF;_Y%H^V>,/^@%H?_@YF_P#D6@#H**Y_[9XP_P"@%H?_ (.9O_D6C[9XP_Z
M6A_^#F;_ .1: .@HKG_MGC#_ * 6A_\ @YF_^1:/MGC#_H!:'_X.9O\ Y%H
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M<W^IV%VK226:,5B:(N,++@ >20HR3@IDD[B #TZ[OK/3XTDO;J"VC=UC5II
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MXX^E>PV-_9ZG9QWEA=P7=K)G9-!()$;!(.&'!P01^% &/XA_Y#GA/_L*R?\
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M?'RR9'(P(U\*ZB;Z%]7T2XOTFLK.,)IVH&UM[:6+/RO$)%!0-A@5#XP<#ID
M]#O]3L-+B674+ZVM(V)"O<2K&"0"QP21V!/T!-0KKFE2WOV&#4;.:^,7G+:Q
MW"&5D(R&"YS@C'/3FL3Q7ID][XA\*7<&CM>BQOGEFG4Q P1F)D_C8'[S(V%S
M_J\]0H.98^';BT\57-S>Z-J-[(NH2WMI?)J9%NBLIP/),HPX!:/[A!&,L,G
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MT001_P#"2PWDE^GE*D7E"&5E(#;]YPP&%(_>$YZUZE0 4444 %%%% !1110
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M/)#[BNX# QD9X')KDW\7>*#X)O-9^UO%NM8[BWF9;<_O/.V2(B#),8#+RPW
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MX$_Y)YX:_P"P5:_^BEKH*Y_P)_R3SPU_V"K7_P!%+0!T%%%% !1110 4444
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M$LE[ 47=C,P67<_FJ6*.RXSD8% 'I]4M4U>PT6U2YU&Z2WB>5(4+9)9W.%4
M<DDGM[GH#7EL^JSMIOB01:O<W$EK&EY]KLM4D>.,>>Q.]#AH'V 9CR8R%)4#
M!RNL>)--FL/%FW6/.L1JVG-;2RW#/#@M"["-V.W&5=MJG@ G % 'KBR1NSJC
MJS1MM< Y*G .#Z'!!_$4ZO)2UCI\GBF./7$M;LZTCO%=ZQ/"KPF*-AF16)B!
MYPX'.U4.5XKT/PM=M?>%=+NG^T[I;9&)N75Y"<=2R@*V>N0 "#D"@#7HHHH
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M>?K_ %YG;JJHBHBA548  P *6BBMCS#G[/\ Y*'K/_8*L/\ T;=UT%<_9_\
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MBLH[5 DHE6+,;DY8Y+D*5*_,2>1A0 >E45R?@F&[2?Q#+=:E=W9.J2QJLXC
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M!!#Y$B?* LB'#<\+TKIZ "BBB@ HHHH **** "BBB@ HHHH **** .?\/?\
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MP61)87B="1D!D<!AD$$9'((/0BM"@ HHHH **** "BBB@ HHHH **** .?\
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M?8_&'_0=T/\ \$TW_P E4 =!17/_ &/QA_T'=#_\$TW_ ,E4?8_&'_0=T/\
M\$TW_P E4 =!17/_ &/QA_T'=#_\$TW_ ,E4?8_&'_0=T/\ \$TW_P E4 =!
M17/_ &/QA_T'=#_\$TW_ ,E4?8_&'_0=T/\ \$TW_P E4 =!17/_ &/QA_T'
M=#_\$TW_ ,E4?8_&'_0=T/\ \$TW_P E4 =!17/_ &/QA_T'=#_\$TW_ ,E4
M?8_&'_0=T/\ \$TW_P E4 =!17/_ &/QA_T'=#_\$TW_ ,E4?8_&'_0=T/\
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MMY&CT>4,%=2I(S<D9P?0T =917/_ &/QA_T'=#_\$TW_ ,E4?8_&'_0=T/\
M\$TW_P E4 =!17/_ &/QA_T'=#_\$TW_ ,E4?8_&'_0=T/\ \$TW_P E4 =!
M17/_ &/QA_T'=#_\$TW_ ,E4?8_&'_0=T/\ \$TW_P E4 =!7/\ @3_DGGAK
M_L%6O_HI:/L?C#_H.Z'_ .":;_Y*JGI.@^*M&T:QTNWU_1F@LK>.WC:31Y2Q
M5%"@G%R!G ]!0!UE%<_]C\8?]!W0_P#P33?_ "51]C\8?]!W0_\ P33?_)5
M'045S_V/QA_T'=#_ /!--_\ )5'V/QA_T'=#_P#!--_\E4 =!17/_8_&'_0=
MT/\ \$TW_P E4?8_&'_0=T/_ ,$TW_R50 >'O^0YXL_["L?_ *16M=!7)V6@
M^*K&ZU&XBU_1B]_<"XE#:/+@,(HXL+_I/3;&IYSR3]!<^Q^,/^@[H?\ X)IO
M_DJ@#H**Y_['XP_Z#NA_^":;_P"2J/L?C#_H.Z'_ .":;_Y*H Z"BN?^Q^,/
M^@[H?_@FF_\ DJC['XP_Z#NA_P#@FF_^2J "\_Y*'HW_ &"K_P#]&VE6/%.E
M3ZYX8U#3+9XTFN8MB-*2%!R.N 3^E9<F@^*I=9MM4;7]&\^WMYK=%&CR[2LC
M1LQ/^DYSF)<<]SU[7/L?C#_H.Z'_ .":;_Y*I-75F73FX34X[K4G^T^)?^@3
MI/\ X,Y/_D>JV@^''M/!*Z!JACDWQS13^2Q*E9&8D D ]&]*=]C\8?\ 0=T/
M_P $TW_R51]C\8?]!W0__!--_P#)5)1UN7*LW!P223UT\OF^Y5T/3O%&F6%I
MHT\NG-9VBK$FHQR/Y[Q+@*#"4VAB!@MO([X[53M_"FK0S)8.;&32K?57U2WF
M\QQ.2SM*(F39@8D<_/N/R@#;DY&M]C\8?]!W0_\ P33?_)5'V/QA_P!!W0__
M  33?_)548G/Z3X;\3Z=)H<CVNCN=.%YO OY?G,S;EQ^X['@_G[5C:7%JWA_
M7_#OA^-M$EUFV\/RVIADOF5& DCPP_=[B<(6V[>@;YN,UW/V/QA_T'=#_P#!
M--_\E4?8_&'_ $'=#_\ !--_\E4 <U<_#_4)+=]*B>R_LY-$@TV&>61FD=XF
M#AGBV8VD\$;^GUQ5L>%=0BL;.2QT+P[IEU::@EV+2RE:.&;$;H2T@A!!^<X&
MPXV]3GC:^Q^,/^@[H?\ X)IO_DJC['XP_P"@[H?_ ()IO_DJ@#*\.^#WT/7)
M9CI&A2)]IGGCU4)_IK+(6;8PV=07*[MYRJCY1GB_?:=K9\<6NL6EMI\EG!I\
MUKB6[=)&:1HWS@1,  8@.O\ %GM@S?8_&'_0=T/_ ,$TW_R51]C\8?\ 0=T/
M_P $TW_R50!D7_@^_P!:\,VD-TUM8:S9%Q;S6T[2H4?AT8E%.UUX(QP0#SBK
M$UAXIMO%^J:O86&CS0W-K#;1"?4)8V'EM(VY@(&'/F= ?X>O/%_['XP_Z#NA
M_P#@FF_^2J/L?C#_ *#NA_\ @FF_^2J '^&_#[:+I5U#=7(N+V^N)+J\GC3R
MU:5^NT9.  %4<DX45QL/P]U&R\(WNB6>C^&8KIK(V*:E$6BFN5W+AY<194[5
M!89?<W<8KK_L?C#_ *#NA_\ @FF_^2J/L?C#_H.Z'_X)IO\ Y*H QI]&\7M?
M:Q>6G]FVCW[6I CO7+;8QB1-Q@.W()PP!/L"<BMHWA+Q#HUOITT<>FRW-A=W
MKK!)?S,LL5PQ?)F,18.IXY5MW7()KHOL?C#_ *#NA_\ @FF_^2J/L?C#_H.Z
M'_X)IO\ Y*H Q;?PKK6EZGI<MFNGW,%GIUW!(\MP\+233NLA(01N%3<@'WB0
M&/7;\V7;>#/%$.B+IYAT<L/#IT;>+Z7&_D!_]3TQ@X]>/>NN^Q^,/^@[H?\
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M]!W0_P#P33?_ "51]C\8?]!W0_\ P33?_)5 '045S_V/QA_T'=#_ /!--_\
M)5'V/QA_T'=#_P#!--_\E4 =!17/_8_&'_0=T/\ \$TW_P E4?8_&'_0=T/_
M ,$TW_R50 >'O^0YXL_["L?_ *16M=!6/H.DWFF-J<]_>P7=U?W8N7:"V,"+
MB*.(*%+N>D0.<]ZV* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
# __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>f10-q_002.jpg
<TEXT>
begin 644 f10-q_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #I T@# 2(  A$! Q$!_\0
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M&,/_ ,51_P )WX/_ .AKT/\ \&,/_P 57044 <__ ,)WX/\ ^AKT/_P8P_\
MQ5'_  G?@_\ Z&O0_P#P8P__ !5=!10!S_\ PG?@_P#Z&O0__!C#_P#%4?\
M"=^#_P#H:]#_ /!C#_\ %5T%07M[;:=8SWMY,L-M;QF261NBJ!DF@#&_X3OP
M?_T->A_^#&'_ .*H_P"$[\'_ /0UZ'_X,8?_ (JL[1O%^L^(K+^UM*\-!M&9
MLP27-\(KFX0=62+85&2"%#R+G )(!KH=$U3^V='M]0^S2VWG GR9<;TPQ&&Q
MT/'([>] &?\ \)WX/_Z&O0__  8P_P#Q5'_"=^#_ /H:]#_\&,/_ ,57044
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MPI+Y/H#Q0!N?\)WX/_Z&O0__  8P_P#Q5'_"=^#_ /H:]#_\&,/_ ,57044
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MWXY,R^&XVMXXY)QJ>GF-)'**S?;(< L 2!GO@X]#4GVSQA_T M#_ /!S-_\
M(M '045S_P!L\8?] +0__!S-_P#(M'VSQA_T M#_ /!S-_\ (M '045S_P!L
M\8?] +0__!S-_P#(M'VSQA_T M#_ /!S-_\ (M '045S_P!L\8?] +0__!S-
M_P#(M'VSQA_T M#_ /!S-_\ (M '045S_P!L\8?] +0__!S-_P#(M'VSQA_T
M M#_ /!S-_\ (M '045S_P!L\8?] +0__!S-_P#(M'VSQA_T M#_ /!S-_\
M(M '045S_P!L\8?] +0__!S-_P#(M'VSQA_T M#_ /!S-_\ (M '045R=EKW
MBJ^NM1MXM T8/87 MY2VL2X+&*.7*_Z-TVR*.<<@_4W/MGC#_H!:'_X.9O\
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M5?"\NA2+>:=H;-<7NH0$- &)1A$)!PS?*,J.S>QQWGVSQA_T M#_ /!S-_\
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M'>EI5&(PV%60Y^[NWC!X.6'<U[O]L\8?] +0_P#P<S?_ "+1]L\8?] +0_\
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MIEB=CQ2.RRQQMLZ-& S-Z?*,5[S]L\8?] +0_P#P<S?_ "+1]L\8?] +0_\
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M:AYDBWKI$ Y(D?8LC8Y(4\ G(##H",]C]L\8?] +0_\ P<S?_(M'VSQA_P!
M+0__  <S?_(M '045S_VSQA_T M#_P#!S-_\BT?;/&'_ $ M#_\ !S-_\BT
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MW_R+1]L\8?\ 0"T/_P ',W_R+0!T%%<_]L\8?] +0_\ P<S?_(M'VSQA_P!
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M$CQ2MN>-OW>TKN^8';N!Z$5T&AZ1;Z!H=EI-H\[V]G"L,;3R%W( QR3_ "&
M.@   H&7Z*** .?O/^2AZ-_V"K__ -&VE=!7)Z]>SV/CK1);?3+O4'.F7RF*
MU:)6 \VT^8^8Z#'&.N>1QUQ<_P"$AU3_ *$S7/\ O]9?_)% '045S_\ PD.J
M?]"9KG_?ZR_^2*/^$AU3_H3-<_[_ %E_\D4 =!17/_\ "0ZI_P!"9KG_ '^L
MO_DBC_A(=4_Z$S7/^_UE_P#)% '045S_ /PD.J?]"9KG_?ZR_P#DBC_A(=4_
MZ$S7/^_UE_\ )% '045R[^+[N/48;!O".N"ZFBDFC3S+/YD0H&.?M&.#(GY^
MQJQ_PD.J?]"9KG_?ZR_^2* .@KRG4+.?4_C;>:$VL:S;V,NB&Z$=MJ<\8CF,
M@7>H#X&!_#C;[5VW_"0ZI_T)FN?]_K+_ .2*Y"_T&^OO%%SXB33/&UI?SVQM
M-UM<:4 D).=JY<D<\[L[O>@"CX=^*EQ:>"M.?6&MKG5);Z>Q2XN;@6L$@B&X
MR/)@A>"!P#DX]:W8/B5-=W]E%;Z/%]GU'26U&QFFO"IF=<9@*B,X<$]B>,'J
M<55E\/P+I6D6.G^#/$FF?V1*9K*>TN;#S(V.=V2\[!@V>0P.:O7=M+?7FB7=
MUX1\32W.CRM+!*UU8[G9E*MO_P!(Y!X.!@9 [<4 %U\3;.R\8)X>N(+=)$GM
MK6Y8W@#B:897RHRH,B*2H9SMQNS@XK!\(^,;ZPMVTA%FU;5+[7;^VLDO;UP%
MB@ 8YE8.P & !@Y)K:-E<IXHN->M?#7BNTENQ$+RW@NM/$5R8\[6;,Q8'! ^
M5ER!@]3G!?08-#LXIWT;QC#<+J9N(+X3::98I[DB)E7$FW:Y90<J<=<C% &S
M#\3Y]3?P\-%T2.Z&MVDUQ$;B],/E/"3YB-B-O3 (ZGL!S41^*\EQ;:%/I^A"
MXCU;3Y[M=]YY9A:$'S$;Y#D<8##D_P!VLB\\+ZJFK^&1HWAG7]-TS1[2XMR\
M-S8_:/W@'*[I60Y^;.1WR.<$6G\(H(]*CM?#?BZTCTRRELH%AN-,(*R@B1FW
M2G+-G.>F>@'- &QX>^)T>M7\4-SI$EC!-HQU>.4SB0E%;8ZE0..02#DY&,A2
M=HRS\9X'\/:GJMOIEO.UG;PWBP1Z@&)ADD,8#D(?+E!P2G. P^:DT3PK_8E_
M:W2>'O%UT+;3VTU8;F?3"C6[,6*MMD!/)ZYSQ22>%9)O"<WAF31?&K:6ZA(X
MC=Z:3"@??L4^;R,@<MN( P" 3D L:S\3M0M/#/BNYAT>*#4M#:%"C7/F)B8#
M8Y^4<C/*],CAB.:ZO7%\0WO@2\&FB&WUZ2U/E"&;<H?T5V5>2. 2  2/3-<7
M)X2%Q;^((;OP]XON5UU8A=E[C35(,?W&3;*,$8'7(/<&NBNI;V]T--*N/"WB
MAHU,;&<7EDLS,CJX.Y;@8)*C[N,=L<8 .7M/')TS0O$%Y:P:O!JNF62.^AZY
M,[^2<\RK*Q+R(2<#)R=H^X&!&MKGQ&U+PIH&FWVIZ-;3^;:+<7#1:@,G+JO[
MM/+W,<,K$D(@R%W$D9J:O9HFC:[>>(/#_BN\6?3G@NKZ>;3A)#;*"Y"+%*J\
M'+?=))QG(P*J:OX*36E5;K0?&O\ R#UT^0K>Z=^]C63S 3F4X.X _+@< 8QQ
M0!M>(OB;/I&L7UC8Z(EVEBUG'/)/=F$E[DG8$41ON4 #)SU) !Q5B#XF6,_C
M3_A'O)A&+PV!?[4/.\X(7)$6,^5QMWY^]QCO7(ZYH7CB^\0MK.FZ?J%O/:PQ
MQ67VRRTNY=BB=3(9@8=S%LA >N1UVCI["SO-/UV[U6V\-^*H/MLJSW5G%<V
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M6'_HV[KH*Y/0;V>^\=:W+<:9=Z>XTRQ41731,Q'FW?S#RW<8YQUSP>.F>LH
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M>:5;7-[:I:W$L8=X$D,@CSSC<54DXZ\#FKE%% !1110!S]Y_R4/1O^P5?_\
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M<K\W(W*PR.X([5N?\)WX/_Z&O0__  8P_P#Q5 '045S_ /PG?@__ *&O0_\
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MW,)B:4#. 7;." 1^N:V/^$[\'_\ 0UZ'_P"#&'_XJC_A._!__0UZ'_X,8?\
MXJ@#FT^%JKH-G:)?V-KJ-C=6]W;7=CI:0(9(00&EC#9D9MS9^8#I@#G=HZIX
M,U75-=T;6)==MOM.FP7,>#8$K(TRE20!*,*!C R3QRQS6G_PG?@__H:]#_\
M!C#_ /%4?\)WX/\ ^AKT/_P8P_\ Q5 ''VWPGO[2STJVC\1VQ73].N;!2VFM
MEQ/NRQ_?=1D8'L?7CN/"NB2>&_"^G:-+=+=-9Q"(3+%Y8< G'R[FP<8SSUYX
MZ57_ .$[\'_]#7H?_@QA_P#BJ/\ A._!_P#T->A_^#&'_P"*H +S_DH>C?\
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M?@__ *&O0_\ P8P__%4 8FC?#J6UFT ZQJZ7\&@1!-/@AM/(7?C'F29=R[8
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M?_@QA_\ BJ/^$[\'_P#0UZ'_ .#&'_XJ@#H**Y__ (3OP?\ ]#7H?_@QA_\
MBJ/^$[\'_P#0UZ'_ .#&'_XJ@#H**Y__ (3OP?\ ]#7H?_@QA_\ BJ/^$[\'
M_P#0UZ'_ .#&'_XJ@#H**Y__ (3OP?\ ]#7H?_@QA_\ BJ/^$[\'_P#0UZ'_
M .#&'_XJ@#H**Y__ (3OP?\ ]#7H?_@QA_\ BJ/^$[\'_P#0UZ'_ .#&'_XJ
M@#H**Y__ (3OP?\ ]#7H?_@QA_\ BJ/^$[\'_P#0UZ'_ .#&'_XJ@#H**Y__
M (3OP?\ ]#7H?_@QA_\ BJ/^$[\'_P#0UZ'_ .#&'_XJ@#H**Y__ (3OP?\
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M%%% !1110!S_ (-_Y =S_P!A74O_ $MFKH*Y_P &_P#(#N?^PKJ7_I;-704
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M[!5U_P"BFKH*Y_QW_P D\\2_]@JZ_P#135T% !1110 4444 %%%% '/^#?\
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MB*$15&<*,#))/YGK2T %%%% !1110 4444 %%%% '/\ @W_D!W/_ &%=2_\
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M"SMNEC(\K8R%_GY4D$#! &* )=*\4W^L:_+I\.A26UO!!;W$TUY/Y<@656(
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M_@]O?_CU'_"&Z7_S]:Y_X/;W_P"/4 =!17/_ /"&Z7_S]:Y_X/;W_P"/4?\
M"&Z7_P _6N?^#V]_^/4 =!17/_\ "&Z7_P _6N?^#V]_^/4?\(;I?_/UKG_@
M]O?_ (]0 >._^2>>)?\ L%77_HIJZ"N#\:>$].MO OB&=+G62\>F7+J)-:O'
M4D1,>5:4AA[$$'O6Y_PANE_\_6N?^#V]_P#CU '045S_ /PANE_\_6N?^#V]
M_P#CU'_"&Z7_ ,_6N?\ @]O?_CU '045S_\ PANE_P#/UKG_ (/;W_X]1_PA
MNE_\_6N?^#V]_P#CU '045S_ /PANE_\_6N?^#V]_P#CU'_"&Z7_ ,_6N?\
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M_P#PANE_\_6N?^#V]_\ CU'_  ANE_\ /UKG_@]O?_CU '045S__  ANE_\
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MBH_ T*VWAN2!#(4CU/4$4R2,[$"\F'+,26/N22>]% $GC+_D!VW_ &%=-_\
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M_P#($G_Q-'_">^&?^@E_Y D_^)HYX]R?KF&_Y^+[T=)17-_\)[X9_P"@E_Y
MD_\ B:/^$]\,_P#02_\ ($G_ ,31SQ[A]<PW_/Q?>CI**YO_ (3WPS_T$O\
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MGG?VE%Y?F9V[L-C..<9I2=E<QKU'3IN:Z?YK_,OOXDT-$9SK%B0HR=MPI/X
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MXK0I!=>.H[]HHDN+SP];33,BXW,7;KZ^G/:NUH **** "BBB@ HHHH ****
M"BBB@ HHHH **** .?\ !O\ R [G_L*ZE_Z6S44>#?\ D!W/_85U+_TMFHH
M/&7_ " [;_L*Z;_Z6PUT%<_XR_Y =M_V%=-_]+8:Z"@ HHHH **PO&+R1>%K
MR>&::&6(!D>*1D(.0.H(SU/%<[;ZGJFG6^I:C#]MDL$T^-D-X7.;@XY7?R5Y
M)../TJ'.SL<5;%JE4Y)+I>_W_P"1W]%<YI>E3W6BVEVVKWWVRX1)Y)?.)0[L
M,5"?="]N #[]JSFO;JQUUXM7DO[4SWBFWNT<M;/'NRL17.$)"XX^;J2<9R<P
MY8IQC&4HV3\UU[]OR\SM**Y:ZU:YE\9:9;0,?L96?A6($S*N#GV!X'N"?2L'
M2-;U-[F+RKJ:XO9;2Z:ZMV8MY<J%BF$/W?X1@ "DYJYG/'PC+EL][?E]^_ZG
MH]%<1X/U.>YU5(?MTMW%+IR3S>9*7\J??M*\_=XYQ7;U49<RN=&'KJO#G2_K
M^F%%%%4=!S_A[_D.>+/^PK'_ .D5K705S_A[_D.>+/\ L*Q_^D5K704 %%%%
M '!ZWH\UCXKO/$/A^U0:E:VL,MQ;1(%_M"-GE$B-CK)A%*L<\J!T)K/LM=L[
M+2HKKP9I=J\VNZBZQ-!:QC(6(R'<ADB#,-K#:74@ECR1M/>1Z-9QZU+JZFZ^
MURH(WS=RF,J.@$1;8,<]%ZDGJ3F"Z\+Z-=V1M)+()$;HW@\F1XF2<DDR(Z$,
MC$D\J1U/J: ,.#7/%=^T&G16>G6&L0V*7=W#>@NCEI'0*IC<[ ?+9LYDV[E&
M#UJO/XMURVD\2W4T.FK::3>K:0PJ'+S&18C&S2$@( 906^4\9'\.YMZ?PAHM
MPMN'@N5>W1HUECO9HY&1FW,KNKAI 6Y(8G)YI\/A3185U5!:/)'JI+7D4T\D
MJ2'&.%9B%XP/E X"CH!@ XKQ;J&K36]QI&HBUGOM.U#2KNWGMO,MX9A+<A56
M1-SD89'ZEA]U@ 16E<^(-66=-/U&STJ\EM=<M;22<1LJ%9%1TD2,EBLB[@.6
MXQD9SBNCC\)Z*FF7&G&UDE@N"ID:>XEED)7&TB1V+@K@%<'Y3R,&FR^$=&FM
M+>U>&Y\NWN!=*PO9@[2CH[N'W.1@<L3T'I0!C6?BO5KBZTZ_,5FVC:CJ$MA'
M B,+B$H742,^XJV3$V5"J5W#EMISFS>+M3N?#FH->V6FRW5O):B>PNK:6)H1
M))AMR/D2 <!75MK%2<C&VNOMO"^CVFKOJD%JR7+RO-CSI#&LC##2+$6V*Y&0
M6"@G<V3R<U&\"^'VT^6Q:WNS!)Y88'4+C=MC)*(&W[@BDDA 0H/.* ([/Q!?
M/XTGT>[$%O"0[6\4EO*DDBH$^9)>8Y0=Y) VLF,$-U'3UE6WAW3;34_[0BCG
M-QAL>9=2R(I;[S*C,5#'NP&<$C/)K5H **** /./BM_S"/\ MM_[)7F]>D?%
M;_F$?]MO_9*\WKAJ_&SX/-_]\G\OR04445F>6%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5L>'?$5WX=OQ/ =\+8$L)/#C^A]#6/78^#?!KZU(
MM]?*R:>IX7H9CZ#V]3503;T.K"4ZTZT50^+\CM/%.H0:K\+-?O;8L8I=(NB-
MPP1^Z;(-=57.^-XTB^''B..-%1%TFZ"JHP /);@5T5>@C]$C?E7-N%%%%!04
M444 %%%% '/^#?\ D!W/_85U+_TMFKH*Y_P;_P @.Y_["NI?^ELU=!0 4444
M %%%% '/V?\ R4/6?^P58?\ HV[K:NK.UOHA%=VT-Q&#N"2H'&?7!K%L_P#D
MH>L_]@JP_P#1MW63\4/^1:MO^OQ?_0'J9.R;.?%552HRJ-7LMCI/^$>T3_H#
MZ?\ ^ R?X4NHZ!HVL1PIJ>DV%ZD&?*6YMDD$><9V[@<=!T]*\!KU[4O$%WH?
MPGEUR/,]Y!IXD0RDMER  S>N"<GUQ6=.:D]CSLMQ\,3.48PY;+R_R1T-KH6C
MV.G3Z=9Z58V]C/N\ZVAMT2.3<-K;E P<@ '/45%#X8\/V[VKPZ'ID;VF?LS)
M:1J8<DD[,#Y>23QW-<OKMM<^$--L=;L]4U&[NQ=V\-VES=R31W:2R*C@1D[(
MSEMRF-5QC&-I(-Z+QE>O)91MI-N&N-5GTM\7C$(\:.RL/W?*MY; ]",C[U;'
MLG0Q:+I4.J2:I%IEG'J$HVR7:0*)7''!?&3T'?L*KKX7\/I93V2Z%I@M+AQ)
M- +2/9(PZ,RXP3[FL7PWXP$FA6UWXGO=)TVXN[B9+93>@>:%D*X 95Y'"\9R
M,$G)Q6;%K-SI\FLI=F_U*-O%5O9QM]J\K[,DBVVWE<'8K/\ < .[.&ZL: .K
M'A3PZJ3H- TL)<(L<RBSCQ(JXVJW'(&!@'I@5')X-\+R[_,\-Z._F,&?=8Q'
M<0" 3\O) )_,U4B\57,ANK\Z6HT"W^TAKX7(\Q3 2')B*CY2R. 0Q)P"0 >,
M4?$B^72[B]D\*7Y"2VJ1;1)$LBS2!/O3QQ_,"1PH899?FQEE .J;PMX>:"X@
M;0=+,-S()9XS9Q[97&2&88^8\GD^M/G\.:'=:?'87&C:=-91N9([>2U1HT<D
MDL%(P"2S<^Y]:YZ;QW)9Z;<S7VGVMK/:ZG_9\_F7V($/E"4.9B@P"K!1N &\
M@9&<U%K'C671SJ%X^A74DUGHR7Y1;Y?+<,QW* "5^4@Y?&2 < C&0#K;[2--
MU2S6SU#3[2[M5(*P7$*R(". 0I!'%,N-#TB\TV+3;G2K&>PBV^7:RVZ-$FT8
M&$(P,#@<5S\GC.ZMH-6%WHWDW=E);)' +D,'%PP6,NX7"8)^?&X  X+5I^&]
M9U#6%U :AIUO926=TUMMANC.'*@$G)C3 Y&/UQTH >_A#PS(LZOX=TEEGD$L
MP:RC(D<9PS?+R?F;D^I]:?'X6\/0M;M%H.EHUL_F0%;.,&)LYW+Q\ISSD55U
MSQ!>Z;K.F:78Z1]LFOQ*4EDN5ABC*#.&.&;\E/XUC7WQ GL_#]GK;:1#'9N?
M+N?M-^L3I,)#&T42[3YK JYYV@@#!ZX .K71=*35GU9-,LUU)QM>\$"B9A@#
M!?&XC  Z] *@U#PQX?U>Z^TZEH6F7MQM"^;<VD<CX'098$XKE=>\;:Y%I/BV
M;3=&@A_L/S(OM%U=_,S"-7#K&J,",/G!8?PYP20LU_XZU33;S4K>X\.)_P 2
MR"WN+N5;\%"DK,I\OY-S$;3@,%SALE<+N -^Z\'^&+^Y>YO/#FD7%Q(<O+-8
MQNS=N25R:V(XXX8DBB14C10JHHP% Z #L*Y%O'$K>)WTNTT.\O+6*<VTMS#%
M*=L@3<>3'Y6W.%R9003TQS5:V\87NI:1H^I7>@O;VNH7T$,'E:B=\9+D%I0H
M'RY PH+A@?FV\B@#H[3PMX>T^YCN;+0=+MIXE*QRPV<:,@.<@$#(!R?S-1_\
M(=X8^RI;?\(YI'V=)#*D7V&+8KD %@-N 2%49]AZ5C:1XYN]2U2SMY]!>SMK
MJ_NM/222Z5Y!+ )"<HH(VD1D9W<-P 1AC)H?C#4=9UNSM3HUO!8WEM-=Q7!O
M6:41QNJ8>/RP%?+KE=Q YY)&* -RR\.Z'IMTMU8Z-I]K<+'Y2RP6J(X3^Z"!
MG'M6G6?K>K1:'I$^H31O(L6T+&F-SLS!549XY9@/QKF+[QW?Z9++8W?A_=J<
M=U:0F*WO0T)CN'*)()&53]X,I&S.0.QW  [>BL?4M9GTC1(KN\M(S?2R1VZ6
MT$Q9&FD<(B[RH.W+#+;>!DX/0\WJ7C'74:.QM]*LX-4BU."TN8Y+QC$5D&]2
MC^5DA@""2H*\\'@T =Y17G^@>(M3L=4FLKV*:\M;C79[);V>Y!=&V,ZJJ!<%
M!L*]5QD8!Y-,'Q/F?2]2U2#PW>SV%O927MM.JRQI,BD<,\D2HI*G=\C2<*V,
MG (!Z'15/39[VYLUFOK2*UE<Y6*.<RX7MD[5PWJ!D#L35R@ HHHH **** "B
MBB@ HHHH Y_P;_R [G_L*ZE_Z6S44>#?^0'<_P#85U+_ -+9J* #QE_R [;_
M +"NF_\ I;#705S_ (R_Y =M_P!A73?_ $MAKH* "BBB@"CJ^EQZSITEC---
M%%)C>8MN6'IR#[?E3XM/B33%T^9FN(1'Y1\T#++TP< #IQTJW12LMR/9QYG*
MVK5OD9-GH$5BL<,=[>-:1/OCMG=2B<Y SMW$#L"QZ=Z8OARW_=QR75W+:I-Y
MPMI&4H7R2#]W=C/.,XXZ5LT4<J,_J]*UK?U]_P"&QC/X8TMM6@U*.W2">$-@
M11HJLQ_B(V\D=0:LVVDQVQGE%Q<2W<RE&NI6#2*.2 HQM4 G. ,>H-:%%'*A
MJA3B[J)3L--AT\2E&DEFF;=+/,VYY#VR?0=@, =A5RBBF:1BHJR"BBB@HY_P
M]_R'/%G_ &%8_P#TBM:Z"N?\/?\ (<\6?]A6/_TBM:Z"@#D_$-OO\;>%R+J^
MC6628210WDL<<@2,NNY%8*WS=<CD<'(XK0\0ZI_9UQHT1L[B=;N_6'S(KCRA
M$=K$%L$%@<?=P0>^.*36?#;:QJEEJ":UJ-C+9!O)6U6 J&8$,Q\R)R20<=<>
MV>:K2^#UECM3)K>JR36][]O:4^1OFE"A0&_=[0 HV@*%X_.@#.T_Q_<3Q6=[
MJ&A-8:;=7%S:B9KI9)(Y8?-)W(HQM(A;D,<,,8(PQFA\9W;A1>Z$\2WFGR7^
MGB"Z#O,B!2R/D*(I,.AP"R\M\W'-7P=X5N#9B;7H;^)H;R\FATZZ>!X4\Z20
MB1?+W$G9*RD,Y )? Z&M2S\$VME;- FJ:E(J6KV=F97C8V4+8RL>4YX5!F3>
M<*!GKD YGQ'XIOKKX>72:%%<6\D.A1WUQ<B^/G6JNA*!796,K?(VYB5..0=Q
M%;DGBI;+5]6A;3[DW%M#810E[HE+I[AW1 %R1& PPSXW$9R"%7+9_AO83::+
M%=7U:&-].73+AHGB!N8%R$#YC(RH9@&4 X.#FK,O@.QFFOGEU'4W6[M[> (T
MJ$P^0=T,B.5WEU8ELLS9).[/% "ZCXCUS2]">_N]#L;>2%Y//,^JJENL:CY7
M$FPL=Q( !0<YSCC-F]\2;/!,?B"VA :YMX9((Y>@>7:$#8[9<9Q5>^\%)J*V
MK76N:K+=6SR.ETP@+_.H0C:8MB_*, JH(RW/S'-L^&(U\&+X<2]G9(K=88+F
M94:1-F#&Q"A5.TA>PSMYYYH S+W7[SPTM_8?9O[0:PTI]2^TW%X5>X(8[PP$
M9"=R N5'  48QGZA=:AH^N2>([*6\GTU+."XU+3GN))@(Y#)NEB#$A638IVJ
M &7<,9Q6M?\ A9_$UNMQJ<]YI=Y+9RV-Y%8RQLDL;'D;F0G:<;E(VMAN0#D#
M0TOPZ-*O_M$6JZA+#]FCMEMIVC=%5,[3NV>83RQR7/WC[8 .-O;.VGTNPNK+
M5=7>"ZUN*)98]9NB)('<# /F="N,8_"NXU^.Y.DRW%E</#=6@-Q%@_*[*I^1
MQ_$C#(([9R,, 1DR^ M/73+33M.OKW2[2UO&O8H[00X$A?>/]9&V%4DX P.<
M'/&)+G0]1M;"\BM;^\U*^U(+;O=WK1*+:,*WS;8T0$#+8 4DLPR0,LH!N:9?
MQZII5GJ$((BNH$G0'J%90P_G5JLK2].NM.NW@24#28K>*&T@W*=FT8/1 1QC
MJSY[;<8.K0!S]Y_R4/1O^P5?_P#HVTKH*Y^\_P"2AZ-_V"K_ /\ 1MI704 %
M%%% !1110 4444 <_>?\E#T;_L%7_P#Z-M*Z"N?O/^2AZ-_V"K__ -&VE=!0
M 4444 %%%% !7/\ C+_D!VW_ &%=-_\ 2V&N@KG_ !E_R [;_L*Z;_Z6PT =
M!1110 4444 >0^#?!KZU(M]?*R:>IX'0S'T'MZG_ "/7(XTBC6.-%1% "JHP
M /041QI%&L<:*B* %51@ >@IU1""BCAP6"IX6GRQWZOO_P  Y_QW_P D\\2_
M]@JZ_P#135T%<_X[_P"2>>)?^P5=?^BFKH*L[@HHHH **** "BBB@#G_  ;_
M ,@.Y_["NI?^ELU=!7/^#?\ D!W/_85U+_TMFKH* "BBB@ HHHH Y^S_ .2A
MZS_V"K#_ -&W=7->T&U\0V*6EW),D:2"4&(@'(!'<'CDU3L_^2AZS_V"K#_T
M;=UT%)J^C(G"-2+A-73.)_X5?HG_ #]:A_W\3_XBNHCTBS71!I$L?VBS\CR&
M2;#;TQ@AO7(J]1244MD8T<+1HMNG%)LYRU\'P03VAN-4U*^M+)@]I9W4B&*%
MA]PY5 [E1P/,9O7E@"(I/ ME+JT=\VHZF(XM0.I1VB2JD2SE2K'*J'(.XD@L
M1U'0D&?5O&-AI%S<I-;7DMO9[/MUU"BF.TWXV[\L&/!!.U6P#DX%5D\>:>^H
M2V_V#4U@AOQITUY);A(HYFV[ =Q#$,6 !"D9(S@$$T=)KZ)HL>A6LMK!=W$U
MNTSRQQS;,0[F+%5*J"5R3][)]ZQI_ <,_P!LSKNK+]JU*/4VVBW^6:/;MQF+
M[HV1\'/W!ZME=-\?Z;J4UOML=3MK6XN)K6.[NH!%&9HRVY""VX'",02H'8D,
M"H:/B#IBV\EQ/8ZG! ;-[ZTD> -]MA7!+1!6)'!4[7"'# D  X +L'A*VM[F
M[V7U\=.NI)9)-,+I]GW2@B0_=WX)9FV[]N6) '&*<W@99]&72I?$6MM;1O"T
M.YX"T0B8.B@F+YOF5#EMS':.<%@81XYO)M8TNUM_"^JF"_MIKF-Y&MU>1$\O
M!53,"H_>#(?:PR..N'_\+$TL6$5\UCJ0MYM(;5XW$2N6B4J&3:K$[QO7J-N#
MG=P< %F/P<83J+0^(-7C>_N_M<C 6YPWE^65 ,6TJ5VC#!ON*1@Y)IW?PXT^
MYM9;1-5U.WM)--32_(B,.U8%[ M&3D\Y.?XCC'&'77CW3SHFLW,EMK%E]ALD
MNR1;*9C%(&"21H=P'*MQ(!C&6 &:AO\ QNUH?$B76GZG;V6DV:2&]MTBED)9
M2=RKN/."",KM&UB^!Q0 FN>$;A;/4IX;S5M4FU 6T5U"&M%9DC8?,H:-48D;
MMRN=I#,,=%J;P_I.LV.GVEM:FZL;.*[5C;W:V<;K%@EU"V\9CVL2, %6SDEO
MX3->?$'0].\16VA3SEKJ1XH6?S81LDD *!D+B0YRO*H5&X9(YQJ:-X@BUJ28
M06=Y%$A)CGE1?+F4,5W(RL1U4_*<,,<J,C(!D^*=,U/4?$WA][%+^&&W,QFO
MK1X,P[U"CY9<[AUS\C<=.<5%?_#?2[U(TCO]0M0MG]C<PF)C(F\N23)&Q#%S
MN)7&3C.<"J>I^)=27Q;J,3R7VF:9H\=O-(ZPP31W(=FRK#<9,N%"ILP0<EAT
M%:5S\0+"PAG^W:;JMO>07$%N]D8%DE'G'$;Y1F383D9W=05^]@$ FC\%6WV+
M7[2ZU/4+R/7 ?M/G>2"I,8CW)LC7!VA1SD?*#CKFM=^ 4OFU)KGQ%K,C:C;Q
M6]P<6PRL;%E(Q#P<L_\ WT?08T=?UZ[TGP7J&N1Z5/\ :;:UDG%I*T>Y"JDY
M<A]N!C)VL3CID\5SNG>,+K0].U=]<CUJ\>RM8M1*SPVBRK ^5.#$X1@&CD;D
M*V#CYN* .@A\*BVOIKFVUO5(!<,);B%&BV2RA0OF',>5)VJ2%(4D<J02#6C\
M$0Q:'IFDIK.J"'3KE;F*3]QO9E.Y0W[K& ?0 ^I-0:UX]73X]>6QT34[V71H
M6DN9 B11)^[W@YD=2RX!^X&/'3E<YK^.K[3-?O)-5L[W^SUTFVOOLT4$>ZT!
M>59'D?>5/W%. V<8PI(8T :EOX$2SGL[B+7-5EDL[Z?4(UD^SA7EEW;PQ$.=
MIWN..1O..BXQ_#/A_5].GN9+>SU.PNKB%S<RW?\ 9X2:7:=I$L2-*[!VR&D#
M<;B02<'<O_B#H>G>*(] FE)NGE2!F66+Y)'&50QE_-.<KRJ%?F'/7%_P[XEB
M\36S7=II]_!:!F5)KJ-8Q(RNR, N[>,%>ZC\\@ $]QI"ZKX;_LK6',YE@6.X
MD1MI+@#Y@0!@Y&00!SV'2LBY\"PW=OMFUO56NS<03M>GR/-;R&+1*?W6S:K$
MMPN22<DY(JI=^+;F?QCH-I8":+29KNYMY[B2!?+NC'!(QV/N)4*Z8.5&XCY2
M5!RRW^*FA7MMJ4]E!=78L;;[64MY+>1I(,X+@"7Y<<$J^Q@"/ESD  ZG6M'M
M=>TJ73[LR*CE662)MLD3J0R.A[,K $=1QR".*S)/!UO-9R))J>H-?/=1W;:@
M?*\[S(P F!Y?E@!1C 3'4]232ZIXPL]%@N)]0M9[>*%(B)))8%61Y,XC#&3
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MT%<_XR_Y =M_V%=-_P#2V&@#H**** "BBB@ HHHH Y_QW_R3SQ+_ -@JZ_\
M135T%<_X[_Y)YXE_[!5U_P"BFKH* "BBB@ HHHH **** .?\&_\ (#N?^PKJ
M7_I;-705S_@W_D!W/_85U+_TMFKH* "BBB@ HHHH Y^S_P"2AZS_ -@JP_\
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M_P %T/\ \31_P@G@_P#Z%30__!=#_P#$UT%% '/_ /"">#_^A4T/_P %T/\
M\31_P@G@_P#Z%30__!=#_P#$UT%% '/_ /"">#_^A4T/_P %T/\ \31_P@G@
M_P#Z%30__!=#_P#$UT%% '/_ /"">#_^A4T/_P %T/\ \31_P@G@_P#Z%30_
M_!=#_P#$UT%% '/_ /"">#_^A4T/_P %T/\ \31_P@G@_P#Z%30__!=#_P#$
MUT%% '/_ /"">#_^A4T/_P %T/\ \31_P@G@_P#Z%30__!=#_P#$UT%% '/_
M /"">#_^A4T/_P %T/\ \31_P@G@_P#Z%30__!=#_P#$UT%% '/_ /"">#_^
MA4T/_P %T/\ \31_P@G@_P#Z%30__!=#_P#$UT%% '/_ /"">#_^A4T/_P %
MT/\ \31_P@G@_P#Z%30__!=#_P#$UT%% '/_ /"">#_^A4T/_P %T/\ \31_
MP@G@_P#Z%30__!=#_P#$UT%% '/_ /"">#_^A4T/_P %T/\ \31_P@G@_P#Z
M%30__!=#_P#$UT%% '/_ /"">#_^A4T/_P %T/\ \31_P@G@_P#Z%30__!=#
M_P#$UT%% '/_ /"">#_^A4T/_P %T/\ \31_P@G@_P#Z%30__!=#_P#$UT%%
M '/_ /"">#_^A4T/_P %T/\ \31_P@G@_P#Z%30__!=#_P#$UT%% '/_ /""
M>#_^A4T/_P %T/\ \31_P@G@_P#Z%30__!=#_P#$UT%% '/_ /"">#_^A4T/
M_P %T/\ \31_P@G@_P#Z%30__!=#_P#$UT%% '/_ /"">#_^A4T/_P %T/\
M\31_P@G@_P#Z%30__!=#_P#$UT%% '/_ /"">#_^A4T/_P %T/\ \31_P@G@
M_P#Z%30__!=#_P#$UT%% '/_ /"">#_^A4T/_P %T/\ \31_P@G@_P#Z%30_
M_!=#_P#$UT%% '/_ /"">#_^A4T/_P %T/\ \31_P@G@_P#Z%30__!=#_P#$
MUT%% '/_ /"">#_^A4T/_P %T/\ \31_P@G@_P#Z%30__!=#_P#$UT%% '/_
M /"">#_^A4T/_P %T/\ \31_P@G@_P#Z%30__!=#_P#$UT%% '/_ /"">#_^
MA4T/_P %T/\ \31_P@G@_P#Z%30__!=#_P#$UT%% '/_ /"">#_^A4T/_P %
MT/\ \31_P@G@_P#Z%30__!=#_P#$UT%% '/_ /"">#_^A4T/_P %T/\ \31_
MP@G@_P#Z%30__!=#_P#$UT%% '/_ /"">#_^A4T/_P %T/\ \31_P@G@_P#Z
M%30__!=#_P#$UT%% '/_ /"">#_^A4T/_P %T/\ \31_P@G@_P#Z%30__!=#
M_P#$UT%% '/_ /"">#_^A4T/_P %T/\ \31_P@G@_P#Z%30__!=#_P#$UT%%
M '/_ /"">#_^A4T/_P %T/\ \31_P@G@_P#Z%30__!=#_P#$UT%% '/_ /""
M>#_^A4T/_P %T/\ \31_P@G@_P#Z%30__!=#_P#$UT%% '/_ /"">#_^A4T/
M_P %T/\ \31_P@G@_P#Z%30__!=#_P#$UT%% '/_ /"">#_^A4T/_P %T/\
M\31_P@G@_P#Z%30__!=#_P#$UT%% '/_ /"">#_^A4T/_P %T/\ \31_P@G@
M_P#Z%30__!=#_P#$UT%% '/_ /"">#_^A4T/_P %T/\ \31_P@G@_P#Z%30_
M_!=#_P#$UT%% '/_ /"">#_^A4T/_P %T/\ \31_P@G@_P#Z%30__!=#_P#$
MUT%% '/_ /"">#_^A4T/_P %T/\ \31_P@G@_P#Z%30__!=#_P#$UT%% '/_
M /"">#_^A4T/_P %T/\ \31_P@G@_P#Z%30__!=#_P#$UT%% '/_ /"">#_^
MA4T/_P %T/\ \31_P@G@_P#Z%30__!=#_P#$UT%% '/_ /"">#_^A4T/_P %
MT/\ \31_P@G@_P#Z%30__!=#_P#$UT%% '/_ /"">#_^A4T/_P %T/\ \31_
MP@G@_P#Z%30__!=#_P#$UT%% '/_ /"">#_^A4T/_P %T/\ \31_P@G@_P#Z
M%30__!=#_P#$UT%% '/_ /"">#_^A4T/_P %T/\ \31_P@G@_P#Z%30__!=#
M_P#$UT%% '/_ /"">#_^A4T/_P %T/\ \31_P@G@_P#Z%30__!=#_P#$UT%%
M '/_ /"">#_^A4T/_P %T/\ \31_P@G@_P#Z%30__!=#_P#$UT%% '/_ /""
M>#_^A4T/_P %T/\ \31_P@G@_P#Z%30__!=#_P#$UT%% '/_ /"">#_^A4T/
M_P %T/\ \31_P@G@_P#Z%30__!=#_P#$UT%% '/_ /"">#_^A4T/_P %T/\
M\31_P@G@_P#Z%30__!=#_P#$UT%% '/_ /"">#_^A4T/_P %T/\ \31_P@G@
M_P#Z%30__!=#_P#$UT%% '/_ /"">#_^A4T/_P %T/\ \31_P@G@_P#Z%30_
M_!=#_P#$UT%% '/_ /"">#_^A4T/_P %T/\ \31_P@G@_P#Z%30__!=#_P#$
MUT%% '/_ /"">#_^A4T/_P %T/\ \31_P@G@_P#Z%30__!=#_P#$UT%% %>Q
@L+/3+..SL+2"TM8\[(8(Q&BY))PHX&22?QHJQ10!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_006.jpg
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !/ 4H# 2(  A$! Q$!_\0
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MZ9DBEN'MF0L$9\'RYF(X4]L5O5B:U_R'?#G_ %^R_P#I-+6W0 4444 %%%%
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F;=HXQ[58HH 9##%;01P01)%#&H2.-%"JB@8  '  ':GT44 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>pcsa-20230331.xsd
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaCF6bP9z5Z8mekhvWB0bXkK7ygjcKKiciDQ6btW0YoD -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:PCSA="http://processapharmaceuticals.com/20230331" elementFormDefault="qualified" targetNamespace="http://processapharmaceuticals.com/20230331">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/BalanceSheets" id="BalanceSheets">
	  <link:definition>00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/StatementsOfOperations" id="StatementsOfOperations">
	  <link:definition>00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/StatementOfChangesInStockholdersEquity" id="StatementOfChangesInStockholdersEquity">
	  <link:definition>00000005 - Statement - Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
	  <link:definition>00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical" id="StatementsOfCashFlowsParenthetical">
	  <link:definition>00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" id="OrganizationAndSummaryOfSignificantAccountingPolicies">
	  <link:definition>00000008 - Disclosure - Organization and Summary of Significant Accounting Policies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/StockholdersEquity" id="StockholdersEquity">
	  <link:definition>00000009 - Disclosure - Stockholders&#8217; Equity</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/Stock-basedCompensation" id="Stock-basedCompensation">
	  <link:definition>00000010 - Disclosure - Stock-based Compensation</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock" id="NetLossPerShareOfCommonStock">
	  <link:definition>00000011 - Disclosure - Net Loss per Share of Common Stock</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/OperatingLeases" id="OperatingLeases">
	  <link:definition>00000012 - Disclosure - Operating Leases</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
	  <link:definition>00000013 - Disclosure - Related Party Transactions</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000014 - Disclosure - Commitments and Contingencies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" id="OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies">
	  <link:definition>00000015 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/Stock-basedCompensationTables" id="Stock-basedCompensationTables">
	  <link:definition>00000016 - Disclosure - Stock-based Compensation (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTables" id="NetLossPerShareOfCommonStockTables">
	  <link:definition>00000017 - Disclosure - Net Loss per Share of Common Stock (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/OperatingLeasesTables" id="OperatingLeasesTables">
	  <link:definition>00000018 - Disclosure - Operating Leases (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" id="OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative">
	  <link:definition>00000019 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
	  <link:definition>00000020 - Disclosure - Stockholders&#8217; Equity (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails" id="ScheduleOfStock-basedCompensationExpenseDetails">
	  <link:definition>00000021 - Disclosure - Schedule of Stock-based Compensation Expense (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockAwardsRsasActivityDetails" id="ScheduleOfRestrictedStockAwardsRsasActivityDetails">
	  <link:definition>00000022 - Disclosure - Schedule of Restricted Stock Awards (&#8220;RSAs&#8221;) Activity (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails" id="ScheduleOfRestrictedStockUnitsRsusActivityDetails">
	  <link:definition>00000023 - Disclosure - Schedule of Restricted Stock Units (&#8220;RSUs&#8221;) Activity (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative" id="Stock-basedCompensationDetailsNarrative">
	  <link:definition>00000024 - Disclosure - Stock-based Compensation (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDiluteDetails" id="ScheduleOfNetLossPerShareBasicAndDiluteDetails">
	  <link:definition>00000025 - Disclosure - Schedule of Net Loss Per Share Basic and Dilute (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockDetailsNarrative" id="NetLossPerShareOfCommonStockDetailsNarrative">
	  <link:definition>00000026 - Disclosure - Net Loss per Share of Common Stock (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingLeasesDetails" id="ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingLeasesDetails">
	  <link:definition>00000027 - Disclosure - Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating Leases (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails" id="ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails">
	  <link:definition>00000028 - Disclosure - Schedule of Annual Lease Liabilities for all Operating Leases (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/OperatingLeasesDetailsNarrative" id="OperatingLeasesDetailsNarrative">
	  <link:definition>00000029 - Disclosure - Operating Leases (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
	  <link:definition>00000030 - Disclosure - Related Party Transactions (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
	  <link:definition>00000031 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="pcsa-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="pcsa-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="pcsa-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="pcsa-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
    <element id="PCSA_ConsultingAgreementMember" name="ConsultingAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_PurchaseAgreementMember" name="PurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_LincolnParkCapitalFundLLCMember" name="LincolnParkCapitalFundLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_SalesAgreementMember" name="SalesAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_SecuritiesPurchaseAgreementMember" name="SecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_RegisteredDirectOfferingMember" name="RegisteredDirectOfferingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_AccreditedInvestorMember" name="AccreditedInvestorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_PlacementAgentMember" name="PlacementAgentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_SpartanCapitalSecuritesLLCMember" name="SpartanCapitalSecuritesLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_TwoThousandAndNineteenPlanMember" name="TwoThousandAndNineteenPlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ThreeDirectorsMember" name="ThreeDirectorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ConsultantMember" name="ConsultantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_CommittedWarrantMember" name="CommittedWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_FacilityLeaseMember" name="FacilityLeaseMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_CorLystLLCMember" name="CorLystLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_AgreementsMember" name="AgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ContractResearchOrganizationsMember" name="ContractResearchOrganizationsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_DueToLicensor" name="DueToLicensor" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_SharesIssuedInConnectionWithPurchaseAgreementValue" name="SharesIssuedInConnectionWithPurchaseAgreementValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_SharesIssuedInConnectionWithPurchaseAgreementShares" name="SharesIssuedInConnectionWithPurchaseAgreementShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_DisclosureOperatingLeasesAbstract" name="DisclosureOperatingLeasesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_BusinessActivitiesAndOrganizationPolicyTextBlock" name="BusinessActivitiesAndOrganizationPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_LiquidityPolicyTextBlock" name="LiquidityPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock" name="ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingLeasesTableTextBlock" name="ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_MaximumValueToBeSoldAtMarketOffering" name="MaximumValueToBeSoldAtMarketOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_GrossProceedsFromIssuanceOfCommonStock" name="GrossProceedsFromIssuanceOfCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_MaximumCommitmenttoPurchaseCommonStockValue" name="MaximumCommitmenttoPurchaseCommonStockValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ThresholdPrice" name="ThresholdPrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_RestrictionsToIssueStock" name="RestrictionsToIssueStock" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_TransactionCostsPercentage" name="TransactionCostsPercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ReimbursementFees" name="ReimbursementFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_UnrecognizedShareBasedCompensationExpense" name="UnrecognizedShareBasedCompensationExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_NumberOfWarrantExercisableShares" name="NumberOfWarrantExercisableShares" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ProceedsFromRentAndOtherCostsReimbursements" name="ProceedsFromRentAndOtherCostsReimbursements" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpectedToVestOutstandingNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpectedToVestOutstandingNumber" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_TwoThousandTwentyThreeMember" name="TwoThousandTwentyThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>pcsa-20230331_cal.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/Cover" xlink:href="pcsa-20230331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/BalanceSheets" xlink:href="pcsa-20230331.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/BalanceSheetsParenthetical" xlink:href="pcsa-20230331.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StatementsOfOperations" xlink:href="pcsa-20230331.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StatementOfChangesInStockholdersEquity" xlink:href="pcsa-20230331.xsd#StatementOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StatementsOfCashFlows" xlink:href="pcsa-20230331.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical" xlink:href="pcsa-20230331.xsd#StatementsOfCashFlowsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="pcsa-20230331.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StockholdersEquity" xlink:href="pcsa-20230331.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/Stock-basedCompensation" xlink:href="pcsa-20230331.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock" xlink:href="pcsa-20230331.xsd#NetLossPerShareOfCommonStock" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/OperatingLeases" xlink:href="pcsa-20230331.xsd#OperatingLeases" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/RelatedPartyTransactions" xlink:href="pcsa-20230331.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/CommitmentsAndContingencies" xlink:href="pcsa-20230331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="pcsa-20230331.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/Stock-basedCompensationTables" xlink:href="pcsa-20230331.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTables" xlink:href="pcsa-20230331.xsd#NetLossPerShareOfCommonStockTables" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/OperatingLeasesTables" xlink:href="pcsa-20230331.xsd#OperatingLeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="pcsa-20230331.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative" xlink:href="pcsa-20230331.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:href="pcsa-20230331.xsd#ScheduleOfStock-basedCompensationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockAwardsRsasActivityDetails" xlink:href="pcsa-20230331.xsd#ScheduleOfRestrictedStockAwardsRsasActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails" xlink:href="pcsa-20230331.xsd#ScheduleOfRestrictedStockUnitsRsusActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="pcsa-20230331.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDiluteDetails" xlink:href="pcsa-20230331.xsd#ScheduleOfNetLossPerShareBasicAndDiluteDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockDetailsNarrative" xlink:href="pcsa-20230331.xsd#NetLossPerShareOfCommonStockDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingLeasesDetails" xlink:href="pcsa-20230331.xsd#ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails" xlink:href="pcsa-20230331.xsd#ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/OperatingLeasesDetailsNarrative" xlink:href="pcsa-20230331.xsd#OperatingLeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="pcsa-20230331.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="pcsa-20230331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssetsNoncurrent" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaapSecurityDeposit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssetsNoncurrent" xlink:to="loc_us-gaapSecurityDeposit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_DueToLicensor" xlink:label="loc_PCSADueToLicensor" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_PCSADueToLicensor" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaapTreasuryStockValue" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapTreasuryStockValue" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StatementOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Condensed Consolidated Statement of Changes in Stockholders&apos; Equity (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapOperatingLeaseExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:label="loc_us-gaapIncreaseDecreaseInDueToRelatedParties" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDueToRelatedParties" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="loc_us-gaapIncreaseDecreaseInOtherReceivables" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherReceivables" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfEquity" xlink:label="loc_us-gaapPaymentsForRepurchaseOfEquity" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsForRepurchaseOfEquity" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical" xlink:title="00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - Organization and Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StockholdersEquity" xlink:title="00000009 - Disclosure - Stockholders&#8217; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Stock-basedCompensation" xlink:title="00000010 - Disclosure - Stock-based Compensation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock" xlink:title="00000011 - Disclosure - Net Loss per Share of Common Stock" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/OperatingLeases" xlink:title="00000012 - Disclosure - Operating Leases" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/RelatedPartyTransactions" xlink:title="00000013 - Disclosure - Related Party Transactions" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/CommitmentsAndContingencies" xlink:title="00000014 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000015 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Stock-basedCompensationTables" xlink:title="00000016 - Disclosure - Stock-based Compensation (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTables" xlink:title="00000017 - Disclosure - Net Loss per Share of Common Stock (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/OperatingLeasesTables" xlink:title="00000018 - Disclosure - Operating Leases (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000019 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000020 - Disclosure - Stockholders&#8217; Equity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:title="00000021 - Disclosure - Schedule of Stock-based Compensation Expense (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockAwardsRsasActivityDetails" xlink:title="00000022 - Disclosure - Schedule of Restricted Stock Awards (&#8220;RSAs&#8221;) Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails" xlink:title="00000023 - Disclosure - Schedule of Restricted Stock Units (&#8220;RSUs&#8221;) Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="00000024 - Disclosure - Stock-based Compensation (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDiluteDetails" xlink:title="00000025 - Disclosure - Schedule of Net Loss Per Share Basic and Dilute (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockDetailsNarrative" xlink:title="00000026 - Disclosure - Net Loss per Share of Common Stock (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingLeasesDetails" xlink:title="00000027 - Disclosure - Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating Leases (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails" xlink:title="00000028 - Disclosure - Schedule of Annual Lease Liabilities for all Operating Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/OperatingLeasesDetailsNarrative" xlink:title="00000029 - Disclosure - Operating Leases (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000030 - Disclosure - Related Party Transactions (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000031 - Disclosure - Commitments and Contingencies (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>pcsa-20230331_def.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/Cover" xlink:href="pcsa-20230331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/BalanceSheets" xlink:href="pcsa-20230331.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/BalanceSheetsParenthetical" xlink:href="pcsa-20230331.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StatementsOfOperations" xlink:href="pcsa-20230331.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StatementOfChangesInStockholdersEquity" xlink:href="pcsa-20230331.xsd#StatementOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StatementsOfCashFlows" xlink:href="pcsa-20230331.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical" xlink:href="pcsa-20230331.xsd#StatementsOfCashFlowsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="pcsa-20230331.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StockholdersEquity" xlink:href="pcsa-20230331.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/Stock-basedCompensation" xlink:href="pcsa-20230331.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock" xlink:href="pcsa-20230331.xsd#NetLossPerShareOfCommonStock" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/OperatingLeases" xlink:href="pcsa-20230331.xsd#OperatingLeases" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/RelatedPartyTransactions" xlink:href="pcsa-20230331.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/CommitmentsAndContingencies" xlink:href="pcsa-20230331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="pcsa-20230331.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/Stock-basedCompensationTables" xlink:href="pcsa-20230331.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTables" xlink:href="pcsa-20230331.xsd#NetLossPerShareOfCommonStockTables" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/OperatingLeasesTables" xlink:href="pcsa-20230331.xsd#OperatingLeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="pcsa-20230331.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative" xlink:href="pcsa-20230331.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:href="pcsa-20230331.xsd#ScheduleOfStock-basedCompensationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockAwardsRsasActivityDetails" xlink:href="pcsa-20230331.xsd#ScheduleOfRestrictedStockAwardsRsasActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails" xlink:href="pcsa-20230331.xsd#ScheduleOfRestrictedStockUnitsRsusActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="pcsa-20230331.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDiluteDetails" xlink:href="pcsa-20230331.xsd#ScheduleOfNetLossPerShareBasicAndDiluteDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockDetailsNarrative" xlink:href="pcsa-20230331.xsd#NetLossPerShareOfCommonStockDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingLeasesDetails" xlink:href="pcsa-20230331.xsd#ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails" xlink:href="pcsa-20230331.xsd#ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/OperatingLeasesDetailsNarrative" xlink:href="pcsa-20230331.xsd#OperatingLeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="pcsa-20230331.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="pcsa-20230331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StatementOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Condensed Consolidated Statement of Changes in Stockholders&apos; Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="loc_us-gaapTreasuryStockCommonMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapTreasuryStockCommonMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodValue_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodShares_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_SharesIssuedInConnectionWithPurchaseAgreementValue" xlink:label="loc_PCSASharesIssuedInConnectionWithPurchaseAgreementValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PCSASharesIssuedInConnectionWithPurchaseAgreementValue_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_SharesIssuedInConnectionWithPurchaseAgreementShares" xlink:label="loc_PCSASharesIssuedInConnectionWithPurchaseAgreementShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PCSASharesIssuedInConnectionWithPurchaseAgreementShares_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical" xlink:title="00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_ConsultingAgreementMember" xlink:label="loc_PCSAConsultingAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSAConsultingAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_PurchaseAgreementMember" xlink:label="loc_PCSAPurchaseAgreementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSAPurchaseAgreementMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_LincolnParkCapitalFundLLCMember" xlink:label="loc_PCSALincolnParkCapitalFundLLCMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_PCSALincolnParkCapitalFundLLCMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_SharesIssuedInConnectionWithPurchaseAgreementShares" xlink:label="loc_PCSASharesIssuedInConnectionWithPurchaseAgreementShares_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PCSASharesIssuedInConnectionWithPurchaseAgreementShares_30" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - Organization and Summary of Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StockholdersEquity" xlink:title="00000009 - Disclosure - Stockholders&#8217; Equity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Stock-basedCompensation" xlink:title="00000010 - Disclosure - Stock-based Compensation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock" xlink:title="00000011 - Disclosure - Net Loss per Share of Common Stock" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/OperatingLeases" xlink:title="00000012 - Disclosure - Operating Leases" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/RelatedPartyTransactions" xlink:title="00000013 - Disclosure - Related Party Transactions" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/CommitmentsAndContingencies" xlink:title="00000014 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000015 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Stock-basedCompensationTables" xlink:title="00000016 - Disclosure - Stock-based Compensation (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTables" xlink:title="00000017 - Disclosure - Net Loss per Share of Common Stock (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/OperatingLeasesTables" xlink:title="00000018 - Disclosure - Operating Leases (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000019 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000020 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapScheduleOfStockByClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_SalesAgreementMember" xlink:label="loc_PCSASalesAgreementMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSASalesAgreementMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_PurchaseAgreementMember" xlink:label="loc_PCSAPurchaseAgreementMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSAPurchaseAgreementMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_SecuritiesPurchaseAgreementMember" xlink:label="loc_PCSASecuritiesPurchaseAgreementMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSASecuritiesPurchaseAgreementMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_ConsultingAgreementMember" xlink:label="loc_PCSAConsultingAgreementMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSAConsultingAgreementMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_LincolnParkCapitalFundLLCMember" xlink:label="loc_PCSALincolnParkCapitalFundLLCMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_PCSALincolnParkCapitalFundLLCMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_SpartanCapitalSecuritesLLCMember" xlink:label="loc_PCSASpartanCapitalSecuritesLLCMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_PCSASpartanCapitalSecuritesLLCMember_140" xlink:type="arc" order="142" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_RegisteredDirectOfferingMember" xlink:label="loc_PCSARegisteredDirectOfferingMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_PCSARegisteredDirectOfferingMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_AccreditedInvestorMember" xlink:label="loc_PCSAAccreditedInvestorMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_PCSAAccreditedInvestorMember_100" xlink:type="arc" order="103" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_PlacementAgentMember" xlink:label="loc_PCSAPlacementAgentMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_PCSAPlacementAgentMember_120" xlink:type="arc" order="123" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_160" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_160" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_160" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_MaximumValueToBeSoldAtMarketOffering" xlink:label="loc_PCSAMaximumValueToBeSoldAtMarketOffering_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_PCSAMaximumValueToBeSoldAtMarketOffering_160" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_160" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_GrossProceedsFromIssuanceOfCommonStock" xlink:label="loc_PCSAGrossProceedsFromIssuanceOfCommonStock_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_PCSAGrossProceedsFromIssuanceOfCommonStock_160" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_160" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_MaximumCommitmenttoPurchaseCommonStockValue" xlink:label="loc_PCSAMaximumCommitmenttoPurchaseCommonStockValue_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_PCSAMaximumCommitmenttoPurchaseCommonStockValue_160" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_ThresholdPrice" xlink:label="loc_PCSAThresholdPrice_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_PCSAThresholdPrice_160" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_RestrictionsToIssueStock" xlink:label="loc_PCSARestrictionsToIssueStock_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_PCSARestrictionsToIssueStock_160" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_TransactionCostsPercentage" xlink:label="loc_PCSATransactionCostsPercentage_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_PCSATransactionCostsPercentage_160" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_ReimbursementFees" xlink:label="loc_PCSAReimbursementFees_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_PCSAReimbursementFees_160" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_160" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_160" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_160" xlink:type="arc" order="14" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:title="00000021 - Disclosure - Schedule of Stock-based Compensation Expense (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapShareBasedCompensation_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockAwardsRsasActivityDetails" xlink:title="00000022 - Disclosure - Schedule of Restricted Stock Awards (&#8220;RSAs&#8221;) Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails" xlink:title="00000023 - Disclosure - Schedule of Restricted Stock Units (&#8220;RSUs&#8221;) Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="00000024 - Disclosure - Stock-based Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_TwoThousandAndNineteenPlanMember" xlink:label="loc_PCSATwoThousandAndNineteenPlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_PCSATwoThousandAndNineteenPlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_ThreeDirectorsMember" xlink:label="loc_PCSAThreeDirectorsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_PCSAThreeDirectorsMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_ConsultantMember" xlink:label="loc_PCSAConsultantMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_PCSAConsultantMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_140" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_140" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent_140" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_140" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_140" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_140" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_140" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_140" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_140" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_140" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_140" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_UnrecognizedShareBasedCompensationExpense" xlink:label="loc_PCSAUnrecognizedShareBasedCompensationExpense_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAUnrecognizedShareBasedCompensationExpense_140" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_140" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_140" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_140" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_140" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_140" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_NumberOfWarrantExercisableShares" xlink:label="loc_PCSANumberOfWarrantExercisableShares_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSANumberOfWarrantExercisableShares_140" xlink:type="arc" order="17" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDiluteDetails" xlink:title="00000025 - Disclosure - Schedule of Net Loss Per Share Basic and Dilute (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockDetailsNarrative" xlink:title="00000026 - Disclosure - Net Loss per Share of Common Stock (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_CommittedWarrantMember" xlink:label="loc_PCSACommittedWarrantMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PCSACommittedWarrantMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_40" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingLeasesDetails" xlink:title="00000027 - Disclosure - Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_FacilityLeaseMember" xlink:label="loc_PCSAFacilityLeaseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_PCSAFacilityLeaseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaapLesseeOperatingLeaseTermOfContract_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseTermOfContract_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_40" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails" xlink:title="00000028 - Disclosure - Schedule of Annual Lease Liabilities for all Operating Leases (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/OperatingLeasesDetailsNarrative" xlink:title="00000029 - Disclosure - Operating Leases (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000030 - Disclosure - Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_CorLystLLCMember" xlink:label="loc_PCSACorLystLLCMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_PCSACorLystLLCMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedAndNonrelatedPartyStatusAxis" xlink:label="loc_us-gaapRelatedAndNonrelatedPartyStatusAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedAndNonrelatedPartyStatusAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedAndNonrelatedPartyStatusDomain" xlink:label="loc_us-gaapRelatedAndNonrelatedPartyStatusDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedAndNonrelatedPartyStatusAxis" xlink:to="loc_us-gaapRelatedAndNonrelatedPartyStatusDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedAndNonrelatedPartyStatusDomain" xlink:label="loc_us-gaapRelatedAndNonrelatedPartyStatusDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedAndNonrelatedPartyStatusAxis" xlink:to="loc_us-gaapRelatedAndNonrelatedPartyStatusDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedAndNonrelatedPartyStatusDomain" xlink:to="loc_us-gaapRelatedPartyMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_ProceedsFromRentAndOtherCostsReimbursements" xlink:label="loc_PCSAProceedsFromRentAndOtherCostsReimbursements_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_PCSAProceedsFromRentAndOtherCostsReimbursements_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaapOtherReceivablesNetCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOtherReceivablesNetCurrent_50" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000031 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_AgreementsMember" xlink:label="loc_PCSAAgreementsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSAAgreementsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_ContractResearchOrganizationsMember" xlink:label="loc_PCSAContractResearchOrganizationsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_PCSAContractResearchOrganizationsMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligation" xlink:label="loc_us-gaapPurchaseObligation_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapPurchaseObligation_20" xlink:type="arc" order="0" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>pcsa-20230331_lab.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="us-gaap_TreasuryStockCommonMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonMember" xlink:to="us-gaap_TreasuryStockCommonMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockCommonMember_lbl" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_ConsultingAgreementMember" xlink:label="PCSA_ConsultingAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ConsultingAgreementMember" xlink:to="PCSA_ConsultingAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ConsultingAgreementMember_lbl" xml:lang="en-US">Consulting Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_PurchaseAgreementMember" xlink:label="PCSA_PurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_PurchaseAgreementMember" xlink:to="PCSA_PurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_PurchaseAgreementMember_lbl" xml:lang="en-US">Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_LincolnParkCapitalFundLLCMember" xlink:label="PCSA_LincolnParkCapitalFundLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_LincolnParkCapitalFundLLCMember" xlink:to="PCSA_LincolnParkCapitalFundLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_LincolnParkCapitalFundLLCMember_lbl" xml:lang="en-US">Lincoln Park Capital Fund LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_SalesAgreementMember" xlink:label="PCSA_SalesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_SalesAgreementMember" xlink:to="PCSA_SalesAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_SalesAgreementMember_lbl" xml:lang="en-US">Sales Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_SecuritiesPurchaseAgreementMember" xlink:label="PCSA_SecuritiesPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_SecuritiesPurchaseAgreementMember" xlink:to="PCSA_SecuritiesPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_RegisteredDirectOfferingMember" xlink:label="PCSA_RegisteredDirectOfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_RegisteredDirectOfferingMember" xlink:to="PCSA_RegisteredDirectOfferingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_RegisteredDirectOfferingMember_lbl" xml:lang="en-US">Registered Direct Offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_AccreditedInvestorMember" xlink:label="PCSA_AccreditedInvestorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_AccreditedInvestorMember" xlink:to="PCSA_AccreditedInvestorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_AccreditedInvestorMember_lbl" xml:lang="en-US">Accredited Investor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_PlacementAgentMember" xlink:label="PCSA_PlacementAgentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_PlacementAgentMember" xlink:to="PCSA_PlacementAgentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_PlacementAgentMember_lbl" xml:lang="en-US">Placement Agent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_SpartanCapitalSecuritesLLCMember" xlink:label="PCSA_SpartanCapitalSecuritesLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_SpartanCapitalSecuritesLLCMember" xlink:to="PCSA_SpartanCapitalSecuritesLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_SpartanCapitalSecuritesLLCMember_lbl" xml:lang="en-US">Spartan Capital Securites LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_TwoThousandAndNineteenPlanMember" xlink:label="PCSA_TwoThousandAndNineteenPlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_TwoThousandAndNineteenPlanMember" xlink:to="PCSA_TwoThousandAndNineteenPlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_TwoThousandAndNineteenPlanMember_lbl" xml:lang="en-US">2019 Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_ThreeDirectorsMember" xlink:label="PCSA_ThreeDirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ThreeDirectorsMember" xlink:to="PCSA_ThreeDirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ThreeDirectorsMember_lbl" xml:lang="en-US">Three Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_ConsultantMember" xlink:label="PCSA_ConsultantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ConsultantMember" xlink:to="PCSA_ConsultantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ConsultantMember_lbl" xml:lang="en-US">Consultant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_CommittedWarrantMember" xlink:label="PCSA_CommittedWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_CommittedWarrantMember" xlink:to="PCSA_CommittedWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_CommittedWarrantMember_lbl" xml:lang="en-US">Committed Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_FacilityLeaseMember" xlink:label="PCSA_FacilityLeaseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_FacilityLeaseMember" xlink:to="PCSA_FacilityLeaseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_FacilityLeaseMember_lbl" xml:lang="en-US">Facility Lease [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US">Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_CorLystLLCMember" xlink:label="PCSA_CorLystLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_CorLystLLCMember" xlink:to="PCSA_CorLystLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_CorLystLLCMember_lbl" xml:lang="en-US">CorLyst, LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedAndNonrelatedPartyStatusAxis" xlink:label="us-gaap_RelatedAndNonrelatedPartyStatusAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedAndNonrelatedPartyStatusAxis" xlink:to="us-gaap_RelatedAndNonrelatedPartyStatusAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedAndNonrelatedPartyStatusAxis_lbl" xml:lang="en-US">Related and Nonrelated Party Status [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US">Related Party [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_AgreementsMember" xlink:label="PCSA_AgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_AgreementsMember" xlink:to="PCSA_AgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_AgreementsMember_lbl" xml:lang="en-US">Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_ContractResearchOrganizationsMember" xlink:label="PCSA_ContractResearchOrganizationsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ContractResearchOrganizationsMember" xlink:to="PCSA_ContractResearchOrganizationsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ContractResearchOrganizationsMember_lbl" xml:lang="en-US">Contract Research Organizations [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and Equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrentAbstract" xlink:label="us-gaap_OtherAssetsNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrentAbstract_lbl" xml:lang="en-US">Other Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use assets, net of accumulated amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Security deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Total Other Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Current maturities of operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_DueToLicensor" xlink:label="PCSA_DueToLicensor" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_DueToLicensor" xlink:to="PCSA_DueToLicensor_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_DueToLicensor_lbl" xml:lang="en-US">Due to licensor</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Due to related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilityCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration" xlink:label="us-gaap_OtherLiabilityCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilityCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration" xlink:to="us-gaap_OtherLiabilityCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilityCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration_lbl" xml:lang="en-US">Other Liability, Current, Related and Nonrelated Party Status [Extensible Enumeration]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Non-current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Non-current operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, par value $0.0001, 50,000,000 shares authorized: 24,631,474 issued and 24,531,474 outstanding at March 31, 2023 and 16,135,400 issued and 16,035,400 outstanding at December 31, 2022</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TreasuryStockValue_lbl" xml:lang="en-US">Treasury stock at cost &#8212; 100,000 shares at March 31, 2023 and December 31, 2022</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="us-gaap_TreasuryStockCommonShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonShares" xlink:to="us-gaap_TreasuryStockCommonShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockCommonShares_lbl" xml:lang="en-US">Treasury stock shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US">Research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other Income (Expense), net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Net Operating Loss Before Income Tax Benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income Tax Benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net Loss Per Common Share - Basic and Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted Average Common Shares Used to Compute Net Loss Per Common Shares - Basic and Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">Stock-Based compensation, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xml:lang="en-US">Acquisition of treasury stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xml:lang="en-US">Acquisition of treasury stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_SharesIssuedInConnectionWithPurchaseAgreementValue" xlink:label="PCSA_SharesIssuedInConnectionWithPurchaseAgreementValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_SharesIssuedInConnectionWithPurchaseAgreementValue" xlink:to="PCSA_SharesIssuedInConnectionWithPurchaseAgreementValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_SharesIssuedInConnectionWithPurchaseAgreementValue_lbl" xml:lang="en-US">Shares issued in connection with purchase agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_SharesIssuedInConnectionWithPurchaseAgreementShares" xlink:label="PCSA_SharesIssuedInConnectionWithPurchaseAgreementShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_SharesIssuedInConnectionWithPurchaseAgreementShares" xlink:to="PCSA_SharesIssuedInConnectionWithPurchaseAgreementShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="PCSA_SharesIssuedInConnectionWithPurchaseAgreementShares_lbl" xml:lang="en-US">Shares issued in connection with purchase agreement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Shares issued in connection with capital raises, net of transaction costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Shares issued in connection with capital raises, net of transaction costs, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Operating Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Non-cash lease expense for right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization of issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of intangible asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Recording of warrant to be issued to purchase 3,160,130 shares of common stock in connection with a consulting agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Net changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl" xml:lang="en-US">Due (from) to related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" xml:lang="en-US">Other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Financing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Net proceeds from common stock issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfEquity" xlink:label="us-gaap_PaymentsForRepurchaseOfEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfEquity" xlink:to="us-gaap_PaymentsForRepurchaseOfEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForRepurchaseOfEquity_lbl" xml:lang="en-US">Acquisition of treasury stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net Increase (Decrease) in Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Cash and Cash Equivalents &#8211; Beginning of Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">Cash and Cash Equivalents &#8211; End of Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Non-Cash Financing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US">Issuance of 123,609 shares of common stock in connection with the Purchase Agreement with Lincoln Park</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Purchase of warrants, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_SharesIssuedInConnectionWithPurchaseAgreementShares" xlink:to="PCSA_SharesIssuedInConnectionWithPurchaseAgreementShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_SharesIssuedInConnectionWithPurchaseAgreementShares_2_lbl" xml:lang="en-US">Shares issued in connection with the Purchase Agreement with Lincoln Park</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US">Organization and Summary of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Stock-based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Net Loss per Share of Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_DisclosureOperatingLeasesAbstract" xlink:label="PCSA_DisclosureOperatingLeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_DisclosureOperatingLeasesAbstract" xlink:to="PCSA_DisclosureOperatingLeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_DisclosureOperatingLeasesAbstract_lbl" xml:lang="en-US">Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_BusinessActivitiesAndOrganizationPolicyTextBlock" xlink:label="PCSA_BusinessActivitiesAndOrganizationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_BusinessActivitiesAndOrganizationPolicyTextBlock" xlink:to="PCSA_BusinessActivitiesAndOrganizationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_BusinessActivitiesAndOrganizationPolicyTextBlock_lbl" xml:lang="en-US">Organization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_LiquidityPolicyTextBlock" xlink:label="PCSA_LiquidityPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_LiquidityPolicyTextBlock" xlink:to="PCSA_LiquidityPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_LiquidityPolicyTextBlock_lbl" xml:lang="en-US">Liquidity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Credit Risk</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock-based Compensation Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock" xlink:label="PCSA_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock" xlink:to="PCSA_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Restricted Stock Awards (&#8220;RSAs&#8221;) Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Restricted Stock Units (&#8220;RSUs&#8221;) Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Net Loss Per Share Basic and Dilute</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingLeasesTableTextBlock" xlink:label="PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingLeasesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingLeasesTableTextBlock" xlink:to="PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingLeasesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Annual Lease Liabilities for all Operating Leases</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Proceeds from sale of common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xml:lang="en-US">Net proceeds from sale of stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of common stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Number of shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_MaximumValueToBeSoldAtMarketOffering" xlink:label="PCSA_MaximumValueToBeSoldAtMarketOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_MaximumValueToBeSoldAtMarketOffering" xlink:to="PCSA_MaximumValueToBeSoldAtMarketOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_MaximumValueToBeSoldAtMarketOffering_lbl" xml:lang="en-US">Maximum value to be sold at the market offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_GrossProceedsFromIssuanceOfCommonStock" xlink:label="PCSA_GrossProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_GrossProceedsFromIssuanceOfCommonStock" xlink:to="PCSA_GrossProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_GrossProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Gross proceeds from common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_3_lbl" xml:lang="en-US">Net proceeds from common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_MaximumCommitmenttoPurchaseCommonStockValue" xlink:label="PCSA_MaximumCommitmenttoPurchaseCommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_MaximumCommitmenttoPurchaseCommonStockValue" xlink:to="PCSA_MaximumCommitmenttoPurchaseCommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_MaximumCommitmenttoPurchaseCommonStockValue_lbl" xml:lang="en-US">Commitment to purchase common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_ThresholdPrice" xlink:label="PCSA_ThresholdPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ThresholdPrice" xlink:to="PCSA_ThresholdPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ThresholdPrice_lbl" xml:lang="en-US">Threshold price</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_RestrictionsToIssueStock" xlink:label="PCSA_RestrictionsToIssueStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_RestrictionsToIssueStock" xlink:to="PCSA_RestrictionsToIssueStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_RestrictionsToIssueStock_lbl" xml:lang="en-US">Restrictions to issue stock</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_TransactionCostsPercentage" xlink:label="PCSA_TransactionCostsPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_TransactionCostsPercentage" xlink:to="PCSA_TransactionCostsPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_TransactionCostsPercentage_lbl" xml:lang="en-US">Cash fee percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_ReimbursementFees" xlink:label="PCSA_ReimbursementFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ReimbursementFees" xlink:to="PCSA_ReimbursementFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ReimbursementFees_lbl" xml:lang="en-US">Reimbursement fees</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xml:lang="en-US">Warrants to purchase common stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Warrant exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Warrant term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number of restricted stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average grant-date fair value per share, outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of shares, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average grant-date fair value per share, awarded</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_lbl" xml:lang="en-US">Number of shares, cancelled</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average grant-date fair value per share, cancelled</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Number of restricted stock shares outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted-average grant-date fair value per share, outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_lbl" xml:lang="en-US">Number of shares, Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average grant-date fair value per share, Beginning balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2_lbl" xml:lang="en-US">Number of shares, awarded</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_2_lbl" xml:lang="en-US">Number of shares, Ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted-average grant-date fair value per share, Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued_lbl" xml:lang="en-US">Number of shares, vested and unissued</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average grant-date fair value per share, vested and unissued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Maximum equity available for issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Shares available for future grants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Expenses and accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Options, forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Options exercisable, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options exercisable weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Exercisable weighted average remaining contractual term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_2_lbl" xml:lang="en-US">Number of shares, cancelled</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unrecognized share based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Weighted average period for recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_UnrecognizedShareBasedCompensationExpense" xlink:label="PCSA_UnrecognizedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_UnrecognizedShareBasedCompensationExpense" xlink:to="PCSA_UnrecognizedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_UnrecognizedShareBasedCompensationExpense_lbl" xml:lang="en-US">Unrecognized restricted stock expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Warrants granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Weighted average exercise price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_2_lbl" xml:lang="en-US">General and administrative expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3_lbl" xml:lang="en-US">Warrants to purchase shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Weighted average remaining contractual life</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_NumberOfWarrantExercisableShares" xlink:label="PCSA_NumberOfWarrantExercisableShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_NumberOfWarrantExercisableShares" xlink:to="PCSA_NumberOfWarrantExercisableShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_NumberOfWarrantExercisableShares_lbl" xml:lang="en-US">Number of warrant exercisable shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_4_lbl" xml:lang="en-US">Net loss available to common stockholders</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xml:lang="en-US">Weighted average number of common shares-basic and diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_2_lbl" xml:lang="en-US">Basic and diluted net loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share, amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Antidilutive securities including from computation of earnings per share, amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Remaining lease term (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining lease term (years) for our facility and equipment leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rate for our facility and equipment leases</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_DisclosureOperatingLeasesAbstract" xlink:to="PCSA_DisclosureOperatingLeasesAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="PCSA_DisclosureOperatingLeasesAbstract_2_lbl" xml:lang="en-US">Schedule Of Annual Lease Liabilities For All Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Present value of lease liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Less: current maturities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Non-current lease liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_2_lbl" xml:lang="en-US">Operating lease borrowing rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_ProceedsFromRentAndOtherCostsReimbursements" xlink:label="PCSA_ProceedsFromRentAndOtherCostsReimbursements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ProceedsFromRentAndOtherCostsReimbursements" xlink:to="PCSA_ProceedsFromRentAndOtherCostsReimbursements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ProceedsFromRentAndOtherCostsReimbursements_lbl" xml:lang="en-US">Rent and other costs reimbursements received</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US">Due from related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligation" xlink:label="us-gaap_PurchaseObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligation" xlink:to="us-gaap_PurchaseObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PurchaseObligation_lbl" xml:lang="en-US">Purchase obligation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_DueToLicensor" xlink:to="PCSA_DueToLicensor_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_DueToLicensor_doc" xml:lang="en-US">Due to licensor.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_BusinessActivitiesAndOrganizationPolicyTextBlock" xlink:to="PCSA_BusinessActivitiesAndOrganizationPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_BusinessActivitiesAndOrganizationPolicyTextBlock_doc" xml:lang="en-US">Business Activities And Organization [policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_LiquidityPolicyTextBlock" xlink:to="PCSA_LiquidityPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_LiquidityPolicyTextBlock_doc" xml:lang="en-US">Liquidity [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_PurchaseAgreementMember" xlink:to="PCSA_PurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_PurchaseAgreementMember_doc" xml:lang="en-US">Purchase agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_LincolnParkCapitalFundLLCMember" xlink:to="PCSA_LincolnParkCapitalFundLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_LincolnParkCapitalFundLLCMember_doc" xml:lang="en-US">Lincoln Park Capital Fund LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingLeasesTableTextBlock" xlink:to="PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingLeasesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingLeasesTableTextBlock_doc" xml:lang="en-US">Schedule of weighted average remaining lease terms and discount rate for our operating leases [table text block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ProceedsFromRentAndOtherCostsReimbursements" xlink:to="PCSA_ProceedsFromRentAndOtherCostsReimbursements_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ProceedsFromRentAndOtherCostsReimbursements_doc" xml:lang="en-US">Rent and other costs reimbursements received.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_CorLystLLCMember" xlink:to="PCSA_CorLystLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_CorLystLLCMember_doc" xml:lang="en-US">CorLyst, LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_MaximumCommitmenttoPurchaseCommonStockValue" xlink:to="PCSA_MaximumCommitmenttoPurchaseCommonStockValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_MaximumCommitmenttoPurchaseCommonStockValue_doc" xml:lang="en-US">Maximum amount committed to purchase.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_SalesAgreementMember" xlink:to="PCSA_SalesAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_SalesAgreementMember_doc" xml:lang="en-US">Sales Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_SecuritiesPurchaseAgreementMember" xlink:to="PCSA_SecuritiesPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_SecuritiesPurchaseAgreementMember_doc" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_RegisteredDirectOfferingMember" xlink:to="PCSA_RegisteredDirectOfferingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_RegisteredDirectOfferingMember_doc" xml:lang="en-US">Registered Direct Offering [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_AccreditedInvestorMember" xlink:to="PCSA_AccreditedInvestorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_AccreditedInvestorMember_doc" xml:lang="en-US">Accredited Investor [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_GrossProceedsFromIssuanceOfCommonStock" xlink:to="PCSA_GrossProceedsFromIssuanceOfCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_GrossProceedsFromIssuanceOfCommonStock_doc" xml:lang="en-US">Gross proceeds from issuance of common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_SharesIssuedInConnectionWithPurchaseAgreementValue" xlink:to="PCSA_SharesIssuedInConnectionWithPurchaseAgreementValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_SharesIssuedInConnectionWithPurchaseAgreementValue_doc" xml:lang="en-US">Shares issued in connection with purchase agreement value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_SharesIssuedInConnectionWithPurchaseAgreementShares" xlink:to="PCSA_SharesIssuedInConnectionWithPurchaseAgreementShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_SharesIssuedInConnectionWithPurchaseAgreementShares_doc" xml:lang="en-US">Shares issued in connection with purchase agreement shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_AgreementsMember" xlink:to="PCSA_AgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_AgreementsMember_doc" xml:lang="en-US">Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ContractResearchOrganizationsMember" xlink:to="PCSA_ContractResearchOrganizationsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ContractResearchOrganizationsMember_doc" xml:lang="en-US">Contract Research Organizations [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_SpartanCapitalSecuritesLLCMember" xlink:to="PCSA_SpartanCapitalSecuritesLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_SpartanCapitalSecuritesLLCMember_doc" xml:lang="en-US">Spartan Capital Securites LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_TransactionCostsPercentage" xlink:to="PCSA_TransactionCostsPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_TransactionCostsPercentage_doc" xml:lang="en-US">Transaction costs percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_PlacementAgentMember" xlink:to="PCSA_PlacementAgentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_PlacementAgentMember_doc" xml:lang="en-US">Placement Agent [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ReimbursementFees" xlink:to="PCSA_ReimbursementFees_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ReimbursementFees_doc" xml:lang="en-US">Reimbursement fees.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ConsultingAgreementMember" xlink:to="PCSA_ConsultingAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ConsultingAgreementMember_doc" xml:lang="en-US">Consulting Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_TwoThousandAndNineteenPlanMember" xlink:to="PCSA_TwoThousandAndNineteenPlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_TwoThousandAndNineteenPlanMember_doc" xml:lang="en-US">2019 Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock" xlink:to="PCSA_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock_doc" xml:lang="en-US">Schedule of share based compensation restricted stock award activity [Table Text Block].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options cancelled in period total fair value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options cancelled in period weighted average grant date fair value.</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpectedToVestOutstandingNumber" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpectedToVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpectedToVestOutstandingNumber" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpectedToVestOutstandingNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpectedToVestOutstandingNumber_doc" xml:lang="en-US">ShareBased compensation arrangement by sharebased payment award other than options expected to vest outstanding number.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than option vested and unvested outstanding.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_doc" xml:lang="en-US">Per share or unit weighted-average fair value of vested and nonvested award under share-based payment arrangement. Excludes share and unit options.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options vested and unissued.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options vested and unissued weighted average grant date fair value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_UnrecognizedShareBasedCompensationExpense" xlink:to="PCSA_UnrecognizedShareBasedCompensationExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_UnrecognizedShareBasedCompensationExpense_doc" xml:lang="en-US">Unrecognized share based compensation expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ConsultantMember" xlink:to="PCSA_ConsultantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ConsultantMember_doc" xml:lang="en-US">Consultant [Member].</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_TwoThousandTwentyThreeMember" xlink:label="PCSA_TwoThousandTwentyThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_TwoThousandTwentyThreeMember" xlink:to="PCSA_TwoThousandTwentyThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_TwoThousandTwentyThreeMember_doc" xml:lang="en-US">2023 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_FacilityLeaseMember" xlink:to="PCSA_FacilityLeaseMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_FacilityLeaseMember_doc" xml:lang="en-US">Facility Lease [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ThreeDirectorsMember" xlink:to="PCSA_ThreeDirectorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ThreeDirectorsMember_doc" xml:lang="en-US">Three Directors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_MaximumValueToBeSoldAtMarketOffering" xlink:to="PCSA_MaximumValueToBeSoldAtMarketOffering_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_MaximumValueToBeSoldAtMarketOffering_doc" xml:lang="en-US">Maximum value to be sold at the market offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_CommittedWarrantMember" xlink:to="PCSA_CommittedWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_CommittedWarrantMember_doc" xml:lang="en-US">Committed Warrant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_RestrictionsToIssueStock" xlink:to="PCSA_RestrictionsToIssueStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_RestrictionsToIssueStock_doc" xml:lang="en-US">Restrictions to issue stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_NumberOfWarrantExercisableShares" xlink:to="PCSA_NumberOfWarrantExercisableShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_NumberOfWarrantExercisableShares_doc" xml:lang="en-US">Number of warrant exercisable shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ThresholdPrice" xlink:to="PCSA_ThresholdPrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ThresholdPrice_doc" xml:lang="en-US">Threshold price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_2_lbl" xml:lang="en-US">Other Assets, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockValue_2_lbl" xml:lang="en-US">Treasury Stock, Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_2_lbl" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_2_lbl" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Receivables</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfEquity" xlink:to="us-gaap_PaymentsForRepurchaseOfEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRepurchaseOfEquity_2_lbl" xml:lang="en-US">Payments for Repurchase of Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_2_lbl" xml:lang="en-US">Equity [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_2_lbl" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_4_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_4_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>pcsa-20230331_pre.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/Cover" xlink:href="pcsa-20230331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/BalanceSheets" xlink:href="pcsa-20230331.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/BalanceSheetsParenthetical" xlink:href="pcsa-20230331.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StatementsOfOperations" xlink:href="pcsa-20230331.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StatementOfChangesInStockholdersEquity" xlink:href="pcsa-20230331.xsd#StatementOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StatementsOfCashFlows" xlink:href="pcsa-20230331.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical" xlink:href="pcsa-20230331.xsd#StatementsOfCashFlowsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="pcsa-20230331.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StockholdersEquity" xlink:href="pcsa-20230331.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/Stock-basedCompensation" xlink:href="pcsa-20230331.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock" xlink:href="pcsa-20230331.xsd#NetLossPerShareOfCommonStock" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/OperatingLeases" xlink:href="pcsa-20230331.xsd#OperatingLeases" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/RelatedPartyTransactions" xlink:href="pcsa-20230331.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/CommitmentsAndContingencies" xlink:href="pcsa-20230331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="pcsa-20230331.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/Stock-basedCompensationTables" xlink:href="pcsa-20230331.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTables" xlink:href="pcsa-20230331.xsd#NetLossPerShareOfCommonStockTables" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/OperatingLeasesTables" xlink:href="pcsa-20230331.xsd#OperatingLeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="pcsa-20230331.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative" xlink:href="pcsa-20230331.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:href="pcsa-20230331.xsd#ScheduleOfStock-basedCompensationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockAwardsRsasActivityDetails" xlink:href="pcsa-20230331.xsd#ScheduleOfRestrictedStockAwardsRsasActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails" xlink:href="pcsa-20230331.xsd#ScheduleOfRestrictedStockUnitsRsusActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="pcsa-20230331.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDiluteDetails" xlink:href="pcsa-20230331.xsd#ScheduleOfNetLossPerShareBasicAndDiluteDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockDetailsNarrative" xlink:href="pcsa-20230331.xsd#NetLossPerShareOfCommonStockDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingLeasesDetails" xlink:href="pcsa-20230331.xsd#ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails" xlink:href="pcsa-20230331.xsd#ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/OperatingLeasesDetailsNarrative" xlink:href="pcsa-20230331.xsd#OperatingLeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="pcsa-20230331.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="pcsa-20230331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrentAbstract" xlink:label="loc_us-gaapOtherAssetsNoncurrentAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaapSecurityDeposit" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsNoncurrentAbstract" xlink:to="loc_us-gaapSecurityDeposit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsNoncurrentAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_DueToLicensor" xlink:label="loc_PCSADueToLicensor" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_PCSADueToLicensor" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilityCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration" xlink:label="loc_us-gaapOtherLiabilityCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapOtherLiabilityCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaapTreasuryStockValue" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapTreasuryStockValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="loc_us-gaapTreasuryStockCommonShares" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapTreasuryStockCommonShares" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StatementOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Condensed Consolidated Statement of Changes in Stockholders&apos; Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="loc_us-gaapTreasuryStockCommonMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapTreasuryStockCommonMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodShares" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_SharesIssuedInConnectionWithPurchaseAgreementValue" xlink:label="loc_PCSASharesIssuedInConnectionWithPurchaseAgreementValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PCSASharesIssuedInConnectionWithPurchaseAgreementValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_SharesIssuedInConnectionWithPurchaseAgreementShares" xlink:label="loc_PCSASharesIssuedInConnectionWithPurchaseAgreementShares" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PCSASharesIssuedInConnectionWithPurchaseAgreementShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapOperatingLeaseExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:label="loc_us-gaapIncreaseDecreaseInDueToRelatedParties" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDueToRelatedParties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="loc_us-gaapIncreaseDecreaseInOtherReceivables" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherReceivables" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfEquity" xlink:label="loc_us-gaapPaymentsForRepurchaseOfEquity" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsForRepurchaseOfEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaapStockIssued1" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_us-gaapStockIssued1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical" xlink:title="00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_ConsultingAgreementMember" xlink:label="loc_PCSAConsultingAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSAConsultingAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_PurchaseAgreementMember" xlink:label="loc_PCSAPurchaseAgreementMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSAPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_LincolnParkCapitalFundLLCMember" xlink:label="loc_PCSALincolnParkCapitalFundLLCMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_PCSALincolnParkCapitalFundLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_SharesIssuedInConnectionWithPurchaseAgreementShares" xlink:label="loc_PCSASharesIssuedInConnectionWithPurchaseAgreementShares" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PCSASharesIssuedInConnectionWithPurchaseAgreementShares" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - Organization and Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StockholdersEquity" xlink:title="00000009 - Disclosure - Stockholders&#8217; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Stock-basedCompensation" xlink:title="00000010 - Disclosure - Stock-based Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock" xlink:title="00000011 - Disclosure - Net Loss per Share of Common Stock">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/OperatingLeases" xlink:title="00000012 - Disclosure - Operating Leases">
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_DisclosureOperatingLeasesAbstract" xlink:label="loc_PCSADisclosureOperatingLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeasesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeasesTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/RelatedPartyTransactions" xlink:title="00000013 - Disclosure - Related Party Transactions">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/CommitmentsAndContingencies" xlink:title="00000014 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000015 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_BusinessActivitiesAndOrganizationPolicyTextBlock" xlink:label="loc_PCSABusinessActivitiesAndOrganizationPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_PCSABusinessActivitiesAndOrganizationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_LiquidityPolicyTextBlock" xlink:label="loc_PCSALiquidityPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_PCSALiquidityPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Stock-basedCompensationTables" xlink:title="00000016 - Disclosure - Stock-based Compensation (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock" xlink:label="loc_PCSAScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_PCSAScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTables" xlink:title="00000017 - Disclosure - Net Loss per Share of Common Stock (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/OperatingLeasesTables" xlink:title="00000018 - Disclosure - Operating Leases (Tables)">
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_DisclosureOperatingLeasesAbstract" xlink:label="loc_PCSADisclosureOperatingLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingLeasesTableTextBlock" xlink:label="loc_PCSAScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingLeasesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureOperatingLeasesAbstract" xlink:to="loc_PCSAScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingLeasesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000019 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000020 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockByClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_SalesAgreementMember" xlink:label="loc_PCSASalesAgreementMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSASalesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_PurchaseAgreementMember" xlink:label="loc_PCSAPurchaseAgreementMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSAPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_SecuritiesPurchaseAgreementMember" xlink:label="loc_PCSASecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSASecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_ConsultingAgreementMember" xlink:label="loc_PCSAConsultingAgreementMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSAConsultingAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_deiLegalEntityAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_LincolnParkCapitalFundLLCMember" xlink:label="loc_PCSALincolnParkCapitalFundLLCMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_PCSALincolnParkCapitalFundLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_SpartanCapitalSecuritesLLCMember" xlink:label="loc_PCSASpartanCapitalSecuritesLLCMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_PCSASpartanCapitalSecuritesLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_RegisteredDirectOfferingMember" xlink:label="loc_PCSARegisteredDirectOfferingMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_PCSARegisteredDirectOfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtTitleOfIndividualAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_AccreditedInvestorMember" xlink:label="loc_PCSAAccreditedInvestorMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_PCSAAccreditedInvestorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_PlacementAgentMember" xlink:label="loc_PCSAPlacementAgentMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_PCSAPlacementAgentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_MaximumValueToBeSoldAtMarketOffering" xlink:label="loc_PCSAMaximumValueToBeSoldAtMarketOffering" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_PCSAMaximumValueToBeSoldAtMarketOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_GrossProceedsFromIssuanceOfCommonStock" xlink:label="loc_PCSAGrossProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_PCSAGrossProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_MaximumCommitmenttoPurchaseCommonStockValue" xlink:label="loc_PCSAMaximumCommitmenttoPurchaseCommonStockValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_PCSAMaximumCommitmenttoPurchaseCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_ThresholdPrice" xlink:label="loc_PCSAThresholdPrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_PCSAThresholdPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_RestrictionsToIssueStock" xlink:label="loc_PCSARestrictionsToIssueStock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_PCSARestrictionsToIssueStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_TransactionCostsPercentage" xlink:label="loc_PCSATransactionCostsPercentage" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_PCSATransactionCostsPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_ReimbursementFees" xlink:label="loc_PCSAReimbursementFees" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_PCSAReimbursementFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:title="00000021 - Disclosure - Schedule of Stock-based Compensation Expense (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockAwardsRsasActivityDetails" xlink:title="00000022 - Disclosure - Schedule of Restricted Stock Awards (&#8220;RSAs&#8221;) Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails" xlink:title="00000023 - Disclosure - Schedule of Restricted Stock Units (&#8220;RSUs&#8221;) Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="00000024 - Disclosure - Stock-based Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_TwoThousandAndNineteenPlanMember" xlink:label="loc_PCSATwoThousandAndNineteenPlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_PCSATwoThousandAndNineteenPlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_ThreeDirectorsMember" xlink:label="loc_PCSAThreeDirectorsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_PCSAThreeDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_ConsultantMember" xlink:label="loc_PCSAConsultantMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_PCSAConsultantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_UnrecognizedShareBasedCompensationExpense" xlink:label="loc_PCSAUnrecognizedShareBasedCompensationExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAUnrecognizedShareBasedCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_NumberOfWarrantExercisableShares" xlink:label="loc_PCSANumberOfWarrantExercisableShares" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSANumberOfWarrantExercisableShares" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDiluteDetails" xlink:title="00000025 - Disclosure - Schedule of Net Loss Per Share Basic and Dilute (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockDetailsNarrative" xlink:title="00000026 - Disclosure - Net Loss per Share of Common Stock (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_CommittedWarrantMember" xlink:label="loc_PCSACommittedWarrantMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PCSACommittedWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingLeasesDetails" xlink:title="00000027 - Disclosure - Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_DisclosureOperatingLeasesAbstract" xlink:label="loc_PCSADisclosureOperatingLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_FacilityLeaseMember" xlink:label="loc_PCSAFacilityLeaseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_PCSAFacilityLeaseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaapLesseeOperatingLeaseTermOfContract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseTermOfContract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails" xlink:title="00000028 - Disclosure - Schedule of Annual Lease Liabilities for all Operating Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_DisclosureOperatingLeasesAbstract" xlink:label="loc_PCSADisclosureOperatingLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/OperatingLeasesDetailsNarrative" xlink:title="00000029 - Disclosure - Operating Leases (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_DisclosureOperatingLeasesAbstract" xlink:label="loc_PCSADisclosureOperatingLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaapLeaseCost" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLeaseCost" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000030 - Disclosure - Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_CorLystLLCMember" xlink:label="loc_PCSACorLystLLCMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_PCSACorLystLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedAndNonrelatedPartyStatusAxis" xlink:label="loc_us-gaapRelatedAndNonrelatedPartyStatusAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedAndNonrelatedPartyStatusAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedAndNonrelatedPartyStatusDomain" xlink:label="loc_us-gaapRelatedAndNonrelatedPartyStatusDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedAndNonrelatedPartyStatusAxis" xlink:to="loc_us-gaapRelatedAndNonrelatedPartyStatusDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedAndNonrelatedPartyStatusDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_ProceedsFromRentAndOtherCostsReimbursements" xlink:label="loc_PCSAProceedsFromRentAndOtherCostsReimbursements" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_PCSAProceedsFromRentAndOtherCostsReimbursements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaapOtherReceivablesNetCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOtherReceivablesNetCurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000031 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_AgreementsMember" xlink:label="loc_PCSAAgreementsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSAAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20230331.xsd#PCSA_ContractResearchOrganizationsMember" xlink:label="loc_PCSAContractResearchOrganizationsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_PCSAContractResearchOrganizationsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligation" xlink:label="loc_us-gaapPurchaseObligation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapPurchaseObligation" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139724388132192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>May 09, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Processa
Pharmaceuticals, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001533743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-1539785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7380
Coca Cola Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hanover<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">21076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(443)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">776-3133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, $0.0001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PCSA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,531,474<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139724386422416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 10,741,602<span></span>
</td>
<td class="nump">$ 6,503,595<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other</a></td>
<td class="nump">1,477,519<span></span>
</td>
<td class="nump">1,883,134<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">12,219,121<span></span>
</td>
<td class="nump">8,386,729<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and Equipment, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrentAbstract', window );"><strong>Other Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets, net of accumulated amortization</a></td>
<td class="nump">207,787<span></span>
</td>
<td class="nump">227,587<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="nump">5,535<span></span>
</td>
<td class="nump">5,535<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Total Other Assets</a></td>
<td class="nump">213,322<span></span>
</td>
<td class="nump">233,122<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">12,432,443<span></span>
</td>
<td class="nump">8,619,851<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current maturities of operating lease liability</a></td>
<td class="nump">81,166<span></span>
</td>
<td class="nump">78,896<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">316,709<span></span>
</td>
<td class="nump">327,548<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_DueToLicensor', window );">Due to licensor</a></td>
<td class="nump">189,000<span></span>
</td>
<td class="nump">189,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Due to related parties</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilityCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration', window );">Other Liability, Current, Related and Nonrelated Party Status [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Related Party [Member]<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">1,573,961<span></span>
</td>
<td class="nump">$ 403,061<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">2,160,836<span></span>
</td>
<td class="nump">998,556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating lease liability</a></td>
<td class="nump">129,358<span></span>
</td>
<td class="nump">150,554<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">2,290,194<span></span>
</td>
<td class="nump">1,149,110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.0001, 50,000,000 shares authorized: 24,631,474 issued and 24,531,474 outstanding at March 31, 2023 and 16,135,400 issued and 16,035,400 outstanding at December 31, 2022</a></td>
<td class="nump">2,463<span></span>
</td>
<td class="nump">1,614<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">78,709,420<span></span>
</td>
<td class="nump">72,016,688<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock at cost &#8212; 100,000 shares at March 31, 2023 and December 31, 2022</a></td>
<td class="num">(300,000)<span></span>
</td>
<td class="num">(300,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(68,269,634)<span></span>
</td>
<td class="num">(64,247,561)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders&#8217; Equity</a></td>
<td class="nump">10,142,249<span></span>
</td>
<td class="nump">7,470,741<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders&#8217; Equity</a></td>
<td class="nump">$ 12,432,443<span></span>
</td>
<td class="nump">$ 8,619,851<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_DueToLicensor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Due to licensor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_DueToLicensor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilityCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates related and nonrelated party status for liability classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilityCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481520/505-30-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139724389412640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">24,631,474<span></span>
</td>
<td class="nump">16,135,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">24,531,474<span></span>
</td>
<td class="nump">16,035,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock shares</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139724388347024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expenses</a></td>
<td class="nump">$ 1,627,480<span></span>
</td>
<td class="nump">$ 2,043,984<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">2,478,055<span></span>
</td>
<td class="nump">1,184,730<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Loss</a></td>
<td class="num">(4,105,535)<span></span>
</td>
<td class="num">(3,228,714)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other Income (Expense), net</a></td>
<td class="nump">83,462<span></span>
</td>
<td class="nump">1,583<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net Operating Loss Before Income Tax Benefit</a></td>
<td class="num">(4,022,073)<span></span>
</td>
<td class="num">(3,227,131)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Benefit</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (4,022,073)<span></span>
</td>
<td class="num">$ (3,227,131)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net Loss Per Common Share - Basic and Diluted</a></td>
<td class="num">$ (0.18)<span></span>
</td>
<td class="num">$ (0.20)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted Average Common Shares Used to Compute Net Loss Per Common Shares - Basic and Diluted</a></td>
<td class="nump">22,770,789<span></span>
</td>
<td class="nump">15,831,118<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139724388590560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Treasury Stock, Common [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2021</a></td>
<td class="nump">$ 1,571<span></span>
</td>
<td class="nump">$ 62,306,861<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (36,823,332)<span></span>
</td>
<td class="nump">$ 25,485,100<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2021</a></td>
<td class="nump">15,710,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">828,887<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">828,897<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-Based compensation, shares</a></td>
<td class="nump">103,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Acquisition of treasury stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (300,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(300,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Acquisition of treasury stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_SharesIssuedInConnectionWithPurchaseAgreementValue', window );">Shares issued in connection with purchase agreement</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">449,988<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">450,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_SharesIssuedInConnectionWithPurchaseAgreementShares', window );">Shares issued in connection with purchase agreement</a></td>
<td class="nump">123,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,227,131)<span></span>
</td>
<td class="num">(3,227,131)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2022</a></td>
<td class="nump">$ 1,593<span></span>
</td>
<td class="nump">63,585,736<span></span>
</td>
<td class="num">$ (300,000)<span></span>
</td>
<td class="num">(40,050,463)<span></span>
</td>
<td class="nump">23,236,866<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Mar. 31, 2022</a></td>
<td class="nump">15,937,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2022</a></td>
<td class="nump">$ 1,614<span></span>
</td>
<td class="nump">72,016,688<span></span>
</td>
<td class="num">$ (300,000)<span></span>
</td>
<td class="num">(64,247,561)<span></span>
</td>
<td class="nump">7,470,741<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="nump">16,135,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">341,498<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">341,504<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-Based compensation, shares</a></td>
<td class="nump">63,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4,022,073)<span></span>
</td>
<td class="num">(4,022,073)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued in connection with capital raises, net of transaction costs</a></td>
<td class="nump">$ 843<span></span>
</td>
<td class="nump">6,351,234<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,352,077<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued in connection with capital raises, net of transaction costs, shares</a></td>
<td class="nump">8,432,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2023</a></td>
<td class="nump">$ 2,463<span></span>
</td>
<td class="nump">$ 78,709,420<span></span>
</td>
<td class="num">$ (300,000)<span></span>
</td>
<td class="num">$ (68,269,634)<span></span>
</td>
<td class="nump">$ 10,142,249<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Mar. 31, 2023</a></td>
<td class="nump">24,631,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_SharesIssuedInConnectionWithPurchaseAgreementShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued in connection with purchase agreement shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_SharesIssuedInConnectionWithPurchaseAgreementShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_SharesIssuedInConnectionWithPurchaseAgreementValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued in connection with purchase agreement value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_SharesIssuedInConnectionWithPurchaseAgreementValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139724385975712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (4,022,073)<span></span>
</td>
<td class="num">$ (3,227,131)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Non-cash lease expense for right-of-use assets</a></td>
<td class="nump">19,800<span></span>
</td>
<td class="nump">22,559<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of issuance costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible asset</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">197,124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">341,504<span></span>
</td>
<td class="nump">828,897<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Recording of warrant to be issued to purchase 3,160,130 shares of common stock in connection with a consulting agreement</a></td>
<td class="nump">1,310,875<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Net changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other</a></td>
<td class="nump">405,615<span></span>
</td>
<td class="nump">216,717<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="num">(18,926)<span></span>
</td>
<td class="num">(23,195)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(10,839)<span></span>
</td>
<td class="nump">97,187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToRelatedParties', window );">Due (from) to related parties</a></td>
<td class="num">(51)<span></span>
</td>
<td class="num">(1,772)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other receivables</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">70,274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(139,975)<span></span>
</td>
<td class="nump">13,301<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(2,114,070)<span></span>
</td>
<td class="num">(1,802,926)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows From Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from common stock issued</a></td>
<td class="nump">6,352,077<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfEquity', window );">Acquisition of treasury stock</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(300,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">6,352,077<span></span>
</td>
<td class="num">(300,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net Increase (Decrease) in Cash</a></td>
<td class="nump">4,238,007<span></span>
</td>
<td class="num">(2,102,926)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and Cash Equivalents &#8211; Beginning of Period</a></td>
<td class="nump">6,503,595<span></span>
</td>
<td class="nump">16,497,581<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and Cash Equivalents &#8211; End of Period</a></td>
<td class="nump">10,741,602<span></span>
</td>
<td class="nump">14,394,655<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-Cash Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Issuance of 123,609 shares of common stock in connection with the Purchase Agreement with Lincoln Park</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 450,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139724389343664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_SharesIssuedInConnectionWithPurchaseAgreementShares', window );">Shares issued in connection with the Purchase Agreement with Lincoln Park</a></td>
<td class="nump">123,609<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Common Stock [Member] | Lincoln Park Capital Fund LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_SharesIssuedInConnectionWithPurchaseAgreementShares', window );">Shares issued in connection with the Purchase Agreement with Lincoln Park</a></td>
<td class="nump">123,609<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_SharesIssuedInConnectionWithPurchaseAgreementShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued in connection with purchase agreement shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_SharesIssuedInConnectionWithPurchaseAgreementShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=PCSA_LincolnParkCapitalFundLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=PCSA_LincolnParkCapitalFundLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139724390813696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Organization and Summary of Significant Accounting Policies</a></td>
<td class="text"><p id="xdx_803_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_z6Dsu1T422L1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
1 &#8211; <span id="xdx_82B_z0oH60v2wmgi">Organization and Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_848_ecustom--BusinessActivitiesAndOrganizationPolicyTextBlock_zWPg5nWOcHCf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline"><span id="xdx_86D_zit5Z1FfCdU7">
  Organization</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We are a clinical-stage biopharmaceutical company focused on incorporating our Regulatory Science Approach into the development of our
Next Generation Chemotherapy (NGC) drugs to improve the safety and efficacy of cancer treatment. Our NGC drugs are modifications of existing
FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution while maintaining the well-known and established
existing mechanisms of killing the cancer cells. By modifying the NGC drugs in this manner, we believe our three NGC treatments will provide
improved safety-efficacy profiles when compared to their currently marketed counterparts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"/>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84A_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zQDXva4NfD7a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_863_zcijPntvMeR2">Basis
of Presentation</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally
accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and with the instructions of the
Securities and Exchange Commission (&#8220;SEC&#8221;) on Form 10-Q and Article 8 of Regulation S-X.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly,
they do not include all the information and disclosures required by U.S. GAAP for complete financial statements. All material intercompany
accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated
financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our
financial position and of the results of operations and cash flows for the periods presented. These condensed consolidated financial
statements should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form
10-K for the year ended December 31, 2022, as filed with the SEC. The results of operations for the interim periods shown in this report
are not necessarily indicative of the results that may be expected for any other interim period or for the full year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_ecustom--LiquidityPolicyTextBlock_z6QHJWnDGuZg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_867_zUgb6NKEM6H6">Liquidity</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have incurred losses since inception, devoting substantially all of our efforts toward research and development, and have an
accumulated deficit of $<span id="xdx_90E_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20230331_zhcAN75ZW7fl" title="Accumulated deficit">68.3
million</span> at March 31, 2023. During the three months ended March 31, 2023, we generated a net loss of $<span id="xdx_902_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20230101__20230331_zeipuBUCSrWe" title="Net loss">4.0
million</span> and we expect to continue to generate operating losses and negative cash flow from operations for the foreseeable
future. Based on our current plans, we believe our current cash balances are adequate for at least the next twelve months. Our
ability to execute our longer-term operating plans, including future clinical trials for our portfolio of drugs depend on
our ability to obtain additional funding from the sale of equity and/or debt securities, a strategic transaction or other funding
transactions. We plan to continue to actively pursue financing alternatives, but there can be no assurance that we will obtain the
necessary funding in the future when necessary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
had <span id="xdx_90E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0d_do_c20230101__20230331_zFoSXWfQhvNi" title="Revenue">no</span>
revenue during the three months ended March 31, 2023 and do not have any revenue under contract or any immediate sales prospects.
Our primary uses of cash are to fund our planned clinical trials, research and development expenditures and other operating
expenses. Cash used to fund operating expenses is impacted by the timing of when we incur and pay these expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2023, we raised gross proceeds of $<span id="xdx_90F_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20230101__20230331_zAfm4ciUPqT3" title="Proceeds from sale of common stock">7.0</span>
million (net proceeds of $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20230101__20230331_zi7er2Ubhrwa" title="Net proceeds from sale of stock">6.4</span> million) from the sale of <span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230101__20230331_zTH5NKFKOIvd" title="Sale of common stock, shares">8,432,192</span>
shares of our common stock, as described in Note 2. We plan to use the net proceeds from these financings to prepare for future clinical trials; and on research and development
expenses, working capital and other general corporate purposes. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_84A_eus-gaap--UseOfEstimates_z9ZfaxUzdiQ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_868_zLciUkfXVJEg">Use
of Estimates</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
preparing our condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP and pursuant to the
rules and regulations of the SEC, we make estimates and judgments that affect the amounts reported in the condensed consolidated
financial statements and accompanying notes. Estimates are used for, but not limited to preclinical and clinical trial expenses,
stock-based compensation, intangible assets, future milestone payments and income taxes. These estimates and assumptions are
continuously evaluated and are based on management&#8217;s experience and knowledge of the relevant facts and circumstances. While
we believe the estimates to be reasonable, actual results could differ materially from those estimates and could impact future
results of operations and cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_z8fVWrWQfhh2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86D_zkvXTL7WAral">Income
Taxes</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
account for income taxes in accordance with ASC Topic 740, <i>Income Taxes.</i> Deferred income taxes are recorded for the expected tax
consequences of temporary differences between the basis of assets and liabilities for financial reporting purposes and amounts recognized
for income tax purposes. At March 31, 2023 and December 31, 2022, we recorded a valuation allowance equal to the full recorded amount
of our net deferred tax assets since it is more-likely-than-not that such benefits will not be realized. The valuation allowance is reviewed
quarterly and is maintained until sufficient positive evidence exists to support its reversal. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
ACS 740-270 <i>Income Taxes &#8211; Interim Reporting</i>, we are required to project our annual federal and state effective income tax
rate and apply it to the year-to-date ordinary operating tax basis loss before income taxes. Based on the projection, no current income
tax benefit or expense is expected for 2023 and the foreseeable future since the deferred tax liability has been offset completely at
 December 31, 2021 and we expect to generate taxable net operating losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_zv0Hleqydarh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline"><span id="xdx_86B_zpUFJDp1Yw2i">Concentration
of Credit Risk</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject us to significant concentration of credit risk consist primarily of our cash and cash equivalents.
We utilize only well-established banks and financial institutions with high credit ratings. Balances on deposit are insured by the Federal
Deposit Insurance Corporation (FDIC) up to specified limits. Total cash held by our banks at March 31, 2023, exceeded FDIC limits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/><p id="xdx_84C_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_ziUOxsYZJIfd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_863_zpOOHZcd0gK3">Recent
Accounting Pronouncements</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standard setting bodies issue new accounting pronouncements.
Updates to the FASB Accounting Standards Codification are communicated through issuance of an Accounting Standards Update (&#8220;ASU&#8221;).
We have implemented all new accounting pronouncements that are in effect and that may impact our condensed consolidated financial statements.
We have evaluated recently issued accounting pronouncements and determined that there is no material impact on our consolidated financial
position or results of operations.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139724385997872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Equity</a></td>
<td class="text"><p id="xdx_805_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zzYuHICslY8j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8211; <span id="xdx_828_zNbNKqUxhbBb">Stockholders&#8217; Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Preferred
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were <span id="xdx_905_eus-gaap--PreferredStockSharesIssued_iI_do_c20230331_zFY0X6ZK9Xn1" title="Preferred stock, shares issued"><span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20230331_zvApIldwVGyf" title="Preferred stock, shares outstanding"><span id="xdx_90C_eus-gaap--PreferredStockSharesIssued_iI_do_c20221231_zOxlHej2AbKe" title="Preferred stock, shares issued"><span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20221231_zP6Ho1mLuBc7" title="Preferred stock, shares outstanding">no</span></span></span></span> issued or outstanding shares of preferred stock at either March 31, 2023 or December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2023, we issued <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpIyeCbEliPa" title="Common stock shares issued">8,432,192</span> shares of our common stock through several fundraising efforts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">ATM
Offering</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 20, 2021, we entered into the Sales Agreement with Oppenheimer &amp; Co. Inc. (the &#8220;Sales Agent&#8221;) under which we
may issue and sell up to $<span id="xdx_90F_ecustom--MaximumValueToBeSoldAtMarketOffering_pn5n6_c20210818__20210820__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember__srt--RangeAxis__srt--MaximumMember_zXYONC3iBkNf" title="Maximum value to be sold at the market offering">30.0</span>
million from time to time under the ATM Offering. We expect to use net proceeds from the ATM Offering over time as a source for
working capital and general corporate purposes. During the three months ended March 31, 2023, we sold <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zrjJJdoDfgo8" title="Number of shares issued">569,648</span>
shares at an average price of $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_c20230331__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_z1IBZhXRYPCi">1.22</span>
per share for aggregate gross proceeds of $<span id="xdx_908_ecustom--GrossProceedsFromIssuanceOfCommonStock_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zmLQDUj3xO3f" title="Gross proceeds from common stock">693,000</span> (net proceeds of $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zeTzdAXw6M64" title="Net proceeds from issuance of common stock">672,000</span>) prior to deducting sales commissions. On February 5, 2023, in connection with our Registered Direct Offering,
we suspended the Sales Agreement with the Sales Agent, but we expect to reinstate it during 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline">Lincoln
Park Capital Fund, LLC Purchase Agreement</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
March 23, 2022, we entered into the Purchase Agreement with Lincoln Park, pursuant to which Lincoln Park has committed to purchase up
to $<span id="xdx_908_ecustom--MaximumCommitmenttoPurchaseCommonStockValue_pn5n6_c20220321__20220323__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__srt--RangeAxis__srt--MaximumMember_zBVsSuIfqZGc" title="Commitment to purchase common stock">15.0</span> million of shares (the &#8220;Purchase Shares&#8221;) of our common stock, subject to the terms and conditions in the Purchase
Agreement with Lincoln Park<span style="background-color: white">, including that the closing sale
price of the common stock on the purchase date is not below a threshold price of $<span id="xdx_90F_ecustom--ThresholdPrice_iI_c20220323__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z56btwRD3os3" title="Threshold price">1.00</span></span>. Any proceeds that we receive under the Purchase Agreement are expected to be used for working capital and
general corporate purposes. During the three months ended March 31, 2023, we sold <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zU5TWDjUhlEa">50,000</span> shares at an average price of $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_c20230331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zYRqYIOM6CCb">1.08</span> per share
for aggregate gross proceeds of $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z5Q5Cxd0qwxd">54,000</span> under the Purchase Agreement with Lincoln Park.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline">Registered
Direct Offering</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
February 14, 2023, we closed a registered direct offering <span style="background-color: white">(the &#8220;Offering&#8221;) </span>
for the sale <span style="background-color: white">of </span><span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230208__20230209__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorMember_zsS7HG7cKUlb">7,812,544 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">shares
of common stock at a purchase price of $<span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230209__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorMember_z1h2BhysrLqj">0.80 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">per
share for gross proceeds of $<span id="xdx_90F_ecustom--GrossProceedsFromIssuanceOfCommonStock_pn5n6_c20230208__20230209__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorMember_zO7UPV6Fh088" title="Gross proceeds from common stock">6.3</span>
million (net proceeds <span style="background-color: white">of</span> $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20230208__20230209__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorMember_z0Wlhqf7egfe" title="Net proceeds from common stock">5.6</span>
million). <span id="xdx_909_ecustom--RestrictionsToIssueStock_c20230208__20230209__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorMember_zxhucPdyFoMi" title="Restrictions to issue stock">The
Purchase Agreement provides that, subject to certain exceptions, until the earlier of (i) 90 days after the closing of the Offering
or (ii) the trading day following the date that our common stock&#8217;s closing price exceeds $2.00 for a period of 10 consecutive
trading days<span style="background-color: white">,</span> neither we nor our subsidiary will issue or enter into any agreement to issue or announce the issuance or proposed
issuance of any shares of common stock or common stock equivalents</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
paid the Placement Agent a cash fee of <span id="xdx_903_ecustom--TransactionCostsPercentage_iI_pid_dp_c20230209__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember_zPSlMeifG4dk" title="Cash fee percentage">8.0</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">%
of the gross proceeds from the Offering, excluding proceeds received from our insiders, and reimbursed the Placement Agent for legal
fees of $<span id="xdx_902_ecustom--ReimbursementFees_c20230208__20230209__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember_zAtfIeMD5mC1" title="Reimbursement fees">60,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">.
The engagement agreement with the Placement Agent requires us to indemnify the Placement Agent and certain of its affiliates against
certain customary liabilities. On February 14, 2023, we amended our consulting agreement with Spartan originally entered into on
August 24, 2022, extending the term of the consulting agreement until February 10, 2024. As compensation for services under the
agreement, on April 17, 2023, we granted Spartan <span style="background-color: white">a </span> warrant to purchase <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230417__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--SpartanCapitalSecuritesLLCMember_zI3wOaNmyfkh" title="Warrants to purchase common stock, shares">3,160,130 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">shares
of our common stock with an exercise price of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230417__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--SpartanCapitalSecuritesLLCMember_zNYWJHkbqt9d" title="Warrant exercise price">1.02</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">.
The warrant will expire <span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_pid_dc_c20230417__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--SpartanCapitalSecuritesLLCMember_zStLGUllcbec" title="Warrant term">three
years</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">from the date
of issuance and contains both call and cashless exercise provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 11pt"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139724388797584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
<td class="text"><p id="xdx_806_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zt9LJXU76mo1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 11pt; text-align: justify; text-indent: -11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>Note
3 - <span id="xdx_829_zudiICKz1p06">Stock-based Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 11pt; text-align: justify; text-indent: -11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
June 19, 2019, our stockholders approved, and we adopted the Processa Pharmaceuticals Inc. 2019 Omnibus Equity Incentive Plan (the &#8220;2019
Plan&#8221;). The 2019 Plan allows us, under the direction of our Board of Directors or a committee thereof, to make grants of stock
options, restricted and unrestricted stock and other stock-based awards to employees, including our executive officers, consultants and
directors. The 2019 Plan provides for the aggregate issuance of <span id="xdx_90C_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20230331__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenPlanMember_zLywRR171CSj" title="Maximum equity available for issuance">6,000,000</span> shares of our common stock. At March 31, 2023, we have <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20230331__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenPlanMember_zzsUxjamZEH4" title="Shares available for future grants">1,394,122</span> shares available
for future grants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline">Stock
Compensation Expense</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zGCTfjHml3fa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
recorded stock-based compensation expense for the three month ended March 31, 2023 and 2022 as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_zsZn6a1OB5Ad" style="display: none">Schedule
of Stock-based Compensation Expense</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20230101__20230331_zNAV8ffA5zB" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20220101__20220331_zJNSaMhMkDH1" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zm5jkrYPMsV4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">99,621</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">191,875</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zYLxalDSMLZj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">241,883</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">637,022</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ShareBasedCompensation_zgAZOmJEGTL3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">341,504</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">828,897</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_zkijGtprwhN6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 11pt; text-align: justify; text-indent: -11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="background-color: white">At
March 31, 2023, we recorded an expense and related accrued liability of $<span id="xdx_90D_eus-gaap--AccruedLiabilitiesCurrent_iI_pn5n6_c20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zczkTpIdGJOl" title="Expenses and accrued liabilities">1.3</span>
million related to the warrant we issued to Spartan<span style="background-color: white">, which is not included in the table
above</span>. No tax benefits were attributed to the stock-based compensation expense because a valuation allowance was maintained
for all net deferred tax assets relating to this expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline">Stock
Options</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span style="background-color: white">During
the three months ended March 31, 2023, </span>stock options to purchase <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zDHskWgdXZwb" title="Options, forfeited">36,885</span>
shares of common stock expired and there were no exercises or grants of stock options.
At March 31, 2023, we had outstanding and exercisable options for the purchase of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z15vcXPRIkV1" title="Options exercisable, shares">141,611</span>
shares with a weighted average exercise price of $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zUGO9g7ausjd" title="Options exercisable weighted average exercise price">18.22</span>,
a weighted average remaining contractual life of <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zK9doGizmHVj" title="Exercisable weighted average remaining contractual term">2.9</span>
years. </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At March 31, 2023, we did not have any
unrecognized stock-based compensation expense related to our granted stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline">Restricted
Stock Awards</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_ecustom--ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock_z955np8I8Vl1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Activity
with respect to our Restricted Stock Awards (RSAs) during the three months ended March 31, 2023 was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_zn8EpLL52mWl" style="display: none">Schedule
of Restricted Stock Awards (&#8220;RSAs&#8221;) Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Number of</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">shares</p></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted- <br/>average <br/>grant-date fair <br/>value per share</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Outstanding at January 1, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z4qfZlL34kp5" style="width: 16%; text-align: right" title="Number of restricted stock, shares outstanding">61,888</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zqnv0RlyN5jk" style="width: 16%; text-align: right" title="Weighted-average grant-date fair value per share, outstanding">4.72</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zs42uO9q0w1c" style="text-align: right" title="Number of shares, granted">90,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_ziFp7wHyKqfb" style="text-align: right" title="Weighted-average grant-date fair value per share, awarded">1.10</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_iN_di_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zjJh5w1Osdyi" style="text-align: right" title="Number of shares, cancelled">(26,118</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zqePEnGG4Dg3" style="text-align: right" title="Weighted-average grant-date fair value per share, cancelled">1.72</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Outstanding and unvested at March 31, 2023</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zohY2FFPI6yf" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of restricted stock shares outstanding">125,770</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zjHA7BiTCDt2" style="padding-bottom: 2.5pt; text-align: right" title="Weighted-average grant-date fair value per share, outstanding">2.75</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_zLOMMcB2NQcg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
January 1, 2023, we granted RSAs totaling <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20230101__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__custom--ThreeDirectorsMember_zrc1LFHRBCB6" title="Number of shares, granted">90,000</span>
shares of common stock to three directors for their service for the six month period ending June 30, 2023 in order to align their
compensation plan with their service period and change the annual service period to begin and end on the date of respective Annual
Meetings rather than the calendar year. Our directors are compensated through a combination of cash and equity. On March 8, 2023,
the directors increased the cash component and decreased the equity component <span style="background-color: white">of their
compensation </span> by equal amounts <span style="background-color: white">on a retroactive basis, </span> to the beginning of their respective service periods. Accordingly, we cancelled
RSAs representing <span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zD6EwNlKSHka" title="Number of shares, cancelled">26,118</span>
shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
March 31, 2023, the total unrecognized stock-based compensation expense related to the outstanding and unvested RSAs was $<span id="xdx_90A_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zGAufNNnOCJg">163,100</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
which is expected to be recognized over a weighted average period of <span id="xdx_90B_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z2WrA7hHJYt5">0.5
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline">Restricted
Stock Units</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zphmx1PqfJjb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Activity
with respect to our Restricted Stock Units (&#8220;RSUs&#8221;) during the three months ended March 31, 2023 was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zhH9RLTTWQ68" style="display: none">Schedule
of Restricted Stock Units (&#8220;RSUs&#8221;) Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Number of</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">shares</p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted- <br/>average <br/>grant-date fair <br/>value per share</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Outstanding at January 1, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iS_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z9jw5ytK7pY4" style="width: 16%; text-align: right" title="Number of shares, Beginning balance">2,713,977</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_iS_pid_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zEWfupI4HKsd" style="width: 16%; text-align: right" title="Weighted-average grant-date fair value per share, Beginning balance">3.69</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zhguMdhwcht7" style="text-align: right" title="Number of shares, awarded">966,503</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z2RVGc7TXZX3" style="text-align: right" title="Weighted-average grant-date fair value per share, awarded">1.10</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Outstanding at March 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iE_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zrCXjEkhuUY" style="text-align: right" title="Number of shares, Ending balance">3,680,480</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_iE_pid_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zM8htVtWC32f" style="text-align: right" title="Weighted-average grant-date fair value per share, Ending balance">3.01</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Vested and unissued</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z3BfsQVG1EHb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, vested and unissued">2,585,247</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zEAovR0UXlE3" style="padding-bottom: 1.5pt; text-align: right" title="Weighted-average grant-date fair value per share, vested and unissued">3.50</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Unvested at March 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zf49VO2uVCy9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, unvested">1,095,233</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zBsZNmcwYMbg" style="padding-bottom: 2.5pt; text-align: right" title="Weighted-average grant-date fair value per share, unvested">1.86</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A6_zmbBc3D2mCH4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At  March 31, 2023, unrecognized stock-based compensation expense of $<span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zjprLk0qJakk" title="Unrecognized share based compensation expense">1.2 million</span> for RSUs is expected to be fully recognized
over a weighted average period of <span id="xdx_90E_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zZDc3SUrFVjj" title="Weighted average period for recognition">2.1</span> years. The unrecognized expense excludes $<span id="xdx_90B_ecustom--UnrecognizedShareBasedCompensationExpense_pp0p0_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLAGdPK2iGX3" title="Unrecognized restricted stock expense">322,000</span> of expense related to certain RSUs
with a performance milestone that is not probable of occurring at this time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<br/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Holders
of our vested RSUs have our promise to issue shares of our common stock upon <span style="background-color: white">meeting the </span> distribution restrictions contained
in their Restricted Stock Unit Award Agreement. The distribution restrictions are different (longer) than the vesting schedule,
imposing an additional restriction on the holder. Unlike RSAs, while certain employees may hold fully vested RSUs, the individual does
not hold any shares or have any rights of a shareholder until the distribution restrictions are met. Upon distribution to the employee,
each RSU converts into one share of our common stock. The RSUs contain dividend equivalent rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline">Warrants</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">During
the three months ended March 31, 2023, we agreed to grant a warrant to purchase a total of <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zTKousqDRLJ2" title="Warrants granted">3,160,130</span>
shares of our common stock as compensation for services provided under an amended consulting agreement with Spartan, the placement
agent for the Offering</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The warrant was issued and
exercisable on April 17, 2023 with an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230214__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zmIHC4vnMhff" title="Warrants, weighted average exercise price">1.02</span>
and expiration date of April 17, 2026. The warrant contains both call and cashless exercise provisions. We recorded $<span id="xdx_90F_eus-gaap--GeneralAndAdministrativeExpense_c20230213__20230214__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zYhaAJhQSsY6" title="General and administrative expense">1,310,875</span>
as a general and administrative expense and related accrued liability representing the fair value of this warrant on February 14,
2023, the date we amended the consulting agreement, since there were no contingent conditions on that date through April 17,
2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
March 31, 2023, we had outstanding stock purchase warrants, including the warrant issued on April 17, 2023, for the purchase of <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_ztrKz3H01X8c" title="Warrants to purchase shares">3,366,480</span> <span style="background-color: white">shares
with a weighted average exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zptTIcza6uVj" title="Weighted average exercise price">1.61</span> and a weighted average remaining contractual life of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z86GevWAyxm" title="Weighted average remaining contractual life">2.8</span> years. Stock purchase warrants
for the purchase of <span id="xdx_90D_ecustom--NumberOfWarrantExercisableShares_iI_pid_c20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zJNemtveKOCj" title="Number of warrant exercisable shares">206,350</span> shares were <span style="background-color: white">exercisable </span> at March 31, 2023 and the remaining outstanding stock purchase warrants <span style="background-color: white">will be exercisable </span>in the second quarter of 2023.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At March 31, 2023, we did not have any unrecognized stock-based compensation expense related to our granted stock purchase warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139724388060624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share of Common Stock<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share of Common Stock</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--EarningsPerShareTextBlock_zwajnyjxMIKc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
4 &#8211; <span id="xdx_824_zvD6ZJbVYCOg">Net Loss per Share of Common Stock</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Net
Loss Per Share</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
net loss per share is computed by dividing our net loss available to common shareholders by the weighted average number of shares of
common stock outstanding (which excludes unvested RSAs and includes vested RSUs) during the period. Diluted loss per share is computed
by dividing our net loss available to common shareholders by the diluted weighted average number of shares of common stock (which includes
the potentially dilutive effect of stock options, unvested RSAs, unvested RSUs and warrants) during the period. Since we experienced
a net loss for both periods presented, basic and diluted net loss per share are the same. As such, diluted loss per share for the three
months ended March 31, 2023 and 2022 excludes the impact of potentially dilutive common shares since those shares would have an anti-dilutive
effect on net loss per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_896_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zLKeQe5DDiRd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
computation of net loss per share for the three months ended March 31, 2023 and 2022 was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zAurCrAKbuoi" style="display: none">Schedule
of Net Loss Per Share Basic and Dilute</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20230101__20230331_zyeTYP7P4ar1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20220101__20220331_zirdy8J7T6Lc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three months ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31,</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Basic and diluted net loss per share:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLoss_zHmR1sqsJXg8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Net loss available to common stockholders</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(4,022,073</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(3,227,131</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zMZIQBWa9k2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Weighted average number of common shares-basic and diluted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22,770,789</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15,831,118</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--EarningsPerShareBasic_zDY3shJyo9sb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Basic and diluted net loss per share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.18</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.20</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p id="xdx_8A7_zyQHFRYBYWd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
diluted net loss per share for the three months ended March 31, 2023 and 2022 excluded <span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230331_zOMeNTwJDNJ8" title="Antidilutive securities excluded from computation of earnings per share, amount">4,729,094</span>
(including the committed warrant to purchase <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20230331__us-gaap--AwardTypeAxis__custom--CommittedWarrantMember_zb788BZbGpp2" title="Antidilutive securities including from computation of earnings per share, amount">3,160,130</span> shares of common stock) and <span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220331_zglh6wHa3pg7" title="Antidilutive securities excluded from computation of earnings per share, amount">795,342</span>
of potentially dilutive common shares, respectively, related to outstanding stock options, warrants and unvested restricted stock
since those shares would have had an anti-dilutive effect on net loss per share during the periods then ended.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139724392250464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_DisclosureOperatingLeasesAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Operating Leases</a></td>
<td class="text"><p id="xdx_808_eus-gaap--LesseeOperatingLeasesTextBlock_zxJNYXvbRy5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5 &#8211; <span id="xdx_827_zuwTiqHxEQK7">Operating Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
lease our office space under an operating lease agreement. This lease does not have significant rent escalation, concessions, leasehold
improvement incentives, or other build-out clauses. Further, the lease does not contain contingent rent provisions. Our office space
lease includes both lease (e.g., fixed payments including rent, taxes, and insurance costs) and non-lease components (e.g., common-area
or other maintenance costs), which are accounted for as a single lease component as we have elected the practical expedient to group
lease and non-lease components for all leases. We also lease office equipment under an operating lease. Our leases do not provide an
implicit rate and, as such, we have used our incremental borrowing rate of <span id="xdx_902_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_c20230331_zod9159Nvdhb" title="Operating lease borrowing rate">8</span>% in determining the present value of the lease payments
based on the information available at the lease commencement date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
costs included in our condensed consolidated statements of operations totaled $<span id="xdx_90A_eus-gaap--LeaseCost_c20230101__20230331_z5sMHnA8D4Ti" title="Lease cost">22,461</span> and $<span id="xdx_90E_eus-gaap--LeaseCost_c20220101__20220331_zo4rhPrwNRck" title="Lease cost">21,918</span> for the three months ended March 31,
2023 and 2022, respectively. The weighted average remaining lease terms and discount rate for our operating leases were as follows at
March 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_ecustom--ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingLeasesTableTextBlock_zWTvc0Hr6mhd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zwkzhvwmqHs3" style="display: none">Schedule
of Weighted Average Remaining Lease Terms and Discount Rate for Operating Leases</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Remaining lease term (years) for our facility lease</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90F_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FacilityLeaseMember_zhqjFJSBVNyg" title="Remaining lease term (years)">2.5</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Remaining lease term (years) for our equipment lease</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zFa8BMp2KGtk" title="Remaining lease term (years)">1.0</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Weighted average remaining lease term (years) for our facility and equipment leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20230331_z4rLk2RbcMlc" title="Weighted average remaining lease term (years) for our facility and equipment leases">2.5</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Weighted average discount rate for our facility and equipment leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_c20230331_zv9J5IpLspQh" title="Weighted average discount rate for our facility and equipment leases">8.0</span></td><td style="text-align: left">%</td></tr>
  </table>

<p id="xdx_8AC_zacF5tSTrhge" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89C_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zYvC53eUIBbe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
lease liabilities for all operating leases were as follows at  March 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zDB11ZHvR0E8" style="display: none">Schedule
of Annual Lease Liabilities for all Operating Leases</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49C_20230331_zMMGQLodYo3d" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pp0p0_maLOLLPz79B_zLytDzBsGHOi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">70,600</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPz79B_zU1KDQOWrjt2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">92,356</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPz79B_z4rpyevdfIGa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2025</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">70,040</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPz79B_zcHS0xvXhXNl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">232,996</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_z5uniCxC4fQ6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Less: Interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(22,472</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zQvgtzm7Bgoh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Present value of lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">210,524</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pp0p0_di_zPt33K7R4S8f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Less: current maturities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(81,166</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_z28dpRADJIk1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Non-current lease liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">129,358</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AB_zfJyCFLexEp5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_DisclosureOperatingLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_DisclosureOperatingLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139724388797584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zllUNX0bPQ7c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
6 &#8211; <span id="xdx_82F_zPY3693Cqlxl">Related Party Transactions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CorLyst,
LLC (&#8220;CorLyst&#8221;) reimburses us for shared costs related to payroll, health insurance and rent based on actual costs incurred,
which are recognized as a reduction of our general and administrative operating expenses being reimbursed in our condensed consolidated
statement of operations. We recorded $<span id="xdx_903_ecustom--ProceedsFromRentAndOtherCostsReimbursements_c20230101__20230331__dei--LegalEntityAxis__custom--CorLystLLCMember_zvzTQfZLsOHd" title="Rent and other costs reimbursements received">30,205</span> and $<span id="xdx_905_ecustom--ProceedsFromRentAndOtherCostsReimbursements_c20220101__20220331__dei--LegalEntityAxis__custom--CorLystLLCMember_zO4XKVA1zlia" title="Rent and other costs reimbursements received">31,262</span> of reimbursements during the three months ended March 31, 2023 and March 31,
2022, respectively. <span id="xdx_90C_eus-gaap--OtherReceivablesNetCurrent_iI_do_c20230331__dei--LegalEntityAxis__custom--CorLystLLCMember__us-gaap--RelatedAndNonrelatedPartyStatusAxis__us-gaap--RelatedPartyMember_zmKGdReXBSy2" title="Due from related parties"><span id="xdx_906_eus-gaap--OtherReceivablesNetCurrent_iI_do_c20220331__dei--LegalEntityAxis__custom--CorLystLLCMember__us-gaap--RelatedAndNonrelatedPartyStatusAxis__us-gaap--RelatedPartyMember_z8cARRZ39jqe" title="Due from related parties">No</span></span> amounts were due from CorLyst at March 31, 2023 or 2022. Our CEO is also the CEO of CorLyst, and CorLyst is a
shareholder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139724491636944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zrMVyJo21Ml7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
7 &#8211; <span id="xdx_821_zBF5RfjHDhld">Commitments and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Purchase
Obligations</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
enter into contracts in the normal course of business with contract research organizations (CROs) and subcontractors to further
develop our products. The contracts are cancelable, with varying provisions regarding termination. If we terminated a cancelable
contract with a specific vendor, we would only be obligated for products or services that we received at  the effective date of
the termination and any applicable cancellation fees. At  March 31, 2023, we are contractually obligated to pay up to $<span id="xdx_90C_eus-gaap--PurchaseObligation_iI_pn5n6_c20230331__us-gaap--TypeOfArrangementAxis__custom--AgreementsMember__dei--LegalEntityAxis__custom--ContractResearchOrganizationsMember_zLn5g3o1b1Ji" title="Purchase obligation">3.0</span>
million of future services under the agreements with the CROs. Our actual contractual obligations will also vary depending on the
progress and results of the remaining clinical trials.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139724385927792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_BusinessActivitiesAndOrganizationPolicyTextBlock', window );">Organization</a></td>
<td class="text"><p id="xdx_848_ecustom--BusinessActivitiesAndOrganizationPolicyTextBlock_zWPg5nWOcHCf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline"><span id="xdx_86D_zit5Z1FfCdU7">
  Organization</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We are a clinical-stage biopharmaceutical company focused on incorporating our Regulatory Science Approach into the development of our
Next Generation Chemotherapy (NGC) drugs to improve the safety and efficacy of cancer treatment. Our NGC drugs are modifications of existing
FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution while maintaining the well-known and established
existing mechanisms of killing the cancer cells. By modifying the NGC drugs in this manner, we believe our three NGC treatments will provide
improved safety-efficacy profiles when compared to their currently marketed counterparts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"/>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zQDXva4NfD7a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_863_zcijPntvMeR2">Basis
of Presentation</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally
accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and with the instructions of the
Securities and Exchange Commission (&#8220;SEC&#8221;) on Form 10-Q and Article 8 of Regulation S-X.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly,
they do not include all the information and disclosures required by U.S. GAAP for complete financial statements. All material intercompany
accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated
financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our
financial position and of the results of operations and cash flows for the periods presented. These condensed consolidated financial
statements should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form
10-K for the year ended December 31, 2022, as filed with the SEC. The results of operations for the interim periods shown in this report
are not necessarily indicative of the results that may be expected for any other interim period or for the full year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_LiquidityPolicyTextBlock', window );">Liquidity</a></td>
<td class="text"><p id="xdx_841_ecustom--LiquidityPolicyTextBlock_z6QHJWnDGuZg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_867_zUgb6NKEM6H6">Liquidity</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have incurred losses since inception, devoting substantially all of our efforts toward research and development, and have an
accumulated deficit of $<span id="xdx_90E_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20230331_zhcAN75ZW7fl" title="Accumulated deficit">68.3
million</span> at March 31, 2023. During the three months ended March 31, 2023, we generated a net loss of $<span id="xdx_902_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20230101__20230331_zeipuBUCSrWe" title="Net loss">4.0
million</span> and we expect to continue to generate operating losses and negative cash flow from operations for the foreseeable
future. Based on our current plans, we believe our current cash balances are adequate for at least the next twelve months. Our
ability to execute our longer-term operating plans, including future clinical trials for our portfolio of drugs depend on
our ability to obtain additional funding from the sale of equity and/or debt securities, a strategic transaction or other funding
transactions. We plan to continue to actively pursue financing alternatives, but there can be no assurance that we will obtain the
necessary funding in the future when necessary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
had <span id="xdx_90E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0d_do_c20230101__20230331_zFoSXWfQhvNi" title="Revenue">no</span>
revenue during the three months ended March 31, 2023 and do not have any revenue under contract or any immediate sales prospects.
Our primary uses of cash are to fund our planned clinical trials, research and development expenditures and other operating
expenses. Cash used to fund operating expenses is impacted by the timing of when we incur and pay these expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2023, we raised gross proceeds of $<span id="xdx_90F_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20230101__20230331_zAfm4ciUPqT3" title="Proceeds from sale of common stock">7.0</span>
million (net proceeds of $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20230101__20230331_zi7er2Ubhrwa" title="Net proceeds from sale of stock">6.4</span> million) from the sale of <span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230101__20230331_zTH5NKFKOIvd" title="Sale of common stock, shares">8,432,192</span>
shares of our common stock, as described in Note 2. We plan to use the net proceeds from these financings to prepare for future clinical trials; and on research and development
expenses, working capital and other general corporate purposes. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--UseOfEstimates_z9ZfaxUzdiQ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_868_zLciUkfXVJEg">Use
of Estimates</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
preparing our condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP and pursuant to the
rules and regulations of the SEC, we make estimates and judgments that affect the amounts reported in the condensed consolidated
financial statements and accompanying notes. Estimates are used for, but not limited to preclinical and clinical trial expenses,
stock-based compensation, intangible assets, future milestone payments and income taxes. These estimates and assumptions are
continuously evaluated and are based on management&#8217;s experience and knowledge of the relevant facts and circumstances. While
we believe the estimates to be reasonable, actual results could differ materially from those estimates and could impact future
results of operations and cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_z8fVWrWQfhh2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86D_zkvXTL7WAral">Income
Taxes</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
account for income taxes in accordance with ASC Topic 740, <i>Income Taxes.</i> Deferred income taxes are recorded for the expected tax
consequences of temporary differences between the basis of assets and liabilities for financial reporting purposes and amounts recognized
for income tax purposes. At March 31, 2023 and December 31, 2022, we recorded a valuation allowance equal to the full recorded amount
of our net deferred tax assets since it is more-likely-than-not that such benefits will not be realized. The valuation allowance is reviewed
quarterly and is maintained until sufficient positive evidence exists to support its reversal. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
ACS 740-270 <i>Income Taxes &#8211; Interim Reporting</i>, we are required to project our annual federal and state effective income tax
rate and apply it to the year-to-date ordinary operating tax basis loss before income taxes. Based on the projection, no current income
tax benefit or expense is expected for 2023 and the foreseeable future since the deferred tax liability has been offset completely at
 December 31, 2021 and we expect to generate taxable net operating losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_zv0Hleqydarh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline"><span id="xdx_86B_zpUFJDp1Yw2i">Concentration
of Credit Risk</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject us to significant concentration of credit risk consist primarily of our cash and cash equivalents.
We utilize only well-established banks and financial institutions with high credit ratings. Balances on deposit are insured by the Federal
Deposit Insurance Corporation (FDIC) up to specified limits. Total cash held by our banks at March 31, 2023, exceeded FDIC limits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_ziUOxsYZJIfd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_863_zpOOHZcd0gK3">Recent
Accounting Pronouncements</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standard setting bodies issue new accounting pronouncements.
Updates to the FASB Accounting Standards Codification are communicated through issuance of an Accounting Standards Update (&#8220;ASU&#8221;).
We have implemented all new accounting pronouncements that are in effect and that may impact our condensed consolidated financial statements.
We have evaluated recently issued accounting pronouncements and determined that there is no material impact on our consolidated financial
position or results of operations.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_BusinessActivitiesAndOrganizationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Activities And Organization [policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_BusinessActivitiesAndOrganizationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_LiquidityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liquidity [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_LiquidityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139724388063696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Schedule of Stock-based Compensation Expense</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zGCTfjHml3fa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
recorded stock-based compensation expense for the three month ended March 31, 2023 and 2022 as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_zsZn6a1OB5Ad" style="display: none">Schedule
of Stock-based Compensation Expense</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20230101__20230331_zNAV8ffA5zB" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20220101__20220331_zJNSaMhMkDH1" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zm5jkrYPMsV4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">99,621</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">191,875</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zYLxalDSMLZj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">241,883</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">637,022</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ShareBasedCompensation_zgAZOmJEGTL3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">341,504</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">828,897</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock', window );">Schedule of Restricted Stock Awards (&#8220;RSAs&#8221;) Activity</a></td>
<td class="text"><p id="xdx_89E_ecustom--ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock_z955np8I8Vl1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Activity
with respect to our Restricted Stock Awards (RSAs) during the three months ended March 31, 2023 was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_zn8EpLL52mWl" style="display: none">Schedule
of Restricted Stock Awards (&#8220;RSAs&#8221;) Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Number of</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">shares</p></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted- <br/>average <br/>grant-date fair <br/>value per share</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Outstanding at January 1, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z4qfZlL34kp5" style="width: 16%; text-align: right" title="Number of restricted stock, shares outstanding">61,888</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zqnv0RlyN5jk" style="width: 16%; text-align: right" title="Weighted-average grant-date fair value per share, outstanding">4.72</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zs42uO9q0w1c" style="text-align: right" title="Number of shares, granted">90,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_ziFp7wHyKqfb" style="text-align: right" title="Weighted-average grant-date fair value per share, awarded">1.10</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_iN_di_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zjJh5w1Osdyi" style="text-align: right" title="Number of shares, cancelled">(26,118</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zqePEnGG4Dg3" style="text-align: right" title="Weighted-average grant-date fair value per share, cancelled">1.72</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Outstanding and unvested at March 31, 2023</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zohY2FFPI6yf" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of restricted stock shares outstanding">125,770</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zjHA7BiTCDt2" style="padding-bottom: 2.5pt; text-align: right" title="Weighted-average grant-date fair value per share, outstanding">2.75</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Restricted Stock Units (&#8220;RSUs&#8221;) Activity</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zphmx1PqfJjb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Activity
with respect to our Restricted Stock Units (&#8220;RSUs&#8221;) during the three months ended March 31, 2023 was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zhH9RLTTWQ68" style="display: none">Schedule
of Restricted Stock Units (&#8220;RSUs&#8221;) Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Number of</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">shares</p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted- <br/>average <br/>grant-date fair <br/>value per share</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Outstanding at January 1, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iS_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z9jw5ytK7pY4" style="width: 16%; text-align: right" title="Number of shares, Beginning balance">2,713,977</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_iS_pid_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zEWfupI4HKsd" style="width: 16%; text-align: right" title="Weighted-average grant-date fair value per share, Beginning balance">3.69</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zhguMdhwcht7" style="text-align: right" title="Number of shares, awarded">966,503</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z2RVGc7TXZX3" style="text-align: right" title="Weighted-average grant-date fair value per share, awarded">1.10</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Outstanding at March 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iE_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zrCXjEkhuUY" style="text-align: right" title="Number of shares, Ending balance">3,680,480</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_iE_pid_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zM8htVtWC32f" style="text-align: right" title="Weighted-average grant-date fair value per share, Ending balance">3.01</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Vested and unissued</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z3BfsQVG1EHb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, vested and unissued">2,585,247</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zEAovR0UXlE3" style="padding-bottom: 1.5pt; text-align: right" title="Weighted-average grant-date fair value per share, vested and unissued">3.50</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Unvested at March 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zf49VO2uVCy9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, unvested">1,095,233</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zBsZNmcwYMbg" style="padding-bottom: 2.5pt; text-align: right" title="Weighted-average grant-date fair value per share, unvested">1.86</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of share based compensation restricted stock award activity [Table Text Block].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139724388920752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share of Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Net Loss Per Share Basic and Dilute</a></td>
<td class="text"><p id="xdx_896_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zLKeQe5DDiRd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
computation of net loss per share for the three months ended March 31, 2023 and 2022 was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zAurCrAKbuoi" style="display: none">Schedule
of Net Loss Per Share Basic and Dilute</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20230101__20230331_zyeTYP7P4ar1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20220101__20220331_zirdy8J7T6Lc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three months ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31,</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Basic and diluted net loss per share:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLoss_zHmR1sqsJXg8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Net loss available to common stockholders</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(4,022,073</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(3,227,131</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zMZIQBWa9k2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Weighted average number of common shares-basic and diluted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22,770,789</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15,831,118</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--EarningsPerShareBasic_zDY3shJyo9sb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Basic and diluted net loss per share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.18</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.20</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139724388767536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_DisclosureOperatingLeasesAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingLeasesTableTextBlock', window );">Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating Leases</a></td>
<td class="text"><p id="xdx_891_ecustom--ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingLeasesTableTextBlock_zWTvc0Hr6mhd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zwkzhvwmqHs3" style="display: none">Schedule
of Weighted Average Remaining Lease Terms and Discount Rate for Operating Leases</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Remaining lease term (years) for our facility lease</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90F_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FacilityLeaseMember_zhqjFJSBVNyg" title="Remaining lease term (years)">2.5</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Remaining lease term (years) for our equipment lease</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zFa8BMp2KGtk" title="Remaining lease term (years)">1.0</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Weighted average remaining lease term (years) for our facility and equipment leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20230331_z4rLk2RbcMlc" title="Weighted average remaining lease term (years) for our facility and equipment leases">2.5</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Weighted average discount rate for our facility and equipment leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_c20230331_zv9J5IpLspQh" title="Weighted average discount rate for our facility and equipment leases">8.0</span></td><td style="text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Annual Lease Liabilities for all Operating Leases</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zYvC53eUIBbe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
lease liabilities for all operating leases were as follows at  March 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zDB11ZHvR0E8" style="display: none">Schedule
of Annual Lease Liabilities for all Operating Leases</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49C_20230331_zMMGQLodYo3d" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pp0p0_maLOLLPz79B_zLytDzBsGHOi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">70,600</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPz79B_zU1KDQOWrjt2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">92,356</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPz79B_z4rpyevdfIGa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2025</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">70,040</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPz79B_zcHS0xvXhXNl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">232,996</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_z5uniCxC4fQ6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Less: Interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(22,472</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zQvgtzm7Bgoh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Present value of lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">210,524</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pp0p0_di_zPt33K7R4S8f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Less: current maturities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(81,166</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_z28dpRADJIk1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Non-current lease liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">129,358</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_DisclosureOperatingLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_DisclosureOperatingLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of weighted average remaining lease terms and discount rate for our operating leases [table text block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139724387934272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 68,269,634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,247,561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">4,022,073<span></span>
</td>
<td class="nump">$ 3,227,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from sale of common stock</a></td>
<td class="nump">7,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from sale of stock</a></td>
<td class="nump">$ 6,352,077<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of common stock, shares</a></td>
<td class="nump">8,432,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139724385635472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 09, 2023</div></th>
<th class="th"><div>Mar. 23, 2022</div></th>
<th class="th"><div>Aug. 20, 2021</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Apr. 17, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,352,077<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_SalesAgreementMember', window );">Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">569,648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_GrossProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 693,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 672,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_SalesAgreementMember', window );">Sales Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_MaximumValueToBeSoldAtMarketOffering', window );">Maximum value to be sold at the market offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Lincoln Park Capital Fund LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ThresholdPrice', window );">Threshold price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Maximum [Member] | Lincoln Park Capital Fund LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_MaximumCommitmenttoPurchaseCommonStockValue', window );">Commitment to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Registered Direct Offering [Member] | Accredited Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="nump">7,812,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="nump">$ 0.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_GrossProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from common stock</a></td>
<td class="nump">$ 6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from common stock</a></td>
<td class="nump">$ 5,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_RestrictionsToIssueStock', window );">Restrictions to issue stock</a></td>
<td class="text">The
Purchase Agreement provides that, subject to certain exceptions, until the earlier of (i) 90 days after the closing of the Offering
or (ii) the trading day following the date that our common stock&#8217;s closing price exceeds $2.00 for a period of 10 consecutive
trading days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Registered Direct Offering [Member] | Placement Agent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_TransactionCostsPercentage', window );">Cash fee percentage</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ReimbursementFees', window );">Reimbursement fees</a></td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_ConsultingAgreementMember', window );">Consulting Agreement [Member] | Spartan Capital Securites LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,160,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,432,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_GrossProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds from issuance of common stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_GrossProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_MaximumCommitmenttoPurchaseCommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount committed to purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_MaximumCommitmenttoPurchaseCommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_MaximumValueToBeSoldAtMarketOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum value to be sold at the market offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_MaximumValueToBeSoldAtMarketOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ReimbursementFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reimbursement fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ReimbursementFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_RestrictionsToIssueStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restrictions to issue stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_RestrictionsToIssueStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ThresholdPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ThresholdPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_TransactionCostsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction costs percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_TransactionCostsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=PCSA_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=PCSA_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=PCSA_LincolnParkCapitalFundLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=PCSA_LincolnParkCapitalFundLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=PCSA_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=PCSA_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=PCSA_RegisteredDirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=PCSA_RegisteredDirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=PCSA_AccreditedInvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=PCSA_AccreditedInvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=PCSA_PlacementAgentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=PCSA_PlacementAgentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=PCSA_ConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=PCSA_ConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=PCSA_SpartanCapitalSecuritesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=PCSA_SpartanCapitalSecuritesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139724387932256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Stock-based Compensation Expense (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total</a></td>
<td class="nump">$ 341,504<span></span>
</td>
<td class="nump">$ 828,897<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total</a></td>
<td class="nump">99,621<span></span>
</td>
<td class="nump">191,875<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total</a></td>
<td class="nump">$ 241,883<span></span>
</td>
<td class="nump">$ 637,022<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139724388519504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Restricted Stock Awards (&#8220;RSAs&#8221;) Activity (Details) - Restricted Stock [Member]<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of restricted stock, shares outstanding | shares</a></td>
<td class="nump">61,888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share, outstanding | $ / shares</a></td>
<td class="nump">$ 4.72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, granted | shares</a></td>
<td class="nump">90,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share, awarded | $ / shares</a></td>
<td class="nump">$ 1.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod', window );">Number of shares, cancelled | shares</a></td>
<td class="num">(26,118)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share, cancelled | $ / shares</a></td>
<td class="nump">$ 1.72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of restricted stock shares outstanding | shares</a></td>
<td class="nump">125,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share, outstanding | $ / shares</a></td>
<td class="nump">$ 2.75<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options cancelled in period total fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options cancelled in period weighted average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139724389452800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Restricted Stock Units (&#8220;RSUs&#8221;) Activity (Details) - Restricted Stock Units (RSUs) [Member]<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding', window );">Number of shares, Beginning balance | shares</a></td>
<td class="nump">2,713,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share, Beginning balance | $ / shares</a></td>
<td class="nump">$ 3.69<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, awarded | shares</a></td>
<td class="nump">966,503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share, awarded | $ / shares</a></td>
<td class="nump">$ 1.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding', window );">Number of shares, Ending balance | shares</a></td>
<td class="nump">3,680,480<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share, Ending balance | $ / shares</a></td>
<td class="nump">$ 3.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued', window );">Number of shares, vested and unissued | shares</a></td>
<td class="nump">2,585,247<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share, vested and unissued | $ / shares</a></td>
<td class="nump">$ 3.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of restricted stock shares outstanding | shares</a></td>
<td class="nump">1,095,233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share, outstanding | $ / shares</a></td>
<td class="nump">$ 1.86<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than option vested and unvested outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of vested and nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options vested and unissued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options vested and unissued weighted average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139724388307168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 14, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Expenses and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,573,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 403,061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,478,055<span></span>
</td>
<td class="nump">$ 1,184,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Expenses and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted average exercise price</a></td>
<td class="nump">$ 1.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,366,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted average remaining contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_NumberOfWarrantExercisableShares', window );">Number of warrant exercisable shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Consultant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Warrants granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,160,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="nump">$ 1,310,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options, forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable weighted average remaining contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod', window );">Number of shares, cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized share based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 163,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | Three Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">966,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized share based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_UnrecognizedShareBasedCompensationExpense', window );">Unrecognized restricted stock expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 322,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=PCSA_TwoThousandAndNineteenPlanMember', window );">2019 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Maximum equity available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,394,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_NumberOfWarrantExercisableShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrant exercisable shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_NumberOfWarrantExercisableShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options cancelled in period total fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_UnrecognizedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognized share based compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_UnrecognizedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=PCSA_ConsultantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=PCSA_ConsultantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=PCSA_ThreeDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=PCSA_ThreeDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=PCSA_TwoThousandAndNineteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=PCSA_TwoThousandAndNineteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139724390795840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Net Loss Per Share Basic and Dilute (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss available to common stockholders</a></td>
<td class="num">$ (4,022,073)<span></span>
</td>
<td class="num">$ (3,227,131)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares-basic and diluted</a></td>
<td class="nump">22,770,789<span></span>
</td>
<td class="nump">15,831,118<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic and diluted net loss per share</a></td>
<td class="num">$ (0.18)<span></span>
</td>
<td class="num">$ (0.20)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139724386506480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share of Common Stock (Details Narrative) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">4,729,094<span></span>
</td>
<td class="nump">795,342<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=PCSA_CommittedWarrantMember', window );">Committed Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Antidilutive securities including from computation of earnings per share, amount</a></td>
<td class="nump">3,160,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=PCSA_CommittedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=PCSA_CommittedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139724388535472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating Leases (Details)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (years) for our facility and equipment leases</a></td>
<td class="text">2 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate for our facility and equipment leases</a></td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=PCSA_FacilityLeaseMember', window );">Facility Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Remaining lease term (years)</a></td>
<td class="text">2 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Remaining lease term (years)</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=PCSA_FacilityLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=PCSA_FacilityLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139724384556496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Annual Lease Liabilities for all Operating Leases (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_DisclosureOperatingLeasesAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2023</a></td>
<td class="nump">$ 70,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">92,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">70,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">232,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Interest</a></td>
<td class="num">(22,472)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">210,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current maturities</a></td>
<td class="num">(81,166)<span></span>
</td>
<td class="num">$ (78,896)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current lease liability</a></td>
<td class="nump">$ 129,358<span></span>
</td>
<td class="nump">$ 150,554<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_DisclosureOperatingLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_DisclosureOperatingLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139724388116368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_DisclosureOperatingLeasesAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease borrowing rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Lease cost</a></td>
<td class="nump">$ 22,461<span></span>
</td>
<td class="nump">$ 21,918<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_DisclosureOperatingLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_DisclosureOperatingLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139724385632800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details Narrative) - CorLyst, LLC [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ProceedsFromRentAndOtherCostsReimbursements', window );">Rent and other costs reimbursements received</a></td>
<td class="nump">$ 30,205<span></span>
</td>
<td class="nump">$ 31,262<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=PCSA_CorLystLLCMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Due from related parties</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ProceedsFromRentAndOtherCostsReimbursements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rent and other costs reimbursements received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ProceedsFromRentAndOtherCostsReimbursements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=PCSA_CorLystLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=PCSA_CorLystLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedAndNonrelatedPartyStatusAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedAndNonrelatedPartyStatusAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139724388798112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_AgreementsMember', window );">Agreements [Member] | Contract Research Organizations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Purchase obligation</a></td>
<td class="nump">$ 3.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=PCSA_AgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=PCSA_AgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=PCSA_ContractResearchOrganizationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=PCSA_ContractResearchOrganizationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>form10-q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:PCSA="http://processapharmaceuticals.com/20230331"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="pcsa-20230331.xsd" xlink:type="simple"/>
    <context id="From2023-01-01to2023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-05-09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <instant>2023-05-09</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_ConsultingAgreementMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:ConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-08-182021-08-20_custom_SalesAgreementMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-18</startDate>
            <endDate>2021-08-20</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_SalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_SalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2022-03-212022-03-23_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-21</startDate>
            <endDate>2022-03-23</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-23_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-23</instant>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2023-02-082023-02-09_custom_SecuritiesPurchaseAgreementMember_custom_RegisteredDirectOfferingMember_custom_AccreditedInvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:AccreditedInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">PCSA:RegisteredDirectOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-08</startDate>
            <endDate>2023-02-09</endDate>
        </period>
    </context>
    <context id="AsOf2023-02-09_custom_SecuritiesPurchaseAgreementMember_custom_RegisteredDirectOfferingMember_custom_AccreditedInvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:AccreditedInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">PCSA:RegisteredDirectOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-09</instant>
        </period>
    </context>
    <context id="AsOf2023-02-09_custom_SecuritiesPurchaseAgreementMember_custom_RegisteredDirectOfferingMember_custom_PlacementAgentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:PlacementAgentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">PCSA:RegisteredDirectOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-09</instant>
        </period>
    </context>
    <context id="From2023-02-082023-02-09_custom_SecuritiesPurchaseAgreementMember_custom_RegisteredDirectOfferingMember_custom_PlacementAgentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:PlacementAgentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">PCSA:RegisteredDirectOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-08</startDate>
            <endDate>2023-02-09</endDate>
        </period>
    </context>
    <context id="AsOf2023-04-17_custom_ConsultingAgreementMember_custom_SpartanCapitalSecuritesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:SpartanCapitalSecuritesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-17</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_TwoThousandAndNineteenPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">PCSA:TwoThousandAndNineteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-01-01_us-gaap_RestrictedStockMember_custom_ThreeDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:ThreeDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_WarrantMember_custom_ConsultantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:ConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-02-14_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-14</instant>
        </period>
    </context>
    <context id="From2023-02-132023-02-14_us-gaap_WarrantMember_custom_ConsultantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:ConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-13</startDate>
            <endDate>2023-02-14</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_CommittedWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PCSA:CommittedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_FacilityLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">PCSA:FacilityLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_CorLystLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:CorLystLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_CorLystLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:CorLystLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_CorLystLLCMember_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedAndNonrelatedPartyStatusAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:CorLystLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_CorLystLLCMember_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedAndNonrelatedPartyStatusAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:CorLystLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_AgreementsMember_custom_ContractResearchOrganizationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:AgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:ContractResearchOrganizationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2023-01-01to2023-03-31">0001533743</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2023-01-01to2023-03-31">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2023-01-01to2023-03-31">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate contextRef="From2023-01-01to2023-03-31">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-03-31"
      id="xdx2ixbrl0058"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0059"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2023-03-31"
      id="xdx2ixbrl0091"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherLiabilityCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration contextRef="AsOf2022-12-31" id="xdx2ixbrl0093">http://fasb.org/us-gaap/2023#RelatedPartyMember</us-gaap:OtherLiabilityCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2023-03-31"
      id="xdx2ixbrl0110"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0111"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-01to2023-03-31"
      id="xdx2ixbrl0172"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-03-31"
      id="xdx2ixbrl0173"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0186"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0192"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-01-012022-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0196"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0197"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0202"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0203"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0205"
      unitRef="USD"
      xsi:nil="true"/>
    <PCSA:SharesIssuedInConnectionWithPurchaseAgreementValue
      contextRef="From2022-01-012022-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0212"
      unitRef="USD"
      xsi:nil="true"/>
    <PCSA:SharesIssuedInConnectionWithPurchaseAgreementValue
      contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0213"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0218"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0219"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0220"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0256"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0257"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0264"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0265"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0270"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0271"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0272"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="From2023-01-01to2023-03-31"
      id="xdx2ixbrl0308"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-01-01to2023-03-31"
      id="xdx2ixbrl0311"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2022-01-012022-03-31"
      id="xdx2ixbrl0318"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="From2023-01-01to2023-03-31"
      id="xdx2ixbrl0337"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-01-012022-03-31"
      id="xdx2ixbrl0350"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsForRepurchaseOfEquity
      contextRef="From2023-01-01to2023-03-31"
      id="xdx2ixbrl0352"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssued1
      contextRef="From2023-01-01to2023-03-31"
      id="xdx2ixbrl0370"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2023-01-01to2023-03-31">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2023-01-01to2023-03-31">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2023-01-01to2023-03-31">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2023-01-01to2023-03-31">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2023-01-01to2023-03-31">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2023-01-01to2023-03-31">001-39531</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2023-01-01to2023-03-31">Processa Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2023-01-01to2023-03-31">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2023-01-01to2023-03-31">45-1539785</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2023-01-01to2023-03-31">7380 Coca Cola Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2023-01-01to2023-03-31">Suite 106</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2023-01-01to2023-03-31">Hanover</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2023-01-01to2023-03-31">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2023-01-01to2023-03-31">21076</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2023-01-01to2023-03-31">(443)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2023-01-01to2023-03-31">776-3133</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2023-01-01to2023-03-31">Common     Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-01-01to2023-03-31">PCSA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-01-01to2023-03-31">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2023-01-01to2023-03-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2023-01-01to2023-03-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2023-01-01to2023-03-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2023-01-01to2023-03-31">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2023-01-01to2023-03-31">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2023-01-01to2023-03-31">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2023-05-09" decimals="INF" unitRef="Shares">24531474</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">10741602</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">6503595</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">1477519</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1883134</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">12219121</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">8386729</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">207787</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">227587</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:SecurityDeposit contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">5535</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">5535</us-gaap:SecurityDeposit>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">213322</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">233122</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">12432443</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">8619851</us-gaap:Assets>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">81166</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">78896</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">316709</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">327548</us-gaap:AccountsPayableCurrent>
    <PCSA:DueToLicensor contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">189000</PCSA:DueToLicensor>
    <PCSA:DueToLicensor contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">189000</PCSA:DueToLicensor>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">51</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">1573961</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">403061</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">2160836</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">998556</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">129358</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">150554</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">2290194</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1149110</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-03-31"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2023-03-31" decimals="INF" unitRef="Shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2023-03-31" decimals="INF" unitRef="Shares">24631474</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2023-03-31" decimals="INF" unitRef="Shares">24531474</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">16135400</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">16035400</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">2463</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1614</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">78709420</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">72016688</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:TreasuryStockCommonShares contextRef="AsOf2023-03-31" decimals="INF" unitRef="Shares">100000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">100000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockValue contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">300000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">300000</us-gaap:TreasuryStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">-68269634</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">-64247561</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">10142249</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">7470741</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">12432443</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">8619851</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">1627480</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">2043984</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">2478055</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">1184730</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">-4105535</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">-3228714</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">83462</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">1583</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">-4022073</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">-3227131</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">-4022073</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">-3227131</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-01to2023-03-31"
      decimals="INF"
      unitRef="USDPShares">-0.18</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-012022-03-31"
      decimals="INF"
      unitRef="USDPShares">-0.20</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-01to2023-03-31"
      decimals="INF"
      unitRef="Shares">22770789</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-012022-03-31"
      decimals="INF"
      unitRef="Shares">15831118</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">15710246</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1571</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">62306861</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-36823332</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">25485100</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">103670</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">10</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">828887</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">828897</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="From2022-01-012022-03-31_us-gaap_TreasuryStockCommonMember"
      decimals="INF"
      unitRef="Shares">100000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2022-01-012022-03-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      unitRef="USD">300000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">300000</us-gaap:StockRepurchasedDuringPeriodValue>
    <PCSA:SharesIssuedInConnectionWithPurchaseAgreementShares
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">123609</PCSA:SharesIssuedInConnectionWithPurchaseAgreementShares>
    <PCSA:SharesIssuedInConnectionWithPurchaseAgreementValue
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">12</PCSA:SharesIssuedInConnectionWithPurchaseAgreementValue>
    <PCSA:SharesIssuedInConnectionWithPurchaseAgreementValue
      contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">449988</PCSA:SharesIssuedInConnectionWithPurchaseAgreementValue>
    <PCSA:SharesIssuedInConnectionWithPurchaseAgreementValue
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">450000</PCSA:SharesIssuedInConnectionWithPurchaseAgreementValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-3227131</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">-3227131</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">15937525</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1593</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">63585736</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-03-31_us-gaap_TreasuryStockCommonMember"
      decimals="INF"
      unitRef="Shares">-100000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      unitRef="USD">-300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-40050463</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">23236866</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">15937525</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1593</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">63585736</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-03-31_us-gaap_TreasuryStockCommonMember"
      decimals="INF"
      unitRef="Shares">-100000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      unitRef="USD">-300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-40050463</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">23236866</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">16135400</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1614</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">72016688</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="INF"
      unitRef="Shares">-100000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      unitRef="USD">-300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-64247561</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">7470741</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">63882</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">6</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">341498</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">341504</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">8432192</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">843</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">6351234</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">6352077</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-4022073</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">-4022073</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">24631474</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">2463</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">78709420</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-03-31_us-gaap_TreasuryStockCommonMember"
      decimals="INF"
      unitRef="Shares">-100000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      unitRef="USD">-300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-68269634</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">10142249</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">24631474</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">2463</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">78709420</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-03-31_us-gaap_TreasuryStockCommonMember"
      decimals="INF"
      unitRef="Shares">-100000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      unitRef="USD">-300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-68269634</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">10142249</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">-4022073</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">-3227131</us-gaap:NetIncomeLoss>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">19800</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">22559</us-gaap:OperatingLeaseExpense>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">3113</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">197124</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">341504</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">828897</us-gaap:ShareBasedCompensation>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-03-31_custom_ConsultingAgreementMember_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">3160130</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">1310875</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">-405615</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">-216717</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">-18926</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">-23195</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">-10839</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">97187</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInDueToRelatedParties
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">-51</us-gaap:IncreaseDecreaseInDueToRelatedParties>
    <us-gaap:IncreaseDecreaseInDueToRelatedParties
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">-1772</us-gaap:IncreaseDecreaseInDueToRelatedParties>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">-70274</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">-139975</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">13301</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">-2114070</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">-1802926</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">6352077</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfEquity
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">300000</us-gaap:PaymentsForRepurchaseOfEquity>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">6352077</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">-300000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">4238007</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">-2102926</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">6503595</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">16497581</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">10741602</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">14394655</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <PCSA:SharesIssuedInConnectionWithPurchaseAgreementShares
      contextRef="From2022-01-012022-03-31_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">123609</PCSA:SharesIssuedInConnectionWithPurchaseAgreementShares>
    <us-gaap:StockIssued1
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">450000</us-gaap:StockIssued1>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_803_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_z6Dsu1T422L1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
1 &#x2013; &lt;span id="xdx_82B_z0oH60v2wmgi"&gt;Organization and Summary of Significant Accounting Policies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_ecustom--BusinessActivitiesAndOrganizationPolicyTextBlock_zWPg5nWOcHCf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86D_zit5Z1FfCdU7"&gt;
  Organization&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;We are a clinical-stage biopharmaceutical company focused on incorporating our Regulatory Science Approach into the development of our
Next Generation Chemotherapy (NGC) drugs to improve the safety and efficacy of cancer treatment. Our NGC drugs are modifications of existing
FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution while maintaining the well-known and established
existing mechanisms of killing the cancer cells. By modifying the NGC drugs in this manner, we believe our three NGC treatments will provide
improved safety-efficacy profiles when compared to their currently marketed counterparts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"/&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zQDXva4NfD7a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_863_zcijPntvMeR2"&gt;Basis
of Presentation&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally
accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information and with the instructions of the
Securities and Exchange Commission (&#x201c;SEC&#x201d;) on Form 10-Q and Article 8 of Regulation S-X.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accordingly,
they do not include all the information and disclosures required by U.S. GAAP for complete financial statements. All material intercompany
accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated
financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our
financial position and of the results of operations and cash flows for the periods presented. These condensed consolidated financial
statements should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form
10-K for the year ended December 31, 2022, as filed with the SEC. The results of operations for the interim periods shown in this report
are not necessarily indicative of the results that may be expected for any other interim period or for the full year.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_ecustom--LiquidityPolicyTextBlock_z6QHJWnDGuZg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_867_zUgb6NKEM6H6"&gt;Liquidity&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
have incurred losses since inception, devoting substantially all of our efforts toward research and development, and have an
accumulated deficit of $&lt;span id="xdx_90E_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20230331_zhcAN75ZW7fl" title="Accumulated deficit"&gt;68.3
million&lt;/span&gt; at March 31, 2023. During the three months ended March 31, 2023, we generated a net loss of $&lt;span id="xdx_902_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20230101__20230331_zeipuBUCSrWe" title="Net loss"&gt;4.0
million&lt;/span&gt; and we expect to continue to generate operating losses and negative cash flow from operations for the foreseeable
future. Based on our current plans, we believe our current cash balances are adequate for at least the next twelve months. Our
ability to execute our longer-term operating plans, including future clinical trials for our portfolio of drugs depend on
our ability to obtain additional funding from the sale of equity and/or debt securities, a strategic transaction or other funding
transactions. We plan to continue to actively pursue financing alternatives, but there can be no assurance that we will obtain the
necessary funding in the future when necessary.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
had &lt;span id="xdx_90E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0d_do_c20230101__20230331_zFoSXWfQhvNi" title="Revenue"&gt;no&lt;/span&gt;
revenue during the three months ended March 31, 2023 and do not have any revenue under contract or any immediate sales prospects.
Our primary uses of cash are to fund our planned clinical trials, research and development expenditures and other operating
expenses. Cash used to fund operating expenses is impacted by the timing of when we incur and pay these expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three months ended March 31, 2023, we raised gross proceeds of $&lt;span id="xdx_90F_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20230101__20230331_zAfm4ciUPqT3" title="Proceeds from sale of common stock"&gt;7.0&lt;/span&gt;
million (net proceeds of $&lt;span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20230101__20230331_zi7er2Ubhrwa" title="Net proceeds from sale of stock"&gt;6.4&lt;/span&gt; million) from the sale of &lt;span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230101__20230331_zTH5NKFKOIvd" title="Sale of common stock, shares"&gt;8,432,192&lt;/span&gt;
shares of our common stock, as described in Note 2. We plan to use the net proceeds from these financings to prepare for future clinical trials; and on research and development
expenses, working capital and other general corporate purposes. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--UseOfEstimates_z9ZfaxUzdiQ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_868_zLciUkfXVJEg"&gt;Use
of Estimates&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
preparing our condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP and pursuant to the
rules and regulations of the SEC, we make estimates and judgments that affect the amounts reported in the condensed consolidated
financial statements and accompanying notes. Estimates are used for, but not limited to preclinical and clinical trial expenses,
stock-based compensation, intangible assets, future milestone payments and income taxes. These estimates and assumptions are
continuously evaluated and are based on management&#x2019;s experience and knowledge of the relevant facts and circumstances. While
we believe the estimates to be reasonable, actual results could differ materially from those estimates and could impact future
results of operations and cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_z8fVWrWQfhh2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86D_zkvXTL7WAral"&gt;Income
Taxes&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
account for income taxes in accordance with ASC Topic 740, &lt;i&gt;Income Taxes.&lt;/i&gt; Deferred income taxes are recorded for the expected tax
consequences of temporary differences between the basis of assets and liabilities for financial reporting purposes and amounts recognized
for income tax purposes. At March 31, 2023 and December 31, 2022, we recorded a valuation allowance equal to the full recorded amount
of our net deferred tax assets since it is more-likely-than-not that such benefits will not be realized. The valuation allowance is reviewed
quarterly and is maintained until sufficient positive evidence exists to support its reversal. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
ACS 740-270 &lt;i&gt;Income Taxes &#x2013; Interim Reporting&lt;/i&gt;, we are required to project our annual federal and state effective income tax
rate and apply it to the year-to-date ordinary operating tax basis loss before income taxes. Based on the projection, no current income
tax benefit or expense is expected for 2023 and the foreseeable future since the deferred tax liability has been offset completely at
 December 31, 2021 and we expect to generate taxable net operating losses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_zv0Hleqydarh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86B_zpUFJDp1Yw2i"&gt;Concentration
of Credit Risk&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially subject us to significant concentration of credit risk consist primarily of our cash and cash equivalents.
We utilize only well-established banks and financial institutions with high credit ratings. Balances on deposit are insured by the Federal
Deposit Insurance Corporation (FDIC) up to specified limits. Total cash held by our banks at March 31, 2023, exceeded FDIC limits.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;&lt;p id="xdx_84C_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_ziUOxsYZJIfd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_863_zpOOHZcd0gK3"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From
time to time, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) or other standard setting bodies issue new accounting pronouncements.
Updates to the FASB Accounting Standards Codification are communicated through issuance of an Accounting Standards Update (&#x201c;ASU&#x201d;).
We have implemented all new accounting pronouncements that are in effect and that may impact our condensed consolidated financial statements.
We have evaluated recently issued accounting pronouncements and determined that there is no material impact on our consolidated financial
position or results of operations.&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <PCSA:BusinessActivitiesAndOrganizationPolicyTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_848_ecustom--BusinessActivitiesAndOrganizationPolicyTextBlock_zWPg5nWOcHCf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86D_zit5Z1FfCdU7"&gt;
  Organization&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;We are a clinical-stage biopharmaceutical company focused on incorporating our Regulatory Science Approach into the development of our
Next Generation Chemotherapy (NGC) drugs to improve the safety and efficacy of cancer treatment. Our NGC drugs are modifications of existing
FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution while maintaining the well-known and established
existing mechanisms of killing the cancer cells. By modifying the NGC drugs in this manner, we believe our three NGC treatments will provide
improved safety-efficacy profiles when compared to their currently marketed counterparts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"/&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</PCSA:BusinessActivitiesAndOrganizationPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_84A_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zQDXva4NfD7a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_863_zcijPntvMeR2"&gt;Basis
of Presentation&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally
accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information and with the instructions of the
Securities and Exchange Commission (&#x201c;SEC&#x201d;) on Form 10-Q and Article 8 of Regulation S-X.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accordingly,
they do not include all the information and disclosures required by U.S. GAAP for complete financial statements. All material intercompany
accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated
financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our
financial position and of the results of operations and cash flows for the periods presented. These condensed consolidated financial
statements should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form
10-K for the year ended December 31, 2022, as filed with the SEC. The results of operations for the interim periods shown in this report
are not necessarily indicative of the results that may be expected for any other interim period or for the full year.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <PCSA:LiquidityPolicyTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_841_ecustom--LiquidityPolicyTextBlock_z6QHJWnDGuZg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_867_zUgb6NKEM6H6"&gt;Liquidity&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
have incurred losses since inception, devoting substantially all of our efforts toward research and development, and have an
accumulated deficit of $&lt;span id="xdx_90E_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20230331_zhcAN75ZW7fl" title="Accumulated deficit"&gt;68.3
million&lt;/span&gt; at March 31, 2023. During the three months ended March 31, 2023, we generated a net loss of $&lt;span id="xdx_902_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20230101__20230331_zeipuBUCSrWe" title="Net loss"&gt;4.0
million&lt;/span&gt; and we expect to continue to generate operating losses and negative cash flow from operations for the foreseeable
future. Based on our current plans, we believe our current cash balances are adequate for at least the next twelve months. Our
ability to execute our longer-term operating plans, including future clinical trials for our portfolio of drugs depend on
our ability to obtain additional funding from the sale of equity and/or debt securities, a strategic transaction or other funding
transactions. We plan to continue to actively pursue financing alternatives, but there can be no assurance that we will obtain the
necessary funding in the future when necessary.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
had &lt;span id="xdx_90E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0d_do_c20230101__20230331_zFoSXWfQhvNi" title="Revenue"&gt;no&lt;/span&gt;
revenue during the three months ended March 31, 2023 and do not have any revenue under contract or any immediate sales prospects.
Our primary uses of cash are to fund our planned clinical trials, research and development expenditures and other operating
expenses. Cash used to fund operating expenses is impacted by the timing of when we incur and pay these expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three months ended March 31, 2023, we raised gross proceeds of $&lt;span id="xdx_90F_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20230101__20230331_zAfm4ciUPqT3" title="Proceeds from sale of common stock"&gt;7.0&lt;/span&gt;
million (net proceeds of $&lt;span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20230101__20230331_zi7er2Ubhrwa" title="Net proceeds from sale of stock"&gt;6.4&lt;/span&gt; million) from the sale of &lt;span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230101__20230331_zTH5NKFKOIvd" title="Sale of common stock, shares"&gt;8,432,192&lt;/span&gt;
shares of our common stock, as described in Note 2. We plan to use the net proceeds from these financings to prepare for future clinical trials; and on research and development
expenses, working capital and other general corporate purposes. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</PCSA:LiquidityPolicyTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2023-03-31" decimals="-5" unitRef="USD">-68300000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-03-31"
      decimals="-5"
      unitRef="USD">-4000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2023-01-01to2023-03-31"
      decimals="-5"
      unitRef="USD">7000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-01-01to2023-03-31"
      decimals="-5"
      unitRef="USD">6400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2023-01-01to2023-03-31"
      decimals="INF"
      unitRef="Shares">8432192</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:UseOfEstimates contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_84A_eus-gaap--UseOfEstimates_z9ZfaxUzdiQ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_868_zLciUkfXVJEg"&gt;Use
of Estimates&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
preparing our condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP and pursuant to the
rules and regulations of the SEC, we make estimates and judgments that affect the amounts reported in the condensed consolidated
financial statements and accompanying notes. Estimates are used for, but not limited to preclinical and clinical trial expenses,
stock-based compensation, intangible assets, future milestone payments and income taxes. These estimates and assumptions are
continuously evaluated and are based on management&#x2019;s experience and knowledge of the relevant facts and circumstances. While
we believe the estimates to be reasonable, actual results could differ materially from those estimates and could impact future
results of operations and cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_z8fVWrWQfhh2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86D_zkvXTL7WAral"&gt;Income
Taxes&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
account for income taxes in accordance with ASC Topic 740, &lt;i&gt;Income Taxes.&lt;/i&gt; Deferred income taxes are recorded for the expected tax
consequences of temporary differences between the basis of assets and liabilities for financial reporting purposes and amounts recognized
for income tax purposes. At March 31, 2023 and December 31, 2022, we recorded a valuation allowance equal to the full recorded amount
of our net deferred tax assets since it is more-likely-than-not that such benefits will not be realized. The valuation allowance is reviewed
quarterly and is maintained until sufficient positive evidence exists to support its reversal. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
ACS 740-270 &lt;i&gt;Income Taxes &#x2013; Interim Reporting&lt;/i&gt;, we are required to project our annual federal and state effective income tax
rate and apply it to the year-to-date ordinary operating tax basis loss before income taxes. Based on the projection, no current income
tax benefit or expense is expected for 2023 and the foreseeable future since the deferred tax liability has been offset completely at
 December 31, 2021 and we expect to generate taxable net operating losses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_zv0Hleqydarh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86B_zpUFJDp1Yw2i"&gt;Concentration
of Credit Risk&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially subject us to significant concentration of credit risk consist primarily of our cash and cash equivalents.
We utilize only well-established banks and financial institutions with high credit ratings. Balances on deposit are insured by the Federal
Deposit Insurance Corporation (FDIC) up to specified limits. Total cash held by our banks at March 31, 2023, exceeded FDIC limits.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_84C_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_ziUOxsYZJIfd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_863_zpOOHZcd0gK3"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From
time to time, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) or other standard setting bodies issue new accounting pronouncements.
Updates to the FASB Accounting Standards Codification are communicated through issuance of an Accounting Standards Update (&#x201c;ASU&#x201d;).
We have implemented all new accounting pronouncements that are in effect and that may impact our condensed consolidated financial statements.
We have evaluated recently issued accounting pronouncements and determined that there is no material impact on our consolidated financial
position or results of operations.&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_805_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zzYuHICslY8j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
2 &#x2013; &lt;span id="xdx_828_zNbNKqUxhbBb"&gt;Stockholders&#x2019; Equity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Preferred
Stock&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
were &lt;span id="xdx_905_eus-gaap--PreferredStockSharesIssued_iI_do_c20230331_zFY0X6ZK9Xn1" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20230331_zvApIldwVGyf" title="Preferred stock, shares outstanding"&gt;&lt;span id="xdx_90C_eus-gaap--PreferredStockSharesIssued_iI_do_c20221231_zOxlHej2AbKe" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20221231_zP6Ho1mLuBc7" title="Preferred stock, shares outstanding"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; issued or outstanding shares of preferred stock at either March 31, 2023 or December 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Common
Stock&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three months ended March 31, 2023, we issued &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpIyeCbEliPa" title="Common stock shares issued"&gt;8,432,192&lt;/span&gt; shares of our common stock through several fundraising efforts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;ATM
Offering&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 20, 2021, we entered into the Sales Agreement with Oppenheimer &amp;amp; Co. Inc. (the &#x201c;Sales Agent&#x201d;) under which we
may issue and sell up to $&lt;span id="xdx_90F_ecustom--MaximumValueToBeSoldAtMarketOffering_pn5n6_c20210818__20210820__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember__srt--RangeAxis__srt--MaximumMember_zXYONC3iBkNf" title="Maximum value to be sold at the market offering"&gt;30.0&lt;/span&gt;
million from time to time under the ATM Offering. We expect to use net proceeds from the ATM Offering over time as a source for
working capital and general corporate purposes. During the three months ended March 31, 2023, we sold &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zrjJJdoDfgo8" title="Number of shares issued"&gt;569,648&lt;/span&gt;
shares at an average price of $&lt;span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_c20230331__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_z1IBZhXRYPCi"&gt;1.22&lt;/span&gt;
per share for aggregate gross proceeds of $&lt;span id="xdx_908_ecustom--GrossProceedsFromIssuanceOfCommonStock_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zmLQDUj3xO3f" title="Gross proceeds from common stock"&gt;693,000&lt;/span&gt; (net proceeds of $&lt;span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zeTzdAXw6M64" title="Net proceeds from issuance of common stock"&gt;672,000&lt;/span&gt;) prior to deducting sales commissions. On February 5, 2023, in connection with our Registered Direct Offering,
we suspended the Sales Agreement with the Sales Agent, but we expect to reinstate it during 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Lincoln
Park Capital Fund, LLC Purchase Agreement&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;On
March 23, 2022, we entered into the Purchase Agreement with Lincoln Park, pursuant to which Lincoln Park has committed to purchase up
to $&lt;span id="xdx_908_ecustom--MaximumCommitmenttoPurchaseCommonStockValue_pn5n6_c20220321__20220323__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__srt--RangeAxis__srt--MaximumMember_zBVsSuIfqZGc" title="Commitment to purchase common stock"&gt;15.0&lt;/span&gt; million of shares (the &#x201c;Purchase Shares&#x201d;) of our common stock, subject to the terms and conditions in the Purchase
Agreement with Lincoln Park&lt;span style="background-color: white"&gt;, including that the closing sale
price of the common stock on the purchase date is not below a threshold price of $&lt;span id="xdx_90F_ecustom--ThresholdPrice_iI_c20220323__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z56btwRD3os3" title="Threshold price"&gt;1.00&lt;/span&gt;&lt;/span&gt;. Any proceeds that we receive under the Purchase Agreement are expected to be used for working capital and
general corporate purposes. During the three months ended March 31, 2023, we sold &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zU5TWDjUhlEa"&gt;50,000&lt;/span&gt; shares at an average price of $&lt;span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_c20230331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zYRqYIOM6CCb"&gt;1.08&lt;/span&gt; per share
for aggregate gross proceeds of $&lt;span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z5Q5Cxd0qwxd"&gt;54,000&lt;/span&gt; under the Purchase Agreement with Lincoln Park.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Registered
Direct Offering&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 11pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;On
February 14, 2023, we closed a registered direct offering &lt;span style="background-color: white"&gt;(the &#x201c;Offering&#x201d;) &lt;/span&gt;
for the sale &lt;span style="background-color: white"&gt;of &lt;/span&gt;&lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230208__20230209__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorMember_zsS7HG7cKUlb"&gt;7,812,544 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;shares
of common stock at a purchase price of $&lt;span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230209__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorMember_z1h2BhysrLqj"&gt;0.80 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;per
share for gross proceeds of $&lt;span id="xdx_90F_ecustom--GrossProceedsFromIssuanceOfCommonStock_pn5n6_c20230208__20230209__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorMember_zO7UPV6Fh088" title="Gross proceeds from common stock"&gt;6.3&lt;/span&gt;
million (net proceeds &lt;span style="background-color: white"&gt;of&lt;/span&gt; $&lt;span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20230208__20230209__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorMember_z0Wlhqf7egfe" title="Net proceeds from common stock"&gt;5.6&lt;/span&gt;
million). &lt;span id="xdx_909_ecustom--RestrictionsToIssueStock_c20230208__20230209__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorMember_zxhucPdyFoMi" title="Restrictions to issue stock"&gt;The
Purchase Agreement provides that, subject to certain exceptions, until the earlier of (i) 90 days after the closing of the Offering
or (ii) the trading day following the date that our common stock&#x2019;s closing price exceeds $2.00 for a period of 10 consecutive
trading days&lt;span style="background-color: white"&gt;,&lt;/span&gt; neither we nor our subsidiary will issue or enter into any agreement to issue or announce the issuance or proposed
issuance of any shares of common stock or common stock equivalents&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 11pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 11pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;We
paid the Placement Agent a cash fee of &lt;span id="xdx_903_ecustom--TransactionCostsPercentage_iI_pid_dp_c20230209__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember_zPSlMeifG4dk" title="Cash fee percentage"&gt;8.0&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;%
of the gross proceeds from the Offering, excluding proceeds received from our insiders, and reimbursed the Placement Agent for legal
fees of $&lt;span id="xdx_902_ecustom--ReimbursementFees_c20230208__20230209__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember_zAtfIeMD5mC1" title="Reimbursement fees"&gt;60,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;.
The engagement agreement with the Placement Agent requires us to indemnify the Placement Agent and certain of its affiliates against
certain customary liabilities. On February 14, 2023, we amended our consulting agreement with Spartan originally entered into on
August 24, 2022, extending the term of the consulting agreement until February 10, 2024. As compensation for services under the
agreement, on April 17, 2023, we granted Spartan &lt;span style="background-color: white"&gt;a &lt;/span&gt; warrant to purchase &lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230417__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--SpartanCapitalSecuritesLLCMember_zI3wOaNmyfkh" title="Warrants to purchase common stock, shares"&gt;3,160,130 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;shares
of our common stock with an exercise price of $&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230417__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--SpartanCapitalSecuritesLLCMember_zNYWJHkbqt9d" title="Warrant exercise price"&gt;1.02&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;.
The warrant will expire &lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_pid_dc_c20230417__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--SpartanCapitalSecuritesLLCMember_zStLGUllcbec" title="Warrant term"&gt;three
years&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;from the date
of issuance and contains both call and cashless exercise provisions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 11pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 11pt"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 11pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2023-03-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2023-03-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">8432192</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <PCSA:MaximumValueToBeSoldAtMarketOffering
      contextRef="From2021-08-182021-08-20_custom_SalesAgreementMember_srt_MaximumMember"
      decimals="-5"
      unitRef="USD">30000000.0</PCSA:MaximumValueToBeSoldAtMarketOffering>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-03-31_custom_SalesAgreementMember"
      decimals="INF"
      unitRef="Shares">569648</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-03-31_custom_SalesAgreementMember"
      decimals="INF"
      unitRef="USDPShares">1.22</us-gaap:SharesIssuedPricePerShare>
    <PCSA:GrossProceedsFromIssuanceOfCommonStock
      contextRef="From2023-01-012023-03-31_custom_SalesAgreementMember"
      decimals="0"
      unitRef="USD">693000</PCSA:GrossProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-01-012023-03-31_custom_SalesAgreementMember"
      decimals="0"
      unitRef="USD">672000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <PCSA:MaximumCommitmenttoPurchaseCommonStockValue
      contextRef="From2022-03-212022-03-23_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember_srt_MaximumMember"
      decimals="-5"
      unitRef="USD">15000000.0</PCSA:MaximumCommitmenttoPurchaseCommonStockValue>
    <PCSA:ThresholdPrice
      contextRef="AsOf2022-03-23_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="USDPShares">1.00</PCSA:ThresholdPrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-03-31_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">50000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-03-31_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="USDPShares">1.08</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-01-012023-03-31_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember"
      decimals="0"
      unitRef="USD">54000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-02-082023-02-09_custom_SecuritiesPurchaseAgreementMember_custom_RegisteredDirectOfferingMember_custom_AccreditedInvestorMember"
      decimals="INF"
      unitRef="Shares">7812544</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-02-09_custom_SecuritiesPurchaseAgreementMember_custom_RegisteredDirectOfferingMember_custom_AccreditedInvestorMember"
      decimals="INF"
      unitRef="USDPShares">0.80</us-gaap:SharesIssuedPricePerShare>
    <PCSA:GrossProceedsFromIssuanceOfCommonStock
      contextRef="From2023-02-082023-02-09_custom_SecuritiesPurchaseAgreementMember_custom_RegisteredDirectOfferingMember_custom_AccreditedInvestorMember"
      decimals="-5"
      unitRef="USD">6300000</PCSA:GrossProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-02-082023-02-09_custom_SecuritiesPurchaseAgreementMember_custom_RegisteredDirectOfferingMember_custom_AccreditedInvestorMember"
      decimals="-5"
      unitRef="USD">5600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <PCSA:RestrictionsToIssueStock contextRef="From2023-02-082023-02-09_custom_SecuritiesPurchaseAgreementMember_custom_RegisteredDirectOfferingMember_custom_AccreditedInvestorMember">The
Purchase Agreement provides that, subject to certain exceptions, until the earlier of (i) 90 days after the closing of the Offering
or (ii) the trading day following the date that our common stock&#x2019;s closing price exceeds $2.00 for a period of 10 consecutive
trading days</PCSA:RestrictionsToIssueStock>
    <PCSA:TransactionCostsPercentage
      contextRef="AsOf2023-02-09_custom_SecuritiesPurchaseAgreementMember_custom_RegisteredDirectOfferingMember_custom_PlacementAgentMember"
      decimals="INF"
      unitRef="Pure">0.080</PCSA:TransactionCostsPercentage>
    <PCSA:ReimbursementFees
      contextRef="From2023-02-082023-02-09_custom_SecuritiesPurchaseAgreementMember_custom_RegisteredDirectOfferingMember_custom_PlacementAgentMember"
      decimals="0"
      unitRef="USD">60000</PCSA:ReimbursementFees>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-04-17_custom_ConsultingAgreementMember_custom_SpartanCapitalSecuritesLLCMember"
      decimals="INF"
      unitRef="Shares">3160130</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-04-17_custom_ConsultingAgreementMember_custom_SpartanCapitalSecuritesLLCMember"
      decimals="INF"
      unitRef="USDPShares">1.02</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2023-04-17_custom_ConsultingAgreementMember_custom_SpartanCapitalSecuritesLLCMember">P3Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_806_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zt9LJXU76mo1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 11pt; text-align: justify; text-indent: -11pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;Note
3 - &lt;span id="xdx_829_zudiICKz1p06"&gt;Stock-based Compensation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 11pt; text-align: justify; text-indent: -11pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;On
June 19, 2019, our stockholders approved, and we adopted the Processa Pharmaceuticals Inc. 2019 Omnibus Equity Incentive Plan (the &#x201c;2019
Plan&#x201d;). The 2019 Plan allows us, under the direction of our Board of Directors or a committee thereof, to make grants of stock
options, restricted and unrestricted stock and other stock-based awards to employees, including our executive officers, consultants and
directors. The 2019 Plan provides for the aggregate issuance of &lt;span id="xdx_90C_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20230331__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenPlanMember_zLywRR171CSj" title="Maximum equity available for issuance"&gt;6,000,000&lt;/span&gt; shares of our common stock. At March 31, 2023, we have &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20230331__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenPlanMember_zzsUxjamZEH4" title="Shares available for future grants"&gt;1,394,122&lt;/span&gt; shares available
for future grants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Stock
Compensation Expense&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zGCTfjHml3fa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;We
recorded stock-based compensation expense for the three month ended March 31, 2023 and 2022 as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BB_zsZn6a1OB5Ad" style="display: none"&gt;Schedule
of Stock-based Compensation Expense&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20230101__20230331_zNAV8ffA5zB" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20220101__20220331_zJNSaMhMkDH1" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zm5jkrYPMsV4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;99,621&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;191,875&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zYLxalDSMLZj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;241,883&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;637,022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--ShareBasedCompensation_zgAZOmJEGTL3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;341,504&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;828,897&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zkijGtprwhN6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 11pt; text-align: justify; text-indent: -11pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="background-color: white"&gt;At
March 31, 2023, we recorded an expense and related accrued liability of $&lt;span id="xdx_90D_eus-gaap--AccruedLiabilitiesCurrent_iI_pn5n6_c20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zczkTpIdGJOl" title="Expenses and accrued liabilities"&gt;1.3&lt;/span&gt;
million related to the warrant we issued to Spartan&lt;span style="background-color: white"&gt;, which is not included in the table
above&lt;/span&gt;. No tax benefits were attributed to the stock-based compensation expense because a valuation allowance was maintained
for all net deferred tax assets relating to this expense.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Stock
Options&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;span style="background-color: white"&gt;During
the three months ended March 31, 2023, &lt;/span&gt;stock options to purchase &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zDHskWgdXZwb" title="Options, forfeited"&gt;36,885&lt;/span&gt;
shares of common stock expired and there were no exercises or grants of stock options.
At March 31, 2023, we had outstanding and exercisable options for the purchase of &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z15vcXPRIkV1" title="Options exercisable, shares"&gt;141,611&lt;/span&gt;
shares with a weighted average exercise price of $&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zUGO9g7ausjd" title="Options exercisable weighted average exercise price"&gt;18.22&lt;/span&gt;,
a weighted average remaining contractual life of &lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zK9doGizmHVj" title="Exercisable weighted average remaining contractual term"&gt;2.9&lt;/span&gt;
years. &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At March 31, 2023, we did not have any
unrecognized stock-based compensation expense related to our granted stock options.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Restricted
Stock Awards&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_ecustom--ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock_z955np8I8Vl1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Activity
with respect to our Restricted Stock Awards (RSAs) during the three months ended March 31, 2023 was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B9_zn8EpLL52mWl" style="display: none"&gt;Schedule
of Restricted Stock Awards (&#x201c;RSAs&#x201d;) Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Number of&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;shares&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Weighted- &lt;br/&gt;average &lt;br/&gt;grant-date fair &lt;br/&gt;value per share&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Outstanding at January 1, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z4qfZlL34kp5" style="width: 16%; text-align: right" title="Number of restricted stock, shares outstanding"&gt;61,888&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zqnv0RlyN5jk" style="width: 16%; text-align: right" title="Weighted-average grant-date fair value per share, outstanding"&gt;4.72&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zs42uO9q0w1c" style="text-align: right" title="Number of shares, granted"&gt;90,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_ziFp7wHyKqfb" style="text-align: right" title="Weighted-average grant-date fair value per share, awarded"&gt;1.10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Cancelled&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_iN_di_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zjJh5w1Osdyi" style="text-align: right" title="Number of shares, cancelled"&gt;(26,118&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zqePEnGG4Dg3" style="text-align: right" title="Weighted-average grant-date fair value per share, cancelled"&gt;1.72&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Outstanding and unvested at March 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zohY2FFPI6yf" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of restricted stock shares outstanding"&gt;125,770&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zjHA7BiTCDt2" style="padding-bottom: 2.5pt; text-align: right" title="Weighted-average grant-date fair value per share, outstanding"&gt;2.75&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zLOMMcB2NQcg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;On
January 1, 2023, we granted RSAs totaling &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20230101__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__custom--ThreeDirectorsMember_zrc1LFHRBCB6" title="Number of shares, granted"&gt;90,000&lt;/span&gt;
shares of common stock to three directors for their service for the six month period ending June 30, 2023 in order to align their
compensation plan with their service period and change the annual service period to begin and end on the date of respective Annual
Meetings rather than the calendar year. Our directors are compensated through a combination of cash and equity. On March 8, 2023,
the directors increased the cash component and decreased the equity component &lt;span style="background-color: white"&gt;of their
compensation &lt;/span&gt; by equal amounts &lt;span style="background-color: white"&gt;on a retroactive basis, &lt;/span&gt; to the beginning of their respective service periods. Accordingly, we cancelled
RSAs representing &lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zD6EwNlKSHka" title="Number of shares, cancelled"&gt;26,118&lt;/span&gt;
shares of common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
March 31, 2023, the total unrecognized stock-based compensation expense related to the outstanding and unvested RSAs was $&lt;span id="xdx_90A_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zGAufNNnOCJg"&gt;163,100&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
which is expected to be recognized over a weighted average period of &lt;span id="xdx_90B_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z2WrA7hHJYt5"&gt;0.5
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Restricted
Stock Units&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zphmx1PqfJjb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Activity
with respect to our Restricted Stock Units (&#x201c;RSUs&#x201d;) during the three months ended March 31, 2023 was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B3_zhH9RLTTWQ68" style="display: none"&gt;Schedule
of Restricted Stock Units (&#x201c;RSUs&#x201d;) Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Number of&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;shares&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Weighted- &lt;br/&gt;average &lt;br/&gt;grant-date fair &lt;br/&gt;value per share&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Outstanding at January 1, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iS_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z9jw5ytK7pY4" style="width: 16%; text-align: right" title="Number of shares, Beginning balance"&gt;2,713,977&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_iS_pid_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zEWfupI4HKsd" style="width: 16%; text-align: right" title="Weighted-average grant-date fair value per share, Beginning balance"&gt;3.69&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zhguMdhwcht7" style="text-align: right" title="Number of shares, awarded"&gt;966,503&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z2RVGc7TXZX3" style="text-align: right" title="Weighted-average grant-date fair value per share, awarded"&gt;1.10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Outstanding at March 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iE_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zrCXjEkhuUY" style="text-align: right" title="Number of shares, Ending balance"&gt;3,680,480&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_iE_pid_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zM8htVtWC32f" style="text-align: right" title="Weighted-average grant-date fair value per share, Ending balance"&gt;3.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Vested and unissued&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z3BfsQVG1EHb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, vested and unissued"&gt;2,585,247&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zEAovR0UXlE3" style="padding-bottom: 1.5pt; text-align: right" title="Weighted-average grant-date fair value per share, vested and unissued"&gt;3.50&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Unvested at March 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zf49VO2uVCy9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, unvested"&gt;1,095,233&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zBsZNmcwYMbg" style="padding-bottom: 2.5pt; text-align: right" title="Weighted-average grant-date fair value per share, unvested"&gt;1.86&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zmbBc3D2mCH4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At  March 31, 2023, unrecognized stock-based compensation expense of $&lt;span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zjprLk0qJakk" title="Unrecognized share based compensation expense"&gt;1.2 million&lt;/span&gt; for RSUs is expected to be fully recognized
over a weighted average period of &lt;span id="xdx_90E_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zZDc3SUrFVjj" title="Weighted average period for recognition"&gt;2.1&lt;/span&gt; years. The unrecognized expense excludes $&lt;span id="xdx_90B_ecustom--UnrecognizedShareBasedCompensationExpense_pp0p0_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLAGdPK2iGX3" title="Unrecognized restricted stock expense"&gt;322,000&lt;/span&gt; of expense related to certain RSUs
with a performance milestone that is not probable of occurring at this time.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;br/&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Holders
of our vested RSUs have our promise to issue shares of our common stock upon &lt;span style="background-color: white"&gt;meeting the &lt;/span&gt; distribution restrictions contained
in their Restricted Stock Unit Award Agreement. The distribution restrictions are different (longer) than the vesting schedule,
imposing an additional restriction on the holder. Unlike RSAs, while certain employees may hold fully vested RSUs, the individual does
not hold any shares or have any rights of a shareholder until the distribution restrictions are met. Upon distribution to the employee,
each RSU converts into one share of our common stock. The RSUs contain dividend equivalent rights.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Warrants&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;During
the three months ended March 31, 2023, we agreed to grant a warrant to purchase a total of &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zTKousqDRLJ2" title="Warrants granted"&gt;3,160,130&lt;/span&gt;
shares of our common stock as compensation for services provided under an amended consulting agreement with Spartan, the placement
agent for the Offering&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;. The warrant was issued and
exercisable on April 17, 2023 with an exercise price of $&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230214__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zmIHC4vnMhff" title="Warrants, weighted average exercise price"&gt;1.02&lt;/span&gt;
and expiration date of April 17, 2026. The warrant contains both call and cashless exercise provisions. We recorded $&lt;span id="xdx_90F_eus-gaap--GeneralAndAdministrativeExpense_c20230213__20230214__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zYhaAJhQSsY6" title="General and administrative expense"&gt;1,310,875&lt;/span&gt;
as a general and administrative expense and related accrued liability representing the fair value of this warrant on February 14,
2023, the date we amended the consulting agreement, since there were no contingent conditions on that date through April 17,
2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
March 31, 2023, we had outstanding stock purchase warrants, including the warrant issued on April 17, 2023, for the purchase of &lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_ztrKz3H01X8c" title="Warrants to purchase shares"&gt;3,366,480&lt;/span&gt; &lt;span style="background-color: white"&gt;shares
with a weighted average exercise price of $&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zptTIcza6uVj" title="Weighted average exercise price"&gt;1.61&lt;/span&gt; and a weighted average remaining contractual life of &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z86GevWAyxm" title="Weighted average remaining contractual life"&gt;2.8&lt;/span&gt; years. Stock purchase warrants
for the purchase of &lt;span id="xdx_90D_ecustom--NumberOfWarrantExercisableShares_iI_pid_c20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zJNemtveKOCj" title="Number of warrant exercisable shares"&gt;206,350&lt;/span&gt; shares were &lt;span style="background-color: white"&gt;exercisable &lt;/span&gt; at March 31, 2023 and the remaining outstanding stock purchase warrants &lt;span style="background-color: white"&gt;will be exercisable &lt;/span&gt;in the second quarter of 2023.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At March 31, 2023, we did not have any unrecognized stock-based compensation expense related to our granted stock purchase warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2023-03-31_custom_TwoThousandAndNineteenPlanMember"
      decimals="INF"
      unitRef="Shares">6000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2023-03-31_custom_TwoThousandAndNineteenPlanMember"
      decimals="INF"
      unitRef="Shares">1394122</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zGCTfjHml3fa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;We
recorded stock-based compensation expense for the three month ended March 31, 2023 and 2022 as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BB_zsZn6a1OB5Ad" style="display: none"&gt;Schedule
of Stock-based Compensation Expense&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20230101__20230331_zNAV8ffA5zB" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20220101__20220331_zJNSaMhMkDH1" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zm5jkrYPMsV4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;99,621&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;191,875&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zYLxalDSMLZj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;241,883&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;637,022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--ShareBasedCompensation_zgAZOmJEGTL3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;341,504&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;828,897&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-03-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">99621</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-03-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">191875</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-03-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">241883</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-03-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">637022</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">341504</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">828897</us-gaap:ShareBasedCompensation>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-03-31_us-gaap_WarrantMember"
      decimals="-5"
      unitRef="USD">1300000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2023-01-012023-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">36885</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2023-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">141611</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">18.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2023-01-012023-03-31_us-gaap_EmployeeStockOptionMember">P2Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <PCSA:ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_89E_ecustom--ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock_z955np8I8Vl1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Activity
with respect to our Restricted Stock Awards (RSAs) during the three months ended March 31, 2023 was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B9_zn8EpLL52mWl" style="display: none"&gt;Schedule
of Restricted Stock Awards (&#x201c;RSAs&#x201d;) Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Number of&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;shares&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Weighted- &lt;br/&gt;average &lt;br/&gt;grant-date fair &lt;br/&gt;value per share&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Outstanding at January 1, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z4qfZlL34kp5" style="width: 16%; text-align: right" title="Number of restricted stock, shares outstanding"&gt;61,888&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zqnv0RlyN5jk" style="width: 16%; text-align: right" title="Weighted-average grant-date fair value per share, outstanding"&gt;4.72&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zs42uO9q0w1c" style="text-align: right" title="Number of shares, granted"&gt;90,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_ziFp7wHyKqfb" style="text-align: right" title="Weighted-average grant-date fair value per share, awarded"&gt;1.10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Cancelled&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_iN_di_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zjJh5w1Osdyi" style="text-align: right" title="Number of shares, cancelled"&gt;(26,118&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zqePEnGG4Dg3" style="text-align: right" title="Weighted-average grant-date fair value per share, cancelled"&gt;1.72&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Outstanding and unvested at March 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zohY2FFPI6yf" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of restricted stock shares outstanding"&gt;125,770&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zjHA7BiTCDt2" style="padding-bottom: 2.5pt; text-align: right" title="Weighted-average grant-date fair value per share, outstanding"&gt;2.75&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</PCSA:ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2022-12-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">61888</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2022-12-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="USDPShares">4.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2023-01-012023-03-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">90000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-03-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="USDPShares">1.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod
      contextRef="From2023-01-012023-03-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">26118</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-03-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="USDPShares">1.72</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2023-03-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">125770</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2023-03-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="USDPShares">2.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2023-01-012023-01-01_us-gaap_RestrictedStockMember_custom_ThreeDirectorsMember"
      decimals="INF"
      unitRef="Shares">90000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod
      contextRef="From2023-01-012023-03-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">26118</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2023-03-31_us-gaap_RestrictedStockMember"
      decimals="0"
      unitRef="USD">163100</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2023-01-012023-03-31_us-gaap_RestrictedStockMember">P0Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zphmx1PqfJjb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Activity
with respect to our Restricted Stock Units (&#x201c;RSUs&#x201d;) during the three months ended March 31, 2023 was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B3_zhH9RLTTWQ68" style="display: none"&gt;Schedule
of Restricted Stock Units (&#x201c;RSUs&#x201d;) Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Number of&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;shares&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Weighted- &lt;br/&gt;average &lt;br/&gt;grant-date fair &lt;br/&gt;value per share&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Outstanding at January 1, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iS_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z9jw5ytK7pY4" style="width: 16%; text-align: right" title="Number of shares, Beginning balance"&gt;2,713,977&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_iS_pid_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zEWfupI4HKsd" style="width: 16%; text-align: right" title="Weighted-average grant-date fair value per share, Beginning balance"&gt;3.69&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zhguMdhwcht7" style="text-align: right" title="Number of shares, awarded"&gt;966,503&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z2RVGc7TXZX3" style="text-align: right" title="Weighted-average grant-date fair value per share, awarded"&gt;1.10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Outstanding at March 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iE_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zrCXjEkhuUY" style="text-align: right" title="Number of shares, Ending balance"&gt;3,680,480&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_iE_pid_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zM8htVtWC32f" style="text-align: right" title="Weighted-average grant-date fair value per share, Ending balance"&gt;3.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Vested and unissued&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z3BfsQVG1EHb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, vested and unissued"&gt;2,585,247&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zEAovR0UXlE3" style="padding-bottom: 1.5pt; text-align: right" title="Weighted-average grant-date fair value per share, vested and unissued"&gt;3.50&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Unvested at March 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zf49VO2uVCy9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, unvested"&gt;1,095,233&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zBsZNmcwYMbg" style="padding-bottom: 2.5pt; text-align: right" title="Weighted-average grant-date fair value per share, unvested"&gt;1.86&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding
      contextRef="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">2713977</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue
      contextRef="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="USDPShares">3.69</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2023-01-012023-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">966503</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="USDPShares">1.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding
      contextRef="AsOf2023-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">3680480</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue
      contextRef="AsOf2023-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="USDPShares">3.01</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued
      contextRef="AsOf2023-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">2585247</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue
      contextRef="AsOf2023-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="USDPShares">3.50</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2023-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">1095233</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2023-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="USDPShares">1.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2023-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-5"
      unitRef="USD">1200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2023-01-012023-03-31_us-gaap_RestrictedStockUnitsRSUMember">P2Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <PCSA:UnrecognizedShareBasedCompensationExpense
      contextRef="From2023-01-012023-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      unitRef="USD">322000</PCSA:UnrecognizedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2023-01-012023-03-31_us-gaap_WarrantMember_custom_ConsultantMember"
      decimals="INF"
      unitRef="Shares">3160130</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-02-14_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">1.02</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-02-132023-02-14_us-gaap_WarrantMember_custom_ConsultantMember"
      decimals="0"
      unitRef="USD">1310875</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-03-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">3366480</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-03-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">1.61</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="From2023-01-012023-03-31_us-gaap_WarrantMember">P2Y9M18D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <PCSA:NumberOfWarrantExercisableShares
      contextRef="AsOf2023-03-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">206350</PCSA:NumberOfWarrantExercisableShares>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_80D_eus-gaap--EarningsPerShareTextBlock_zwajnyjxMIKc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
4 &#x2013; &lt;span id="xdx_824_zvD6ZJbVYCOg"&gt;Net Loss per Share of Common Stock&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Net
Loss Per Share&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
net loss per share is computed by dividing our net loss available to common shareholders by the weighted average number of shares of
common stock outstanding (which excludes unvested RSAs and includes vested RSUs) during the period. Diluted loss per share is computed
by dividing our net loss available to common shareholders by the diluted weighted average number of shares of common stock (which includes
the potentially dilutive effect of stock options, unvested RSAs, unvested RSUs and warrants) during the period. Since we experienced
a net loss for both periods presented, basic and diluted net loss per share are the same. As such, diluted loss per share for the three
months ended March 31, 2023 and 2022 excludes the impact of potentially dilutive common shares since those shares would have an anti-dilutive
effect on net loss per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zLKeQe5DDiRd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
computation of net loss per share for the three months ended March 31, 2023 and 2022 was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B2_zAurCrAKbuoi" style="display: none"&gt;Schedule
of Net Loss Per Share Basic and Dilute&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20230101__20230331_zyeTYP7P4ar1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20220101__20220331_zirdy8J7T6Lc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Three months ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Basic and diluted net loss per share:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--NetIncomeLoss_zHmR1sqsJXg8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 60%; text-align: left"&gt;Net loss available to common stockholders&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(4,022,073&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(3,227,131&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zMZIQBWa9k2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Weighted average number of common shares-basic and diluted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;22,770,789&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;15,831,118&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--EarningsPerShareBasic_zDY3shJyo9sb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"&gt;Basic and diluted net loss per share&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(0.18&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(0.20&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zyQHFRYBYWd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
diluted net loss per share for the three months ended March 31, 2023 and 2022 excluded &lt;span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230331_zOMeNTwJDNJ8" title="Antidilutive securities excluded from computation of earnings per share, amount"&gt;4,729,094&lt;/span&gt;
(including the committed warrant to purchase &lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20230331__us-gaap--AwardTypeAxis__custom--CommittedWarrantMember_zb788BZbGpp2" title="Antidilutive securities including from computation of earnings per share, amount"&gt;3,160,130&lt;/span&gt; shares of common stock) and &lt;span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220331_zglh6wHa3pg7" title="Antidilutive securities excluded from computation of earnings per share, amount"&gt;795,342&lt;/span&gt;
of potentially dilutive common shares, respectively, related to outstanding stock options, warrants and unvested restricted stock
since those shares would have had an anti-dilutive effect on net loss per share during the periods then ended.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_896_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zLKeQe5DDiRd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
computation of net loss per share for the three months ended March 31, 2023 and 2022 was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B2_zAurCrAKbuoi" style="display: none"&gt;Schedule
of Net Loss Per Share Basic and Dilute&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20230101__20230331_zyeTYP7P4ar1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20220101__20220331_zirdy8J7T6Lc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Three months ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Basic and diluted net loss per share:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--NetIncomeLoss_zHmR1sqsJXg8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 60%; text-align: left"&gt;Net loss available to common stockholders&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(4,022,073&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(3,227,131&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zMZIQBWa9k2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Weighted average number of common shares-basic and diluted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;22,770,789&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;15,831,118&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--EarningsPerShareBasic_zDY3shJyo9sb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"&gt;Basic and diluted net loss per share&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(0.18&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(0.20&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">-4022073</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">-3227131</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-01to2023-03-31"
      decimals="INF"
      unitRef="Shares">22770789</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-012022-03-31"
      decimals="INF"
      unitRef="Shares">15831118</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-01to2023-03-31"
      decimals="INF"
      unitRef="USDPShares">-0.18</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-012022-03-31"
      decimals="INF"
      unitRef="USDPShares">-0.20</us-gaap:EarningsPerShareBasic>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-01to2023-03-31"
      decimals="INF"
      unitRef="Shares">4729094</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-03-31_custom_CommittedWarrantMember"
      decimals="INF"
      unitRef="Shares">3160130</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-03-31"
      decimals="INF"
      unitRef="Shares">795342</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_808_eus-gaap--LesseeOperatingLeasesTextBlock_zxJNYXvbRy5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
5 &#x2013; &lt;span id="xdx_827_zuwTiqHxEQK7"&gt;Operating Leases&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
lease our office space under an operating lease agreement. This lease does not have significant rent escalation, concessions, leasehold
improvement incentives, or other build-out clauses. Further, the lease does not contain contingent rent provisions. Our office space
lease includes both lease (e.g., fixed payments including rent, taxes, and insurance costs) and non-lease components (e.g., common-area
or other maintenance costs), which are accounted for as a single lease component as we have elected the practical expedient to group
lease and non-lease components for all leases. We also lease office equipment under an operating lease. Our leases do not provide an
implicit rate and, as such, we have used our incremental borrowing rate of &lt;span id="xdx_902_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_c20230331_zod9159Nvdhb" title="Operating lease borrowing rate"&gt;8&lt;/span&gt;% in determining the present value of the lease payments
based on the information available at the lease commencement date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lease
costs included in our condensed consolidated statements of operations totaled $&lt;span id="xdx_90A_eus-gaap--LeaseCost_c20230101__20230331_z5sMHnA8D4Ti" title="Lease cost"&gt;22,461&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--LeaseCost_c20220101__20220331_zo4rhPrwNRck" title="Lease cost"&gt;21,918&lt;/span&gt; for the three months ended March 31,
2023 and 2022, respectively. The weighted average remaining lease terms and discount rate for our operating leases were as follows at
March 31, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_ecustom--ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingLeasesTableTextBlock_zWTvc0Hr6mhd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B9_zwkzhvwmqHs3" style="display: none"&gt;Schedule
of Weighted Average Remaining Lease Terms and Discount Rate for Operating Leases&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Remaining lease term (years) for our facility lease&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FacilityLeaseMember_zhqjFJSBVNyg" title="Remaining lease term (years)"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Remaining lease term (years) for our equipment lease&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zFa8BMp2KGtk" title="Remaining lease term (years)"&gt;1.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Weighted average remaining lease term (years) for our facility and equipment leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20230331_z4rLk2RbcMlc" title="Weighted average remaining lease term (years) for our facility and equipment leases"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Weighted average discount rate for our facility and equipment leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_c20230331_zv9J5IpLspQh" title="Weighted average discount rate for our facility and equipment leases"&gt;8.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zacF5tSTrhge" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zYvC53eUIBbe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Annual
lease liabilities for all operating leases were as follows at  March 31, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_zDB11ZHvR0E8" style="display: none"&gt;Schedule
of Annual Lease Liabilities for all Operating Leases&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49C_20230331_zMMGQLodYo3d" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pp0p0_maLOLLPz79B_zLytDzBsGHOi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;70,600&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPz79B_zU1KDQOWrjt2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;92,356&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPz79B_z4rpyevdfIGa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;70,040&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPz79B_zcHS0xvXhXNl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;232,996&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_z5uniCxC4fQ6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"&gt;Less: Interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(22,472&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zQvgtzm7Bgoh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Present value of lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;210,524&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pp0p0_di_zPt33K7R4S8f" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Less: current maturities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(81,166&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_z28dpRADJIk1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Non-current lease liability&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;129,358&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zfJyCFLexEp5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="AsOf2023-03-31" decimals="INF" unitRef="Pure">0.08</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LeaseCost
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">22461</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">21918</us-gaap:LeaseCost>
    <PCSA:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingLeasesTableTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_891_ecustom--ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingLeasesTableTextBlock_zWTvc0Hr6mhd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B9_zwkzhvwmqHs3" style="display: none"&gt;Schedule
of Weighted Average Remaining Lease Terms and Discount Rate for Operating Leases&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Remaining lease term (years) for our facility lease&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FacilityLeaseMember_zhqjFJSBVNyg" title="Remaining lease term (years)"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Remaining lease term (years) for our equipment lease&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zFa8BMp2KGtk" title="Remaining lease term (years)"&gt;1.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Weighted average remaining lease term (years) for our facility and equipment leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20230331_z4rLk2RbcMlc" title="Weighted average remaining lease term (years) for our facility and equipment leases"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Weighted average discount rate for our facility and equipment leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_c20230331_zv9J5IpLspQh" title="Weighted average discount rate for our facility and equipment leases"&gt;8.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</PCSA:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingLeasesTableTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="AsOf2023-03-31_custom_FacilityLeaseMember">P2Y6M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="AsOf2023-03-31_us-gaap_EquipmentMember">P1Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2023-03-31">P2Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="AsOf2023-03-31" decimals="INF" unitRef="Pure">0.080</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_89C_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zYvC53eUIBbe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Annual
lease liabilities for all operating leases were as follows at  March 31, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_zDB11ZHvR0E8" style="display: none"&gt;Schedule
of Annual Lease Liabilities for all Operating Leases&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49C_20230331_zMMGQLodYo3d" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pp0p0_maLOLLPz79B_zLytDzBsGHOi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;70,600&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPz79B_zU1KDQOWrjt2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;92,356&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPz79B_z4rpyevdfIGa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;70,040&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPz79B_zcHS0xvXhXNl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;232,996&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_z5uniCxC4fQ6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"&gt;Less: Interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(22,472&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zQvgtzm7Bgoh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Present value of lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;210,524&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pp0p0_di_zPt33K7R4S8f" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Less: current maturities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(81,166&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_z28dpRADJIk1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Non-current lease liability&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;129,358&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">70600</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">92356</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">70040</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">232996</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">22472</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">210524</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">81166</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">129358</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_80B_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zllUNX0bPQ7c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
6 &#x2013; &lt;span id="xdx_82F_zPY3693Cqlxl"&gt;Related Party Transactions&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;CorLyst,
LLC (&#x201c;CorLyst&#x201d;) reimburses us for shared costs related to payroll, health insurance and rent based on actual costs incurred,
which are recognized as a reduction of our general and administrative operating expenses being reimbursed in our condensed consolidated
statement of operations. We recorded $&lt;span id="xdx_903_ecustom--ProceedsFromRentAndOtherCostsReimbursements_c20230101__20230331__dei--LegalEntityAxis__custom--CorLystLLCMember_zvzTQfZLsOHd" title="Rent and other costs reimbursements received"&gt;30,205&lt;/span&gt; and $&lt;span id="xdx_905_ecustom--ProceedsFromRentAndOtherCostsReimbursements_c20220101__20220331__dei--LegalEntityAxis__custom--CorLystLLCMember_zO4XKVA1zlia" title="Rent and other costs reimbursements received"&gt;31,262&lt;/span&gt; of reimbursements during the three months ended March 31, 2023 and March 31,
2022, respectively. &lt;span id="xdx_90C_eus-gaap--OtherReceivablesNetCurrent_iI_do_c20230331__dei--LegalEntityAxis__custom--CorLystLLCMember__us-gaap--RelatedAndNonrelatedPartyStatusAxis__us-gaap--RelatedPartyMember_zmKGdReXBSy2" title="Due from related parties"&gt;&lt;span id="xdx_906_eus-gaap--OtherReceivablesNetCurrent_iI_do_c20220331__dei--LegalEntityAxis__custom--CorLystLLCMember__us-gaap--RelatedAndNonrelatedPartyStatusAxis__us-gaap--RelatedPartyMember_z8cARRZ39jqe" title="Due from related parties"&gt;No&lt;/span&gt;&lt;/span&gt; amounts were due from CorLyst at March 31, 2023 or 2022. Our CEO is also the CEO of CorLyst, and CorLyst is a
shareholder.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <PCSA:ProceedsFromRentAndOtherCostsReimbursements
      contextRef="From2023-01-012023-03-31_custom_CorLystLLCMember"
      decimals="0"
      unitRef="USD">30205</PCSA:ProceedsFromRentAndOtherCostsReimbursements>
    <PCSA:ProceedsFromRentAndOtherCostsReimbursements
      contextRef="From2022-01-012022-03-31_custom_CorLystLLCMember"
      decimals="0"
      unitRef="USD">31262</PCSA:ProceedsFromRentAndOtherCostsReimbursements>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="AsOf2023-03-31_custom_CorLystLLCMember_us-gaap_RelatedPartyMember"
      decimals="0"
      unitRef="USD">0</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="AsOf2022-03-31_custom_CorLystLLCMember_us-gaap_RelatedPartyMember"
      decimals="0"
      unitRef="USD">0</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_80D_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zrMVyJo21Ml7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
7 &#x2013; &lt;span id="xdx_821_zBF5RfjHDhld"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Purchase
Obligations&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
enter into contracts in the normal course of business with contract research organizations (CROs) and subcontractors to further
develop our products. The contracts are cancelable, with varying provisions regarding termination. If we terminated a cancelable
contract with a specific vendor, we would only be obligated for products or services that we received at  the effective date of
the termination and any applicable cancellation fees. At  March 31, 2023, we are contractually obligated to pay up to $&lt;span id="xdx_90C_eus-gaap--PurchaseObligation_iI_pn5n6_c20230331__us-gaap--TypeOfArrangementAxis__custom--AgreementsMember__dei--LegalEntityAxis__custom--ContractResearchOrganizationsMember_zLn5g3o1b1Ji" title="Purchase obligation"&gt;3.0&lt;/span&gt;
million of future services under the agreements with the CROs. Our actual contractual obligations will also vary depending on the
progress and results of the remaining clinical trials.&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:PurchaseObligation
      contextRef="AsOf2023-03-31_custom_AgreementsMember_custom_ContractResearchOrganizationsMember"
      decimals="-5"
      unitRef="USD">3000000.0</us-gaap:PurchaseObligation>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>45
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MAD)N/XAL3Y38E-\4;H52(BT/UYP!?FT ]U="J.<3_9FB_BRU_ ]02P,$%
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M^CB]OM%B59U(/PJM15%=+AG-F#0&\'XNA-[>F ^T?]28_0]02P,$%     @
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M*TL]S$]+^FF@=@9TOE'*'A<N0/\;RGX!4$L#!!0    ( !10KU;HT06Y<0D
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MN]XV.Q$0L!"YJPEX(8O0V@P19%*I@EP":U^266/K1 :Y3B]K7K7)=8%%(/&
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MF6-L5HX6X/W*@J>:&U+0?4:^_#=02P,$%     @ %%"O5M67G*:G!0  HPP
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MUYDT>!6VCTO.4$1D@-_G$B\O[H46Z/XWX^1?4$L#!!0    ( !10KU84J#Z
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M'2"J<D6FB* 3US3R.GU'E>J1-DPXD^_JG*<YX&-:5!G)5F*'VJ+=+:^(@\B
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MU)R4"V]I5Y*>7WZOT0HO]09.D9QSBY$G5-X;Y1W"28N0O8 PAJ]&^]+!'[K
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M2</\>9EI:(GOO,*T92T:5OP**X$;)6UAX+/,,/L_/B1=G;CX1=PB/@J\87H
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MT."*F<P;J29JN<"C#U<Y;+ S809L!ZW751%0&=@*N<@%AS6J3)LC'[O1M<Q
M*_D,*0G1*$A -%H[TE0\^ <C.*GM"N9\H$&.-+LHI0N*8IYCF&:0$0!)VO/6
M';9!+::>@565%-PS;,G*YCQ')'WF#JZ#XML&"S2#3FTY-9/$]H4J25ZQ9Z@K
MOWH'H_[@M0<=[\RC$LTJ3%WK7X!RS6CJK-U@GS?S[,6]^2H0OY6@2Y&84^B@
M?WH<@6DF;;-QN@K3+=6.9F58%O1Q0N,=Z#S7]+[;C4_0?>YF?P!02P,$%
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M<.'*H1X228]7ND"R-/"$%'L50IS*1TH$ @>%(7!471!L$THM<N!3OJ^)J[2
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M]ZW4A):UA8_4O6.E$A?4G8XFXF1T+,Z&QT?3X>';:5_:3MNTG?:F[=YQ47W
M+$/<Z;JRURNA.WL0&^V+!8-&H8DV(^F/-.) <'4&]EI%H AJ)50GC,==QZ!-
M965=1<>I,/!$MLI4(ZYI74V+)!AS"G+YH&C4JRVGU=^J9!U,8<3)U0I0"VR4
MA\X2X+OK\C]"_*3A6?]@!AOM18]8@:=[^#H4&%F9(ZAC^3#-(;;-22%P='/C
MN1L2-\ 8-P3?FOCA@,[5"?=3/)8!/33Y%FN]1'.7P)=W:"$5M1(<@Q$U;PKP
MO-SN3*9C1HZZED]D;.#[YV&#G"HOZ\YA5810 )^5J1Q@J1YE5G%*>2GT!*N
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M--2WW#"G#P4J:T#[*RG-?F(#M)^>Y"]02P,$%     @ %%"O5I9W>3,C P
M9P@  !D   !X;"]W;W)K<VAE971S+W-H965T,3@N>&ULK59K;],P%/W>7W$5
M'MJDTB3N8UMI*VT\!-* :1OPV4UN6PO'#K:STG_/M9-F&Y12)+ZTMG//N>?8
MU[F9K+7Y9E>(#GX44MEIM'*N',>QS598<-O3)2IZLM"FX(ZF9AG;TB#/ ZB0
M,4N245QPH:+9)*Q=F=E$5TX*A5<&;%44W&PN4.KU-$JC[<*U6*Z<7XAGDY(O
M\0;=Y_+*T"QN67)1H+)"*S"XF$;GZ?ABZ.-#P!>!:_M@#-[)7.MO?O(^GT:)
M%X02,^<9./W=X2N4TA.1C.\-9]2F],"'XRW[V^"=O,RYQ5=:?A6Y6TVCTPAR
M7/!*NFN]?H>-GR PT]*&7U@WL4D$666=+AHP*2B$JO_YCV8?#@&P!L""[CI1
M4/F:.SZ;&+T&XZ.)S0^"U8 F<4+Y0[EQAIX*PKG9IQ(-=T(MX1+)G(6C6SZ7
M:(\GL2-Z'Q1G#=5%3<7^0-6'#UJYE84W*L?\,3XF6:TVMM5VP?82?N"F!_VT
M"RQA_3U\_=9K/_#U#_2ZRV+-,-C-X&_(V)8\PVE$5\"BN<-H]OQ).DI>[M$W
M:/4-]K'/;NC&Y95$T OX&LH)<SB_(]%+A&OT5ZP5#[=H"@M<Y?!:V$Q7RL$U
M=PAT3^$0HX=)Z?QO*9U[L Q@1V XVB W]C@@=&5@P3,AA=LT,:PW/ R'WRM1
MTBO#-4%I+^FT\GDCW_R3 F_K%UH;!/W&FV_-FZWYOQ.=]A)XMJ=TAFWI# \N
MG7.E*BZ;L[D4?.[S"TKF)7$I#RJ/O>EVWX,Z;Z?>5+DCKV[S-N[7:!"X#Y#4
M'*B$'-"=SU;MI1_#PT+\9V,=SP%/X23ICI+$SP9PQKK]X<B/AWX]&22=6^V(
MMM9=\HT_'SKB/NN>G8TZEVCM&-XKJA*T#HX8ZPY.&!QWKKQQ.LD[+JNP[[\;
M9VG2';)!PY%5QG@ M9+*U %'IVDW'8V([:-6+[8!CXDV9"!E9Z3Z%'952OS@
MY5^@68869R&48MT'VM6VBY[7S>,^O&[!M/E+H2P)6! TZ9U0%9BZK=43I\O0
M2N;:46,*PQ5]":#Q ?1\H;7;3GR"]MMB]A-02P,$%     @ %%"O5I2W%I9-
M P  + P  !D   !X;"]W;W)K<VAE971S+W-H965T,3DN>&ULK5==;]HP%/TK
M5C9-G=0UGR3  *DMF[:'=JBHV\.T!S>Y@-7$9K:!;K]^MA,R/DQ:*G@ V_$Y
M]Y[CCUQZ*\8?Q0Q HJ<BIZ+OS*2<=UU7I#,HL+A@<Z#JR83Q DO5Y5-7S#G@
MS("*W T\+W8+3*@SZ)FQ$1_TV$+FA,*(([$H"LS_7$'.5GW'=]8#=V0ZDWK
M'?3F> ICD/?S$5<]MV;)2 %4$$81ATG?N?2[PXZ>;R9\)[ 2&VVDE3PP]J@[
M7[.^X^F$((=4:@:L?I9P#7FNB50:ORM.IPZI@9OM-?MGHUUI>< "KEG^@V1R
MUG?:#LI@@A>YO&.K+U#I:6F^E.7"?*-5-==S4+H0DA456&50$%K^XJ?*APV
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MIV^NMF-_:N8[OA_T:K-&5-TZJN[>J*YEGIA%B=Z?<UC)7UVA=W%S#&ZO@,R
MM>[-7NK7[LV!R!HJ>+4*WCN7L7=(J0Y$UI"J5TO5>UL9E[#N5GT&@>?8.U7\
MU,H.;+_7;:]BOP[*WQO4-\B!X4SOSC"6-T?*!</JSGQ1'>\E?^WF'(BLH4-0
MZQ"\<QT'AY3J0&0-J6SKL1FPWE;)%6[[5^MT;-]W=VJYQ<YS>_IB;12SN=6Q
M$& +W<AQ%"G!RYN_7JV;Q:%ND7;61ZJ)U)W0(TW9@<I[?9'F'&4PEY36:4^>
M,%8V=>5$T$+W13,J9)>EAXELA($I _E]3JG83)2#NK4._P-02P,$%     @
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M(5,+Y/R24K'O*(#RU>;] E!+ P04    "  44*]6)>Z6Z(0#   O"P  &0
M 'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6RMEFUOVS80Q[_*01V*!FBL)TN6
M$UN G:Y8@64(8F1]4>P%+9UM(A+ID93= /OP(RE%=F99;8:\D4B*=_S=7T?R
M)GLN'N4&4<'WLF!RZFR4VEZYKLPV6!(YX%MD^LN*BY(HW15K5VX%DMP:E84;
M>%[LEH0R)YW8L3N13GBE"LKP3H"LRI*(ISD6?#]U?.=YX)ZN-\H,N.ED2]:X
M0/6PO1.ZY[9><EHBDY0S$+B:.C/_:NZ'QL#.^)/B7AZUP82RY/S1=+[D4\<S
M1%A@IHP+HE\[O,&B,)XTQ]^-4Z==TQ@>MY^]?[;!ZV"61.(-+[[27&VF3N)
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M*)HN:>MON2^\.?C7I]-F\F QH5[7"V>]OQ-53ZN)?_(V%/2P&(JFB]VZ8>X
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M5RY\54IDJ0W*,S\*@IZ?,UYX\<B.360\$I7.>($3":K*<R8W%YB)]=@+O>W
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MO:.7%54P%^4OENMBZEUZ)(<UW9;Z3NR_0./'"LQ$J>POV;O:X85'LJW2HFK
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MQJ9CAQG^%H T ?A\+H3>3LP+FA^-^!=02P,$%     @ %%"O5DJ"_5A2 @
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MCVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^
MKSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE
M?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @
M%%"O5O& "KHY P  =A4   \   !X;"]W;W)K8F]O:RYX;6S%F$M3VS 0@/^*
MQB=Z:!,[(3R&,$.A#V88R&!*CXQB;V(-LI1*<E+X]5W9#2A0=GH1.266'.7S
M2MIOK:.5-O=3K>_9[UHJ.TXJYQ:'O9XM*JBY_:07H+!GIDW-'5Z:><\N#/#2
M5@"NEKVLWQ_U:BY4<GRT'FMB>N&%=E XH14V^H9; 2O[W.\OV5)8,152N(=Q
MTGZ7D+!:*%&+1RC'23]AMM*K[]J(1ZT<EWEAM)3C).TZ;L$X4;QJSCWD#9_:
MML7QZ35'D'$RZN. ,V&L:^]HQ^?(N 2\N;MJG/XJI -SQAU\,[I9"#7WP^!3
M](+':..P_NR">&C^)XQZ-A,%G.FBJ4&Y+HX&I =4MA(+FS#%:Q@GIWH)QC\/
M_L%YV3V;0Z@@4N908(<Y+UN\F"BJ!&6A9/C-:BE*Y"C99RZY*H %D!D!F6T1
M\BX+( <$Y& KD+G'P9\&D$,"<KA%R(U([A*0N]N$' 20(P)RM$W(80"Y1T#N
MQ86\,G.NQ&/;P;A"O*:NN7E@>L9R,0\@]PG(_;B0N=/%?:5E"<;>L2^_&G1&
M0'9 D!V\ ]G'*>]FN<:1;'M3F+K[5.[NQ^6[Q'$OM+5L 8;E%3?@)Q9):YSN
MW(68I&(B.^8*\;!5S=D%8"QMR$59)8VLE6O?B%,[X<8]L!O#<7K;LF:#D%)*
M&MTI=2V<O\FVVQ=3C8\CJ$)LAI%22AK9*622V7!*2DDEC6R5MS8SV\$*T9,\
M8U):22-[A=S3F]&DQ)+&-LN+/?TWBO9#"$A))8UL%7I5AD5$2ADF?0_%O) ?
MVSD#QX6T[#*LORG39)%-D^,892/;M?B/C11B4J;)(ILFQ+P&ZXPHNJ(,B=G)
M*L0D7V<BBX?$_!&6%QEEGRRR?=[.F.WZ##$I_V21_1-&\RE[3IZR9XA)^2>+
M[!\ZL8<)*:/\DT7V3QC-GR#FE5^9)TO,]G/ Q1IB4O[)(OLGQ#Q1JN&R$Q&[
M$'PJ9(A)62B+;:%7FGQ*[=P8'F)2%LHB6^CM2K@%#@]8* L-(EN(+(?93HA)
M66C0'?FMS_E*F D%Y27^A<7V@LMB8IC_Z-Y0AKN^0I@U4IYBVY6ZT+Q<'QNN
MCSR/_P!02P,$%     @ %%"O5H]ZM&%= 0  )!,  !H   !X;"]?<F5L<R]W
M;W)K8F]O:RYX;6PN<F5L<\W8S8Z",!2&X5LAO0#+.574B;B:C=N)-T"P@)&_
MT$Y&[WX(+O CLYB-Z5F1EG#ZAL43PN'+UIF_=JVKKKV+[DW=NE15WO<?6KN\
MLDWF5EUOV_%.T0U-YL?E4.H^RV]9:37'<:*'UQGJ>'B=&9T?O?W/Q*XHKKG]
M[/+OQK;^C\'ZIQMNKK+6J^B<#:7UJ=+W>MYV>KK0:IRLHM,E5</I0DJ'#F((
MXO!!!H),^* U!*W#!VT@:!,^*(&@)'S0%H*VX8-V$+0+'[2'H'WX((I1QEA
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M;W!S+V%P<"YX;6Q02P$"% ,4    "  44*]6D+).TN\    K @  $0
M        @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    "  44*]6
MF5R<(Q &  "<)P  $P              @ '- 0  >&PO=&AE;64O=&AE;64Q
M+GAM;%!+ 0(4 Q0    ( !10KU90A1+'ZP4  ,0?   8              "
M@0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    "  44*]6
M2=VU<5(&  "B&@  &               @($O#@  >&PO=V]R:W-H965T<R]S
M:&5E=#(N>&UL4$L! A0#%     @ %%"O5KL0I!^^ @  Z0<  !@
M     ("!MQ0  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    (
M !10KU8AKPWFH0,  +@+   8              " @:L7  !X;"]W;W)K<VAE
M971S+W-H965T-"YX;6Q02P$"% ,4    "  44*]6_4UR)Q,&  #M(P  &
M            @(&"&P  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#
M%     @ %%"O5F(C7,<V!@  X!@  !@              ("!RR$  'AL+W=O
M<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( !10KU8C8)G*CP(  )(&
M   8              " @3<H  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q0
M2P$"% ,4    "  44*]6Z-$%N7$)  !2%@  &               @('\*@
M>&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ %%"O5M67G*:G
M!0  HPP  !@              ("!HS0  'AL+W=O<FMS:&5E=',O<VAE970Y
M+GAM;%!+ 0(4 Q0    ( !10KU;CE[BHFP8  -D0   9              "
M@8 Z  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ %%"O
M5A2H/H 0!   F H  !D              ("!4D$  'AL+W=O<FMS:&5E=',O
M<VAE970Q,2YX;6Q02P$"% ,4    "  44*]6-R!1I:$$  #7"@  &0
M        @(&910  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0
M   ( !10KU93C1FCS@(  #@&   9              " @7%*  !X;"]W;W)K
M<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ %%"O5G,,!EXH P  ^@8
M !D              ("!=DT  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q0
M2P$"% ,4    "  44*]6?%S,@/0)  "9&0  &0              @('54
M>&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( !10KU8=,S '
MX ,  (\*   9              " @0!;  !X;"]W;W)K<VAE971S+W-H965T
M,38N>&UL4$L! A0#%     @ %%"O5D!Z?)/? @  A@8  !D
M ("!%U\  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    "  4
M4*]6EG=Y,R,#  !G"   &0              @($M8@  >&PO=V]R:W-H965T
M<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( !10KU:4MQ:630,  "P,   9
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M970R,RYX;6Q02P$"% ,4    "  44*]6"G\= E8(   73@  &0
M    @(')?0  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    (
M !10KU8?%LPAUP(  $T'   9              " @5:&  !X;"]W;W)K<VAE
M971S+W-H965T,C4N>&UL4$L! A0#%     @ %%"O5H/X,+[X @  1@D  !D
M             ("!9(D  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"
M% ,4    "  44*]6;0[)Z,,"  !7"0  &0              @(&3C   >&PO
M=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( !10KU8-P4J- @,
M %P*   9              " @8V/  !X;"]W;W)K<VAE971S+W-H965T,C@N
M>&UL4$L! A0#%     @ %%"O5MRWXG1< @  6 8  !D              ("!
MQI(  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    "  44*]6
M*VM9;,$"  !T"   &0              @(%9E0  >&PO=V]R:W-H965T<R]S
M:&5E=#,P+GAM;%!+ 0(4 Q0    ( !10KU9*@OU84@(  "D%   9
M      " @5&8  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%
M  @ %%"O5I7JS)L= P  :A$   T              ( !VIH  'AL+W-T>6QE
M<RYX;6Q02P$"% ,4    "  44*]6EXJ[',     3 @  "P
M@ $BG@  7W)E;',O+G)E;'-02P$"% ,4    "  44*]6\8 *NCD#  !V%0
M#P              @ $+GP  >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @
M%%"O5H]ZM&%= 0  )!,  !H              ( !<:(  'AL+U]R96QS+W=O
M<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ %%"O5N];R@F& 0  U1,  !,
M             ( !!J0  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     "<
,)P"("@  O:4

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>72</ContextCount>
  <ElementCount>168</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>31</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/BalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/StatementsOfOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/StatementOfChangesInStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/StatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/Stock-basedCompensation</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - Net Loss per Share of Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock</Role>
      <ShortName>Net Loss per Share of Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Operating Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/OperatingLeases</Role>
      <ShortName>Operating Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/Stock-basedCompensationTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/Stock-basedCompensation</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Net Loss per Share of Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTables</Role>
      <ShortName>Net Loss per Share of Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Operating Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/OperatingLeasesTables</Role>
      <ShortName>Operating Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/OperatingLeases</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Stockholders??? Equity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>Stockholders??? Equity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/StockholdersEquity</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Schedule of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails</Role>
      <ShortName>Schedule of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Schedule of Restricted Stock Awards (???RSAs???) Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockAwardsRsasActivityDetails</Role>
      <ShortName>Schedule of Restricted Stock Awards (???RSAs???) Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - Schedule of Restricted Stock Units (???RSUs???) Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails</Role>
      <ShortName>Schedule of Restricted Stock Units (???RSUs???) Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - Stock-based Compensation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative</Role>
      <ShortName>Stock-based Compensation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - Schedule of Net Loss Per Share Basic and Dilute (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDiluteDetails</Role>
      <ShortName>Schedule of Net Loss Per Share Basic and Dilute (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - Net Loss per Share of Common Stock (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockDetailsNarrative</Role>
      <ShortName>Net Loss per Share of Common Stock (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingLeasesDetails</Role>
      <ShortName>Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - Schedule of Annual Lease Liabilities for all Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails</Role>
      <ShortName>Schedule of Annual Lease Liabilities for all Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - Operating Leases (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/OperatingLeasesDetailsNarrative</Role>
      <ShortName>Operating Leases (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/OperatingLeasesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - Related Party Transactions (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>Related Party Transactions (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/RelatedPartyTransactions</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="form10-q.htm">form10-q.htm</File>
    <File>ex31-1.htm</File>
    <File>ex31-2.htm</File>
    <File>ex32-1.htm</File>
    <File>pcsa-20230331.xsd</File>
    <File>pcsa-20230331_cal.xml</File>
    <File>pcsa-20230331_def.xml</File>
    <File>pcsa-20230331_lab.xml</File>
    <File>pcsa-20230331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>f10-q_001.jpg</File>
    <File>f10-q_002.jpg</File>
    <File>image_006.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="290">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>50
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "form10-q.htm": {
   "axisCustom": 0,
   "axisStandard": 11,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 290,
    "http://xbrl.sec.gov/dei/2023": 30
   },
   "contextCount": 72,
   "dts": {
    "calculationLink": {
     "local": [
      "pcsa-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "pcsa-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "form10-q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "pcsa-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pcsa-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "pcsa-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "elementCount": 287,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2023": 32,
    "http://processapharmaceuticals.com/20230331": 2,
    "http://xbrl.sec.gov/dei/2023": 4,
    "total": 38
   },
   "keyCustom": 23,
   "keyStandard": 145,
   "memberCustom": 17,
   "memberStandard": 13,
   "nsprefix": "PCSA",
   "nsuri": "http://processapharmaceuticals.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://processapharmaceuticals.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - Stock-based Compensation",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://processapharmaceuticals.com/role/Stock-basedCompensation",
     "shortName": "Stock-based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - Net Loss per Share of Common Stock",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock",
     "shortName": "Net Loss per Share of Common Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - Operating Leases",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://processapharmaceuticals.com/role/OperatingLeases",
     "shortName": "Operating Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - Related Party Transactions",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://processapharmaceuticals.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://processapharmaceuticals.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "PCSA:BusinessActivitiesAndOrganizationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "15",
     "role": "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "PCSA:BusinessActivitiesAndOrganizationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - Stock-based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "16",
     "role": "http://processapharmaceuticals.com/role/Stock-basedCompensationTables",
     "shortName": "Stock-based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - Net Loss per Share of Common Stock (Tables)",
     "menuCat": "Tables",
     "order": "17",
     "role": "http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTables",
     "shortName": "Net Loss per Share of Common Stock (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "PCSA:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - Operating Leases (Tables)",
     "menuCat": "Tables",
     "order": "18",
     "role": "http://processapharmaceuticals.com/role/OperatingLeasesTables",
     "shortName": "Operating Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "PCSA:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000019 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative)",
     "menuCat": "Details",
     "order": "19",
     "role": "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "shortName": "Organization and Summary of Significant Accounting Policies (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "PCSA:LiquidityPolicyTextBlock",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://processapharmaceuticals.com/role/BalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000020 - Disclosure - Stockholders\u2019 Equity (Details Narrative)",
     "menuCat": "Details",
     "order": "20",
     "role": "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative",
     "shortName": "Stockholders\u2019 Equity (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000021 - Disclosure - Schedule of Stock-based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "21",
     "role": "http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails",
     "shortName": "Schedule of Stock-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-012023-03-31_us-gaap_ResearchAndDevelopmentExpenseMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "PCSA:ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-12-31_us-gaap_RestrictedStockMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000022 - Disclosure - Schedule of Restricted Stock Awards (\u201cRSAs\u201d) Activity (Details)",
     "menuCat": "Details",
     "order": "22",
     "role": "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockAwardsRsasActivityDetails",
     "shortName": "Schedule of Restricted Stock Awards (\u201cRSAs\u201d) Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "PCSA:ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-12-31_us-gaap_RestrictedStockMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000023 - Disclosure - Schedule of Restricted Stock Units (\u201cRSUs\u201d) Activity (Details)",
     "menuCat": "Details",
     "order": "23",
     "role": "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails",
     "shortName": "Schedule of Restricted Stock Units (\u201cRSUs\u201d) Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedLiabilitiesCurrent",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000024 - Disclosure - Stock-based Compensation (Details Narrative)",
     "menuCat": "Details",
     "order": "24",
     "role": "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
     "shortName": "Stock-based Compensation (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-03-31_us-gaap_WarrantMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:AccruedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000025 - Disclosure - Schedule of Net Loss Per Share Basic and Dilute (Details)",
     "menuCat": "Details",
     "order": "25",
     "role": "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDiluteDetails",
     "shortName": "Schedule of Net Loss Per Share Basic and Dilute (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000026 - Disclosure - Net Loss per Share of Common Stock (Details Narrative)",
     "menuCat": "Details",
     "order": "26",
     "role": "http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockDetailsNarrative",
     "shortName": "Net Loss per Share of Common Stock (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "PCSA:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingLeasesTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000027 - Disclosure - Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating Leases (Details)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingLeasesDetails",
     "shortName": "Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "PCSA:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingLeasesTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000028 - Disclosure - Schedule of Annual Lease Liabilities for all Operating Leases (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails",
     "shortName": "Schedule of Annual Lease Liabilities for all Operating Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000029 - Disclosure - Operating Leases (Details Narrative)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://processapharmaceuticals.com/role/OperatingLeasesDetailsNarrative",
     "shortName": "Operating Leases (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:LeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://processapharmaceuticals.com/role/BalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-012023-03-31_custom_CorLystLLCMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "PCSA:ProceedsFromRentAndOtherCostsReimbursements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000030 - Disclosure - Related Party Transactions (Details Narrative)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative",
     "shortName": "Related Party Transactions (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-012023-03-31_custom_CorLystLLCMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "PCSA:ProceedsFromRentAndOtherCostsReimbursements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-03-31_custom_AgreementsMember_custom_ContractResearchOrganizationsMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PurchaseObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000031 - Disclosure - Commitments and Contingencies (Details Narrative)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "shortName": "Commitments and Contingencies (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-03-31_custom_AgreementsMember_custom_ContractResearchOrganizationsMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PurchaseObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://processapharmaceuticals.com/role/StatementsOfOperations",
     "shortName": "Condensed Consolidated Statements of Operations (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement - Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://processapharmaceuticals.com/role/StatementOfChangesInStockholdersEquity",
     "shortName": "Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://processapharmaceuticals.com/role/StatementsOfCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-012022-03-31_us-gaap_CommonStockMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "PCSA:SharesIssuedInConnectionWithPurchaseAgreementShares",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-012022-03-31_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember_us-gaap_CommonStockMember",
      "decimals": "INF",
      "lang": null,
      "name": "PCSA:SharesIssuedInConnectionWithPurchaseAgreementShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000008 - Disclosure - Organization and Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000009 - Disclosure - Stockholders\u2019 Equity",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://processapharmaceuticals.com/role/StockholdersEquity",
     "shortName": "Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 31,
   "tag": {
    "PCSA_AccreditedInvestorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accredited Investor [Member]",
        "label": "Accredited Investor [Member]"
       }
      }
     },
     "localname": "AccreditedInvestorMember",
     "nsuri": "http://processapharmaceuticals.com/20230331",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "PCSA_AgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreements [Member]",
        "label": "Agreements [Member]"
       }
      }
     },
     "localname": "AgreementsMember",
     "nsuri": "http://processapharmaceuticals.com/20230331",
     "presentation": [
      "http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "PCSA_BusinessActivitiesAndOrganizationPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Activities And Organization [policy Text Block]",
        "label": "Organization"
       }
      }
     },
     "localname": "BusinessActivitiesAndOrganizationPolicyTextBlock",
     "nsuri": "http://processapharmaceuticals.com/20230331",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "PCSA_CommittedWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Committed Warrant [Member]",
        "label": "Committed Warrant [Member]"
       }
      }
     },
     "localname": "CommittedWarrantMember",
     "nsuri": "http://processapharmaceuticals.com/20230331",
     "presentation": [
      "http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "PCSA_ConsultantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consultant [Member].",
        "label": "Consultant [Member]"
       }
      }
     },
     "localname": "ConsultantMember",
     "nsuri": "http://processapharmaceuticals.com/20230331",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "PCSA_ConsultingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consulting Agreement [Member]",
        "label": "Consulting Agreement [Member]"
       }
      }
     },
     "localname": "ConsultingAgreementMember",
     "nsuri": "http://processapharmaceuticals.com/20230331",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "PCSA_ContractResearchOrganizationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract Research Organizations [Member]",
        "label": "Contract Research Organizations [Member]"
       }
      }
     },
     "localname": "ContractResearchOrganizationsMember",
     "nsuri": "http://processapharmaceuticals.com/20230331",
     "presentation": [
      "http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "PCSA_CorLystLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CorLyst, LLC [Member]",
        "label": "CorLyst, LLC [Member]"
       }
      }
     },
     "localname": "CorLystLLCMember",
     "nsuri": "http://processapharmaceuticals.com/20230331",
     "presentation": [
      "http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "PCSA_DisclosureOperatingLeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases",
        "verboseLabel": "Schedule Of Annual Lease Liabilities For All Operating Leases"
       }
      }
     },
     "localname": "DisclosureOperatingLeasesAbstract",
     "nsuri": "http://processapharmaceuticals.com/20230331",
     "xbrltype": "stringItemType"
    },
    "PCSA_DueToLicensor": {
     "auth_ref": [],
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due to licensor.",
        "label": "Due to licensor"
       }
      }
     },
     "localname": "DueToLicensor",
     "nsuri": "http://processapharmaceuticals.com/20230331",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "PCSA_FacilityLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility Lease [Member]",
        "label": "Facility Lease [Member]"
       }
      }
     },
     "localname": "FacilityLeaseMember",
     "nsuri": "http://processapharmaceuticals.com/20230331",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "PCSA_GrossProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross proceeds from issuance of common stock",
        "label": "Gross proceeds from common stock"
       }
      }
     },
     "localname": "GrossProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://processapharmaceuticals.com/20230331",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "PCSA_LincolnParkCapitalFundLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lincoln Park Capital Fund LLC [Member]",
        "label": "Lincoln Park Capital Fund LLC [Member]"
       }
      }
     },
     "localname": "LincolnParkCapitalFundLLCMember",
     "nsuri": "http://processapharmaceuticals.com/20230331",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "PCSA_LiquidityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity [Policy Text Block]",
        "label": "Liquidity"
       }
      }
     },
     "localname": "LiquidityPolicyTextBlock",
     "nsuri": "http://processapharmaceuticals.com/20230331",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "PCSA_MaximumCommitmenttoPurchaseCommonStockValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount committed to purchase.",
        "label": "Commitment to purchase common stock"
       }
      }
     },
     "localname": "MaximumCommitmenttoPurchaseCommonStockValue",
     "nsuri": "http://processapharmaceuticals.com/20230331",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "PCSA_MaximumValueToBeSoldAtMarketOffering": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum value to be sold at the market offering.",
        "label": "Maximum value to be sold at the market offering"
       }
      }
     },
     "localname": "MaximumValueToBeSoldAtMarketOffering",
     "nsuri": "http://processapharmaceuticals.com/20230331",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "PCSA_NumberOfWarrantExercisableShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrant exercisable shares.",
        "label": "Number of warrant exercisable shares"
       }
      }
     },
     "localname": "NumberOfWarrantExercisableShares",
     "nsuri": "http://processapharmaceuticals.com/20230331",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "PCSA_PlacementAgentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Placement Agent [Member]",
        "label": "Placement Agent [Member]"
       }
      }
     },
     "localname": "PlacementAgentMember",
     "nsuri": "http://processapharmaceuticals.com/20230331",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "PCSA_ProceedsFromRentAndOtherCostsReimbursements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rent and other costs reimbursements received.",
        "label": "Rent and other costs reimbursements received"
       }
      }
     },
     "localname": "ProceedsFromRentAndOtherCostsReimbursements",
     "nsuri": "http://processapharmaceuticals.com/20230331",
     "presentation": [
      "http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "PCSA_PurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase agreement [Member]",
        "label": "Purchase Agreement [Member]"
       }
      }
     },
     "localname": "PurchaseAgreementMember",
     "nsuri": "http://processapharmaceuticals.com/20230331",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "PCSA_RegisteredDirectOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Registered Direct Offering [Member]",
        "label": "Registered Direct Offering [Member]"
       }
      }
     },
     "localname": "RegisteredDirectOfferingMember",
     "nsuri": "http://processapharmaceuticals.com/20230331",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "PCSA_ReimbursementFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursement fees.",
        "label": "Reimbursement fees"
       }
      }
     },
     "localname": "ReimbursementFees",
     "nsuri": "http://processapharmaceuticals.com/20230331",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "PCSA_RestrictionsToIssueStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restrictions to issue stock.",
        "label": "Restrictions to issue stock"
       }
      }
     },
     "localname": "RestrictionsToIssueStock",
     "nsuri": "http://processapharmaceuticals.com/20230331",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "PCSA_SalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Agreement [Member]",
        "label": "Sales Agreement [Member]"
       }
      }
     },
     "localname": "SalesAgreementMember",
     "nsuri": "http://processapharmaceuticals.com/20230331",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "PCSA_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of share based compensation restricted stock award activity [Table Text Block].",
        "label": "Schedule of Restricted Stock Awards (\u201cRSAs\u201d) Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock",
     "nsuri": "http://processapharmaceuticals.com/20230331",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of weighted average remaining lease terms and discount rate for our operating leases [table text block]",
        "label": "Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating Leases"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingLeasesTableTextBlock",
     "nsuri": "http://processapharmaceuticals.com/20230331",
     "presentation": [
      "http://processapharmaceuticals.com/role/OperatingLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "PCSA_SecuritiesPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities Purchase Agreement [Member]",
        "label": "Securities Purchase Agreement [Member]"
       }
      }
     },
     "localname": "SecuritiesPurchaseAgreementMember",
     "nsuri": "http://processapharmaceuticals.com/20230331",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than option vested and unvested outstanding.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding",
        "periodEndLabel": "Number of shares, Ending balance",
        "periodStartLabel": "Number of shares, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding",
     "nsuri": "http://processapharmaceuticals.com/20230331",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of vested and nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue",
        "periodEndLabel": "Weighted-average grant-date fair value per share, Ending balance",
        "periodStartLabel": "Weighted-average grant-date fair value per share, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue",
     "nsuri": "http://processapharmaceuticals.com/20230331",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options cancelled in period total fair value.",
        "label": "Number of shares, cancelled",
        "negatedLabel": "Number of shares, cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod",
     "nsuri": "http://processapharmaceuticals.com/20230331",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockAwardsRsasActivityDetails",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options cancelled in period weighted average grant date fair value.",
        "label": "Weighted-average grant-date fair value per share, cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://processapharmaceuticals.com/20230331",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockAwardsRsasActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options vested and unissued.",
        "label": "Number of shares, vested and unissued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued",
     "nsuri": "http://processapharmaceuticals.com/20230331",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options vested and unissued weighted average grant date fair value.",
        "label": "Weighted-average grant-date fair value per share, vested and unissued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue",
     "nsuri": "http://processapharmaceuticals.com/20230331",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "PCSA_SharesIssuedInConnectionWithPurchaseAgreementShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued in connection with purchase agreement shares.",
        "label": "Shares issued in connection with the Purchase Agreement with Lincoln Park",
        "verboseLabel": "Shares issued in connection with purchase agreement"
       }
      }
     },
     "localname": "SharesIssuedInConnectionWithPurchaseAgreementShares",
     "nsuri": "http://processapharmaceuticals.com/20230331",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementOfChangesInStockholdersEquity",
      "http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "PCSA_SharesIssuedInConnectionWithPurchaseAgreementValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued in connection with purchase agreement value.",
        "label": "Shares issued in connection with purchase agreement"
       }
      }
     },
     "localname": "SharesIssuedInConnectionWithPurchaseAgreementValue",
     "nsuri": "http://processapharmaceuticals.com/20230331",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "PCSA_SpartanCapitalSecuritesLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Spartan Capital Securites LLC [Member]",
        "label": "Spartan Capital Securites LLC [Member]"
       }
      }
     },
     "localname": "SpartanCapitalSecuritesLLCMember",
     "nsuri": "http://processapharmaceuticals.com/20230331",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "PCSA_ThreeDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Directors [Member]",
        "label": "Three Directors [Member]"
       }
      }
     },
     "localname": "ThreeDirectorsMember",
     "nsuri": "http://processapharmaceuticals.com/20230331",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "PCSA_ThresholdPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold price.",
        "label": "Threshold price"
       }
      }
     },
     "localname": "ThresholdPrice",
     "nsuri": "http://processapharmaceuticals.com/20230331",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "PCSA_TransactionCostsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction costs percentage.",
        "label": "Cash fee percentage"
       }
      }
     },
     "localname": "TransactionCostsPercentage",
     "nsuri": "http://processapharmaceuticals.com/20230331",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "PCSA_TwoThousandAndNineteenPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2019 Plan [Member]",
        "label": "2019 Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandAndNineteenPlanMember",
     "nsuri": "http://processapharmaceuticals.com/20230331",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "PCSA_UnrecognizedShareBasedCompensationExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized share based compensation expense.",
        "label": "Unrecognized restricted stock expense"
       }
      }
     },
     "localname": "UnrecognizedShareBasedCompensationExpense",
     "nsuri": "http://processapharmaceuticals.com/20230331",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r420",
      "r422",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r160",
      "r193",
      "r281",
      "r296",
      "r314",
      "r315",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r383",
      "r384",
      "r389",
      "r392",
      "r393",
      "r397",
      "r448",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r160",
      "r192",
      "r193",
      "r220",
      "r221",
      "r222",
      "r280",
      "r281",
      "r296",
      "r314",
      "r315",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r383",
      "r384",
      "r389",
      "r392",
      "r393",
      "r397",
      "r400",
      "r444",
      "r448",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r160",
      "r192",
      "r193",
      "r220",
      "r221",
      "r222",
      "r280",
      "r281",
      "r296",
      "r314",
      "r315",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r383",
      "r384",
      "r389",
      "r392",
      "r393",
      "r397",
      "r400",
      "r444",
      "r448",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490"
     ],
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r442",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r10",
      "r396"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued expenses",
        "verboseLabel": "Expenses and accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r228",
      "r229",
      "r230",
      "r312",
      "r438",
      "r439",
      "r440",
      "r476",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r171",
      "r263",
      "r390",
      "r391",
      "r434"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r4",
      "r27",
      "r28"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of intangible asset"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive securities excluded from computation of earnings per share, amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r73",
      "r90",
      "r106",
      "r135",
      "r141",
      "r145",
      "r150",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r169",
      "r170",
      "r242",
      "r244",
      "r256",
      "r286",
      "r336",
      "r396",
      "r408",
      "r446",
      "r447",
      "r483"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r86",
      "r95",
      "r106",
      "r150",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r169",
      "r170",
      "r242",
      "r244",
      "r256",
      "r396",
      "r446",
      "r447",
      "r483"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total Current Assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockDetailsNarrative",
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockAwardsRsasActivityDetails",
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r47",
      "r63",
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Organization and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r19",
      "r88",
      "r385"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r19",
      "r60",
      "r104"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash and Cash Equivalents \u2013 End of Period",
        "periodStartLabel": "Cash and Cash Equivalents \u2013 Beginning of Period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r1",
      "r60"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net Increase (Decrease) in Cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [
      "r92",
      "r93",
      "r94",
      "r134",
      "r173",
      "r174",
      "r175",
      "r177",
      "r180",
      "r185",
      "r187",
      "r304",
      "r305",
      "r306",
      "r307",
      "r392",
      "r429",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Warrant exercise price",
        "verboseLabel": "Weighted average exercise price"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Purchase of warrants, shares",
        "terseLabel": "Warrants to purchase shares",
        "verboseLabel": "Warrants to purchase common stock, shares"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Antidilutive securities including from computation of earnings per share, amount"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r14",
      "r45",
      "r287",
      "r323"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r67",
      "r155",
      "r156",
      "r382",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "verboseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Maximum equity available for issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r398",
      "r399",
      "r400",
      "r402",
      "r403",
      "r404",
      "r405",
      "r438",
      "r439",
      "r476",
      "r491",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementOfChangesInStockholdersEquity",
      "http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r49",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r6",
      "r49",
      "r324",
      "r342",
      "r492",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r49",
      "r288",
      "r396"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock, par value $0.0001, 50,000,000 shares authorized: 24,631,474 issued and 24,531,474 outstanding at March 31, 2023 and 16,135,400 issued and 16,035,400 outstanding at December 31, 2022"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r46",
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r194",
      "r197",
      "r224",
      "r225",
      "r227",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Stock-based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r102",
      "r114",
      "r115",
      "r116",
      "r117",
      "r118",
      "r123",
      "r124",
      "r126",
      "r127",
      "r128",
      "r132",
      "r254",
      "r255",
      "r283",
      "r294",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Net Loss Per Common Share - Basic and Diluted",
        "verboseLabel": "Basic and diluted net loss per share"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDiluteDetails",
      "http://processapharmaceuticals.com/role/StatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r122",
      "r129",
      "r130",
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Net Loss per Share of Common Stock"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r226"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Unrecognized share based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r6",
      "r84",
      "r99",
      "r100",
      "r101",
      "r109",
      "r110",
      "r111",
      "r113",
      "r119",
      "r121",
      "r133",
      "r151",
      "r152",
      "r189",
      "r228",
      "r229",
      "r230",
      "r238",
      "r239",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r253",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r271",
      "r297",
      "r298",
      "r299",
      "r312",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementOfChangesInStockholdersEquity",
      "http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r58",
      "r346"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and administrative expenses",
        "verboseLabel": "General and administrative expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfOperations",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r55",
      "r75",
      "r135",
      "r140",
      "r144",
      "r146",
      "r284",
      "r292",
      "r388"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net Operating Loss Before Income Tax Benefit"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r153",
      "r154",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r154",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement."
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r77",
      "r83",
      "r120",
      "r121",
      "r138",
      "r233",
      "r240",
      "r295"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income Tax Benefit"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r98",
      "r231",
      "r232",
      "r234",
      "r235",
      "r236",
      "r237",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r3"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r3"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "verboseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDueToRelatedParties": {
     "auth_ref": [
      "r3"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.",
        "label": "Due (from) to related parties"
       }
      }
     },
     "localname": "IncreaseDecreaseInDueToRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r430",
      "r433"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Operating lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "auth_ref": [
      "r3"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in receivables classified as other.",
        "label": "Increase (Decrease) in Other Receivables",
        "negatedLabel": "Other receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r3"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "auth_ref": [
      "r4"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.",
        "label": "Recording of warrant to be issued to purchase 3,160,130 shares of common stock in connection with a consulting agreement"
       }
      }
     },
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r267",
      "r395"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/OperatingLeasesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Schedule of Annual Lease Liabilities for all Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/OperatingLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r270"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r270"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r270"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r481"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r270"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: Interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Remaining lease term (years)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "verboseLabel": "Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/OperatingLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r11",
      "r106",
      "r150",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r169",
      "r170",
      "r243",
      "r244",
      "r245",
      "r256",
      "r322",
      "r387",
      "r408",
      "r446",
      "r483",
      "r484"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r54",
      "r74",
      "r290",
      "r396",
      "r436",
      "r443",
      "r478"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r13",
      "r87",
      "r106",
      "r150",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r169",
      "r170",
      "r243",
      "r244",
      "r245",
      "r256",
      "r396",
      "r446",
      "r483",
      "r484"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows From Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r60",
      "r61",
      "r62"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows From Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r56",
      "r62",
      "r76",
      "r85",
      "r96",
      "r97",
      "r101",
      "r106",
      "r112",
      "r114",
      "r115",
      "r116",
      "r117",
      "r120",
      "r121",
      "r125",
      "r135",
      "r140",
      "r144",
      "r146",
      "r150",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r169",
      "r170",
      "r255",
      "r256",
      "r293",
      "r344",
      "r364",
      "r365",
      "r388",
      "r406",
      "r446"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://processapharmaceuticals.com/role/StatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "negatedLabel": "Net loss",
        "totalLabel": "Net Loss",
        "verboseLabel": "Net loss available to common stockholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDiluteDetails",
      "http://processapharmaceuticals.com/role/StatementOfChangesInStockholdersEquity",
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows",
      "http://processapharmaceuticals.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Cash Financing Activities"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r135",
      "r140",
      "r144",
      "r146",
      "r388"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating Loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r479"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Non-cash lease expense for right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r266"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r266"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Current maturities of operating lease liability",
        "negatedLabel": "Less: current maturities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets",
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r266"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Non-current operating lease liability",
        "verboseLabel": "Non-current lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets",
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r265"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating lease right-of-use assets, net of accumulated amortization"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r269",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Weighted average discount rate for our facility and equipment leases",
        "verboseLabel": "Operating lease borrowing rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/OperatingLeasesDetailsNarrative",
      "http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r268",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average remaining lease term (years) for our facility and equipment leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "totalLabel": "Total Other Assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r12",
      "r396"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Due to related parties"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilityCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration": {
     "auth_ref": [
      "r91",
      "r168",
      "r276",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates related and nonrelated party status for liability classified as other and current.",
        "label": "Other Liability, Current, Related and Nonrelated Party Status [Extensible Enumeration]"
       }
      }
     },
     "localname": "OtherLiabilityCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Income (Expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Due from related parties"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfEquity": {
     "auth_ref": [
      "r18",
      "r307"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common and preferred stock.",
        "label": "Payments for Repurchase of Equity",
        "negatedLabel": "Acquisition of treasury stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r48",
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r48",
      "r324",
      "r342",
      "r492",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r432"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses and other"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r2"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Net proceeds from common stock issued",
        "terseLabel": "Net proceeds from common stock",
        "verboseLabel": "Net proceeds from sale of stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r5",
      "r285",
      "r291",
      "r396"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and Equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PurchaseObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.",
        "label": "Purchase obligation"
       }
      }
     },
     "localname": "PurchaseObligation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedAndNonrelatedPartyStatusAxis": {
     "auth_ref": [
      "r107",
      "r108",
      "r275",
      "r276",
      "r277",
      "r278",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r341",
      "r343",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by related and nonrelated party status.",
        "label": "Related and Nonrelated Party Status [Axis]"
       }
      }
     },
     "localname": "RelatedAndNonrelatedPartyStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedAndNonrelatedPartyStatusDomain": {
     "auth_ref": [
      "r107",
      "r108",
      "r275",
      "r276",
      "r277",
      "r278",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r341",
      "r343",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related and nonrelated party status."
       }
      }
     },
     "localname": "RelatedAndNonrelatedPartyStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyMember": {
     "auth_ref": [
      "r107",
      "r108",
      "r275",
      "r276",
      "r277",
      "r278",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r341",
      "r343",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family.",
        "label": "Related Party [Member]"
       }
      }
     },
     "localname": "RelatedPartyMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [
      "r347",
      "r348",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r272",
      "r273",
      "r274",
      "r276",
      "r279",
      "r309",
      "r310",
      "r311",
      "r349",
      "r350",
      "r351",
      "r370",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r475"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockAwardsRsasActivityDetails",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r51",
      "r71",
      "r289",
      "r300",
      "r301",
      "r308",
      "r325",
      "r396"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated undistributed earnings (deficit).",
        "label": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets",
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r84",
      "r109",
      "r110",
      "r111",
      "r113",
      "r119",
      "r121",
      "r151",
      "r152",
      "r228",
      "r229",
      "r230",
      "r238",
      "r239",
      "r246",
      "r248",
      "r249",
      "r251",
      "r253",
      "r297",
      "r299",
      "r312",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated undistributed earnings (deficit).",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r136",
      "r137",
      "r139",
      "r142",
      "r143",
      "r147",
      "r148",
      "r149",
      "r190",
      "r191",
      "r282"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Proceeds from sale of common stock"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of common stock, shares"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Net Loss Per Share Basic and Dilute"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r43",
      "r44",
      "r347",
      "r348",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r8",
      "r9",
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.",
        "label": "Schedule of Stock-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r195",
      "r196",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockDetailsNarrative",
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockAwardsRsasActivityDetails",
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Schedule of Restricted Stock Units (\u201cRSUs\u201d) Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r29",
      "r30",
      "r31",
      "r32",
      "r33",
      "r34",
      "r35",
      "r69",
      "r70",
      "r71",
      "r92",
      "r93",
      "r94",
      "r134",
      "r173",
      "r174",
      "r175",
      "r177",
      "r180",
      "r185",
      "r187",
      "r304",
      "r305",
      "r306",
      "r307",
      "r392",
      "r429",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SecurityDeposit": {
     "auth_ref": [
      "r431"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.",
        "label": "Security deposit"
       }
      }
     },
     "localname": "SecurityDeposit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r3"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Total",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails",
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Number of shares, granted",
        "verboseLabel": "Number of shares, awarded"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockAwardsRsasActivityDetails",
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Weighted-average grant-date fair value per share, awarded"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockAwardsRsasActivityDetails",
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r209",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Number of restricted stock shares outstanding",
        "periodStartLabel": "Number of restricted stock, shares outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockAwardsRsasActivityDetails",
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r209",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted-average grant-date fair value per share, outstanding",
        "periodStartLabel": "Weighted-average grant-date fair value per share, outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockAwardsRsasActivityDetails",
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average remaining contractual life"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [
      "r195",
      "r196",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockDetailsNarrative",
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockAwardsRsasActivityDetails",
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of non-option equity instruments granted to participants.",
        "label": "Warrants granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Shares available for future grants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Options exercisable, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Options exercisable weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Options, forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockDetailsNarrative",
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockAwardsRsasActivityDetails",
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Exercisable weighted average remaining contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance, shares",
        "periodStartLabel": "Balance, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r6",
      "r17",
      "r84",
      "r99",
      "r100",
      "r101",
      "r109",
      "r110",
      "r111",
      "r113",
      "r119",
      "r121",
      "r133",
      "r151",
      "r152",
      "r189",
      "r228",
      "r229",
      "r230",
      "r238",
      "r239",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r253",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r271",
      "r297",
      "r298",
      "r299",
      "r312",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementOfChangesInStockholdersEquity",
      "http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r133",
      "r282",
      "r302",
      "r313",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r324",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r343",
      "r345",
      "r346",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r366",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementOfChangesInStockholdersEquity",
      "http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r133",
      "r282",
      "r302",
      "r313",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r324",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r343",
      "r345",
      "r346",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r366",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementOfChangesInStockholdersEquity",
      "http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r20",
      "r21",
      "r22"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Issuance of 123,609 shares of common stock in connection with the Purchase Agreement with Lincoln Park"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r6",
      "r48",
      "r49",
      "r71",
      "r304",
      "r366",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Shares issued in connection with capital raises, net of transaction costs, shares",
        "verboseLabel": "Number of shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementOfChangesInStockholdersEquity",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r6",
      "r48",
      "r49",
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Stock-Based compensation, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r6",
      "r48",
      "r49",
      "r71",
      "r312",
      "r366",
      "r379",
      "r407"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Shares issued in connection with capital raises, net of transaction costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r41",
      "r48",
      "r49",
      "r71"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Stock-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r6",
      "r48",
      "r49",
      "r71",
      "r307",
      "r366",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "negatedLabel": "Acquisition of treasury stock, shares"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r6",
      "r48",
      "r49",
      "r71",
      "r312",
      "r366",
      "r380",
      "r407"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "negatedLabel": "Acquisition of treasury stock"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r49",
      "r52",
      "r53",
      "r65",
      "r326",
      "r342",
      "r367",
      "r368",
      "r396",
      "r408",
      "r436",
      "r443",
      "r478",
      "r492"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.",
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Beginning balance, value",
        "totalLabel": "Total Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets",
      "http://processapharmaceuticals.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r68",
      "r105",
      "r172",
      "r174",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r186",
      "r189",
      "r252",
      "r369",
      "r371",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity.",
        "label": "Equity [Text Block]",
        "verboseLabel": "Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TreasuryStockCommonMember": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common [Member]"
       }
      }
     },
     "localname": "TreasuryStockCommonMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonShares": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury stock shares"
       }
      }
     },
     "localname": "TreasuryStockCommonShares",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r16",
      "r36",
      "r37"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury stock at cost \u2014 100,000 shares at March 31, 2023 and December 31, 2022"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r24",
      "r25",
      "r26",
      "r78",
      "r79",
      "r81",
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [
      "r398",
      "r399",
      "r402",
      "r403",
      "r404",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrant term"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r123",
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Common Shares Used to Compute Net Loss Per Common Shares - Basic and Diluted",
        "verboseLabel": "Weighted average number of common shares-basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDiluteDetails",
      "http://processapharmaceuticals.com/role/StatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org//260/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org//718/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "808",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iv)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(i)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//842-20/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org//850/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(e)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(f)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(14))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(15))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(17))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(19))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(8))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(9))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(e)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r409": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r411": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r412": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r413": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r414": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r415": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r416": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r417": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r418": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r419": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r421": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r422": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r423": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r424": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r425": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r426": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r427": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r428": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org//450/tableOfContent",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org//205/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org//235/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org//275/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org//440/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org//505/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a)(5))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>51
<FILENAME>0001493152-23-017001-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-23-017001-xbrl.zip
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M'%8K/3;B$\&TF$@Q%1$<( W[D',-KB<SW!\K;9G*V%NE4_2K_?H(;\9*PY#
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M7?X3!0   BT   H   !E>#,R+3$N:'1M[5IM;R(W$/Z.Q'^80[HHD7@-E[X
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M-^=;TT,VJL_2P'$@^J0/F8*7AEK)LT01P<UG6*-A.J<V[<C6\)0-U-"2;"<
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MQ: PCL#ATXEJ;J42"6FC&%>\B$K(T_$UUX*!B5;935D& T/OW7EB1P%;%$J
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MCU) 94AUV6I%Z":ZF4DXA@V-UYY_5*^>_,"A+<=4:?$6S&A4 !!1IF11!,8
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MUM0D$O(BG#YVX$(5*>P"2 9.)6?OJ=H_Q/?L'R]0/M_@")-*,M$PYA>4V$9
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M99J2?QLQ@-_74O^&]/A?)MB$QHB0\1="TG_,<.>WZOTMO]1_NV;[F=E^_ _
MW[+[\V^%6!X0_C\])3XAB/C4.XWC+NA'[B_H>[;%(X3IQB(F#8)).'"I\/P#
MW50O WC_6/_Q->IK+#?%^ZYJWUW":>?_:<E[' 85YE>M!MD167$23RVJ)C.#
M^WP&[2%L- A\B$ZQP6 S1-L_C.,OU=K_-HF>AZS+HRN'=+0]3;C5+!T-R]>I
MD02I&>H\2=D4-$!!*4"D%F=N^?,@+>#[/[=\?S'F?>Q.#Z(<7G\O(2:W&DU_
MZC?UIN%\I4.9'.Q#O*(** JRPKFS[H^KY"_RB.*L'FVG_>:Y.? _:!$K/UG1
ME;V->_;:6&:,GQ=EU["HN<?<Q2T<6G=(V8NN(Z#QC<K^U=2E0]HW^-?&?J'U
M/P"Y:G7_I0[1'J)%E UVR>WQTBQ-LN$\_Y#/+#2$6-^H_.A\-O!C%(=>2///
M-$VP_;!)WSKJUVIM08T\'4ID+(F/DH5V;$S-9IPJ_;3[A:3_&"OG7U><$-^_
MTI6XV_']Z:@R"&--4<HO5HV@5HM-NQ@1O _/7;Y\ .0?4TS"K(+=6:VR"/5Z
M/=Y94V@2'?6/"ZN&1U#,T[$>U7H3Q4QEN*:(,^AM7 ZC2\\H $4RBY)(^]Q^
M0H (:Y" 3#;.?Y+.CCR[Q9U '?L>5DM\]0!DZ'-[+?RR&?6=&[,,E6_4V*L(
M+E!(XH1 =-]IY5_J3YS/9T_&L>J+S&7@V578NV;4"&?08[V,3D283VZE#RJ4
MP!]FCZS+C22H$90T@O>?BK_P06*KXHDW111(:RUK[<NQ,04W.78UFDE&@Y[K
M7[]W#/S5:'*HUFA145'!M5O&SDUR7B:H<OSC\H=)\(M*F2Q[?,N('/=4Y(7N
MX5_]R5-GH]E"Z$K)H$1V<BM%\D)3E_">8)0LE!^WX9 _)+1!K3-M-%[>UEO\
M$?G;3T'M'9NO,L/NGX>I7]JS5GYZPD-($^?HUC.K1W."6>K#-K4U9=^D4I77
M&A/,MQ8ABRC_A:2$?V[+C"9*@L(@2 FKX.\K;4;49<^,C7'N'FRDY:TE[QI?
MA<UFE$7VQT$+^#@#F<N74AWX5#QQ_ :8G!O+<V[5$U9CA*_'YW;4'17M:4+%
MM?AIU<U$47^R$/H/&=@@A@-+#>,5-JQ+:]O] CTO,H<'GVD4%U[2+\/G_46A
M=>AS?-V+W11[Z[4^S4*^:4E;">4V1=8JOX:<-3 QPC@;E88HS)";'P""I;K\
M--LJ2UZ>=SHZ+!S><8OOD]]W\R:1V"O+PGS>DXLBIKH N'^X[,)#+JMY.0M;
M6R^G4@G$UWJR)E&]J@2.LO3+ +;6^H^Z(X*]JIW'4&1#SIWQNBW9L=Z!-*+R
M32$Y@R.\&.#7\.MJ+X_)+4>C^43$_UR&[8@6JN'U$CF/KCTN FK'Q,%Z%B">
M0S-?&4 2(-M! +>HF*L[_ZIZP6U?/9S'5-(=KU?L/0TCXOPYR _%45+N+W9:
M=0O9T'>C?=,$C9L[*;28U%JH#L-%37\!HHB(+'5'-,%[.6*VL.<#^J@<+?M1
M[WV02T^5U59MZ->3UJI/%6BT& 6T3T6:8[N1@;T_(]E?AJIDX6;'U[E*7TUZ
M6ZO+\*:52%W6Q3[\E#VQP?$C\$S*#.-)S//=^D*+I6>SMM1OPV=5&]NB=-G(
MFYE32MQ8O68M2&7]<$]+[''>8'\EV/RTX>>R_!]!)YW6M-&<XJOH;BE=8Q6I
M8*OOAT\384^BKD*[&M"&9-5@FN2(CLU.VC>+HSGN:]SC+"Z!N0V55K5?#*/>
M,8>@!U#@*+NQ(*,NM+\XA#/[#U2W[00KLXV]*EIQAKZY+DE)FW]=3J8W]VG9
MQZ E7[=3_) A#B7AMW!]%N;WM"<4N!;065C,%.9T>?:89?T@GJU_FWC#-90"
MQ[''((J34U1@^>][;M=+C1FN,=3\$NK0['9O>>O;>"9)--AU-1,X?"_DTK=%
MB3?G@ ]4+Y.KZ65(E96]2WQSWL+NX.1$<3I7ZC12*;E%8V:>@("Q'AHLA>T!
M3$ZM1[\Z;:]K ^EKN,^=WL_ O+1/(M:=$?@&=O>81M(3G JUI"&FZR-:6S"Q
M3\F$E<Z&D\%$5]S$4?)?73U(ZZ+X#]75H=]K9(S517B7#,JB.Q4G*O'E3K!#
MRIWG5:992ZGU9VW?M\@QOLJF.19DZCO%<-BT!16PS/7!8<!-_WU\XU2@.R/9
MDQ1K:?.T;I9V(G=2C_$$]&8OW1@GJ^<#;TJ,^ ')_-1X@573R&9?O ^W^,F>
M5N1HAG#RLPATT0 =3LKFRXI/O'8L!0X=U&P =U:-5:24MP!VJ-8GZ#?,26V&
M[V0R_135'[VB<BK*=/ZB/IKZ6,Y'[*)6\Q^_V)5+'MQ(@TYZVS@NBGB#3"5%
M^)6^HM(*O0#@$P/+K00*;FDO;4JX8JV^C6W/YRIC_[A48>"@;+PFL3:D?P ^
M1Z4]0:ZK2]'36]#4NA6?*FBJYTM_TM8Q]N@J+"3;U$\*YY[)OY;GO@<ML]X:
M.\&2)GN*7V"]=B>EP/%PYD;Q*Z4/Z3C1RSUR+VQQ*N5< 'G&;]O%<!:GY?D9
MQ[F+O!%;^?G-MHUP=UU9QC3:,F7UV99B/1%YM?!EJ@D?X#4?VL^7B7GT]S7*
MQP['BATB=->6%5UC5917_\E(/!)?(/_480NE^]KO<+[6V.Z=*A>K;X\5?0*D
MT#+@5E?'4NW(BK+XU0?1TQ_,TU"?(VI/<AE$(J3/""7_(8#9>C_K$BG227T<
M$XTCX74365;32U#5BZ=5&\<T^(SO[2M+.OVV:D(8*@,(M]S+V,H[:Q=R<Y[*
M"BD<L6.)85+D3;APC47@B.+"0DLU E-D\7=BP$W^79SGF,PZ6E5T-2QN-6*T
MFTC"S1<6Q9<HF(7YU2&$UDQ-QPP%.ER+GR&7B:7?170*LZ1Z'F U=V2BJ_H2
MO(K09GT0_910/2H5;G(V>>__UX&J_[LCVG_WO-<_5A_Y/\GP?ZH"\]=__]'Y
MH^;X^]_$PAF!?VWEOAT9C^B;^S?ZUK\CJ/OVEXW.G?]L;OYOK/J<W;^FBOQ-
M^0&X([?05E=+G)T9LX'8$?9@1YZ\]I^N=!H 4TD:_<W9.J:,Z)RFI#<3,[-*
M3=6L)9HY=0WB,B\9MSTJ5U:BYA#X*92X8!#)Z]N7JW+:[K9L7$)$),_$3V7I
M<E\79IK$R70 3LFST  8NLQ*73CC08)];$\FC;XH"DF%8.O4K2)*B)=-446H
MB&^N+-@UE&7MM*M4>0 =PY8]0%2P*CXNU]!R*6\-4YR:2*/?M%A7$7N^[(#M
M(&Z&#NHG2^7:$L%;&R(8W!U$@H$L9A*G_6SSK=/$6[MIZ$V:VL<\<S+S!@'"
MX!1+TMO&^VX,B\0WD665+J1@JB]<.[?\6;UV$#NJCP4@XA!>CK)BI-3SX0C#
M=K*5[(8IKDAB93*:N">K,W8;<8*,JQ;P;#(];PT$$"*'@G0V;)XU+>,NZ48C
MUY?E[;V4LEF3ZTMDC/FRJD0Z:U5B[&A& @1&VVM^R?3BSWKTZ#D6_3\0R=_
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M M/"+9?2Z'15_8B2/@H.YE/XY?2S;0_F+I34_U(^F%N!TH2:X>H?09'3G O
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MTZ#.)3?UTE_P2:U?]7&?: (:[_PVW_VF9Z/!1^8&3R$C\.GF=?-6L3N=1.V
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MA7.@%BZNJ;&U(//D3OI=^&;JQ22I@CIT/T3>;;&3G",W\PUI:V@>G )1,SC
M70'?]]*&1@JR]F5YUF?=.-7GF9V'GI9/"*UR+FIK5LSS;WBOKY)8C^2PRY](
M/ZP,\V<BJ=;;$F$9DL9]S-7T[?V>GL'.,JK*"OPB!\^?\9Q2R-RYR5 #GSZ;
M(V $2!O*A(C$#SBQAI48+SS@'C)'XQM13K &G_U(WX#^8;BWJT1I36"\BQ@M
MQJ*F>'<J)8/XJ W/8+G./(A'7L.S,L<L+ 'K+!2^'=-).$9EO]':3V#TL4U)
M]N2H>'5.RZ+IFC/L&.^$#\'8[VLS5M0F3&-EG1078C= @ 6^:Y>-DQ,:M8!-
MXY%^=ZW'Z&)-;.9]0L\P9PPM.4#] B><887O?!ZJ''/-C(A_RH)5@^^[L(<#
MT($XY24"=@O=&#]W$$+,^6APC"5TH6[N]TEY3HV8]:4@O:Z1)NUDJON01Q4S
M"OS %ARK&R='#O&\#5J8;4%.N\KE8]/SWOM,4]<2;=[FQK;'+[()T_6)M%H!
MO<V9"\A]Z\W8B/Y]PBAI-@<8"AI=!+_Z8X-[N"\4S>:4_UO'1C'7'^$0$K)4
M;WP=-]@DODXE.;UPTN44:$ ZHG"%=$R:74CIS1)[()5[UR\V>R59JWHBT\)^
M@6.IWXA/5O\3#<FR?740"HJ+3)^KS$!=RUEGLZVZ7$MM5?/ =;2$.G81/&BM
M"V)#4  QJD+"VH4[EC'(GQD5.6QX.*DW35KBULJA"1>*ZNHQ2Q&V/5F:>%.Z
MJ'!IHL/:K7KSN<F=TY5E;0)5A*3<$D^N9D-V7"!_.T2CYTG\<'."K"O>&\??
M3[ []/R<(7VV6E@5YL%J*HF21K\ 9F[VM=#R_O74".?3 .5K7M R59LR'L:B
M(TV_Y3UL:)>_'$&O%AP@A-Y%OEQLB:+C6C$,>]U!0M2H^9*U>22%K'C825M^
M A["2+^14IWMK6(_;@Y<'Y&=V\",(MAL6 M(QZWWO=2:86 M;M9(=&@NLG\%
MU C1(D1+_((2*P%T X2V[E3X8'CZN;]J'V$GIT74![.VOU?O^U@QPSI@$,-0
M\6N3"](W2[A"4<<LXQ2M! -JFFY7(\6D0/#+@$\'G[68>7SCN6<*VTVCV0-%
MCHO3QB!)S&;H+(6CJ=#"A'=/; W(%>W=;1E4KRM#*(,#_@%]"66&9OJX+![?
M; WM^>(RC9]-". 30PH92$PETE6)@>  +^)I[8,R';9B(^C^JKV"V?2B(BX;
MPH#*,:9CF27=_WH4X'H:RJM@OL''CWBTI%&T'F]?3['\D6K$^AW2<)\'BT;<
MNB?C%,/)J<-12 V=\JE\BG)M0U5C:)<IDP%D6I;O&9SS.%=GGYAX:Q%25J"U
MF L.*Z#F#<.YE+\AJWOTWZ^ WY\R'NB_GG$_A/4R"CO\<E9'#,Y)QI[5Y+6E
M,K106XZ)=N;U]D*8>@7X.PF_ C+9,UX!WD4OF/T:2(=2R7M3AHLSC/:8E+#7
M5@XS]_2A#V_KU0KJBS?8ZP6RX$[A%0!_$O0*$ 0*O (@OCW1$!?Q[^6\5'][
M@^-6I^*#]BIS&6>1^UY7L-.O@#-,@:ZH.W%[@0<HTU? '4+&AOA,AO4K0*WH
M#:W7W^9L-]$<R?WU^!-I$_$SQ!OP>(*1.\LYE&OP*IEY!>PM/4Y>:&%>M;5F
MF;X_XL>6N"K&5'/@D(1<RD1IUV_DY+5EAGCPT6C_ZR\7\6_\;QO8&WW0^B!7
M?_:M-C+)'+-;L^>7;KV2?NR$KG%RT@;!CQT["P&T;Z7*K#_QFNOVST3$0:*1
M;,:.)-2%@V0WD*UFPQM-)CHH[J+%A^?%A\#<%9QLWC!K/:LGKWL5H;.UMX,*
M_?\X9,&"(1YCB?HR_E3\ZV\I*V!0]]):^EY:JC'1U!65@%/QZ79+NX#, P)5
M=G-4W#]I%_]G;6+^E]J"_Q>M6XQ[\=#O4KH3DH67\6VLL6^SG(#4G4&XN#L>
M9K5[3S_Y\-]@PRO@@7VJ["Y(Y:7S[/FD:-OE%6 4Y177;GGB:@Q''"==:NP1
M8=+X*\;^A:;8]8JW_05#X%DZXY[T%;!$,\4KL#'P1L$[,^6H6@)(G;>-HG1C
MM!*CQ60Y+1P*/ IZVJ_>37F=&5/^\11G'7T[:L.)4O(=XSPA5V/7:-DSVC&2
M1PP8@"[7*L#=-Z>V/^C2/JSF.7=NT?Z4<)J;A_&@X>'F/L0M'GBM10U>DWY9
MN[1WLZ!E>DXL'8CP/&3M/!.$PH5_1W@Y*@KG5^![-*2E@"\9^7R-[R96-]S/
M@G[';-49+C'RZ.@W@%\YUQ>P.5#>\H;4CRBZ)36B3]'9]O4JQ21IAU+#T06A
M 2P9,HBECEUS/.8%[=-S729$6\>H]MA,A7"N2&A'@;A<. -'R<L78W:R9]K5
M!>P_#\H6>$R[CHSL^[N3(K<RUFX$$I^.B(:%YFJTO+Y,6M1"$HV+QH\_BNQ?
M\D);??DEX?'K43XUH4]\Y=Z[;$GZG#ZC5.-@WM5A);6NOI(U,R6:#/\+"!)@
MJ^*('U.S56:&V$[@_&-:$BA_U&1?9\ZLD:37%#$_HM^U36!,D"'X;I\*BL(J
M:%7/S:26/$A&BYJ.'3Y^C47DTT>0'&,;3B!NWYB7>KO3QK.5?$V->:OEX#4B
M3T]3?9S]KJK8C&&W^.X)V:E%VKI]!P[7@HR=!.@!$6.65OUBDXF5?7,#"?01
M.E!I[.OZAYA^S*2RH^2ZM%+39,>,O$6ML.=#D*8.+[X:1B4T?$8X"HKKS:D@
MRJ0]LK!H$PC'035#G..#IK@9T,LU4(Q>?K@=!HH%C1UJPI+$]H!51NC)%+:!
M#5'/'+,8_/P3S&1;HA1RR3MB;(NZ?A!SPG1U&GSC9"SMMB3P>]B\6"/)N*&E
M,8*T/OZ=(F44U]ZN58LUHPHN6<!!P;Q]V-MQC0CE/IJP"N0:1<U/+8N<^!!<
M%AE? 7M/HNO'PIHM<^1A*K5U08K3L"F5O]7%(IR8Z)I'Y>7&G@/YM1NXBEW6
M911OU>MF=N=I=^)732C#QJ97GN)%$(:Q3\_QN&""H<BV:)=$'<[-DMUO8Q=[
M/8#DLPTC$V1#VOQ!NYK;#H0>HA0IQ:9-H\V:IJX!>5<(.WA2:O%*R-[67T$L
MOBA\O0!;6W<^E^V9,F*%>M^3HR'0YY(2$<[TS^XSR8:KRBIKD=:Y17K+[^=,
M*P[1EBIF3G6;&HS']NE&J'(  (QJHL5!_4$^6!@C+ZO5[DT:&?[;KVA@G9HB
M4]MZ_-0J^M^21)/5MH&D2"O\NKF;M9:U/(BXZ[XG#^!5C8A5:;NOA5- 7&!F
MNC47YX$@SHTZ4:EA\5&3[V&\-#A$.0 Y;!.RN-;)\W;O7G",??NR_VO_]!-,
M8;_>&YB*;P3:Y9M4];(R:1SLXI([M\\F.,;=P8$@PY]I;-?ZVO ;\<+HZW5C
M#B[A+<E .Y@*D8RV<E!D97**N8[%3D1D$Z5T>DV-<S7[P+VHT5 U^AA%D0'\
MG[&^S$/, BU\)I!T5F(-,^6LQ4L\#:5E]H^!<=(3N JS.0:&'0XD&U4HSOW"
MJCIG 6;M9\&=V<B6XZ-A"MA=ZP>C-9M6O!3C/(_/MQZK3!G)382(/>HJ(1;;
MS5-6>DVA7-H43 T6F#^X.M<)#%Q]45U!=&YB:1L2M>;O\%S4<>+HY9/(=%K"
MQFEY? 8R4?1X48MZ-^/F5=1KXIUWTK;<4N! "@1)/:)/&Q<4GDKR.45]JLG[
MO PY<ANO %3U R=LFY7:!FKRR ]HI&11/ZOMQDM5Z^:N4H:[C<U_J<G9H[7'
M8':Q'"/7I&7N002^N]XL'MWTP%OK>9<E5;A$D3U1LRKU-3, A^_=F,1@?W:L
M(-Z5LJ8GQ03%-,7,YMS5_/2Z+FB%;MF(:F$+(H,3;I?@P[+KK*2[DJE5N9R^
M[:?ZJM >;<(O&OZJP6O5A,Z 6S)YV&=,,4+SKXV-@6!DV2&UW1"C4+(TM=P(
MGX\S4*!<2"$"&Y7"?Y;5 _Y79>U<_VV9_X^@H#$JV$:&P]O!P4<M4037]YH*
M!_L5T"]4EA[M+00-B2IO9M 8*U9CYL8=4[18<$ODM1F<.\-KL^%2TEZ34QOX
M^79U49TEV#_$O]O"<*] V-NN7SU*Z2SD['@MT.HJ3"-LF(Y"C7\:X>7"Z!(P
MDNGUP;B0X*JC8ZNMNKI^^E@1/,>$ 2\[T,FI";+F@^.%Z,"!>@,Z<YZ#//6-
M"Y470;2ZK3/)U[*/]X</^W;@N"?NN@@7[!ORZ^,4_U")O(!,%Z<*Q?>:-.Z9
M)\N.D8E\7\\Y^(GG*,]>VG/VJP\3N(7518#?%$*V8LA4%']$C2#TLM-SZT?#
M<96K9*<675H.YD38*V41%1V5S3W9KVAX%J3MJ\OF5IF7YAX4F^>N:B[5**ND
M'(M-$I]6-+_3K)L58" AUE>RIRF5$[RSG*O'H\^U+*.GB/A45^MB(&+$D_:S
M$ J0"NEIR7=^,*-XH[P8?WZBHNAK=G!RFEWW[+ZX!X[,0N)'J)C2/5MMJ7/Z
MO-W:PBY]*0H)0CGQYM&?)W7T@&@LK$G V_/U'+6X 1E)JJ\$XN&XEV!:21M^
MC])$.#9K4ETBOTK(_GB3A$;Z59+29#^'#]:E8XOWNN#WFN>:#R(V\<Z+9>G*
MH(;&PVDSK8(H9E''WTHE-/]J21+$8-/Z,2X6B&O%/R$R=:]0VEI2W<P^9P$3
MH=9$0[!%H&P9L!4!U5..?L"A\J$D*]RV]N=YWZ/G&<H^1LQ!ZMS.Z B6XY3F
MBAP!FDC>=KP*0F%.$=D9C/-IUT';Y!FJ0GU%HYT7-(>A\MR/:O&/RX.WLCMD
MWN*E #<^S,N3V,W&,IF;4_25AC> 3&Y,=BAWL4H%J'I:ENP8XQJS&V2+Y0AE
MP)9IU+F3=B#L[[JY37J9YHDXV<$7&A/6:U3JY(2I<LE$S:<JQSX/"F'C:)"*
M.G9+,?2 Y"G%_QU;8^[B.M;LC6##8NLWS!.(S[G'EJ5/OEM[;JXP9>GP_&5"
M/!^\(F5L[BZHUJDXA '"=+4$(/F=#L#E'N'-I62:GGK]6NDWM\BEOQVD[<\N
M)*@FZH"4$2YPCI*:I1_-J[E K,2-*RWPE2#_#HW<2R;?@2[VCN R?'T>_YSZ
M\S&OW/J*I_.JS ?IEICRT"(]"$,(<EV!  G>FR=SN9Y5ZHG=L_C:(E7M0<?X
M>-E2C]RF:O%VJ!\R@4IV 92XU)"54#L#<*:B[L=VF\4S=UZ;LU$]]9_<9&1G
M2PRB%*('0BB6 QR!)\U.#NOK%5!U+6W4,W0U<@2=^4?83O$WW+E0XU+YZ:IT
M&B9Q,56J2#2V_">2.*2L$"??52*<B[^!^E!1P?NK9 T9W?,)V&8/::NE9$PA
M7RU#D,&??X1*K1MLY\]9_?1^E*PE--^,J MSVW3;YUU#[N:;4EUI^7HK-$^.
MZ;T@ 5&!*:FYK9="0M0KZK+GZP#GA7N$I6AF>^A?/%;_?K4E)CM)EA0$R^DK
M.H9MB?G3F #OBOO_8.M):B[=4#O<>#8ONMM\-W;X\2-%!<'INLY_7?+^WID,
M_B_:I3=$3OE&!9"]%JCGWY@ W9],_H<7R;W ]M^8YJ^ ['AO[K^TC?@?6!K_
M<]'^NX(IG7GZI%8'WLR17<&EGJ6[CG49VV;@1 *3\"^ ONZ$7K>FWBTL*2<0
MIT];4I6Z\)KL[+,D1;+1SP*J[^$Y3:9)7DMO'[VB-5N[O7D;=922SCNU-9-T
MA/KZYJK8XVC:,6#,1#/Z2:?02CW9^UGO/1#U_!/Y*MXK("M(\A70L?!&NWZU
ML,GPU<S-!%P752C16_H/[\ 0RCYM0<&ESM!PN"V#<U)-&QIL\^<]$TX/7>;B
ML@YC&/QR6\[BAN5R63>-C6N-!+\?4[NOI@3SVK+''L2*G-V48Z3C1WJAC)O=
M- %7TD:')2V_N/ACP%D$A(8SK1-8/FRU3C^)9YGU*>0?J3L<!#@-T96!9,(.
M'6-]KDOAC4)WX?=\O\?C8O#:DL*J*#+#D_K"GZH3%*2HFW)/$2.U/WT">61W
MBR1W;909U%&-[V2*_*C"HE+#S^1$G8X-#<ER3C_D,Y,JQ?LM8\NZF*/,'E,&
M+$ Y%ROZ#&9_7AEQM5VAF=W/1!6H.7L>=JYR6Q$6GBEX%+URNIDG!J?HU3V#
M/ZOIH:\W 4DPQ9$0(A8&\8AHI^FO=="=/;"E9_(KZ^/%&YJJ6S2\&%PQB!GC
MR-;7TS+/IRE##VJ19;LE:Q^5\SR AE8-#"EVU'U)?+"J/LE5D56?FA@-]:([
MMM\+$A 5;;3_/K82#),XFQ[/.U ';C.YT*&0@@13!"_)D%3]K37:7B2'WX\O
MFZS2QG:KRR;R\G"[8.'9RNJ9"Y--+0W'2QJ8>JXC-D(B[=P;WL>W_EC=16RV
M;ZA+YLJR^0EB1RKA"UZ?J8'8!0<%UHY^]; %3\V94S%8E']2;G4FQ-SYZ!TH
M0J&D0E)=C 3IJ>W'1^QOOV%Z,QP_R4;([.9#G/:<580_2&8(E^,"TA.S1A'B
MZ^@H2\Z62B1KB%^AB,@/_@QBTU6#.(B9>6.5;T@=:%FK,?[AG14OAP<2$U8H
MV(6RGDG,WS#WHZ$1[0( .15ERT[)"N<@.6WG.A>LE=933:5$ETBTZ!VG8W$^
M9%<#'#!YL4FGJ<CVYD0,$T!3E?S5;YC-UYF@^JCI)/S[1)DR^+.SLB0V>A'.
M?0<4V=.:_9ZS5#>X+&.3&'7<;6,X>#0M;J=FOHJOB&20$<3L*)FJ[R74&>OC
M:W.((0]'O'&,K10F@>=>KQX?/9>00$N$6LVME3-R4L)!ZX_T?N;C]IST WL+
M6^+QQJ1TW> FQ8SZH53B'(7/IB$G+D,#%BF,2[\F0920[RYBG&-],M<7'K$^
M#N3:F8V?6UEPOCS?P[-^%@.^AZ.YX@$N4:%-F34[LTKK(FE+65N_/JRO?@Y1
MU%4W\3?!K$=M:5S._,$(P:LBNHE(J. NS'<<&=T$DLL9-D$7"Q<A&S14$V8D
MQS\Y0VV#8VO-7=Q_,)/3SUE25<]E]GQ8'7T/R27O::@=_KUH+_5'#174"&U-
M!EH-N';T)+:DY)9%?5F4K:5.0?)#7^Y[O/OP%/$5A)VJ@G@R):D,5.=<;9-Z
MR1R>MI0"D5*K=W6AX(TYF=5O^:^ GP%<^)ZBT9#,&"JE"H($*@L.ID^FIH7=
M>2O@CHN2><B#TKP +VOYJHWPF/%)_B_RA=L7-N!)T?^WDOGW[7^;7.B_+*/\
M/<5;]G=ER'\YMG\;W]]?A/,VP+\5PO_2J1M.X*]M0-]B0="+</J'/W6<C =1
MAW_ZO7]UJ?_=V"I(^!]=O?\O5YB#-K&?@O'FG]TR=JG-_^)P!2YK"#E9WMPR
M]K,R(_':%AKJ[0NMSPQJT^%-%A;-AJ^)92P/FB?<O4WH$WW&R]7: ]?A*^#I
M$_^?R.'V)W)0O46.Y!;65C[[N6G1B,(*0RJ@",T.)I_8B#X<9;AB]6XSJYUO
M[@;^X?3<"L.+<8*S57<]N#_0GD].H7XZ9[J$U2TX1R0F#[0OD=CCG?VK$(K'
M=OFVV)-HU@&94JBNOF5>6KETH]BM(8_=;'.T0:@2P]+.MX7)HF(=X#B?)91U
M@-5DD&S8EJ"/[-^(KMYO&?9AKTP>B>!VLYC2OX4-^Z$=U?3S8P[JL"'.\^+8
MMY/GZ=B8Z5AE.P)@?O.F9,VS&$[^#$7ZN"H:51R=XH4$_PAYA^PGHV6AI8NZ
MT14<^722<Z+J(N'GL*+%TKRTN+SEJ96!NLU=#IATL?"NWQ@!)$![L%WJO'8;
M\EG3TJ!E&_YD#W.<*2D6$]"V$2RQY!>>ZFHPVYR&*-&2/&=>2MWG F2Z,8Y?
MP<WJ@U^0N+?QF9[RQOX>/P7&;&CPEV%@$L):K@E?ME XC9039)8%L&ET/^B;
M$F%63].=?#0%9EZ(>&-':!J\#_=5T@@W($"R47;@0Y68\Q=6FBJQZE&[Z)UM
MDJKF'.. "E_W5*)5!_KC6=W8*RM/+OQF>D[ZI(#5/>NXA</%J]\*<$FK:]],
M$Y>9SL4[J[]TYV+/(A4UQHW)%U-(K:"&6.9<FN8;H#YP*%4?NNSAOINA,)9!
ME4T#YE[,03,G^5C\IL64U>#BDW4" $[$_=SIL[[<68E#R/<U5(;Y<PU%)60-
M#MSRUQHQH)I$\S*@1!7TG77IAH 6(23&;,-\NE+3X0B2 9MY#>=Q&3=:<;NM
MIOC:9B&H27 )=IP^&XX[+843A ,]Q S37& GBMI2Y^0N+>6Y>;4@C[*L?"&,
M:C4:8GJC[QX=F# ANI(X. /RC=".[^^DNFU$,13NO+Y*;/P<1Z?[J4L61,P=
M;KU&?<&U[JI@M\& O#K,6J]-/%4 <D+_>K$HUB>&V\U$&CNX_9 ,V 9>ZZ!I
MF'VM.@(M=P++RQ(5I4R$TCG"F9B9"^\#-R)\7 E.Q@GAPLM/Z("E6=4SY726
M.\RLU@M+XK3S^/*I4%14H<SOZ"*](5E&IS>(D5FJ,U .R%=UN!(7Q>-C,U*?
MVMUBQ[5E-&?L/5A4(SFO^;BG'CB77.E&$*F4_S2DR41E;CP7#S6>S)O9FOO3
M4I(&6 *?7?U%W4B%%C?%:>AKJC=$'Z,0=-W*VU+E /^D_R/>-6WF9K10U-C!
MHJZRM 9B?:4R5V^7US]Z/:LK'!8J8@7OCJ'K5WC81AH.*7V?@AX6PIXCZO T
M"8%K^/2X/R_S=.[HQ@K9,%YV3@K5+94\I+?C&0"**!$#HL_TF^3&,[N,&&)_
M]63)]>- .9U>J ##D&F:4N,7097/:;F 1KY?+\5>Y?MUR9H)_P][;QE59]-M
M"VZ"!X(%@CL$"^X.(7AP=P@.V;B[).C&P\;=W=V#N]O&W=V]>;M[]#UOOA[W
M?-^XYYYSQ^W^L?]5U5/U[*IGS55KKKEX8C>Z(N_J+L3?-4>@FRHD&/Z.P2O0
MQQ,0UH[L#-E%#2@Y\M/<DS>'."50I!IOM;1$JB;[(732 5A!'"J57!LE9KIF
M]R99MK#=?VDVL3?!!TBNJIG%$_AE@_S3I  ;)C-\XA2-AVC:U1.:!](PS! *
M&L[YYZ'H0Y"44],;NWF26-0Z:X#C_;O=*0_!/%U$R,9(7=C0,/8O[5A<2L%
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MP>1S45>QCJPZ&O9;[T99A"S#C7G'%'?YT^GEN&N:UEY;VD%K[^W*'_:XJD8
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M:I<)U90"1F9FMN_%E!._B&P]=O\0XA5P*F7B@H'%LM4N[*74#"]>7#[<._3
M!EJ7:5JJ05*S"E?F?X]!^EW&42G5#2JV,JTH;,'#QF8K2&S#;X_QD^@-U5?>
M55]'!5,$_^ZE8XT:\A2IT)?C7MVT5<FY3>')^66S:TY_F#B42#]$#(20IKC"
M:@W>C87;_R0?FZGU/T,2GVKFA2LHTE'?'?TT*;REHTL"FP4LJ4FR6AN[)+0
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MAM LFJ<CYXX%KO$FN+Y6LU)4!J_K9&=R3 A'<\+XGR??XP&N-$/P?Z1L*VM
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ME-.,U;O5+6(C[M298.N:.Z%O*HOQ\^3O8W?R<#HZUALM *M>G_;C-#_^S+$
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MJ5M.5JM6+(K'-]]J&KVE"K65.?"3P"7$@>Y;KZ.+.TWSSSHMIXV&#!6&X4F
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M HAX 9RQ[[?^2914E_WQ\81\ZO=V?3*[H*EDD9LS']TSIM,KV!/F%WP!$+\
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MP-P:>?H<HD23VRPTR'9JX0D=[?#FHG:H&WW XZON^MI@_0F#1(TOSE*ST 8
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M]*IIN")]NZ PL]O>ECH,#O*4>U"T)Y= +DM4XAFS&E8K(Y34+ZZP? '8&[X
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M,?8 ZY>OL+8[_*<CW[Z](E3@/VL4M(";"]FPE[XB*)KG48RZRAX>X[->BFB
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M<F6FVFH8J,&(CBE XTOM5SJ!\"&H="&>;R:ISO&RW$6/-77G'EVA/_2;Y#\
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M:MHVH; T)5^FX:XE@A(&.PGT &YJ7H8]9Y+.<$)X:23\##431+HR>!J&S16
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M2,(A"NV9K&F?:/%!U#QEK5_9LNVWI=T905]=P_HVO&'O%G&Q:7:$D*L[MP2
M^O<\J_#.UVG[]D;,I636^I*T?=@^R/YPE.+RN88W(A1-&&'BXU?2?7DU.6:Y
M7=\HX,N_353- Z)/#O@H>:?:GK4@?Z"8_N#(9MF4KNT1/O0$6^)&0* [9M,L
M9,13D/XB%_3ZU-;79*(JR2JBJ]:G3#(#16N^&5. '+L.3O:WP727*0<;]%O4
M"AT@SX]0RB,E,UWQ1J+8OT/YO;*M11)W2L#!.]>WI4><Q2A-_SYG^;^H_X)B
MF5V9V_=T6=8Q[/2R8_!41@Q^88^'3>SL+$$52A"_NO(3;A$&S&IKP(#QN9(<
MA#[C4X0&&/"Q*AT&%'Z<D3!8B5,:6FN:7^;?S+#U]8FE<XT:N1APQ@#D2(Y#
MXJ4T_&O[J,[@_[ F-SX80/,-14+ZP7?:GX3? 75BM^0C,&"@[O\1C*NGWF54
M=54]F7<=%K%(Z)?&=PTU;!C$^:DL][$3]E$"_=1WRI &[^[[0#VJ>VQ+&+"I
M!^PR58$.LQ[B1P[A'S+ZT/&3,/Y7"$O:55#NTE7R%[V^9)/9UJ:02RG/I>$*
M8C95!"$7"/EDQV]VQ@.% 7V^%-G!W.WL+]NCE:;LJ17ESPYJMPS"-0&'B-N1
M)@=::X&EN&:"T5O]R>^.U=^?%8=9-#>-5Q5&"9UI-4I]/.QY8;Z(QUN*62A/
MY7>4+7MC%2.VB_2'-6\[W4OG_T) H##ST8W*9!L[-/?8B76K2?$\;%OFO4\D
MWF!.F/V1&K)0C-\K>7^Q6Q90!*\>5I_]QG0T<44&18-]#X=X.RTU(+=:Y=9G
MM_QY;@/G&LX:="7PH&J)UG]>,P>'J8;R(14/;2T9RN^U7:84I4BD\_.^U*.F
M!F.*ST9)-K@%ZCN+<?",>#ON,T#%@F@^I_%"3^VXJBKB)")U/KU_T9UCI'.[
M:)9L]/,"0@SZAO%'(CF\<ALMNR#\8!KBK ^^'X4+=,H*>&]'>A7OM5CUZ@],
MJ),JJI0[\68V\S%9DIF]*U43\\YJDAE ?!6 ]=SX8)EGW/3FL?X^*9V;_MQ<
MCHZ1*GW .COVER22=UC#:%T[UA>@/\M6],\D(G2Q6H8MK*&\W:I1M*Y(?ZE>
M/=I0]():80'IBT;A)#QG80L!N;GV2U">KNR:WXOP/E*L[UHM[R[!:BMZH>.9
MNN+6G(:IMB38X\2'S[1+!LZ._]O%X-F1#?66KQ"4F@7U]CQ=]7:^NS9LQ8GZ
M997(4F?U:(?LO7_@KM-&S=HQ[2&CIA/_W.$/F>S$S%:?T^NS#;)6R_8^9;]>
M=3O>>7UK4KYL%R>>KN?3]/.$O+$Z5&?V.YQ5_-]]O9K_S%IQ2E67"QRQ=:H+
MJMF.-:S[3J$WL1T6-T[@5EX0SH<)_ATAMU&6HBNAM4.*6YZ\JZ1Y'[I)C<[O
ME@LN[>*<*//=&;A!H:M8/1N,/'._*/G8+PN1JU0[WA-<K5%%U;..[?K&AL^1
MGL4OZ2OP!M(Y1F"/!3MS+O?ESHRS4]UJ0MM:\*-]BJWM9XA:WB)RPT7*X**A
M8*XP#<:-?'=9_LTZ5'P'+,5[]Y@GR*DT^MT@I_6\,?WOZ"=2=3%!,67.R-X4
M*(6^!IYIYJ ZY:6>!K";?[F<8J;P8-#;B>-XN]Q. 8!C,>=0K3^'9_=W1BQP
M@O&J(V2M/^*Q4;C\Q.V-3-3"UTF]E]QO'W]$B1)UYD>@^]%K?J78?XT= @U7
MQ"BW.;5-F(M8KWE<KC"!)UDJ[@67Q-6/D'84\-];%4E[<W-X+XA@ SI<TI+<
MC?$"'(,8COG91ZWMB.3-1D+_=%U!O$+X6EQEV1NQMO>VVH*&'UL^U=A7?AXO
M^ZXIHZ'1>BH_!/18(<Z4_89SE#Q^=GG]T(X>/G#:4;*'G8^I8[=J;>VI64.3
M80['<'S#:T[4M71'EUZNSM0TY>P>+'0694D6[RIA6CPC>2=^]AW[9W-](.\<
M>+BO "8FG-'8[ZQXJ\+7\<.:*I%U/'8XB*(A;+AE*;@,3=1>EF+0%:GO)#$[
M?>O(3=>&+<1-K,O4R^7U*_VO%'LVKUX_G]5,V#DZ6G[N+6"Z.--Z]QNR</.'
MV>[Q#?5ER^=[+:S6X[-&]5-BV1P&-&B0(M0*CDR(0X7D&6-F=%?O9"6@RO'1
MMZ]/=-*?.CW^^FE\L[$I:Y[!%;XF-HKIM<1"*X(3^8FA6&R;T#J$Q'K,9L*&
MDEQN(].2132?N^0*T>0PB,+W7/OE["8>-E58 .G!,CG1"')*[L*0SZ-@J6([
M(K72:$^YN^\:'RTW";40<5KK;B?A]K1]IS/>,,_WI"9*%(_8TNONF)(>.O-N
M-G!D?G%;7&_S6V,,Y78BOL)0#7DUY<C^9.)HV6ML6N>M7,]'F43--Z,^M*PA
M(0LT[2IH;[0=G"C:**F^F871H4:T].0P!P6B7+,7RO_*$((3;<T&![\>C=FV
MR%*;1K ]?4NWREOD_KD(N+Q(%0P\'4*/OO$ QU2C!NA]Q\D]AOR1P_SX0\Z"
M1BOA3#3JA56'5[Q-C_X(VY7WG+A:[7>1IUL9>A&R!@/BXHM7YA?:DZS5,63:
M8^3,$S'MVLQ=.]6_FGYCH03X?Z1C9#+T=VMI)QC,2Y5(;6"-?1HF2)JER1SD
MZK(BH0T)2OY27?@;4Z&=RD_7O$I9MW,P[B%L89WGJ9L7F1K)5WX>*<]R(;7-
M-$2)7O)Z,S$FY"7(U)J2Z6IC_8[TVEW.\3NN)NLV;NK[9Q811C'[4KRH_+1T
MYN:^C;]H+-6?'0+<VB4DK[/DC7[=#_L7EJC#J*/9W-$)<N<FF^;GB_[*\JOE
ML:(K_9^QE3GOEY?U(5C$;$5Q:OVCW:MBPA^9W[_\QAP'$%_\DGV8-U*R@XGB
M;QY+&>YKT^J\2\RN+*5ZGX.#!PV+-2WS#NE*A+CE*OM9^'B(W-VF3O\0+3)2
MZB/@(S%L23#7I*W6NX !Z%<0Q1/01<($>(M,M<7.!KPN4I!X*X4(]3D(Z:?6
M?F>S@NS1:G>CF)Y)UA7W32&9NZ'Q,D'I>P&OCU:LJRRU##(:.E&P"+MJXXE6
MQ@PG6WR!LLCP9_L)Y<I!W;CG*(0Y2&H   B=RM,A#+:9MMX8]X=K;_1D>21
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M\:9 J@ST[4,5:.6 _5XN_QZ/XN7]VQ&W>QB@"SJ5_H>1PP T[%(8(&G9# -
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M7]G3?[P_^6U/G#AY?_P;J>HKOYXTS(;K"MX6C^E\K'Q]$?#NELP-A+YSG5,
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M@/G]YT?>*-\S6&]QS,4#NWQILO1LMMTC_H.7^=W2)#(X1V(VL!6>$&0XI J
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M=9GC#V>L.]ETCUF4+1@7U @L,;%?7G'\<$1E9[UP&C- \M!86PRO_^&P8>G
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MFQ.^F"P<[45H3)B0,73(232Z"!YQ[*2<U@/.MP&OBQ5+@]91[<CQ(QH* "X
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M<&/4R$U464Z.UM,N%9.D>TSF?,Y/)M@GXW^ZJM N/R7\(#7#FKVPU&UL0NW
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MJ&$_*NEJAF/SL^"@3S@OO 4]RP+,&$/TY^RF.G[<\']^_.@70^,5O:-J?=[
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M\F.B.50HIH]F(3&T4+A!,F8I$=.[IBH:_:/!XV5H&KQAZA=OV ;1I;:,+A2
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M8.Q"[N]L3"H_ +4:>B7?^'-B%&N5R^P$0B&7)Q>=Q@PO$(*AGB]^\]$+@E4
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M9SD_**YRCU>Z<+>&,K-KUVYA_N$+_<]:+)MIC;I5?O3RXX'5+E<J])_%)_Q
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M3AL1ZSI1W>+^PDMN[ A.7H-LNOU:++@6,3DT&;P.V50BDXOO9JCWHN^6KB/
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M,3&KU?+2+7M\;BB6F^D'^0H]/[21T[:'XFQW-?+I/6/T$./T]G&PHM]94#,
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MAZQB7U!+8C.E[\+7@D>R:T88"KT3:\;&/)8\%%,8!<RG#E:S*K B#5>*:(#
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MVX'X<4H)*2K)?]4)#AK-@H;'(;M71F+7E0(@XP'Q:G>P&K9R,R1-,/MP*"<
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MA3\H95<7"Z(6X,S6A$@ZB8#TL"[&.D5R-9O&I/,=B4[I8%5JWME(405':TO
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MP^Y]PA--?4Y@?DC"84-L"[QY(!1/"242XB]AKZHG>"6/5?A<B-/$V1JT/%O
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M_B2ZEZP\JN5=LY;;"\&G)H(*9%-.IT;T_5#R)UL>3Q()3SNY35.8,5-2<.>
M2]>PC1Q*.%-BP(4"B]CX 49WQ*>9-GN?@\7XO*S?O"AKRVE1+8A*[SP8L1T#
M9G*8S@C>2_M$J:Q['WR^[6N[@V)4)MO+95&JL/HQ_#\;BE<:0[R?%>;SA]L]
ML0*\_^&E'9!0&@&<6];!FT9^Y^O]G?7-&WS[^?'=A^;*%S'#SI_[D5TLU U$
M5,4ZEPQ^:[7^]?[V>/??]XV_OQQ==%Z\.K<CX\P/0ZK2OY:IQ",.]I)N52<X
M?)@KSXIKF0Z<+>L'!U@LT E>RA-<8 *0_ENOEG:&6@;6^_06KG' 7G::Q8('
MU\V5UXTS]P[G4F+4%8T!I^C9?@D,]7'KUG)<,CRPQ%&D8I*"@Q"_28&8K'?A
M9=K9X%\T2RG)Y>AVTA:/AU %L^DI(VAC<=P'_J053Z0PL+EBN60<.RXM:?1J
MBX5'+[<E7C+-LM,9++%2N1Q.QO9!>'J18V%Q"#V:(K3M-B*#XZ-XO]B=,=.;
MD_KQ$^^55/6Y^W--$=8[C@ '#M;+P8Y8R1Z@_T(9!3%@RA A8+METKRJ)D_9
M$CN0PUCX_\DX!?58,N#\PKC9-=4W,I^6[A(EI(N%<2#F^%Z$ETSXA(IG>GV+
M]REW&_53#%5\V5<Q-./.C]V6M+W@_T7.MOQRL2 /P<M9Z',9)+'(R0-9 X?$
MT:'7$K=T[(2!W=P) S,]\>O]V0?[+WOG^-BY:JWC)($7KVZZ-@^ABR,V^X'1
M<RY=ZAJ-'06@;M$:S03(3@.H?KT_C(.CX/!#(_:=J:8!*(-3F2O&:R7-F'E6
M#?R?JW8S< "I-?YA3!P&,*)-F;:8U1=^R6V-!#":B$DOCZ5^</@U)WAY/[!O
MOESN7=:MH#(#UDX.@7F8]M-@% B\BZ$GCFKA7LC>'...5-7>5'EOG* UV'^_
M=[-[UES(WE3GLS?<A3O+#(IYSCW8G=N@B;E(?O78>?K/-T-R.^/X&NNP"J5J
M,L0O<FS$4F7=+R:^5ETB+0XH9\*"N/GF]13NT']7$69HM:C1SU(IS')9,__!
M>'OG@1%LHP7W]?YM[ZH2_@C?_]-))D$]')PJRXA(H*RE3H;+Y)W_^=BX 7KM
M(FZPV-$<F4^/&"6Q-;X^(+7%X\J&TV[@U,VV0,K_OMC.5K+5S3)VV^Y-AN49
MNQ<OG\4&5U5.O3JG[:V9U>J>6:E-1E.=9GOS[ZE>3I%)L*M2(XJT:(EX$IQ?
M[S_^^^ZOUY^M@^_5!USC&=#.]!L]-7#K4,%$$MM+Q92VAX)BJX'O^J G305Z
M--,ISUF4C,C^5\V]O;*YMS]Y$LSR$4B?^5D^5&J-P&G;,??!?\B?2[^!M7Q6
M%EY]3"9<:(CC+[6P^W[@'X2-9:B(ZI0J0H#Z36/_/Q6 YI#U\C#TR E&3>ZQ
M+4+DYQHXJFBT7'J O!B)/S=D3?ZJ9_8HT3[IQ*JS Q=/.K&9P0+WOMX/_GI[
M>O7E]9?/B\D/;>H2\M=R$0?%PI@D\@/R62(KW!K;WW'H18Y,[R8=$"?BJ\CW
M1TFN;3C;>-@#_1+E%FG?7WRTSV_NWA^?O]]79;;ZZ[!:4[POH;4-;S0RZ3U;
MO#0U#XQ>/,F:F\OJEF*QU\V]ZH%9/JB/;F';2O?ZH-/E1%1UD=.#/G/+:VI,
MTE3-&DE#HB D4V;=V-O??_UOXTV_7YUX_LG2YLL DY8ZMBI;=2GFK6^Q7=\C
MRF5>TNW.GNWN0N[S4&ZNXW9W[]Y:M7YG[_G=Y_EZ;7L'.V:M/J:]>:KJ'!.!
M:A##$_[B#LQT87.VJ%Z50ZFB>AXZ(8JALH"%Q<+XTA]L0,R6_QCCJG^&:ZNH
M',EC)?5,:H-FP+:K;K#MYHMM5]U@VZTGMMV:FOR+!,A<?/?%F1V&MGT!DMA"
ML( S&XS"<%0+AIZR&/_%K_<_WY]_^>>V<37867G_4+5A[(QLPP"'-[Z[<7Z\
M_7GRUX<]<,/DN@U>^*;I8C7<X\]PBJY-W:,QIIS:V*F.TMA.T(U\=7;\24L'
M1G1"\5L$%$RZRS HX\##T'TB6$2\4RZ9CR;>PR;<!C:KZ-N8OB94Q,"_9=0D
M-*(\-([@(^"B^]AL:S1BQVUM@XUF-%TK!C8J&:=Q@']B_(\,)1(54 /V(%IT
MG)J+S++E=J@^ "I1Y]]MV:5.R33:SD^P]OK<&ZR[6 %!BT363YHE3\T$81P0
M*'/3#[%.'G\) FF;GX?FN^_10\2CV4S=!K// EM6+AL[/L&FU1Y$$)#-+I7
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M\H.S01B9Q<+9V9&QA0=;+?\A?DL_5?YX:02VTVO$ >8/8\XM41=^BQNO=*B
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M_$;M"N [L6J1@$=<'RNM+!=,1/AEX.-!8>@"?X-NH81M 6&&1PI?HB2+;(C
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MD ,)_X8M-062F1JZ>L<C%2C.H6!GB0ZEIQ!?GK1H N\DD)E(9:6_/(1L;R3
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M)/&P5@*"Q5\"*2I7G,1IQX3 M&D&VFYPE[98MBD$D\#6$$$S6^XK_5N<CNA
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MZJQ/]Z*89E>T,'8 ISY0XU76AXM[TR$T$O- /NQ!C]]HCI$& #D=ASD=6M,
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M(W!;8.HG:?:.\(50UA8J!]U".7W!>"X7M\;T]?O<LY%&OA]B3_5\1?$#]6@
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M&BC!JIZR4T XJ1OC>^W4= SHP*)5*X\E'FI1L:UV>D QEA6W,4(TT9D.$ 8
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MA>;XH_<[CC%%":&_>G^B*!5_(>=AA*EW2N:/$4XP_R%;^*/W[M7)+\@[/#2
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M)RWKH<C=/E.AS?#!C4*<ZGZ*>17,E6@>*=J(5)??O-THOX&Z*"[*:KPEQ*'
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M>Q8?H3XFQO/W2"T:T V*<_<:['%%SZR"#:M!FJVJN[*[-?=(NWKB%:B1]@H
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M5@_Y6F%L%96POB_3)(W(ALUD5W.^XV^*2-#+>XU&L,$>1"+HA(,SS!6ARNM
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MRPD-S"$I1D* 6*%&IJ%%+8RX-*+B08AQ3=(ER].>QI:I0A;T2PT=T"$WQE*
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MM,Y$&0;.0-K#Z&%Q#FZPZ 3BD5MP@U$!C"%R02D_]9 ?Q@ 9IMF+L9\GVO4
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M^K;)*A%^?3ZQB3[D:56ZC[*]?072Y+)E$TV9=29^(OCHVV^])HU"7F9O$'X
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MA-6#%I32L4,CCCY>@^B.QM#.%@3S.?L7/'Y8T20'JS/,(+5S3-2(HX]"(=#
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M'=$0N0&GVI(0N[6+M^ @H!P+*C;=AP<<["( P Q=6Q")DXDGLC_N[%^@"HN
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M=3P_V;@N78B@FP4)I:;9TQ_*"[(P@K#,[H^!]OHO(6HW=?T"-1P&S]-!.TG
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MH2L5^LT$+=%_]O&JQ[(E/:81F'\XK_XR7:K@+#5!4VO*<%7 K*7E6+ZEBVU
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M,BTQ+FAT;5!+ 0(4 Q0    ( !10KU:^6+HE]!L! '== 0 -
M  "  = 4  !F,3 M<5\P,#$N:G!G4$L! A0#%     @ %%"O5@-][,KUA@
M4+$   T              ( ![S ! &8Q,"UQ7S P,BYJ<&=02P$"% ,4
M"  44*]6:D2>F ;(   '7P< #               @ $/N $ 9F]R;3$P+7$N
M:'1M4$L! A0#%     @ %%"O5L++]7)M&@  91L   T              ( !
M/X " &EM86=E7S P-BYJ<&=02P$"% ,4    "  44*]6\1<LFE0+  "C:0
M$0              @ '7F@( <&-S82TR,#(S,#,S,2YX<V102P$"% ,4
M"  44*]6V$+6+ 4,   8C0  %0              @ %:I@( <&-S82TR,#(S
M,#,S,5]C86PN>&UL4$L! A0#%     @ %%"O5OEG_.J=&   YZ ! !4
M         ( !DK(" '!C<V$M,C R,S S,S%?9&5F+GAM;%!+ 0(4 Q0    (
M !10KU;JS4400S\  &&+ P 5              "  6++ @!P8W-A+3(P,C,P
M,S,Q7VQA8BYX;6Q02P$"% ,4    "  44*]6K4EVX4@J  #*S ( %0
M        @ '8"@, <&-S82TR,#(S,#,S,5]P<F4N>&UL4$L%!@     ,  P
*W@(  %,U P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
